Research activity information

• The anti-migration effect of partially covered self-expandable metal stents for unresectable malignant distal biliary obstruction: A multicenter comparative study.

  Shinya Kohashi, Arata Sakai, Keisuke Furumatsu, Takeshi Ezaki, Takao Iemoto, Takeshi Tanaka, Masahiro Tsujimae, Takashi Kobayashi, Atsuhiro Masuda, Yuzo Kodama

  OBJECTIVES: Covered self-expandable metal stents are commonly used for unresectable malignant distal biliary obstruction. Partially covered self-expandable metal stents have uncovered sections at both ends; however, their anti-migration effect remains unclear. The objective of this study was to evaluate that effect by comparing such stents with fully covered self-expandable metal stents for patients with unresectable malignant distal biliary obstruction. METHODS: This was a multicenter, retrospective comparative study of partially covered stents with fully covered stents for unresectable malignant distal biliary obstruction. Stent migration, recurrent biliary obstruction, and the time to recurrent biliary obstruction were compared between them. RESULTS: Thirty-nine patients with partially covered stents were included and compared with 42 patients with fully covered stents. The partially covered group had a significantly lower stent migration rate (3% vs. 36%; p < 0.001). The recurrent biliary obstruction rate was significantly lower in the partially covered group (21% vs. 43%; p = 0.036). The non-recurrent biliary obstruction rate at 6 months was 90% and 68% in the partially and fully covered groups, respectively. The time to recurrent biliary obstruction was significantly longer in the partially covered group (Gray's test, p = 0.016). Only partially covered stent placement was significantly associated with a lower risk of stent migration (subdistribution hazard ratio = 0.077; 95% confidence interval = 0.01-0.60; p = 0.014) in the multivariable analysis. CONCLUSIONS: The anti-migration effect of partially covered self-expandable metal stents was associated with a reduced recurrence of biliary obstruction and prolonged time to such obstruction.

  Apr. 2025, DEN open, 5(1) (1), e70100, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Factors associated with the development of bacterial pneumonia and the preventive potential of peroral endoscopic myotomy in patients with esophageal motility disorders: a case-control study.

  Hitomi Hori, Hirofumi Abe, Shinwa Tanaka, Hiroya Sakaguchi, Kazunori Tsuda, Chise Ueda, Fumiaki Kawara, Takashi Toyonaga, Masato Kinoshita, Satoshi Urakami, Tatsuya Nakai, Shinya Hoki, Hiroshi Tanabe, Yuzo Kodama

  BACKGROUND: Patients with esophageal motility disorders (EMDs) sometimes develop bacterial pneumonia (BP). However, factors associated with BP in patients with EMDs and whether peroral endoscopic myotomy (POEM) reduces BP development are unclear. Therefore, this study aimed to identify factors associated with BP development and evaluate the preventive potential of POEM in patients with EMDs. METHODS: This study included 623 patients diagnosed with EMDs at our institution between April 2015 and March 2023. Factors associated with BP were analyzed by comparing characteristics between patients who developed BP within 1 year before diagnosis using multivariable analysis. The potential of POEM to prevent BP development was assessed using Cox regression analysis, considering treatment status as a time-varying covariate. RESULTS: Of the 623 patients, 31 (5.0%) developed BP within 1 year before diagnosis. Older age (odds ratio [OR] = 1.29, 95% confidence interval [CI] 1.04-1.59, p = 0.019; 10-year increments), lower body mass index (OR = 0.87, 95% CI 0.78-0.98, p = 0.026), and manometric diagnosis of spastic esophageal disorders (OR = 2.97, 95% CI 1.24-7.16, p = 0.015) were significantly associated with BP. Treatment status of POEM was proved to be a significant factor for developing BP using Cox regression analysis (hazard ratio = 0.17, 95% CI 0.039-0.75, p = 0.019). CONCLUSIONS: Risk factors associated with BP in patients with EMDs were older age, lower body mass index, and manometric diagnosis of spastic esophageal disorders. POEM could decrease spasm-related bolus reflux, improve patients' nutritional status through resolution of transit disturbance, and reduce respiratory complications, suggesting that POEM could help prevent BP development.

  Mar. 2025, Journal of gastroenterology, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Efficacy of a novel small-caliber therapeutic endoscope in peroral endoscopic myotomy for esophageal motility disorders: a propensity score matching analysis.

  Hirofumi Abe, Shinwa Tanaka, Hiroya Sakaguchi, Chise Ueda, Masato Kinoshita, Hitomi Hori, Tatsuya Nakai, Tetsuya Yoshizaki, Shinya Hoki, Hiroshi Tanabe, Satoshi Urakami, Takashi Toyonaga, Yuzo Kodama

  BACKGROUND: EG-840TP is a novel small-caliber therapeutic endoscope with a large working channel. We aimed to evaluate the treatment outcomes of peroral endoscopic myotomy using EG-840TP compared to those using a conventional therapeutic endoscope (GIF-H290T). METHODS: Patients who underwent peroral endoscopic myotomy for achalasia and non-achalasia esophageal motility disorders were enrolled between March 2021 and March 2023. Procedure times and other treatment outcomes were compared between patients treated with EG-840TP and GIF-H290T using propensity score matching analysis. In the subgroup analysis, patients were divided into subsets based on myotomy length, morphology, esophageal dilation, and operator skill, and the procedure time was compared between the matched groups. RESULTS: A total of 154 patients were enrolled in this study, and 39 patients treated using each type of scope were matched. The EG-840TP group tended to have a shorter procedure time than the GIF-H290T group. There were no significant differences between the groups in terms of short-term clinical success or perioperative adverse events. In the subgroup analysis, the procedure time of the EG-840TP group was significantly shorter than that of the GIF-H290T group when patients had a straight esophagus (44 min vs. 54 min, p = 0.0015) and the operator was a non-expert (49 min vs. 64 min, p = 0.031). CONCLUSIONS: POEM using EG-840TP showed procedure time, clinical success, and adverse events equivalent to those of a conventional therapeutic endoscope. However, EG-840TP potentially contributed to a shorter procedure time in patients with a straight esophagus or in non-expert operators than GIF-H290T.

  Feb. 2025, Esophagus : official journal of the Japan Esophageal Society, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Anti-integrin αvβ6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.

  Makoto Okabe, Shuji Yamamoto, Masahiro Shiokawa, Tadakazu Hisamatsu, Hajime Yamazaki, Risa Nakanishi, Kensuke Hamada, Hiroki Kitamoto, Takeshi Kuwada, Norimitsu Uza, Aki Sakatani, Toshimitsu Fujii, Masashi Ohno, Minoru Matsuura, Tomoyoshi Shibuya, Naoki Ohmiya, Makoto Ooi, Namiko Hoshi, Kei Moriya, Kiichiro Tsuchiya, Yoshiharu Yamaguchi, Reiko Kunisaki, Masahiro Takahara, Tomohisa Takagi, Tetsuo Takehara, Fumihito Hirai, Kazuki Kakimoto, Motohiro Esaki, Hiroshi Nakase, Fukunori Kinjo, Takehiro Torisu, Shuji Kanmura, Kazuyuki Narimatsu, Katsuyoshi Matsuoka, Hiroto Hiraga, Kaoru Yokoyama, Yusuke Honzawa, Makoto Naganuma, Masayuki Saruta, Yuzo Kodama, Tsutomu Chiba, Hiroshi Seno

  BACKGROUND: A serum biomarker for diagnosing ulcerative colitis (UC) remains to be established. Although we recently reported an anti-integrin αvβ6 antibody (V6 Ab) for diagnosing UC with high sensitivity and specificity, no large-scale validation study exists. This study aimed to validate the diagnostic value of V6 Ab for UC using a nationwide multicenter cohort study. METHODS: We measured V6 Ab titers in patients definitively diagnosed with UC, Crohn's disease (CD), or other gastrointestinal disorders (OGDs). The primary outcome was the diagnostic value of V6 Ab. Secondary outcomes were factors associated with false-negative results in patients with UC and false-positive results in patients without UC and the heterogeneity of the diagnostic value of V6 Ab among the participating facilities. RESULTS: We enrolled 1241, 796, and 206 patients with UC, CD, and OGD, respectively, from 28 Japanese high-volume referral centers. The diagnostic sensitivity of V6 Ab for UC was 87.7%, and its specificities for CD and OGDs were 82.0% and 87.4%, respectively. Multivariable logistic regression analysis showed that false-negative results were associated with older age at the time of sample collection, current smokers, lower partial Mayo score, and not receiving advanced therapies in patients with UC, and false-positive results were associated with colonic CD in patients with CD. No factor was associated with false-positive results in patients with OGDs. There were no significant differences in the diagnostic value of V6 Ab among the centers. CONCLUSIONS: The diagnostic value of V6 Ab for UC was validated in the large-scale nationwide multicenter study.

  Jan. 2025, Journal of gastroenterology, 60(1) (1), 86 - 95, English, Domestic magazine

  Scientific journal


• Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

  NOBUAKI ISHIHARA, SHOHEI KOMATSU, YOSHIHIKO YANO, YOSHIMI FUJISHIMA, JUN ISHIDA, MASAHIRO KIDO, HIDETOSHI GON, KENJI FUKUSHIMA, TAKESHI URADE, TOSHIHIKO YOSHIDA, KENTARO TAI, KEISUKE ARAI, HIROAKI YANAGIMOTO, HIROCHIKA TOYAMA, TAKANORI MATSUURA, TOSHIFUMI TADA, YUZO KODAMA, TAKUMI FUKUMOTO

  Anticancer Research USA Inc., Dec. 2024, Anticancer Research, 45(1) (1), 251 - 260

  Scientific journal


• A new treatment for blown-out myotomy, a diverticulum formed after peroral endoscopic myotomy.

  Hiroya Sakaguchi, Shinwa Tanaka, Hirofumi Abe, Douglas Motomura, Hitomi Hori, Takashi Toyonaga, Yuzo Kodama

  Dec. 2024, Endoscopy, 56(S 01) (S 01), E74-E75, English, International magazine

  Scientific journal


• Peroral endoscopic myotomy using a novel thin therapeutic scope.

  Hiroshi Tanabe, Hiroya Sakaguchi, Hirofumi Abe, Hitomi Hori, Chise Ueda, Shinwa Tanaka, Yuzo Kodama

  Dec. 2024, Endoscopy, 56(S 01) (S 01), E522-E523, English, International magazine

  Scientific journal


• Predictive factors for refractory anastomotic stricture after cervical triangular anastomosis with gastric conduit reconstruction through the posterior mediastinum in minimally invasive esophagectomy

  Hiroshi Saiga, Taro Oshikiri, Hironobu Goto, Yasufumi Koterazawa, Takashi Kato, Yukari Adachi, Toshitatsu Takao, Ryuichiro Sawada, Hitoshi Harada, Naoki Urakawa, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Yuzo Kodama, Yoshihiro Kakeji

  Elsevier BV, Dec. 2024, Journal of Gastrointestinal Surgery, 28(12) (12), 2001 - 2007

  Scientific journal


• Endoscopic submucosal dissection for severe fibrosis using a combined water pressure and circumferential-inversion method.

  Hiroshi Takayama, Toshitatsu Takao, Douglas Motomura, Hitomi Hori, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama

  Dec. 2024, Endoscopy, 56(S 01) (S 01), E35-E36, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 未来の膵胆道癌診療に向けた基礎研究と臨床研究の融合 早期膵癌患者由来オルガノイド樹立と早期膵癌の微小環境の解析

  辻前 正弘, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Oct. 2024, 日本消化器病学会雑誌, 121(臨増大会) (臨増大会), A732 - A732, Japanese


• Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a multicenter retrospective study.

  Mika Miki, Atsuhiro Masuda, Mamoru Takenaka, Hideyuki Shiomi, Takao Iemoto, Hidetaka Tsumura, Masahiro Tsujimae, Hirochika Toyama, Keitaro Sofue, Eisuke Ueshima, Shunsuke Omoto, Akihiro Yoshida, Tomohiro Fukunaga, Hidekazu Tanaka, Ryota Nakano, Shogo Ota, Takashi Kobayashi, Arata Sakai, Maki Kanzawa, Tomoo Itoh, Yuzo Kodama

  BACKGROUND: Focal pancreatic parenchymal atrophy (FPPA) and upstream pancreatic atrophy (UPA) may indicate the presence of early pancreatic cancer. In early pancreatic cancer, the tumor occasionally spreads laterally along the main pancreatic duct, presenting challenges in determining the extent of surgical resection. This study aimed to investigate the association of pancreatic atrophy pattern and intraductal cancer extension. METHODS: Thirty-two patients with early-stage pancreatic cancer who underwent surgery at five participating centers were enrolled. Pancreatic atrophy was defined as the narrowing of parenchyma compared to the surrounding parenchyma and was classified as either FPPA (partial atrophy surrounding the pancreatic duct stenosis) or UPA (global atrophy caudal to the site of duct stenosis). Intraductal cancer extension was defined as an extension exceeding 10 mm. RESULTS: Preoperative computed tomography revealed FPPA, UPA, and no parenchymal atrophy in 13, 13, and 6 patients. Cases with FPPA or UPA showed significantly longer cancer extensions than those without atrophy (P = 0.005 and P = 0.03, respectively). Intraductal cancer extension was present in all but one case of FPPA. 69% (9/13) of the cases with UPA showed intraductal cancer extension, whereas cases without atrophy showed no intraductal cancer extension. Importantly, two patients with FPPA or UPA showed positive resection margins during surgery and three patients with FPPA or UPA showed recurrence in the remnant pancreas. CONCLUSIONS: The presence of FPPA and UPA indicates lateral cancer extension in early-stage pancreatic cancer. Preoperative assessment of the pancreatic parenchyma may provide valuable insights for determining the extent of surgical resection.

  Sep. 2024, Journal of gastroenterology, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Risk-scoring system predicting need for hospital-specific interventional care after peroral endoscopic myotomy.

  Hirofumi Abe, Shinwa Tanaka, Hiroya Sakaguchi, Chise Ueda, Hitomi Hori, Tatsuya Nakai, Tetsuya Yoshizaki, Fumiaki Kawara, Takashi Toyonaga, Masato Kinoshita, Satoshi Urakami, Shinya Hoki, Hiroshi Tanabe, Yuzo Kodama

  OBJECTIVES: Early identification of patients needing hospital-specific interventional care (HIC) following endoscopic treatment is valuable for optimizing postoperative hospital stays. We aimed to develop and validate a risk-scoring system for predicting HIC in patients who underwent peroral endoscopic myotomy (POEM). METHODS: This study included patients with esophageal motility disorders who underwent POEM at our hospital between April 2015 and March 2023. HIC was defined as any of the following situations: fasting for gastrointestinal rest to manage adverse events (AEs); intravenous administration of medications such as antibiotics and blood transfusion; endoscopic, radiologic, and surgical interventions; intensive care unit management; or other life-threatening events. A risk-scoring system for predicting HIC after postoperative day (POD) 1 was developed using multivariable logistic regression and was internally validated using bootstrapping and decision curve analysis. RESULTS: Of the 589 patients, 50 (8.5%) experienced HIC after POD1. Risk scores were assigned for four factors as follows: age (0 points for <70 years, 1 point for 70-79 years, 2 points for ≥80 years), preoperative prognostic nutritional index (0 points for >45, 1 point for 40-45, 4 points for <40), postoperative surgical site AEs on second-look endoscopy (7 points), and postoperative pneumonia on chest radiography (6 points). The discriminative ability (concordance statistics, 0.85; 95% confidence interval, 0.78-0.91) and calibration (slope 1.00; 0.74-1.28) were satisfactory. The decision curve analysis demonstrated its clinical usefulness. CONCLUSION: This risk-scoring system can predict the HIC after POD1 and provide useful information for determining discharge.

  Sep. 2024, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, English, International magazine

  Scientific journal


• 膵癌の腫瘍免疫・予後に関連する腫瘍内細菌叢の探索(Association of Intratumoral Microbiome with Tumor Immunity and Prognosis in Human Pancreatic Cancer)

  入江 洋介, 増田 充弘, 阿部 晶平, 松本 知訓, 井上 潤, 辻前 正弘, 田中 雄志, 酒井 新, 小林 隆, 今井 俊夫, 原 英二, 児玉 裕三, 増田 充弘

  (一社)日本癌学会, Sep. 2024, 日本癌学会総会記事, 83回, J - 2054, English


• 同時性・異時性多発膵癌の起源(Clonal origin of synchronous or metachronous multiple pancreatic cancers)

  平野 智紀, 垣内 伸之, 大山 智宏, 竹内 康英, 穴澤 貴行, 長井 和之, 増井 俊彦, 南口 早智子, 田中 雄志, 増田 充弘, 児玉 裕三, 田中 洋子, 宮野 悟, 宇座 徳光, 妹尾 浩, 小川 誠司, 宮野 悟

  (一社)日本癌学会, Sep. 2024, 日本癌学会総会記事, 83回, P - 2290, English


• Treatment and Prognosis for Pancreatic Duct Disruption Associated With Pancreatic Cancer: A Case Series of 15 Patients.

  Yuki Oka, Takeshi Tanaka, Takashi Kobayashi, Atsuhiro Masuda, Arata Sakai, Masahiro Tsujimae, Masanori Gonda, Hirochika Toyama, Takumi Fukumoto, Yuzo Kodama

  Background Pancreatic duct (PD) disruption can occasionally be attributed to pancreatic cancer. Therapeutic interventions for PD disruption due to pancreatic cancer and their influence on pancreatic cancer prognosis remain unclear. This study investigated the therapeutic modalities and prognostic implications of PD disruption in pancreatic cancer. Methods This retrospective study included 15 patients with PD disruption concomitant with pancreatic cancer between April 2011 and March 2023. As an endoscopic intervention for PD disruption, endoscopic pancreatic stenting (EPS) or endoscopic ultrasonography-guided pancreatic fluid collection drainage (EUS-PFD) was performed. Technical success was defined as stent placement and clinical success was defined as an improvement in PD disruption. Results Of the 15 cases of PD disruption, two involved only pancreatic juice leakage without symptoms, four involved pancreatic pseudocyst (PPC) without infection, and nine involved PPC with infection. Four patients underwent EPS, nine underwent EUS-PFD, and two underwent lumen-apposing metal stent placement. All patients achieved both technical and clinical success without complications. The clinical stage of pancreatic cancer ranged from carcinoma in situ to the metastatic phase. For the treatment of pancreatic cancer, five patients underwent surgical resection, and eight underwent chemotherapy. There was no obvious recurrence of peritoneal sowing. The median overall survival from the diagnosis of pancreatic cancer in the resected and non-resected cases was 74 and 9.6 months, respectively. Conclusion Endoscopic intervention was effective in all cases of PD disruption due to pancreatic cancer. Furthermore, even in cases of pancreatic cancer after PD disruption, survival rates were similar to those in cases without PD disruption and were achieved through surgical resection or chemotherapy.

  Aug. 2024, Cureus, 16(8) (8), e67482, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 慢性膵炎臨床診断基準2019の検証と次回改訂に向けた展開 慢性膵炎臨床診断基準2019におけるEUS画像診断の妥当性の検証

  猪股 典子, 増田 充弘, 黄 哲久, 横谷 勇佑, 岡 勇樹, 重里 徳子, 入江 洋介, 三木 美香, 原田 宣幸, 孝橋 信哉, 長尾 佳映, 植村 久尋, 増田 重人, 權田 真知, 阿部 晶平, 田中 雄志, 辻前 正弘, 酒井 新, 小林 隆, 児玉 裕三

  (一社)日本膵臓学会, Jul. 2024, 膵臓, 39(3) (3), A206 - A206, Japanese


• 自己免疫性膵炎診療ガイドライン2020の検証 多機関共同研究から見たIgG4陰性自己免疫性膵炎の特徴

  岡 勇樹, 増田 充弘, 辻前 正弘, 中野 遼太, 加藤 隆夫, 藤田 光一, 平田 祐一, 芦名 茂人, 那賀川 峻, 荻巣 恭平, 古松 恵介, 藤垣 誠治, 重里 徳子, 塩見 英之, 船津 英司, 佐貫 毅, 有坂 好史, 岡部 純弘, 児玉 裕三

  (一社)日本膵臓学会, Jul. 2024, 膵臓, 39(3) (3), A262 - A262, Japanese


• EUS-FNA Resectable膵体尾部癌に対するEUS-TAの是非の検討

  横谷 勇佑, 田中 雄志, 辻前 正弘, 小林 隆, 酒井 新, 増田 充弘, 外山 博近, 児玉 裕三

  (一社)日本膵臓学会, Jul. 2024, 膵臓, 39(3) (3), A336 - A336, Japanese


• Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Takuya Mimura, Akihiro Minami, Kenji Momose, Hirotaka Hirano, Motofumi Tanaka, Yuki Ueda, Kentaro Tai, Yuki Yasuhara, Daisuke Nakagawa, Atsushi Yamamoto, Masahiro Kido, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: Sorafenib and lenvatinib have long been used as a first-line treatment for advanced hepatocellular carcinoma (HCC). Along with the development of systemic chemotherapy for HCC, the concept of conversion hepatectomy has recently become widespread. The present study aimed to assess the clinical outcomes of sorafenib and lenvatinib for HCC regarding the possibility of conversion hepatectomy in clinical practice. PATIENTS AND METHODS: A total of 295 patients with advanced HCC receiving sorafenib and lenvatinib, accounting for 306 treatments (sorafenib, n=157; lenvatinib, n=149, 11 patients received lenvatinib after sorafenib treatment) at five different institutions were enrolled. Patients were assessed for their clinical characteristics and therapeutic response using both Response Evaluation Criteria in Solid Tumors criteria (RECIST) and modified RECIST (mRECIST) criteria. Additionally, an indication of surgery after tyrosine kinase inhibitor administration was determined based on the tumor status of patients. RESULTS: The median survival times of patients treated with sorafenib and lenvatinib were 12.8 and 16.4 months, respectively, without significant difference (p=0.1645). The objective response rates (ORR) of sorafenib based on mRECIST and RECIST were 10.1% and 5.9%, respectively, and those of lenvatinib were 38.1% and 19.0%, respectively. Among the 306 treatments, two cases (sorafenib and lenvatinib, one each) underwent hepatectomy after systemic chemotherapy. CONCLUSION: Few cases with unresectable HCC were amenable to conversion hepatectomy after sorafenib and lenvatinib treatments due to the limited ORR by RECIST. Cautious approach must be taken when administering neoadjuvant chemotherapy aimed at conversion hepatectomy.

  Jul. 2024, Anticancer research, 44(7) (7), 3097 - 3103, English, International magazine

  Scientific journal


• Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis.

  Masataka Yokode, Masahiro Shiokawa, Hisato Kawakami, Takeshi Kuwada, Yoshihiro Nishikawa, Yuya Muramoto, Hiroki Kitamoto, Makoto Okabe, Hajime Yamazaki, Norihiro Okamoto, Toshihiro Morita, Kazuya Ohno, Risa Nakanishi, Ikuhisa Takimoto, Muneji Yasuda, Koki Chikugo, Shimpei Matsumoto, Hiroyuki Yoshida, Sakiko Ota, Takeharu Nakamura, Hirokazu Okada, Tomonori Hirano, Nobuyuki Kakiuchi, Tomoaki Matsumori, Shuji Yamamoto, Norimitsu Uza, Makoto Ooi, Yuzo Kodama, Tsutomu Chiba, Hidetoshi Hayashi, Hiroshi Seno

  BACKGROUND: No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis. METHODS: Serum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients. RESULTS: Anti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls (P < 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies (P < 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis (P = 0.001) and steroid resistance (P = 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC. CONCLUSIONS: Anti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis.

  May 2024, British journal of cancer, 130(9) (9), 1552 - 1560, English, International magazine

  Scientific journal


• Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma

  AKIRA KOIZUMI, SHOHEI KOMATSU, SATOSHI OMIYA, YOSHIHIKO YANO, YOSHIMI FUJISHIMA, JUN ISHIDA, MASAHIRO KIDO, HIDETOSHI GON, KENJI FUKUSHIMA, TAKESHI URADE, SHINICHI SO, TOSHIHIKO YOSHIDA, KEISUKE ARAI, RYOSUKE FUJINAKA, YUHI SHIMURA, HIROAKI YANAGIMOTO, HIROCHIKA TOYAMA, YOSHIHIDE UEDA, YUZO KODAMA, TAKUMI FUKUMOTO

  Anticancer Research USA Inc., Apr. 2024, Anticancer Research, 44(5) (5), 2055 - 2061

  Scientific journal


• Randomised controlled, patient-blinded, multicentre, superiority trial to evaluate the efficacy of the line-attached sheath-type traction device for endoscopic submucosal dissection in patients with superficial gastric neoplasms

  Hirofumi Abe, Tomoya Sako, Yoshinobu Yamamoto, Atsushi Ikeda, Fumiaki Kawara, Takayuki Ose, Toshitatsu Takao, Yasuaki Kitamura, Ryusuke Ariyoshi, Yoshinori Morita, Tsukasa Ishida, Takuya Ikegawa, Ryosuke Ishida, Tetsuya Yoshizaki, Hiroya Sakaguchi, Takashi Toyonaga, Yuzo Kodama

  Apr. 2024, BMJ Open

  [Refereed]

  Scientific journal


• Temporal progression of pancreatic cancer computed tomography findings until diagnosis: A large-scale multicenter study.

  Masanori Gonda, Atsuhiro Masuda, Takashi Kobayashi, Takao Iemoto, Saori Kakuyama, Takeshi Ezaki, Takuya Ikegawa, Yuichi Hirata, Hidetaka Tsumura, Kyohei Ogisu, Ryota Nakano, Seiji Fujigaki, Takashi Nakagawa, Megumi Takagi, Kodai Yamanaka, Yu Sato, Koichi Fujita, Keisuke Furumatsu, Takao Kato, Arata Sakai, Hideyuki Shiomi, Tsuyoshi Sanuki, Yoshifumi Arisaka, Yoshihiro Okabe, Hirochika Toyama, Keitaro Sofue, Yuzo Kodama

  BACKGROUND: Focal parenchymal atrophy and main pancreatic duct (MPD) dilatation have been identified as early signs of pancreatic ductal adenocarcinoma. However, limited evidence exists regarding their temporal progression due to previous study limitations with restricted case numbers. OBJECTIVE: To ascertain a more precise frequency assessment of suspicious pancreatic ductal adenocarcinoma findings as well as delineate the temporal progression of them. METHODS: A multicenter retrospective study was conducted on patients diagnosed with pancreatic ductal adenocarcinoma between 2015 and 2021. We included patients who had undergone at least one computed tomography (CT) scan ≥6 months before diagnosing pancreatic ductal adenocarcinoma. The temporal progression of suspicious pancreatic ductal adenocarcinoma findings on CT was investigated. RESULTS: Out of 1832 patients diagnosed with pancreatic ductal adenocarcinoma, 320 had a previous CT before their diagnosis. Suspicious pancreatic ductal adenocarcinoma findings were detected in 153 cases (47.8%), with focal parenchymal atrophy (26.6%) being the most common followed by MPD dilatation (11.3%). Focal parenchymal atrophy was the earliest detectable sign among all suspicious findings and became visible on average 2.7 years before diagnosis, and the next most common, MPD dilatation, 1.1 years before diagnosis. Other findings, such as retention cysts, were less frequent and appeared around 1 year before diagnosis. Focal parenchymal atrophy followed by MPD dilatation was observed in 10 patients but not in reverse order. Focal parenchymal atrophy was more frequently detected in the pancreatic body/tail. No significant relationship was found between the pathological pancreatic ductal adenocarcinoma differentiation or tumor stage and the time course of the CT findings. All cases of focal parenchymal atrophy progressed just prior to diagnosis, and the atrophic area was occupied by tumor at diagnosis. Main pancreatic duct dilatation continued to progress until diagnosis. CONCLUSION: This large-scale study revealed that the temporal progression of focal parenchymal atrophy is the earliest detectable sign indicating pancreatic ductal adenocarcinoma. These results provide crucial insights for early pancreatic ductal adenocarcinoma detection.

  Mar. 2024, United European gastroenterology journal, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 自己免疫性膵炎・IgG4関連硬化性胆管炎の病態解明と診療戦略 自己免疫性膵炎における静脈狭窄・静脈瘤の頻度とステロイド治療への反応性 16施設による多施設共同研究

  重里 徳子, 増田 充弘, 加藤 隆夫, 平田 祐一, 中野 遼太, 藤田 光一, 辻前 正弘, 酒井 新, 小林 隆, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2024, 日本消化器病学会雑誌, 121(臨増総会) (臨増総会), A81 - A81, Japanese


• オルガノイドが切り拓く消化器病研究新時代 消化器内視鏡検体を用いた早期膵癌オルガノイドの樹立

  辻前 正弘, 増田 充弘, 重里 徳子, 入江 洋介, 三木 美香, 田中 雄志, 酒井 新, 小林 隆, 今井 俊夫, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2024, 日本消化器病学会雑誌, 121(臨増総会) (臨増総会), A187 - A187, Japanese


• 膵石に対する内視鏡治療の成績と外科治療移行のタイミングに関する検討

  酒井 新, 原田 宜幸, 田中 雄志, 辻前 正弘, 小林 隆, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2024, 日本消化器病学会雑誌, 121(臨増総会) (臨増総会), A431 - A431, Japanese


• Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

  Nobuaki Ishihara, Shohei Komatsu, Keitaro Sofue, Eisuke Ueshima, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takamichi Murakami, Takumi Fukumoto

  AIM: The IMbrave150 trial revealed that atezolizumab plus bevacizumab (AtezoBv) showed a higher objective response rate (ORR) in patients with advanced hepatocellular carcinoma (HCC). Although conversion therapy after AtezoBv has been recently reported, markers predictive of its efficacy, particularly radiological imaging markers, have not yet been identified. The present study focused on tumor morphological appearance on radiological imaging and evaluated whether it could be associated with AtezoBv efficacy. METHODS: Ninety-five intrahepatic lesions in 74 patients who were given AtezoBv for advanced HCC were recruited for evaluation. The lesions were divided into two groups, simple nodular (SN group) and non-simple nodular (non-SN group), based on the gross morphology on pretreatment imaging, and retrospectively evaluated for treatment response and other relevant clinical outcomes. RESULTS: Assessing the size of individual tumors after treatment, waterfall plots showed that tumor shrinkage in the non-SN group including 56 lesions was higher than that in the SN group comprising 39 lesions. The ORR was significantly higher in the non-SN group (39.3% vs. 15.4%, p = 0.012). Additionally, the median time to nodular progression was longer in the non-SN group (21.0 months vs. 8.1 months, p = 0.119) compared to the SN group. Six patients with non-SN lesions underwent sequential local therapy. CONCLUSIONS: Atezolizumab plus bevacizumab may show increased therapeutic efficacy in patients with tumors with a higher potential for aggressive oncological behavior, such as non-SN lesions. Treatment strategies focusing on conversion therapy may be crucial in patients with non-SN lesions.

  Feb. 2024, Hepatology research : the official journal of the Japan Society of Hepatology, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Peroral Endoscopic Myotomy in Pediatric Patients with Achalasia up to 12 Years of Age: A Pilot Study in a Single-Center Experience in Japan.

  Yoshitomo Samejima, Shohei Yoshimura, Yuichi Okata, Hiroya Sakaguchi, Hirofumi Abe, Shinwa Tanaka, Yuzo Kodama, Yuko Bitoh

  INTRODUCTION:  Peroral endoscopic myotomy (POEM) is a minimally invasive endoscopic procedure for achalasia; its indication has expanded from adults to children. We aimed to evaluate the postoperative efficacy and antireflex status of POEM in young children with achalasia aged 12 years or younger. PATIENTS: AND METHODS:  Pediatric patients with achalasia aged 18 years or younger who underwent POEM in our hospital between 2016 and 2021 were included and divided into two age groups: group A (≤ 12 years) and group B (13-18 years). The success rate (Eckardt score ≤ 3), endoscopic reflux findings, and antiacid use at 1 year postoperatively were compared between the groups. RESULTS:  Ten patients (four boys and six girls; Chicago classification type I: five, type II: four, and unclassified: one) were included. Mean age and preoperative Eckardt scores in groups A (n = 4) and B (n = 6) were 9.2 ± 3.0 versus 15.6 ± 0.6 years (p = 0.001) and 5.5 ± 3.9 versus 7.2 ± 3.7 (p = 0.509), respectively, and mean operative time and myotomy length were 51.3 ± 16.6 versus 52.5 ± 13.2 minutes (p = 0.898) and 10.8 ± 4.6 versus 9.8 ± 3.2 cm (p = 0.720), respectively. The 1-year success rate was 100% in both groups. Mild esophagitis (Los Angeles classification B) was endoscopically found in one patient in each group (16.7 vs. 25.0%, p = 0.714), and antiacid use was required in three patients (group A, two; group B, one; 50.0 vs. 16.7%, p = 0.500). CONCLUSION:  The success rate of POEM within 1 year in young children with achalasia aged 12 years or younger was equal to that in adolescent patients. However, young children tended to require antiacids 1 year postoperatively; therefore, long-term follow-up is necessary.

  Feb. 2024, European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie, 34(1) (1), 97 - 101, English, International magazine

  Scientific journal


• Relapse and side effects of steroid therapy beyond 3 years in autoimmune pancreatitis: A multicenter retrospective study.

  Masahiro Tsujimae, Atsuhiro Masuda, Megumi Takagi, Takao Kato, Ryota Nakano, Koichi Fujita, Yuichi Hirata, Saori Kakuyama, Keisuke Furumatsu, Takashi Nakagawa, Kyohei Ogisu, Seiji Fujigaki, Takao Iemoto, Takeshi Ezaki, Yosuke Yagi, Takuya Ikegawa, Kodai Yamanaka, Yu Sato, Noriko Juri, Takashi Kobayashi, Arata Sakai, Hideyuki Shiomi, Tsuyoshi Sanuki, Yoshifumi Arisaka, Yoshihiro Okabe, Yuzo Kodama

  BACKGROUND: The impact of extended steroid administration on patients with autoimmune pancreatitis after a 3-year maintenance period remains poorly understood. This study analyzed the advantage and disadvantage of continuing steroid therapy beyond 3 years. METHODS: In this retrospective multicenter study across 17 institutions, patients who successfully completed 3 years of maintenance therapy without experiencing relapse were categorized into two groups: the maintenance therapy discontinuation group, who discontinued steroid therapy after the initial 3-year period, and maintenance therapy continuation group, who continued steroid therapy beyond 3 years. The cumulative relapse rate after 3 years of maintenance therapy was the primary outcome. Relapse predictors were compared using the Gray test for cumulative relapse incidence by specific factor. RESULTS: Of 211 patients, 105 experienced no relapse during the 3-year maintenance therapy and were divided into two groups: 69 in the maintenance therapy discontinuation group and 36 in the maintenance therapy continuation group. The relapse rate was lower in the maintenance therapy continuation group than in the maintenance therapy discontinuation group (P = 0.035). Predictors of relapse after 3 years included cessation of maintenance therapy (hazard ratio [HR] = 3.76; 95 % confidence interval [CI] = 1.07-13.3, P = 0.040) and renal involvement (HR = 2.88; 95 % CI = 1.04-7.99, P = 0.042). The maintenance therapy continuation group showed a significantly higher prevalence of macrovascular complications, compared with the maintenance therapy discontinuation group (P = 0.005). CONCLUSIONS: Cessation of steroid maintenance therapy and renal involvement were predictors of relapse after 3 years of maintenance therapy. However, the long-term use of steroids may increase the risk of macrovascular complications.

  Jan. 2024, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], English, International magazine

  Scientific journal


• Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma.

  Shohei Abe, Atsuhiro Masuda, Tomonori Matsumoto, Jun Inoue, Hirochika Toyama, Arata Sakai, Takashi Kobayashi, Takeshi Tanaka, Masahiro Tsujimae, Kohei Yamakawa, Masanori Gonda, Shigeto Masuda, Hisahiro Uemura, Shinya Kohashi, Noriko Inomata, Kae Nagao, Yoshiyuki Harada, Mika Miki, Yosuke Irie, Noriko Juri, Testuhisa Ko, Yusuke Yokotani, Yuki Oka, Shogo Ota, Maki Kanzawa, Tomoo Itoh, Toshio Imai, Takumi Fukumoto, Eiji Hara, Yuzo Kodama

  BACKGROUND: Recent evidence suggests that the presence of microbiome within human pancreatic ductal adenocarcinoma (PDAC) tissue potentially influences cancer progression and prognosis. However, the significance of tumor-resident microbiome remains unclear. We aimed to elucidate the impact of intratumoral bacteria on the pathophysiology and prognosis of human PDAC. METHODS: The presence of intratumoral bacteria was assessed in 162 surgically resected PDACs using quantitative polymerase chain reaction (qPCR) and in situ hybridization (ISH) targeting 16S rRNA. The intratumoral microbiome was explored by 16S metagenome sequencing using DNA extracted from formalin-fixed paraffin-embedded tissues. The profile of intratumoral bacteria was compared with clinical information, pathological findings including tumor-infiltrating T cells, tumor-associated macrophage, fibrosis, and alterations in four main driver genes (KRAS, TP53, CDKN2A/p16, SMAD4) in tumor genomes. RESULTS: The presence of intratumoral bacteria was confirmed in 52 tumors (32%) using both qPCR and ISH. The 16S metagenome sequencing revealed characteristic bacterial profiles within these tumors, including phyla such as Proteobacteria and Firmicutes. Comparison of bacterial profiles between cases with good and poor prognosis revealed a significant positive correlation between a shorter survival time and the presence of anaerobic bacteria such as Bacteroides, Lactobacillus, and Peptoniphilus. The abundance of these bacteria was correlated with a decrease in the number of tumor-infiltrating T cells positive for CD4, CD8, and CD45RO. CONCLUSIONS: Intratumoral infection of anaerobic bacteria such as Bacteroides, Lactobacillus, and Peptoniphilus is correlated with the suppressed anti-PDAC immunity and poor prognosis.

  Jan. 2024, Journal of gastroenterology, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Maintenance steroid therapy is associated with decreased risk of malignancy and better prognosis of patients with autoimmune pancreatitis: A multicenter cohort study in Japan.

  Tetsuya Takikawa, Kazuhiro Kikuta, Takanori Sano, Tsukasa Ikeura, Nao Fujimori, Takeji Umemura, Itaru Naitoh, Hiroshi Nakase, Hiroyuki Isayama, Atsushi Kanno, Ken Kamata, Yuzo Kodama, Dai Inoue, Akio Ido, Toshiharu Ueki, Hiroshi Seno, Hiroaki Yasuda, Eisuke Iwasaki, Takayoshi Nishino, Kensuke Kubota, Toshihiko Arizumi, Atsushi Tanaka, Kazushige Uchida, Ryotaro Matsumoto, Shin Hamada, Seiji Nakamura, Kazuichi Okazaki, Yoshifumi Takeyama, Atsushi Masamune

  BACKGROUND/OBJECTIVES: The association between autoimmune pancreatitis (AIP) and pancreatic cancer (PC) remains controversial. This study aimed to clarify the long-term prognosis and risk of malignancies in AIP patients in Japan. METHODS: We conducted a multicenter retrospective cohort study on 1364 patients with type 1 AIP from 20 institutions in Japan. We calculated the standardized incidence ratio (SIR) for malignancies compared to that in the general population. We analyzed factors associated with overall survival, pancreatic exocrine insufficiency, diabetes mellitus, and osteoporosis. RESULTS: The SIR for all malignancies was increased (1.21 [95 % confidence interval: 1.05-1.41]) in patients with AIP. Among all malignancies, the SIR was highest for PC (3.22 [1.99-5.13]) and increased within 2 years and after 5 years of AIP diagnosis. Steroid use for ≥6 months and ≥50 months increased the risk of subsequent development of diabetes mellitus and osteoporosis, respectively. Age ≥65 years at AIP diagnosis (hazard ratio [HR] = 3.73) and the development of malignancies (HR = 2.63), including PC (HR = 7.81), were associated with a poor prognosis, whereas maintenance steroid therapy was associated with a better prognosis (HR = 0.35) in the multivariate analysis. Maintenance steroid therapy was associated with a better prognosis even after propensity score matching for age and sex. CONCLUSIONS: Patients with AIP are at increased risk of developing malignancy, especially PC. PC is a critical prognostic factor for patients with AIP. Although maintenance steroid therapy negatively impacts diabetes mellitus and osteoporosis, it is associated with decreased cancer risk and improved overall survival.

  Jan. 2024, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], English, International magazine

  Scientific journal


• 胆膵内視鏡のトラブルシューティング 悪性遠位胆管狭窄に対する金属ステント留置における急性膵炎

  横谷 勇佑, 小林 隆, 増田 充弘, 酒井 新, 田中 雄志, 辻前 正弘, 児玉 裕三

  日本消化器病学会-近畿支部, Jan. 2024, 日本消化器病学会近畿支部例会プログラム・抄録集, 120回, 70 - 70, Japanese


• Needle-tract seeding following endoscopic ultrasound-guided fine-needle aspiration using a 25G needle for pancreatic tail cancer.

  Yosuke Irie, Arata Sakai, Takashi Kobayashi, Atsuhiro Masuda, Maki Kanzawa, Hirochika Toyama, Yuzo Kodama

  Jan. 2024, Journal of medical ultrasonics (2001), 51(1) (1), 143 - 144, English, Domestic magazine

  Scientific journal


• Peroral endoscopic myotomy for a pediatric case of suspected congenital esophageal stenosis

  Hirofumi Abe, Douglas Motomura, Shinwa Tanaka, Hiroya Sakaguchi, Hiroshi Tanabe, Hitomi Hori, Takashi Toyonaga, Yuzo Kodama

  Dec. 2023, VideoGIE

  [Refereed]

  Scientific journal


• A novel strategy facilitating endoscopic submucosal dissection of proximal colonic lesions: the rubber band and sheath method.

  Hirofumi Abe, Takashi Toyonaga, Douglas Motomura, Ryosuke Ishida, Hiroya Sakaguchi, Tetsuya Yoshizaki, Yuzo Kodama

  Dec. 2023, Endoscopy, 55(S 01) (S 01), E672-E673, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis.

  Haruka Miyazaki, Namiko Hoshi, Tsukasa Ishida, Chiharu Nishioka, Sachiko Ouchi, Daisuke Shirasaka, Tomoo Yoshie, Yoshinori Munetomo, Yoshio Sakamoto, Tatsuya Osuga, Saori Matsui, Toshiki Hyodo, Tamami Denda, Daisuke Watanabe, Makoto Ooi, Yuzo Kodama

  Not all patients with ulcerative colitis (UC) respond initially to treatment with biologic agents, and predicting their efficacy prior to treatment is difficult. Vedolizumab, a humanized monoclonal antibody against alpha 4 beta 7 (α4β7) integrin, suppresses immune cell migration by blocking the interaction between α4β7 integrin and mucosal addressin cell adhesion molecule 1. Reports about histological features that predict vedolizumab efficacy are scarce. So, we examined the association between histological features and vedolizumab efficacy. This was a multicenter, retrospective study of patients with UC treated with vedolizumab. Biopsy specimens taken from the colonic mucosa prior to vedolizumab induction were used, and the areas positively stained for CD4, CD68, and CD45 were calculated. Clinical and histological features were compared between those with and without remission at week 22, and the factors associated with clinical outcomes were identified. We enrolled 42 patients. Patients with a high CD4+ infiltration showed a better response to vedolizumab [odds ratio (OR) = 1.44, P = 0.014]. The concomitant use of corticosteroids and high Mayo scores had a negative association with the vedolizumab response (OR = 0.11, P = 0.008 and OR = 0.50, P = 0.009, respectively). Histological evaluation for CD4+ cell infiltration may be helpful in selecting patients who can benefit from vedolizumab.

  Nov. 2023, Scientific reports, 13(1) (1), 20262 - 20262, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Outcomes of endoscopic submucosal dissection for esophageal cancer with segmental absence of intestinal musculature.

  Tetsuya Yoshizaki, Yoshinobu Yamamoto, Tomoya Sako, Yasuaki Kitamura, Takayuki Ose, Tsukasa Ishida, Atsushi Ikeda, Ryusuke Ariyoshi, Mineo Iwatate, Fumiaki Kawara, Shinwa Tanaka, Toshitatsu Takao, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama

  BACKGROUND AND AIMS: Perforation during esophageal endoscopic submucosal dissection (ESD) typically results from electrical damage. However, there are cases in which perforation occurs due to segmental absence of intestinal musculature (SAIM) without iatrogenic muscular injury. We investigated the occurrence rate and clinical course of SAIM during esophageal ESD. METHODS: We conducted a retrospective review of esophageal ESDs performed between 2013 and 2019 in 10 centers in Japan. RESULTS: Five of 1708 patients (0.29%) received ESD for esophageal cancer and had SAIM. The median muscular defect size was 20 mm. All lesions were resected without discontinuation. After resection, three patients were closed with Endoloop. Four patients had mediastinal emphysema. All patients were managed conservatively. CONCLUSIONS: SAIM is a very rare condition, which is usually only diagnosed during ESD. Physicians performing esophageal ESD should be aware about SAIM. When SAIM is detected, the ESD technique should be modified to prevent full-thickness perforation.

  Nov. 2023, Gastrointestinal endoscopy, English, International magazine

  Scientific journal


• 経口胆道鏡が有用であった胆嚢管癌の一例

  芦崎 理沙, 田中 雄志, 横谷 勇佑, 岡 勇樹, 權田 真知, 辻前 正弘, 小林 隆, 酒井 新, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Nov. 2023, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 111回, 109 - 109, Japanese


• Metabolic Syndrome Accelerates the Age-Related Increase of Intraductal Papillary Mucinous Neoplasm of the Pancreas.

  Shunta Tanaka, Masahiro Tsujimae, Atsuhiro Masuda, Jun Inoue, Noriko Inomata, Hisahiro Uemura, Shinya Kohashi, Kae Nagao, Shigeto Masuda, Shohei Abe, Masanori Gonda, Kohei Yamakawa, Shigeto Ashina, Ryota Nakano, Takeshi Tanaka, Yasutaka Yamada, Arata Sakai, Takashi Kobayashi, Hideyuki Shiomi, Koichi Fujita, Takahiro Anami, Tsuyoshi Fujita, Akihiko Watanabe, Yuzo Kodama

  OBJECTIVES: Aging is associated with a high prevalence of pancreatic cysts and intraductal papillary mucinous neoplasms (IPMNs). Metabolic syndrome (MS) may increase the risk of neoplasms, including those that develop in the pancreas. However, the influence of factors associated with MS on the development of IPMN remains unclear. METHODS: A total of 9363 patients who underwent abdominal ultrasound examinations between April 2012 and May 2013 were included in this study. Multivariate logistic regression analysis was performed to identify factors associated with the presence of IPMN by age. RESULTS: Pancreatic cysts were detected in 198 of 9363 patients, of whom 129 were found to have IPMNs. The presence of IPMN significantly correlated with age (10-year increments; odds ratio, 2.73; 95% CI, 2.28-3.29; P < 0.001). High body mass index, history of smoking, hyperlipidemia, hypertension, and MS were associated with a higher prevalence of IPMN with advancing age. In multivariate analysis, the presence of IPMN was more frequent in elderly patients with MS (odds ratio, 3.14; 95% CI, 3.14-6.72; P = 0.003). CONCLUSIONS: The present study suggests that the incidence of IPMN increases with age and is accelerated in the presence of MS.

  Oct. 2023, Pancreas, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn's disease in Japan.

  Haruka Miyazaki, Daisuke Watanabe, Yuki Ito, Sayaka Ikeda, Norihiro Okamoto, Eri Tokunaga, Yuna Ku, Makoto Ooi, Namiko Hoshi, Yuzo Kodama

  BACKGROUND/PURPOSE OF THIS STUDY: It has been recommended that individuals with inflammatory bowel disease (IBD) be vaccinated against Coronavirus disease - 19 (COVID-19). Recently, we documented the incidence of side effects (SEs) after COVID-19 immunization among individuals with IBD in Japan. However, the study did not show differences between the types of IBD or the patients' clinical backgrounds. In this survey, we aimed at investigating whether the frequency of SEs differed among patients with IBD. METHODS: A cross-sectional survey was conducted among adult patients with IBD at Kobe University between March 2022 and September 2022. RESULTS: Total 195 patients, including 134 with ulcerative colitis (UC) and 61 with Crohn's disease (CD), completed the questionnaire and were included in the analysis. Of these, 92.3%, 91.3% and 44.1% received the initial, second and third dose of the COVID-19 vaccine, respectively. The frequency of local symptoms following the initial, second and third dose of the vaccine was comparable between patients with UC and CD (69.6% vs. 72.7%, 64.2% vs. 69.1% and 63.5% vs. 73.9%, respectively). Muscle pain after the initial and second doses of the COVID-19 vaccine was more common among patients treated with corticosteroids (58.1% vs. 37.6% and 60.0% vs. 31.8%, p < 0.05). Female sex, younger age and current or former smoking were associated with an increased incidence of fever or chills after the initial dose of the vaccine (p < 0.05). In contrast, corticosteroid use was identified as a factor associated with an increased incidence of muscle pain after the initial dose of vaccine (p < 0.05). CONCLUSION: The use of corticosteroids could increase the risk of muscle pain following COVID-19 vaccination. Additionally, factors such as female sex, younger age and current or former smoking can affect the incidence of fever or chills. This information should encourage patients with IBD to get vaccinated against COVID-19.

  Oct. 2023, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 42(5) (5), 701 - 707, English, International magazine

  Scientific journal


• Use of Peroral Pancreatoscopy in the Diagnosis of Elusive Intraductal Papillary Mucinous Neoplasm With High-Grade Dysplasia.

  Mabel Angela T Sarita, Arata Sakai, Masahiro Tsujimae, Takashi Kobayashi, Atsuhiro Masuda, Maki Kanzawa, Hirochika Toyama, Yuzo Kodama

  Intraductal papillary mucinous neoplasm (IPMN) is a premalignant lesion of the pancreas that can occasionally manifest as recurrent acute pancreatitis. In this report, we discuss a unique case of a 49-year-old woman who presented with recurrent acute pancreatitis of an unknown cause for several years. Workup using peroral pancreatoscopy eventually showed main-duct IPMN with high-grade dysplasia as the obscure cause of recurrent acute pancreatitis. This case report highlights the clinical course of main-duct IPMN and the evolving role of peroral pancreatoscopy in patients with recurrent acute pancreatitis.

  Oct. 2023, ACG case reports journal, 10(10) (10), e01165, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• Histological diagnosis of polyploidy discriminates an aggressive subset of hepatocellular carcinomas with poor prognosis.

  Takanori Matsuura, Yoshihide Ueda, Yoshiyuki Harada, Kazuki Hayashi, Kisara Horisaka, Yoshihiko Yano, Shinichi So, Masahiro Kido, Takumi Fukumoto, Yuzo Kodama, Eiji Hara, Tomonori Matsumoto

  BACKGROUND: Although genome duplication, or polyploidization, is believed to drive cancer evolution and affect tumor features, its significance in hepatocellular carcinoma (HCC) is unclear. We aimed to determine the characteristics of polyploid HCCs by evaluating chromosome duplication and to discover surrogate markers to discriminate polyploid HCCs. METHODS: The ploidy in human HCC was assessed by fluorescence in situ hybridization for multiple chromosomes. Clinicopathological and expression features were compared between polyploid and near-diploid HCCs. Markers indicating polyploid HCC were explored by transcriptome analysis of cultured HCC cells. RESULTS: Polyploidy was detected in 36% (20/56) of HCCs and discriminated an aggressive subset of HCC that typically showed high serum alpha-fetoprotein, poor differentiation, and poor prognosis compared to near-diploid HCCs. Molecular subtyping revealed that polyploid HCCs highly expressed alpha-fetoprotein but did not necessarily show progenitor features. Histological examination revealed abundant polyploid giant cancer cells (PGCCs) with a distinct appearance and frequent macrotrabecular-massive architecture in polyploid HCCs. Notably, the abundance of PGCCs and overexpression of ubiquitin-conjugating enzymes 2C indicated polyploidy in HCC and efficiently predicted poor prognosis in combination. CONCLUSIONS: Histological diagnosis of polyploidy using surrogate markers discriminates an aggressive subset of HCC, apart from known HCC subgroups, and predict poor prognosis in HCC.

  Sep. 2023, British journal of cancer, 129(8) (8), 1251 - 1260, English, International magazine

  Scientific journal


• 膵癌の腫瘍間質膠原線維量と分子病理学的特徴、腫瘍免疫、予後との関連性(Association of Tumor-Stromal Collagen Quantity in PDAC with Molecular Pathology, Tumor Immunity, and Prognosis)

  重里 徳子, 増田 充弘, 芦名 茂人, 辻前 正弘, 田中 雄志, 原田 宜幸, 酒井 新, 小林 隆, 児玉 裕三

  (一社)日本癌学会, Sep. 2023, 日本癌学会総会記事, 82回, 1929 - 1929, English


• 同時性・異時性多発膵癌のクローン起源について(Clonal origin of synchronous or metachronous multiple pancreatic cancers)

  平野 智紀, 垣内 伸之, 竹内 康英, 増井 俊彦, 白石 友一, 宮野 悟, 宇座 徳光, 児玉 裕三, 増田 充弘, 田中 雄志, 妹尾 浩, 小川 誠司

  (一社)日本癌学会, Sep. 2023, 日本癌学会総会記事, 82回, 1993 - 1993, English


• ARF6-AMAP1経路は免疫抑制性ケモカインの発現を誘導し、免疫回避に有利に機能する(ARF6-AMAP1 pathway is linked to induction of immunosuppressive chemokine expression for favor immune evasion)

  橋本 あり, 半田 悠, 畑 宗一郎, 奥崎 大介, 麓 佳月, 蔦保 暁生, 西川 義浩, 児玉 裕三, 平野 聡, 橋本 茂, 佐邊 壽孝

  (一社)日本癌学会, Sep. 2023, 日本癌学会総会記事, 82回, 1922 - 1922, English


• 【膵臓がん研究の最前線】膵がんにおけるRARγを介したシグナルの機能 細胞の系統決定に着目した膵がん研究

  山川 康平, 二井 諒子, 児玉 裕三, 青井 貴之

  (株)北隆館, Sep. 2023, BIO Clinica, 38(10) (10), 824 - 828, Japanese


• Assessment of predictive factors associated with the technical difficulty of endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma: Japanese multicenter retrospective study.

  Yoshinobu Yamamoto, Tetsuya Yoshizaki, Saeko Kushida, Shinwa Tanaka, Takayuki Ose, Tsukasa Ishida, Yasuaki Kitamura, Tomoya Sako, Mineo Iwatate, Atsushi Ikeda, Ryusuke Ariyoshi, Fumiaki Kawara, Hirofumi Abe, Toshitatsu Takao, Yoshinori Morita, Yasushi Sano, Eiji Umegaki, Hogara Nishisaki, Takashi Toyonaga, Yuzo Kodama

  OBJECTIVES: Endoscopic submucosal dissection (ESD) for superficial esophageal squamous cell carcinoma (ESCC) is performed for the treatment of lesions with varied backgrounds and factors. However, the predictive factors associated with the technical difficulty of ESD remain unknown in patients with varied lesions. Therefore, this study aimed to identify the predictive factors associated with the technical difficulty of ESD for ESCC using a retrospective cohort. METHODS: This multicenter, retrospective study was conducted in 10 hospitals in Japan. Consecutive patients who underwent esophageal ESD between January 2013 and December 2019 were enrolled. Lesions of subepithelial tumors, adenocarcinoma, and adenoma were excluded. Difficult lesions were defined as ESD requiring a long procedure time (≥120 min), perforation development, piecemeal resection, or discontinued ESD. In the present study, the clinical factors were assessed to identify the technical difficulty of ESD using univariate and multivariate analyses. RESULTS: Among 1708 lesions treated with esophageal ESD, eight subepithelial tumors, 44 adenocarcinomas, and two adenomas were excluded. Finally, 1505 patients with 1654 lesions were analyzed, and 217 patients with 217 lesions (13.1%) were classified as patients with difficult lesions. In multivariate analysis, the predictive factors associated with the technical difficulty of ESD were as follows: tumors with varices, tumors with diverticulum, antiplatelet use (discontinued), circumference of tumor (≥1/2), preoperative tumor size ≥30 mm, trainee, and nonhigh-volume center. CONCLUSION: This multicenter retrospective study identified the predictive factors associated with the technical difficulty of ESD for ESCC with varied backgrounds and factors.

  Aug. 2023, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, English, International magazine

  Scientific journal


• Anti-integrin αvβ6 autoantibodies in patients with primary sclerosing cholangitis.

  Hiroyuki Yoshida, Masahiro Shiokawa, Takeshi Kuwada, Yuya Muramoto, Sakiko Ota, Yoshihiro Nishikawa, Hirona Maeda, Nobuyuki Kakiuchi, Kanako Okamoto, Hajime Yamazaki, Masataka Yokode, Takeharu Nakamura, Shimpei Matsumoto, Tomonori Hirano, Hirokazu Okada, Saiko Marui, Yuko Sogabe, Tomoaki Matsumori, Atsushi Mima, Norimitsu Uza, Yuji Eso, Atsushi Takai, Ken Takahashi, Yoshihide Ueda, Yuzo Kodama, Tsutomu Chiba, Hiroshi Seno

  BACKGROUND: Patients with primary sclerosing cholangitis (PSC) possess autoantibodies against biliary epithelial cells. However, the target molecules remain unknown. METHODS: The sera of patients with PSC and controls were subjected to enzyme-linked immunosorbent assays to detect autoantibodies using recombinant integrin proteins. Integrin αvβ6 expression in the bile duct tissues was examined using immunofluorescence. The blocking activity of the autoantibodies was examined using solid-phase binding assays. RESULTS: Anti-integrin αvβ6 antibodies were detected in 49/55 (89.1%) patients with PSC and 5/150 (3.3%) controls (P < 0.001), with a sensitivity and specificity of 89.1% and 96.7%, respectively, for PSC diagnosis. When focusing on the presence or absence of IBD, the proportion of the positive antibodies in PSC with IBD was 97.2% (35/36) and that in PSC alone was 73.7% (14/19) (P = 0.008). Integrin αvβ6 was expressed in bile duct epithelial cells. Immunoglobulin (Ig)G from 15/33 patients with PSC blocked integrin αvβ6-fibronectin binding through an RGD (Arg-Gly-Asp) tripeptide motif. CONCLUSIONS: Autoantibodies against integrin αvβ6 were detected in most patients with PSC; anti-integrin αvβ6 antibody may serve as a potential diagnostic biomarker for PSC.

  Aug. 2023, Journal of gastroenterology, 58(8) (8), 778 - 789, English, Domestic magazine

  Scientific journal


• Benefits of pancreatic parenchymal endoscopic ultrasonography in predicting microscopic precancerous lesions of pancreatic cancer.

  Kohei Yamakawa, Noriko Inomata, Atsuhiro Masuda, Mamoru Takenaka, Hirochika Toyama, Keitaro Sofue, Arata Sakai, Takashi Kobayashi, Takeshi Tanaka, Masahiro Tsujimae, Shigeto Ashina, Masanori Gonda, Shohei Abe, Shigeto Masuda, Hisahiro Uemura, Shinya Kohashi, Kae Nagao, Yoshiyuki Harada, Mika Miki, Yosuke Irie, Noriko Juri, Hideyuki Shiomi, Maki Kanzawa, Tomoo Itoh, Takumi Fukumoto, Yuzo Kodama

  Pancreatic cancer primarily arises from microscopic precancerous lesions, such as pancreatic intraepithelial neoplasia (PanIN) and acinar-to-ductal metaplasia (ADM). However, no established method exists for predicting pancreatic precancerous conditions. Endoscopic ultrasonography (EUS) can detect changes in pancreatic parenchymal histology, including fibrosis. This study aimed to elucidate the relationship between pancreatic parenchymal EUS findings and microscopic precancerous lesions. We retrospectively analyzed 114 patients with pancreatobiliary tumors resected between 2010 and 2020 and evaluated the association between pancreatic parenchymal EUS findings and the number of PanIN, ADM, and pancreatic duct gland (PDG). Of the 114 patients, 33 (29.0%), 55 (48.2%), and 26 (22.8%) had normal EUS findings, hyperechoic foci/stranding without lobularity, and hyperechoic foci/stranding with lobularity, respectively. Multivariate analyses revealed that abnormal EUS findings were significantly associated with the frequency of PanIN (hyperechoic foci/stranding without lobularity: OR [95% CI] = 2.7 [1.0-7.3], with lobularity: 6.5 [1.9-22.5], Ptrend = 0.01) and ADM (hyperechoic foci/stranding without lobularity: 3.1 [1.1-8.2], with lobularity: 9.7 [2.6-36.3], Ptrend = 0.003) but not with PDG (hyperechoic foci/stranding without lobularity: 2.2 [0.8-5.8], with lobularity: 3.2 [1.0-10.2], Ptrend = 0.12). We observed a trend toward a significantly higher number of precancerous lesions in the following order: normal findings, hyperechoic foci/stranding without lobularity, and hyperechoic foci/stranding with lobularity. Pancreatic parenchymal EUS findings were associated with the increased frequency of PanIN and ADM. Lobularity may help predict the increased number of precancerous lesions.

  Jul. 2023, Scientific reports, 13(1) (1), 12052 - 12052, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma.

  Shigeto Ashina, Atsuhiro Masuda, Kohei Yamakawa, Tsuyoshi Hamada, Masahiro Tsujimae, Takeshi Tanaka, Hirochika Toyama, Keitaro Sofue, Hideyuki Shiomi, Arata Sakai, Takashi Kobayashi, Shohei Abe, Masanori Gonda, Shigeto Masuda, Noriko Inomata, Hisahiro Uemura, Shinya Kohashi, Kae Nagao, Yoshiyuki Harada, Mika Miki, Noriko Juri, Yosuke Irie, Maki Kanzawa, Tomoo Itoh, Jun Inoue, Toshio Imai, Takumi Fukumoto, Yuzo Kodama

  BACKGROUND: Abundant collagen deposition is a hallmark of pancreatic ductal adenocarcinomas (PDACs). This study clarified the interactive relationship between tumor-stromal collagen, molecular and immune characteristics, and tumor pr ogression in human PDAC. METHODS: We performed a comprehensive examination using an integrative molecular pathological epidemiology database on 169 cases with resected PDAC . The amount of tumor-stromal collagen was quantified through digital imaging analysis for Elastica van Gieson-stained whole-section tumor slides. We analyzed the association of tumor-stromal collagen with gene alterations (KRAS, TP53, CDKN2A/p16, and SMAD4), immune parameters (CD4+ tumor-infiltrating lymphocytes [TILs], CD8+ TILs, FOXP3+ TILs, and tertiary lymphoid structures), and patient prognosis. RESULTS: Low amounts of tumor-stromal collagen were associated with poor differentiation (multivariable OR = 3.82, 95%CI = 1.41-12.2, P = 0.008) and CDKN2A/p16 alteration (OR [95%CI] = 2.06 [1.08-4.02], P = 0.03). Tumors with low collagen levels had shorter overall survival (HR [95%CI] = 2.38 [1.59-3.56], P < 0.0001). In the S-1 and gemcitabine (GEM) treatment groups, low tumor-stromal collagen was linked to poor prognosis of patients with PDAC (S-1 group: multivariable HR [95%CI] = 2.76 [1.36-5.79], P = 0.005; GEM group: multivariate HR [95%CI] = 2.91 [1.34-6.71], P = 0.007). Additionally, low amounts of tumor-stromal collagen were also linked to low levels of CD4+ TILs (P = 0.046), CD8+ TILs (P = 0.09), and tertiary lymphoid structures (P = 0.001). CONCLUSIONS: Tumor-stromal collagen deposition may play a crucial role in modulating tumor-immune microenvironment and determining response to adjuvant chemotherapy and patient survival outcomes.

  Jul. 2023, Journal of gastroenterology, 58(10) (10), 1055 - 1067, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Factors Associated with Overlap between Functional Dyspepsia and Nonerosive Reflux Disease in Endoscopy-based Helicobacter pylori-uninfected Japanese Health Checkup Participants: A Prospective, Multicenter Cross-sectional Study.

  Tsuyoshi Fujita, Eiji Umegaki, Atsuhiro Masuda, Masao Kobayashi, Yukinao Yamazaki, Shuichi Terao, Tsuyoshi Sanuki, Akihiko Okada, Manabu Murakami, Akihiko Watanabe, Daisuke Obata, Hayato Yoshinaka, Hiromu Kutsumi, Takeshi Azuma, Yuzo Kodama

  Objective We assessed the factors associated with overlap between functional dyspepsia (FD) and nonerosive reflux disease (NERD) in endoscopy-based Helicobacter pylori-uninfected Japanese health checkup participants. Methods We utilized baseline data from 3,085 individuals who underwent upper endoscopy for health screening in a prospective, multicenter cohort study. The participants were asked to complete a questionnaire detailing their upper abdominal symptoms and lifestyle. Anxiety was assessed using the State-Trait Anxiety Inventory (STAI) score. FD, postprandial distress syndrome (PDS), and epigastric pain syndrome (EPS) were defined according to the Rome III criteria. NERD was defined as heartburn or regurgitation ≥1 day/week without erosive esophagitis. Results Of the 3,085 participants, 73 (2.4%), 97 (3.1%), and 84 (2.7%) had FD alone, NERD alone, and FD-NERD overlap, respectively. Factors associated with FD-NERD-overlap participants compared with participants with neither FD nor NERD were women [odds ratio (OR): 2.08, 95% confidence interval (CI) 1.24-3.52], body mass index (BMI) <18.5 (OR: 2.87, 95% CI: 1.56-5.07), alcohol consumption ≥20 g/day (OR: 1.85, 95% CI: 1.06-3.15), and a high STAI score (OR: 2.53, 95% CI: 1.62-4.00). Increasing age (OR: 1.06, 95% CI: 1.01-1.11) and EPS symptoms [pure EPS (OR: 3.67, 95% CI: 1.65-8.51) and PDS-EPS overlap (OR: 11.6, 95% CI: 4.09-37.2)] were associated with FD-NERD overlap vs. FD alone. Women (OR: 3.17, 95% CI: 1.47-7.04), BMI <18.5 (OR: 3.03, 95% CI: 1.04-9.90), and acid reflux symptoms ≥2 days a week (OR: 3.57, 95% CI: 1.83-7.14) were associated with FD-NERD overlap vs. NERD alone. Conclusion Understanding the clinical features of overlap between FD and NERD will lead to better management.

  Jul. 2023, Internal medicine (Tokyo, Japan), English, Domestic magazine

  Scientific journal


• Biological and clinical significance of the YKL‐40/osteopontin–integrin β4–p70S6K axis induced by macrophages in early oesophageal squamous cell carcinoma

  Satoshi Urakami, Yu‐ichiro Koma, Shuichi Tsukamoto, Yuki Azumi, Shoji Miyako, Yu Kitamura, Takayuki Kodama, Mari Nishio, Manabu Shigeoka, Hirofumi Abe, Yu Usami, Yuzo Kodama, Hiroshi Yokozaki

  Abstract M2 macrophages contribute to the progression of oesophageal squamous cell carcinoma (ESCC); however, the roles of M2 macrophages in early ESCC remain unclear. To clarify the biological mechanisms underlying the interaction between M2 macrophages and oesophageal epithelial cells in early‐stage ESCC, in vitro co‐culture assays between the immortalised oesophageal epithelial cell line Het‐1A and cytokine‐defined M2 macrophages were established. Co‐culture with M2 macrophages promoted the proliferation and migration of Het‐1A cells via the mTOR–p70S6K signalling pathway activated by YKL‐40, also known as chitinase 3‐like 1, and osteopontin (OPN) that were hypersecreted in the co‐culture supernatants. YKL‐40 and OPN promoted the above phenotypes of Het‐1A by making a complex with integrin β4 (β4). Furthermore, YKL‐40 and OPN promoted M2 polarisation, proliferation, and migration of macrophages. To validate the pathological and clinical significances of in vitro experimental results, immunohistochemistry of human early ESCC tissues obtained by endoscopic submucosal dissection (ESD) was performed, confirming the activation of the YKL‐40/OPN–β4–p70S6K axis in the tumour area. Moreover, epithelial expression of β4 and the number of epithelial and stromal infiltrating YKL‐40‐ and OPN‐positive cells correlated with the Lugol‐voiding lesions (LVLs), a well‐known predictor of the incidence of metachronous ESCC. Furthermore, the combination of high expression of β4 and LVLs or high numbers of epithelial and stromal infiltrating YKL‐40‐ and OPN‐positive immune cells could more clearly detect the incidence of metachronous ESCC than each of the parameters alone. Our results demonstrated that the YKL‐40/OPN–β4–p70S6K axis played important roles in early‐stage ESCC, and the high expression levels of β4 and high numbers of infiltrating YKL‐40‐ and OPN‐positive immune cells could be useful predictive parameters for the incidence of metachronous ESCC after ESD. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

  Wiley, Jul. 2023, The Journal of Pathology

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 当院における早期膵癌の診療と膵癌精密検診の現状

  三木 美香, 酒井 新, 辻前 正弘, 田中 雄志, 小林 隆, 増田 充弘, 児玉 裕三

  (一社)日本膵臓学会, Jul. 2023, 膵臓, 38(3) (3), A369 - A369, Japanese


• Safety and efficacy of endoscopic submucosal dissection for superficial esophageal cancer with esophageal varices.

  Tatsuya Nakai, Tetsuya Yoshizaki, Shinwa Tanaka, Yoshinobu Yamamoto, Tomoya Sako, Yasuaki Kitamura, Takayuki Ose, Tsukasa Ishida, Atsushi Ikeda, Ryusuke Ariyoshi, Mineo Iwatate, Fumiaki Kawara, Toshitatsu Takao, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama

  BACKGROUND: Heavy drinking is associated with esophageal cancer and esophageal varices. However, there are limited reports of endoscopic resection for esophageal cancer with esophageal varices. In this multicenter study, we clarified the safety and efficacy of endoscopic submucosal dissection for superficial esophageal cancer with esophageal varices. METHODS: In this multicenter, retrospective, observational study, patients underwent esophageal endoscopic submucosal dissection at 10 referral centers in Japan from January 2013 to December 2019. We analyzed characteristics including backgrounds and varices, treatment outcomes, and adverse events in cases with esophageal varices. RESULTS: A total of 1708 patients were evaluated, 27 (1.6%) of whom had esophageal varices. In patients with esophageal varices, the en bloc resection rate and R0 resection rate were 100% and 77.8%, respectively. Patients with esophageal varices had longer procedure times than patients without esophageal varices (p = 0.015). There was no significant difference in adverse events. There was no significant difference in procedure time and number of adverse events between patients who underwent pretreatment and those who did not. There was no significant difference in these outcomes for patients with lesions on varices compared to those without. Child-Pugh classification and location of the lesions also did not affect these outcomes. CONCLUSIONS: Esophageal cancer with esophageal varices could be treated endoscopically safely and effectively.

  Jul. 2023, Esophagus : official journal of the Japan Esophageal Society, 20(3) (3), 515 - 523, English, Domestic magazine

  Scientific journal


• Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma.

  Yoshihiko Yano, Atsushi Yamamoto, Takuya Mimura, Saeko Kushida, Seiya Hirohata, Seitetsu Yoon, Hirotaka Hirano, Soo Ki Kim, Yuri Hatazawa, Kenji Momose, Hiroki Hayashi, Takuo Kado, Katsuhisa Nishi, Hidenori Tanaka, Takanori Matsuura, Ryutaro Yoshida, Naoki Asaji, Eiichiro Yasutomi, Yuuki Shiomi, Akihiro Minami, Shohei Komatsu, Takumi Fukumoto, Yoshihide Ueda, Yuzo Kodama

  BACKGROUND AND AIM: The purpose of this study was to analyze factors associated with the overall survival (OS) of atezolizumab/bevacizumab combination therapy for advanced hepatocellular carcinoma (aHCC). We also assessed the OS of patients with ineffective therapy and those who discontinued treatment owing to adverse events (AEs). METHODS: This retrospective multicenter study involved 139 patients with aHCC who received atezolizumab/bevacizumab combination therapy between November 2020 and September 2022. RESULTS: The median duration of treatment was 136.5 days, and the median observation period was 316 days. The overall response rate was 40%, and the disease control rate was 78% according to mRECIST criteria. Grade ≥2 AEs occurred in 63 patients (43%) and led to treatment discontinuation in 16 patients. Multivariate analysis revealed that treatment response and occurrence of grade ≥2 AEs after therapy, as well as low level of albumin-bilirubin (ALBI) grade and low level of des-gamma carboxy prothrombin (DCP) before therapy, were extracted as factors that contributed to OS. Log-rank tests with the Kaplan-Meier method showed significant differences in OS among these factors. The OS of patients who discontinued owing to AEs was significantly shorter than that of other patients. CONCLUSION: Not only factors before therapy but also treatment response and the appearance of AEs are involved in OS for atezolizumab/bevacizumab combination therapy. Although the development of AEs also contributed to OS, appropriate management of AEs is important to avoid discontinuing treatment with this combination.

  Jul. 2023, JGH open : an open access journal of gastroenterology and hepatology, 7(7) (7), 476 - 481, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway

  Takeharu Nakamura, Yoshihiro Nishikawa, Masahiro Shiokawa, Haruhiko Takeda, Masataka Yokode, Shimpei Matsumoto, Yuya Muramoto, Sakiko Ota, Hiroyuki Yoshida, Hirokazu Okada, Takeshi Kuwada, Saiko Marui, Tomoaki Matsumori, Takahisa Maruno, Norimitsu Uza, Yuzo Kodama, Etsuro Hatano, Hiroshi Seno

  Jun. 2023, The Journal of Pathology

  Scientific journal


• ASO Visual Abstract: Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma-A Retrospective Analysis.

  Shigeto Masuda, Kohei Yamakawa, Atsuhiro Masuda, Hirochika Toyama, Keitaro Sofue, Yoshihide Nanno, Shohei Komatsu, Satoshi Omiya, Arata Sakai, Takashi Kobayashi, Takeshi Tanaka, Masahiro Tsujimae, Shigeto Ashina, Masanori Gonda, Shohei Abe, Hisahiro Uemura, Shinya Kohashi, Noriko Inomata, Kae Nagao, Yoshiyuki Harada, Mika Miki, Yosuke Irie, Noriko Juri, Maki Kanzawa, Tomoo Itoh, Takumi Fukumoto, Yuzo Kodama

  Jun. 2023, Annals of surgical oncology, 30(9) (9), 5790 - 5791, English, International magazine

  Scientific journal


• 消化管腫瘍に対する内視鏡診療の現況と展望 食道内視鏡治療後の多発病変に対する再内視鏡治療困難症例の臨床的特徴

  石田 亮介, 吉崎 哲也, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jun. 2023, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 110回, 76 - 76, Japanese


• Long-Term Outcomes of Endoscopic Submucosal Dissection for Early Remnant Gastric Cancer: A Retrospective Multicenter Study.

  Kazunori Tsuda, Shinwa Tanaka, Tetsuya Yoshizaki, Yoshinobu Yamamoto, Takayuki Ose, Tsukasa Ishida, Yasuaki Kitamura, Daisuke Obata, Mineo Iwatate, Atsushi Ikeda, Ryusuke Ariyoshi, Fumiaki Kawara, Hiroshi Takihara, Hirofumi Abe, Toshitatsu Takao, Yoshinori Morita, Yasushi Sano, Eiji Umegaki, Hogara Nishisaki, Takashi Toyonaga, Yuzo Kodama

  INTRODUCTION: Favorable long-term outcomes of endoscopic submucosal dissection (ESD) for early remnant gastric cancer (ERGC) have been reported in single-center studies from advanced institutions. However, no studies have examined the long-term outcomes using a multicenter database. This study aimed to investigate the long-term outcomes of the aforementioned approach using a large multicenter database. METHODS: This retrospective multicenter cohort study included 242 cases with 256 lesions that underwent ESD for ERGC between April 2009 and March 2019 across 12 centers. We investigated the long-term outcomes of these patients with the Kaplan-Meier method, and the relationship between curability, additional treatment, or hospital category, and the survival time was evaluated using the log-rank test. RESULTS: During the median follow-up period of 48.4 months, the 5-year overall survival rate was 81.3%, and the 5-year gastric cancer-specific survival rate was 98.1%. The survival time of patients of endoscopic curability (eCura) C-2 without additional surgery was significantly shorter than the corresponding of patients of eCura A/B/C-1 and eCura C-2 with additional surgery. There was no significant difference in either overall survival or gastric cancer-specific survival rate between the high-volume and non-high-volume hospitals. CONCLUSION: The gastric cancer-specific survival of ESD for ERGC using a multicenter database was favorable. ESD for ERGC is widely applicable regardless of the hospital case volume. Management in accordance with the latest guidelines will lead to long-term survival.

  Jun. 2023, Digestion, 1 - 10, English, International magazine

  Scientific journal


• 【食道・胃・大腸癌の最新情報】胃癌 胃がん内視鏡治療の進歩

  阪口 博哉, 児玉 裕三, 掛地 吉弘

  大道学館出版部, Jun. 2023, 臨牀と研究, 100(6) (6), 694 - 698, Japanese


• A case of pancreatic ductal adenocarcinoma concomitant with IgG4-related disease in the pancreas and the stomach.

  Masanori Gonda, Takashi Kobayashi, Kenji Notohara, Shohei Abe, Kohei Yamakawa, Arata Sakai, Atsuhiro Masuda, Hirochika Toyama, Takumi Fukumoto, Yuzo Kodama

  A 75-year-old Japanese woman visited a hospital with a stomachache. The patient was diagnosed with localized mild acute pancreatitis. Blood tests revealed elevated serum IgG4 levels. Contrast-enhanced computed tomography showed a hypovascular mass, 3 cm in size, in the pancreatic body with dilation of the upstream duct. Additionally, it showed another tumorous lesion of 10 mm in size in the anterior wall of the stomach, and endoscopic examination confirmed a submucosal tumor (SMT) sized 10 mm in the anterior wall of the stomach. Endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) of the pancreas revealed an adenocarcinoma concomitant with marked IgG4-positive cell infiltration. Hence, distal pancreatectomy with local gastrectomy was performed, and the final diagnosis was concluded as pancreatic ductal adenocarcinoma (PDAC) complicated by IgG4-related diseases (IgG4-RD) in the pancreas and stomach. IgG4-RD of the digestive tract is exceedingly rare. The correlation between PDAC and autoimmune pancreatitis or malignancy and IgG4-RD is controversial. However, the clinical course and histopathological examination, in this case, provide valuable suggestive findings for further discussion.

  May 2023, Clinical journal of gastroenterology, 16(5) (5), 785 - 790, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Blockage of retinoic acid signaling via RARγ suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression of the G1-S phase

  Kohei Yamakawa, Michiyo Koyanagi-Aoi, Akihito Machinaga, Nobuyuki Kakiuchi, Tomonori Hirano, Yuzo Kodama, Takashi Aoi

  Abstract Background Our study and several studies have reported that in some cancers, including pancreatic ductal adenocarcinoma (PDAC), the expression of squamous lineage markers, such as esophagus-tissue-specific genes, correlated with a poor prognosis. However, the mechanism by which the acquisition of squamous lineage phenotypes leads to a poor prognosis remains unclear. We previously reported that retinoic acid signaling via retinoic acid receptor γ (RARγ signaling) determines the differentiation lineage into the esophageal squamous epithelium. These findings hypothesized that the activation of RARγ signaling contributed to acquiring squamous lineage phenotypes and malignant behavior in PDAC. Methods This study utilized public databases and immunostaining of surgical specimens to examine RARγ expression in PDAC. We evaluated the function of RARγ signaling by inhibitors and siRNA knockdown using a PDAC cell line and patient-derived PDAC organoids. The mechanism of the tumor-suppressive effects by blocking RARγ signaling was examined by a cell cycle analysis, apoptosis assays, RNA sequencing and Western blotting. Results RARγ expression in pancreatic intraepithelial neoplasia (PanIN) and PDAC was higher than that in the normal pancreatic duct. Its expression correlated with a poor patient prognosis in PDAC. In PDAC cell lines, blockade of RARγ signaling suppressed cell proliferation by inducing cell cycle arrest in the G1 phase without causing apoptosis. We demonstrated that blocking RARγ signaling upregulated p21 and p27 and downregulated many cell cycle genes, including cyclin-dependent kinase 2 (CDK2), CDK4 and CDK6. Furthermore, using patient-derived PDAC organoids, we confirmed the tumor-suppressive effect of RARγ inhibition and indicated the synergistic effects of RARγ inhibition with gemcitabine. Conclusions This study clarified the function of RARγ signaling in PDAC progression and demonstrated the tumor-suppressive effect of selective blockade of RARγ signaling against PDAC. These results suggest that RARγ signaling might be a new therapeutic target for PDAC.

  Springer Science and Business Media LLC, May 2023, Cancer Cell International, 23(1) (1)

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis.

  Shigeto Masuda, Kohei Yamakawa, Atsuhiro Masuda, Hirochika Toyama, Keitaro Sofue, Yoshihide Nanno, Shohei Komatsu, Satoshi Omiya, Arata Sakai, Takashi Kobayashi, Takeshi Tanaka, Masahiro Tsujimae, Shigeto Ashina, Masanori Gonda, Shohei Abe, Hisahiro Uemura, Shinya Kohashi, Noriko Inomata, Kae Nagao, Yoshiyuki Harada, Mika Miki, Yosuke Irie, Noriko Juri, Maki Kanzawa, Tomoo Itoh, Takumi Fukumoto, Yuzo Kodama

  BACKGROUND: Sarcopenia, defined as a loss of skeletal muscle mass and quality, is found in 30-65% of patients with pancreatic ductal adenocarcinoma (PDAC) at diagnosis, and is a poor prognostic factor. However, it is yet to be evaluated why sarcopenia is associated with poor prognosis. Therefore, this study elucidated the tumor characteristics of PDAC with sarcopenia, including driver gene alterations and tumor microenvironment. PATIENTS AND METHODS: We retrospectively analyzed 162 patients with PDAC who underwent pancreatic surgery between 2008 and 2017. We defined sarcopenia by measuring the skeletal muscle mass at the L3 level using preoperative computed tomography images and evaluated driver gene alteration (KRAS, TP53, CDKN2A/p16, and SMAD4) and tumor immune (CD4+, CD8+, and FOXP3+) and fibrosis status (stromal collagen). RESULTS: In localized-stage PDAC (stage ≤ IIa), overall survival (OS) and recurrence-free survival were significantly shorter in the sarcopenia group than in the non-sarcopenia group (2-year OS 89.7% versus 59.1%, P = 0.03; 2-year RFS 74.9% versus 50.0%, P = 0.02). Multivariate analysis revealed that sarcopenia was an independent poor prognostic factor in localized-stage PDAC. Additionally, tumor-infiltrating CD8+ T cells in the sarcopenia group were significantly less than in the non-sarcopenia group (P = 0.02). However, no difference was observed in driver gene alteration and fib.rotic status. These findings were not observed in advanced-stage PDAC (stage ≥ IIb). CONCLUSIONS: Sarcopenia was associated with a worse prognosis and decreased tumor-infiltrating CD8+ T cells in localized-stage PDAC. Sarcopenia may worsen a patient's prognosis by suppressing local tumor immunity.

  May 2023, Annals of surgical oncology, 30(9) (9), 5776 - 5787, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Disseminated Mycobacterium avium Complex Infection in a Patient Treated With Immunosuppressants.

  Yuki Ito, Daisuke Watanabe, Sayaka Ikeda, Norihiro Okamoto, Haruka Miyazaki, Eri Tokunaga, Yuna Ku, Makoto Ooi, Namiko Hoshi, Yuzo Kodama

  Mycobacterium avium complex (MAC) is an important cause of opportunistic infections in immunosuppressed hosts, such as patients with HIV infection and solid organ transplant recipients. MAC disease usually presents in 4 distinct clinical categories: chronic pulmonary disease, disseminated disease, skin/soft-tissue infection, and superficial lymphadenitis. However, clinical reports on gastrointestinal (GI) MAC disease are rare, especially in patients without HIV infection or a history of organ transplantation. We describe a case of non-HIV-associated GI MAC disease in a patient with long-term mycophenolate mofetil use. In this case, MAC organisms in the GI tract and ascites were observed. Endoscopy revealed a unique colonic image with large, deep epithelial denudations. This suggests that apart from patients with HIV infection or transplant recipients, those treated with immunosuppressants can have disseminated MAC. Therefore, internal physicians need to monitor patients undergoing mycophenolate mofetil immunosuppressant therapy.

  Apr. 2023, ACG case reports journal, 10(4) (4), e01033, English, International magazine


• 当院での虫垂開口部の大腸病変に対するESDの治療戦略と成績

  津田 一範, 吉崎 哲也, 豊永 高史, 永木 瑞穂, 石田 亮介, 堀 瞳, 高山 弘志, 上田 千勢, 阪口 博哉, 阿部 洋文, 池澤 伸明, 鷹尾 まど佳, 鷹尾 俊達, 森田 圭紀, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2023, Gastroenterological Endoscopy, 65(Suppl.1) (Suppl.1), 892 - 892, Japanese


• 消化器診療におけるAIの現状と展望 AIを用いた造影CTによる膵癌診断支援システムの構築

  祖父江 慶太郎, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2023, 日本消化器病学会雑誌, 120(臨増総会) (臨増総会), A36 - A36, Japanese


• Clinicopathological Features and the Prevalence of Oxyntic Gland Neoplasm: A Single-center Retrospective Study.

  Hikari Asahara, Toshitatsu Takao, Yumiko Asahara, Masakyo Asahara, Douglas Motomura, Hiroya Sakaguchi, Tetsuya Yoshizaki, Nobuaki Ikezawa, Madoka Takao, Yoshinori Morita, Takashi Toyonaga, Masato Komatsu, Ryoji Kushima, Yuzo Kodama

  Objective We explored the clinicopathological characteristics and disease frequency of oxyntic gland neoplasms (OGNs). Methods We retrospectively evaluated the data of patients pathologically diagnosed with OGN at an internal medicine clinic. Patients A total of 13,240 upper gastrointestinal endoscopies were performed on 7,488 patients between December 1, 2017, and March 31, 2021. Results We identified 27 patients with 30 histopathologically confirmed OGNs, yielding a disease frequency of 0.36% (27/7,488). Furthermore, multiple simultaneous lesions were found in 3 of 27 patients (11%). One (3.3%) of the 30 lesions was present in the antrum, whereas the remaining lesions occurred in the body of the stomach. Nine (33%) of the 27 patients had no history of Helicobacter pylori infection, whereas the remaining 18 (67%) were either currently or had been previously infected. Nevertheless, 27/30 lesions (90%) still occurred in non-atrophied regions. After endoscopic treatment, a histopathological examination of the resected specimens revealed submucosal infiltration in 8 (44%) of the 18 lesions; however, none of the lesions showed submucosal desmoplasia. For all patients with submucosal involvement, only observation was performed. There were no recurrent lesions found on follow-up. Conclusion The period prevalence of OGN was 0.36%, which is much higher than previously reported. The discovery of a small submucosal appearing lesion with a faded yellow or white color and dilated microvasculature, especially in a non-atrophic area of the stomach, should raise suspicion for an OGN, which can be endoscopically managed.

  Feb. 2023, Internal medicine (Tokyo, Japan), English, Domestic magazine

  Scientific journal


• LAT1 expression influences Paneth cell number and tumor development in ApcMin/+ mice

  Yunlong Sui, Namiko Hoshi, Ryuichi Ohgaki, Lingling Kong, Ryutaro Yoshida, Norihiro Okamoto, Masato Kinoshita, Haruka Miyazaki, Yuna Ku, Eri Tokunaga, Yuki Ito, Daisuke Watanabe, Makoto Ooi, Masakazu Shinohara, Kengo Sasaki, Yoh Zen, Takenori Kotani, Takashi Matozaki, Zibin Tian, Yoshikatsu Kanai, Yuzo Kodama

  Abstract Background Amino acid transporters play an important role in supplying nutrition to cells and are associated with cell proliferation. L-type amino acid transporter 1 (LAT1) is highly expressed in many types of cancers and promotes tumor growth; however, how LAT1 affects tumor development is not fully understood. Methods To investigate the role of LAT1 in intestinal tumorigenesis, mice carrying LAT1 floxed alleles that also expressed Cre recombinase from the promoter of gene encoding Villin were crossed to an Apc^Min/+ background (LAT1^fl/fl; vil-cre; Apc^Min/+), which were subject to analysis; organoids derived from those mice were also analyzed. Results This study showed that LAT1 was constitutively expressed in normal crypt base cells, and its conditional deletion in the intestinal epithelium resulted in fewer Paneth cells. LAT1 deletion reduced tumor size and number in the small intestine of Apc^Min/+ mice. Organoids derived from LAT1-deleted Apc^Min/+ intestinal crypts displayed fewer spherical organoids with reduced Wnt/β-catenin target gene expression, suggesting a low tumor-initiation capacity. Wnt3 expression was decreased in the absence of LAT1 in the intestinal epithelium, suggesting that loss of Paneth cells due to LAT1 deficiency reduced the risk of tumor initiation by decreasing Wnt3 production. Conclusions LAT1 affects intestinal tumor development in a cell-extrinsic manner through reduced Wnt3 expression in Paneth cells. Our findings may partly explain how nutrient availability can affect the risk of tumor development in the intestines.

  Springer Science and Business Media LLC, Feb. 2023, Journal of Gastroenterology

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 胃・十二指腸ESDにおける高難度症例への対処 幽門輪に接する胃・十二指腸腫瘍に対するESD治療成績と術後合併症の検討

  高山 弘志, 豊永 高史, 池澤 伸明, 吉崎 哲也, 阿部 洋文, 阪口 博哉, 鷹尾 俊達, 森田 圭紀, 児玉 裕三

  (一社)日本胃癌学会, Feb. 2023, 日本胃癌学会総会記事, 95回, 228 - 228, Japanese


• Outcomes of the Sequential Treatment of Unresectable Hepatocellular Carcinoma Using Lenvatinib.

  Daisuke Nakagawa, Shohei Komatsu, Yoshihiko Yano, Masahiro Kido, Kaori Kuramitsu, Atsushi Yamamoto, Satoshi Omiya, Yuhi Shimura, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: The chemotherapeutic landscape for hepatocellular carcinomas (HCCs) has changed dramatically with the availability of several treatment options. This study aimed to assess the long-term outcomes of lenvatinib treatment and analyze its feasibility in the sequential treatment of HCCs. PATIENTS AND METHODS: Eighty-five consecutive patients who received lenvatinib for unresectable HCCs were investigated retrospectively. Survival was assessed based on when the patients were first radiologically diagnosed with progressive disease. Among those with radiologically diagnosed stable or progressive disease at 3 months after lenvatinib administration, the cutoff α-fetoprotein (AFP) ratio (ratio of the AFP level after lenvatinib treatment to the pretreatment AFP level) that was predictive of survival was determined using receiver operating characteristic analysis. RESULTS: The median survival time (MST) was significantly worse among patients diagnosed with progressive disease at 1 month after treatment than among those diagnosed at 2-3 or 3-4 months after treatment [MSTs at 1, 2-3, and 3-4 months: 2.2, 10.2, and 17.3 months, respectively (p<0.001)]. An AFP ratio of 1.36 (computed using the AFP level at 3 months after lenvatinib treatment) was significantly predictive of survival in patients with stable or progressive disease (26.3 vs. 11.3 months, p=0.0024). CONCLUSION: The prognosis of patients on lenvatinib who develop early progressive disease is dismal. Thus, their treatment should be ceased or switched. The 3-month AFP ratio of 1.36 may be a potentially useful cutoff for considering a switch to other treatments in patients radiologically diagnosed with stable or progressive disease.

  Feb. 2023, Anticancer research, 43(2) (2), 911 - 918, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma.

  Takeshi Tanaka, Atsuhiro Masuda, Jun Inoue, Tsuyoshi Hamada, Takuya Ikegawa, Hirochika Toyama, Keitaro Sofue, Hideyuki Shiomi, Arata Sakai, Takashi Kobayashi, Shunta Tanaka, Ryota Nakano, Yasutaka Yamada, Shigeto Ashina, Masahiro Tsujimae, Kohei Yamakawa, Shohei Abe, Masanori Gonda, Shigeto Masuda, Noriko Inomata, Hisahiro Uemura, Shinya Kohashi, Kae Nagao, Maki Kanzawa, Tomoo Itoh, Yoshihide Ueda, Takumi Fukumoto, Yuzo Kodama

  BACKGROUND: Tertiary lymphoid structure (TLS) reflects an intense immune response against cancer, which correlates with favorable patient survival. However, the association of TLS with tumor-infiltrating lymphocytes (TILs) and clinical outcomes has not been investigated comprehensively in pancreatic ductal adenocarcinoma (PDAC). METHODS: We utilized an integrative molecular pathological epidemiology database on 162 cases with resected PDAC, and examined TLS in relation to levels of TILs, patient survival, and treatment response. In whole-section slides, we assessed the formation of TLS and conducted immunohistochemistry for tumor-infiltrating T cells (CD4, CD8, CD45RO, and FOXP3). As confounding factors, we assessed alterations of four main driver genes (KRAS, TP53, CDKN2A [p16], and SMAD4) using next-generation sequencing and immunohistochemistry, and tumor CD274 (PD-L1) expression assessed by immunohistochemistry. RESULTS: TLSs were found in 112 patients with PDAC (69.1%). TLS was associated with high levels of CD4+ TILs (multivariable odds ratio [OR], 3.50; 95% confidence interval [CI] 1.65-7.80; P = 0.0002), CD8+ TILs (multivariable OR, 11.0; 95% CI 4.57-29.7, P < 0.0001) and CD45RO+ TILs (multivariable OR, 2.65; 95% CI 1.25-5.80, P = 0.01), but not with levels of FOXP3+ TILs. TLS was associated with longer pancreatic cancer-specific survival (multivariable hazard ratio, 0.37; 95% CI 0.25-0.56, P < 0.0001) and favorable outcomes of adjuvant S-1-treatment. TLS was not associated with driver gene alterations but tumor CD274 negative expression. CONCLUSIONS: Our comprehensive data supports the surrogacy of TLS for vigorous anti-tumor immune response characterized by high levels of helper and cytotoxic T cells and their prognostic role.

  Jan. 2023, Journal of gastroenterology, 58(3) (3), 277 - 291, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Characteristics of Gastric Stasis due to Deformation after Endoscopic Submucosal Dissection in the Lower Part of the Stomach.

  Hiroshi Takayama, Takashi Toyonaga, Tetsuya Yoshizaki, Hirofumi Abe, Tatsuya Nakai, Chise Ueda, Satoshi Urakami, Hidetoshi Kaku, Yusaku Shimamoto, Kei Matsumoto, Kazunori Tsuda, Hiroya Sakaguchi, Shinichi Baba, Hiroshi Takihara, Nobuaki Ikezawa, Shinwa Tanaka, Madoka Takao, Toshitatsu Takao, Yoshinori Morita, Yuzo Kodama

  INTRODUCTION: Gastric stasis due to deformation occurs after endoscopic submucosal dissection in the lower part of the stomach. Endoscopic balloon dilation can improve gastric stasis due to stenosis; however, endoscopic balloon dilation cannot improve gastric stasis due to deformation. Furthermore, the characteristics of gastric stasis due to deformation are unknown. This study aimed to evaluate the characteristics of gastric stasis due to deformation after endoscopic submucosal dissection in the lower part of the stomach, focusing on the differences between stenosis and deformation. METHODS: We retrospectively reviewed 41 patients with gastric stasis after endoscopic submucosal dissection in the lower part of the stomach. We evaluated the characteristics of cases with gastric stasis due to deformation, such as the risk factors of deformation and the rate of deformation in each group with risk factors. RESULTS: Deformation was observed in 12% (5/41) of the patients with gastric stasis. All cases of deformation had a circumferential extent of the mucosal defect greater than 3/4. The number of cases with pyloric dissection was significantly lower in the deformation group than in the non-deformation group (0% vs. 72%; p = 0.004). The deformation group also had a significantly higher number of cases with angular dissection than the non-deformation group (100% vs. 17%; p < 0.001). Moreover, the deformation cases had a significantly larger specimen diameter (p < 0.001). Deformation was observed only in cases with angular and non-pyloric dissections. Deformation was not observed in cases with angular and pyloric dissections. CONCLUSIONS: All cases of gastric stasis due to deformation had a circumferential extent of the mucosal defect greater than 3/4. Deformation was also likely to occur in cases with a larger dissection that exceeded the angular region without pyloric dissection.

  2023, Digestion, 104(4) (4), 320 - 327, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 食道胃接合部癌に対する治療戦略 当院でESD治療を施行した食道胃接合部腺癌の深達度診断に関する検討

  堀 瞳, 吉崎 哲也, 森田 圭紀, 児玉 裕三

  日本消化器病学会-近畿支部, Jan. 2023, 日本消化器病学会近畿支部例会プログラム・抄録集, 118回, 55 - 55, Japanese


• Histological diagnosis of polyploidy discriminates an aggressive subset of hepatocellular carcinomas with poor prognosis

  Takanori Matsuura, Yoshihide Ueda, Yoshiyuki Harada, Kazuki Hayashi, Kisara Horisaka, Yoshihiko Yano, Shinichi So, Masahiro Kido, Takumi Fukumoto, Yuzo Kodama, Eiji Hara, Tomonori Matsumoto

  2023, British Journal of Cancer

  Scientific journal


• Progression of Recurrent Pancreatitis to Chronic Pancreatitis within 3 Years due to SPINK1 Mutation IVS3+2T>C.

  Susumu Horitani, Masahiro Tsujimae, Arata Sakai, Atsuhiro Masuda, Kae Nagao, Shinya Kohashi, Noriko Inomata, Hisahiro Uemura, Shigeto Masuda, Masanori Gonda, Shohei Abe, Kohei Yamakawa, Shigeto Ashina, Yasutaka Yamada, Takeshi Tanaka, Ryota Nakano, Takashi Kobayashi, Hideyuki Shiomi, Yuzo Kodama

  When the etiology of pancreatitis cannot be determined despite sufficient investigation, recurrence and progression to chronic pancreatitis often involve genetic mutations. Herein, we describe a case of recurrent pancreatitis with the IVS3+2T>C mutation in the serine protease inhibitor Kazal type 1 (SPINK1) gene that progressed to chronic pancreatitis in only 3 years. A 35-year-old man was referred to our hospital, where he was diagnosed with mild pancreatitis and was treated conservatively. However, the patient experienced recurrent episodes of pancreatitis, which progressed to become chronic pancreatitis with a pancreatic calcification 1 year later. After 3 years, the patient developed pancreatic duct stenosis and required a pancreatic duct stent placement. Regarding the cause of chronic pancreatitis, alcohol abuse was ruled out based on history taking. Considering the course of treatment, autoimmune pancreatitis and obstructive pancreatitis, such as pancreatic divisum, were also ruled out. Finally, a germline genetic test was performed to determine the etiology of pancreatitis, which revealed the IVS3+2T>C mutation in SPINK1. This case shows the importance of genetic testing in patients with idiopathic pancreatitis to determine their etiology and is a rare incident that can report the progression of the disease from acute to chronic pancreatitis.

  2023, Case reports in gastroenterology, 17(1) (1), 49 - 55, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• Risk-scoring system for predicting challenging cases of peroral endoscopic myotomy.

  Tatsuya Nakai, Hirofumi Abe, Shinwa Tanaka, Fumiaki Kawara, Takashi Toyonaga, Hiroya Sakaguchi, Chise Ueda, Nobuaki Ikezawa, Kazunori Tsuda, Satoshi Urakami, Yuzo Kodama

  OBJECTIVES: Peroral endoscopic myotomy (POEM) is an effective treatment for esophageal motility disorders including achalasia and its variants. However, some surgeons have encountered challenging cases. This study aimed to develop a risk-scoring system to predict challenging cases of POEM. METHODS: Consecutive patients who underwent POEM between April 2015 and March 2020 at our hospital were included in this single-center retrospective study. Challenging cases of POEM were defined as patients with any of the following: (i) procedure time ≥90 min; (ii) mucosal perforation; (iii) pneumothorax; and (iv) major bleeding. A risk-scoring system for predicting challenging cases was developed based on multivariate logistic regression and internal validation was performed using the bootstrap method. Clinical usefulness was evaluated using a decision curve analysis. RESULTS: Of the 467 patients, 59 (12.6%) had challenging POEM. A risk-scoring system consisted of four variables: duration of symptoms ≥5 years (assigned score, 1 point), antithrombotics use (1 point), manometric diagnosis of achalasia variants (2 points), and dilation grade 3 (2 points). Our scoring system showed satisfactory discrimination (area under the receiver operating characteristic curve, 0.69; 95% confidence interval [CI] 0.61-0.77) and calibration (slope, 0.99; 95% CI 0.65-1.35). The decision curve analysis demonstrated its clinical usefulness. CONCLUSIONS: We established a risk-scoring system to predict challenging cases of POEM. This scoring system may aid the selection of patients who require treatment from experienced surgeons.

  Dec. 2022, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, English, International magazine

  Scientific journal


• Context-Dependent Roles of Hes1 in the Adult Pancreas and Pancreatic Tumor Formation

  Yoshihiro Nishikawa, Saiko Marui, Yoshihiro Nishikawa, Masahiro Shiokawa, Masataka Yokode, Shimpei Matsumoto, Yuya Muramoto, Sakiko Ota, Takeharu Nakamura, Hiroyuki Yoshida, Hirokazu Okada, Takeshi Kuwada, Tomoaki Matsumori, Katsutoshi Kuriyama, Akihisa Fukuda, Dieter Saur, Takashi Aoi, Norimitsu Uza, Yuzo Kodama, Tsutomu Chiba, Hiroshi Seno

  Elsevier {BV}, Dec. 2022, Gastroenterology, 163(6) (6), 1613 - 1629.e12, English

  Scientific journal


• 経時的に形態変化を観察し得た表在性非乳頭部十二指腸上皮性腫瘍の一例

  永木 瑞穂, 池澤 伸明, 堀 瞳, 石田 亮介, 高山 弘志, 津田 一範, 阪口 博哉, 阿部 洋文, 吉崎 哲也, 鷹尾 まど佳, 鷹尾 俊達, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Nov. 2022, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 109回, 103 - 103, Japanese


• 【胆膵専門外来〜エキスパートによる至極の指南書〜】慢性疾患の症状コントロール,進展抑制 IgG4関連自己免疫性膵炎

  辻前 正弘, 増田 充弘, 重里 徳子, 入江 洋介, 原田 宜幸, 三木 美香, 植村 久尋, 猪股 典子, 孝橋 信哉, 長尾 佳映, 増田 重人, 權田 真知, 阿部 晶平, 芦名 茂人, 山川 康平, 田中 雄志, 酒井 新, 小林 隆, 児玉 裕三

  医学図書出版(株), Nov. 2022, 胆と膵, 43(特別号) (特別号), 1385 - 1390, Japanese


• Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Atsushi Yamamoto, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: Atezolizumab plus bevacizumab and lenvatinib are the key drugs in the current systemic chemotherapeutic regimen for hepatocellular carcinoma (HCC). Studies have reported the potential effectiveness of lenvatinib introduction after an atezolizumab plus bevacizumab treatment; however, the therapeutic effectiveness of a lenvatinib rechallenge after an atezolizumab plus bevacizumab treatment remains unclear. PATIENTS AND METHODS: Thirteen consecutive patients who were rechallenged with lenvatinib after clinical failure following treatments with lenvatinib and atezolizumab plus bevacizumab were included. A comparative study was conducted on the duration and treatment efficacy of the first and second lenvatinib treatments and on the pre- and post-treatment liver function. RESULTS: The median ratios of the 1-month post-treatment alpha-fetoprotein (AFP) levels to the pretreatment AFP levels were 0.750 and 0.667 for the first and second lenvatinib treatments, respectively, without significant difference (p=0.9327). Meanwhile, the median ratios of the 1-month post-treatment albumin-bilirubin (ALBI) scores to the pretreatment ALBI scores were 1.063 and 0.827 for the first and second lenvatinib treatments, respectively, with significant difference (p=0.015). The median duration of the second lenvatinib treatment was significantly shorter than that of the first lenvatinib treatment [2.8 months (range=0.9-4.7 months) vs. 8.7 months (range=3.1-29.7 months)]. CONCLUSION: Lenvatinib re-administration after atezolizumab plus bevacizumab treatment can act as a double-edged sword, as it exerts an anti-tumor effect while being associated with potential liver function deterioration. However, this treatment sequence can be useful, and requires careful monitoring of the transitions in the liver function and the patient's performance status.

  Nov. 2022, Anticancer research, 42(11) (11), 5479 - 5486, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Lobularity rather than hyperechoic foci/stranding on endoscopic ultrasonography is associated with more severe histological features in chronic pancreatitis.

  Noriko Inomata, Atsuhiro Masuda, Kohei Yamakawa, Mamoru Takenaka, Masahiro Tsujimae, Hirochika Toyama, Keitaro Sofue, Arata Sakai, Takashi Kobayashi, Takeshi Tanaka, Yasutaka Yamada, Shigeto Ashina, Masanori Gonda, Shohei Abe, Shigeto Masuda, Hisahiro Uemura, Shinya Kohashi, Kae Nagao, Yoshiyuki Harada, Mika Miki, Ryota Nakano, Hideyuki Shiomi, Maki Kanzawa, Tomoo Itoh, Takumi Fukumoto, Yuzo Kodama

  BACKGROUND AND AIM: Endoscopic ultrasonography (EUS) findings of the pancreatic parenchyma, such as hyperechoic foci/stranding and lobularity, may be associated with the severity of chronic pancreatitis (CP). However, the correlation between parenchymal EUS findings and histology remains unclear. We designed a large-scale retrospective study analyzing over 200 surgical specimens to elucidate the association between parenchymal EUS findings and histological features. METHODS: Clinical data of 221 patients with pancreatobiliary tumors who underwent preoperative EUS and pancreatic surgery between January 2010 and November 2020 were reviewed to investigate the association between parenchymal EUS findings and histological features at the pancreatic body. None of these patients met the definition of CP. RESULTS: Of the 221 patients, 87 (39.4%), 89 (40.2%), and 45 (20.4%) had normal EUS findings, hyperechoic foci/stranding without lobularity, and hyperechoic foci/stranding with lobularity, respectively. In the multivariate analyses, parenchymal EUS findings significantly correlated with histological CP findings of fibrosis, inflammation, and atrophy (hyperechoic foci/stranding without lobularity vs hyperechoic foci/stranding with lobularity, odds ratio [95% confidence interval]: 4.1 [2.2-7.9] vs 31.3 [9.3-105.6], Ptrend  < 0.001; 3.9 [1.9-8.2] vs 21.8 [8.0-59.4], Ptrend  < 0.001; and 4.0 [2.0-7.8] vs 22.9 [7.0-74.5], Ptrend  < 0.001, respectively). Further, a trend toward higher histological grade was observed in the following order: normal findings, hyperechoic foci/stranding without lobularity, and hyperechoic foci/stranding with lobularity. CONCLUSIONS: Endoscopic ultrasonography findings of the pancreatic parenchyma may be associated with the histological conditions in CP, such as pancreatic fibrosis, inflammation, and atrophy. Lobularity reflects more severe histological conditions than does hyperechoic foci/stranding.

  Oct. 2022, Journal of gastroenterology and hepatology, 38(1) (1), 103 - 111, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• ガイドライン改訂後の膵炎診療の現状と課題 背景膵のEUS所見による組織学的進行度と発癌高リスク膵の予測

  山川 康平, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Oct. 2022, 日本消化器病学会雑誌, 119(臨増大会) (臨増大会), A536 - A536, Japanese


• Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan.

  Haruka Miyazaki, Daisuke Watanabe, Yuki Ito, Norihiro Okamoto, Eri Tokunaga, Yuna Ku, Makoto Ooi, Namiko Hoshi, Yuzo Kodama

  BACKGROUND: Patients with inflammatory bowel disease (IBD) are recommended to receive the coronavirus disease 2019 (COVID-19) vaccine. However, a recent survey showed that patients with IBD are more hesitant to receive the vaccine than the general population. Detailed information on the side effects of the COVID-19 vaccine is necessary to encourage vaccination among patients with IBD. AIM: To investigate the frequency of side effects following COVID-19 vaccination in patients with IBD in Japan. STUDY DESIGN: a cross-sectional survey was conducted using a questionnaire administered to adult patients with IBD in a tertiary medical facility. RESULTS: Among the participants who answered the questionnaire, 92.6%, 91.5%, and 41.5% of the participants had received their first, second, and third doses of the COVID-19 vaccine, respectively. Of the vaccinated participants, 88.3%, 86.3%, and 89.0% experienced side effects after receiving the first, second, and third doses of the vaccine, respectively. The incidences of fever, chills, and headaches were significantly higher among female participants than among male participants (p < 0.05). However, the frequencies of most side effects were comparable between the BNT162b2 mRNA and mRNA-1273 vaccines. CONCLUSION: The findings of our survey can help encourage patients with IBD to receive the COVID-19 vaccine.

  Sep. 2022, Digestive diseases and sciences, English, International magazine

  Scientific journal


• Computed tomography imaging-based predictors of the need for a step-up approach after initial endoscopic ultrasound-guided transmural drainage for pancreatic fluid collections.

  Masahiro Tsujimae, Hideyuki Shiomi, Arata Sakai, Atsuhiro Masuda, Noriko Inomata, Shinya Kohashi, Kae Nagao, Hisahiro Uemura, Shigeto Masuda, Masanori Gonda, Shohei Abe, Shigeto Ashina, Kohei Yamakawa, Takeshi Tanaka, Ryota Nakano, Takashi Kobayashi, Yuzo Kodama

  BACKGROUND: A step-up approach is recommended as a new treatment algorithm for pancreatic fluid collections (PFCs). However, determining which patients with PFCs require a step-up approach after endoscopic ultrasound-guided transmural drainage (EUS-TD) is unclear. If the need for a step-up approach could be predicted, it could be performed early for relevant patients. We aimed to identify PFC-related predictive factors for a step-up approach after EUS-TD. METHODS: This retrospective cohort study included consecutive patients who had undergone EUS-TD for PFCs from January 2008 to May 2020. Multivariable logistic regression analyses were performed to investigate PFC factors related to requiring a step-up approach. A step-up approach was performed for patients who did not respond clinically to EUS-TD. RESULTS: We enrolled 81 patients, of whom 25 (30.9%) required a step-up approach. In multivariate logistic regression analysis, the pre-EUS-TD number of PFC-occupied regions ≥ 3 (multivariate odds ratio [OR] 16.2, 95% confidence interval [CI] 2.68-97.6, P = 0.002), the post-EUS-TD PFC-remaining percentage ≥ 35% (multivariate OR 19.9, 95% CI 2.91-136.1, P = 0.002), and a positive sponge sign, which is a distinctive computed tomography finding in the early stage after EUS-TD (multivariate OR 6.26, 95% CI 1.33-29.3, P = 0.020), were independent predictive factors associated with requiring a step-up approach for PFCs. CONCLUSION: Pre-EUS-TD PFC-occupied regions, post-EUS-TD PFC-remaining percentage, and a positive sponge sign were predictors of the need for a step-up approach. Patients with PFC with these findings should be offered a step-up approach whereas conservative treatment is recommended for patients without these findings. CLINICAL REGISTRATION NUMBER: UMIN 000030898.

  Sep. 2022, Surgical endoscopy, 37(2) (2), 1096 - 1106, English, International magazine

  Scientific journal


• Hes1は膵腫瘍の状況に応じて異なる役割を果たす(Hes1 plays different roles in pancreatic tumor formation depending on the tumor condition)

  西川 義浩, 塩川 雅広, 中村 武晴, 岡田 浩和, 宇座 徳光, 児玉 裕三, 妹尾 浩

  (一社)日本癌学会, Sep. 2022, 日本癌学会総会記事, 81回, J - 3024, English


• 同時性・異時性多発膵癌の遺伝子解析(Genetic analysis of synchronous or metachronous multiple pancreatic cancers)

  平野 智紀, 垣内 伸之, 竹内 康英, 増井 俊彦, 白石 友一, 宮野 悟, 宇座 徳光, 児玉 裕三, 増田 充弘, 田中 雄志

  (一社)日本癌学会, Sep. 2022, 日本癌学会総会記事, 81回, P - 3214, English


• 慢性炎症に伴う胆管上皮におけるクローン拡大(Clonal expansion in bile duct associated with chronic inflammation)

  前田 紘奈, 垣内 伸之, 伊藤 孝司, 小川 絵里, 塩川 雅広, 宇座 徳光, 田中 洋子, 南谷 泰仁, 牧島 秀樹, 保田 宏明, 児玉 裕三, 上本 伸二, 宮野 悟, 小川 誠司

  (一社)日本癌学会, Sep. 2022, 日本癌学会総会記事, 81回, J - 1003, English


• Hes1は膵腫瘍の状況に応じて異なる役割を果たす(Hes1 plays different roles in pancreatic tumor formation depending on the tumor condition)

  西川 義浩, 塩川 雅広, 中村 武晴, 岡田 浩和, 宇座 徳光, 児玉 裕三, 妹尾 浩

  (一社)日本癌学会, Sep. 2022, 日本癌学会総会記事, 81回, J - 3024, English


• Advantage of endoscopic papillectomy for ampullary tumors as an alternative treatment for pancreatoduodenectomy

  Shohei Abe, Arata Sakai, Atsuhiro Masuda, Mika Miki, Yoshiyuki Harada, Kae Nagao, Noriko Inomata, Shinya Kohashi, Hisahiro Uemura, Shigeto Masuda, Shigeto Ashina, Masanori Gonda, Kohei Yamakawa, Masahiro Tsujimae, Yasutaka Yamada, Takeshi Tanaka, Takashi Kobayashi, Ryota Nakano, Hideyuki Shiomi, Daisuke Tsugawa, Hiroaki Yanagimoto, Tetsuo Ajiki, Maki Kanzawa, Takumi Fukumoto, Tomoo Itoh, Yuzo Kodama

  Sep. 2022, SCIENTIFIC REPORTS, 12(1) (1), English

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Computed tomography imaging-based predictors of the need for a step-up approach after initial endoscopic ultrasound-guided transmural drainage for pancreatic fluid collections

  Masahiro Tsujimae, Hideyuki Shiomi, Arata Sakai, Atsuhiro Masuda, Noriko Inomata, Shinya Kohashi, Kae Nagao, Hisahiro Uemura, Shigeto Masuda, Masanori Gonda, Shohei Abe, Shigeto Ashina, Kohei Yamakawa, Takeshi Tanaka, Ryota Nakano, Takashi Kobayashi, Yuzo Kodama

  Sep. 2022, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, English

  Scientific journal


• Steroid therapy has an acceptable role as the initial treatment in autoimmune pancreatitis patients with pancreatic cyst formation: based on a Japanese nationwide study.

  Kensuke Kubota, Takaya Oguchi, Nao Fujimori, Kenta Yamada, Itaru Naitoh, Yoshinobu Okabe, Eisuke Iwasaki, Atsushi Masamune, Tsukasa Ikeura, Terumi Kamisawa, Dai Inoue, Teru Kumagi, Takeshi Ogura, Yuzo Kodama, Akio Katanuma, Kenji Hirano, Kazuo Inui, Hiroyuki Isayama, Junichi Sakagami, Takayoshi Nishino, Atsushi Kanno, Yusuke Kurita, Kazuichi Okazaki, Seiji Nakamura

  BACKGROUND: We attempted to determine the indications and limitations of steroid therapy as the 1st line therapy in patients with autoimmune pancreatitis (AIP) with cyst formation (ACF). METHODS: This Japanese multicenter survey was conducted to examine the merits/demerits of steroid treatment as the initial therapy for ACF. RESULT: Data of a total of 115 patients with ACF were analyzed. Complete remission was achieved in 86% (86/100) of patients who had received steroid treatment, but only 33.3% (5/15) of patients who had not received steroids. Relapse after the remission (n=86) occurred in 7.6% (6/86) of patients who had received steroid therapy, but 40% (2/5) of patients who had not received steroid therapy. Multivariate analysis identified adoption of the wait&watch approach without steroid treatment (odds ratio=0.126, p<0.001) as a significant and independent negative predictor of remission of ACF. As for predictors of relapse, the presence of varix (odds ratio=5.83, p=0.036) was identified as an independent risk factor. CONCLUSION: Steroid therapy plays an important role as 1st line therapy in AIP patients with pancreatic cyst formation, however, varix formation, besides the diameter of the cyst(s), is a risk factor for refractoriness to steroid therapy.

  Aug. 2022, Journal of hepato-biliary-pancreatic sciences, 30(5) (5), 664 - 677, English, Domestic magazine

  Scientific journal


• 【膵臓の発生・生理・解剖から膵炎・膵癌の病態解明に至る最新の知見】急性膵炎におけるCCK受容体経路を介した炎症制御機構

  辻前 正弘, 増田 充弘, 三木 美香, 原田 宜幸, 植村 久尋, 猪股 典子, 長尾 佳映, 阿部 晶平, 權田 真知, 増田 重人, 山川 康平, 芦名 茂人, 田中 雄志, 酒井 新, 小林 隆, 吉川 陽子, 片岡 徹, 児玉 裕三

  医学図書出版(株), Aug. 2022, 胆と膵, 43(8) (8), 751 - 757, Japanese


• 【膵臓の発生・生理・解剖から膵炎・膵癌の病態解明に至る最新の知見】急性膵炎におけるCCK受容体経路を介した炎症制御機構

  辻前 正弘, 増田 充弘, 三木 美香, 原田 宜幸, 植村 久尋, 猪股 典子, 長尾 佳映, 阿部 晶平, 權田 真知, 増田 重人, 山川 康平, 芦名 茂人, 田中 雄志, 酒井 新, 小林 隆, 吉川 陽子, 片岡 徹, 児玉 裕三

  医学図書出版(株), Aug. 2022, 胆と膵, 43(8) (8), 751 - 757, Japanese


• Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report.

  Takeshi Tanaka, Arata Sakai, Masahiro Tsujimae, Yasutaka Yamada, Takashi Kobayashi, Atsuhiro Masuda, Yuzo Kodama

  BACKGROUND: Secondary sclerosing cholangitis, characterized by biliary obstruction, can be caused by drugs such as immune checkpoint inhibitors (ICIs). While there a few reports of sclerosing cholangitis after immune checkpoint inhibitor administration, no case has been reported after discontinuation of such drugs. CASE SUMMARY: A 68-year-old man who underwent chemotherapy for lung adenocarcinoma with bone metastasis presented with abdominal pain and fever 4 mo after the final administration of pembrolizumab. Computed tomography revealed thickening of the gallbladder wall and dilatation of the common bile duct. Endoscopic retro-grade cholangiopancreatography revealed an irregularly narrowed intrahepatic bile duct. Biopsy of the bile duct demonstrated that CD8+ T cells were predominant over CD4+ T cells. Liver biopsy showed dominant infiltration of CD8+ T in the portal tract, but onion-skin lesions were not observed. The patient was diagnosed with immune-related sclerosing cholangitis induced by pembrolizumab. Administration of methylprednisolone and endoscopic nasobiliary drainage were performed, but the cholangiography and laboratory test findings did not improve. No further treatment was administered due to disease progression, and the patient was referred for palliative care. CONCLUSION: Immune-related sclerosing cholangitis may have a late onset, and such cases occurring after discontinuation of ICIs should be carefully managed.

  Jul. 2022, World journal of gastroenterology, 28(28) (28), 3732 - 3738, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• Laparoscopic Endoscopic Cooperative Surgery Using Open-Window Suturing Technique for Treating Non-ampullary Superficial Duodenal Neoplasms Located on the Pancreatic Side.

  Shingo Kanaji, Yoshinori Morita, Takuya Kudo, Kouta Yamada, Takashi Kato, Arata Sakai, Toshitatsu Takao, Ryuichiro Sawada, Hitoshi Harada, Naoki Urakawa, Hironobu Goto, Hiroshi Hasegawa, Kimihiro Yamashita, Takeru Matsuda, Taro Oshikiri, Takashi Toyonaga, Yuzo Kodama, Yoshihiro Kakeji

  PURPOSE: No study has focused on the safety and feasibility of our previously developed open-window suturing technique to close mucosal defects on the pancreatic side after endoscopic submucosal dissection from the opened duodenal wall. This study aimed to evaluate the safety and usefulness of laparoscopic endoscopic cooperative surgery for duodenal tumors for treating superficial non-ampullary duodenal epithelial tumors on the pancreatic side of the duodenum. METHODS: This retrospective study included 61 consecutive patients who underwent surgery during August 2014-November 2021. After dissection when the tumor was on the pancreatic side, we sutured the mucosal defect from the opened duodenal wall. A preoperative endoscopic pancreatic stent was placed for tumors within 1 cm of the ampulla of Vater. The surgical outcomes were compared between tumors on the pancreatic and non-pancreatic sides. RESULTS: There were 27 and 34 patients with tumors on the pancreatic and non-pancreatic sides, respectively. The patient characteristics were similar. Preoperative pancreatic stents were placed in four patients in the pancreatic side group. The median operative time was significantly longer on the pancreatic side than in the non-pancreatic side group (241 vs. 209 min, P = 0.02). In one patient in the pancreatic side group, an intraoperative injury of the ampulla of Vater was successfully treated with intraoperative management. There were no significant differences in the incidence of postoperative grade II or higher complications between the groups. CONCLUSIONS: Laparoscopic endoscopic cooperative surgery for duodenal tumors for treating superficial non-ampullary duodenal epithelial tumors on the pancreatic side is safe and feasible.

  Jul. 2022, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 26(11) (11), 2266 - 2273, English, International magazine

  Scientific journal


• (III章)胆・膵 自己免疫性膵炎

  辻前 正弘, 児玉 裕三

  (株)総合医学社, Jul. 2022, 消化器内科学レビュー, 2022-'23, 285 - 290, Japanese


• Speech Recognition System Generates Highly Accurate Endoscopic Reports in Clinical Practice.

  Hiroshi Takayama, Toshitatsu Takao, Ryo Masumura, Yoshikazu Yamaguchi, Ryo Yonezawa, Hiroya Sakaguchi, Yoshinori Morita, Takashi Toyonaga, Kazutaka Izumiyama, Yuzo Kodama

  Objective Endoscopic reports are conventionally written at the end of each procedure, and the endoscopist must complete the report from memory. To make endoscopic reporting more efficient, we developed a new speech recognition (SR) system that generates highly accurate endoscopic reports based on structured data entry. We conducted a pilot study to examine the performance of this SR system in an actual endoscopy setting with various types of background noise. Methods In this prospective observational pilot study, participants who underwent upper endoscopy with our SR system were included. The primary outcome was the correct recognition rate of the system. We compared the findings generated by the SR system with the findings in the handwritten report prepared by the endoscopist. The initial correct recognition rate, number of revisions, finding registration time, and endoscopy time were also analyzed. Results Upper endoscopy was performed in 34 patients, generating 128 findings of 22 disease names. The correct recognition rate was 100%, and the median number of revisions was 0. The median finding registration time was 2.57 (interquartile range [IQR], 2.33-2.92) seconds, and the median endoscopy time was 234 (IQR, 194-227) seconds. Conclusion The SR system demonstrated high recognition accuracy in the clinical setting. The finding registration time was extremely short.

  Jun. 2022, Internal medicine (Tokyo, Japan), English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 胆膵内視鏡治療の工夫とリスクマネージメント 急性膵炎局所合併症における治療困難例の特徴と早期インターベンションの可能性

  辻前 正弘, 酒井 新, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jun. 2022, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 108回, 50 - 50, Japanese


• 胆管空腸吻合部狭窄に対して直視型EUSを用いて再建腸管からの胆管空腸瘻孔形成術に成功した1例

  嶋田 侑記, 田中 雄志, 小林 隆, 三木 美香, 原田 宜幸, 猪股 典子, 植村 久尋, 孝橋 信哉, 長尾 佳映, 阿部 晶平, 権田 真知, 増田 重人, 芦名 茂人, 辻前 正弘, 山川 康平, 山田 恭孝, 酒井 新, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jun. 2022, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 108回, 85 - 85, Japanese


• 胆膵内視鏡治療の工夫とリスクマネージメント 急性膵炎局所合併症における治療困難例の特徴と早期インターベンションの可能性

  辻前 正弘, 酒井 新, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jun. 2022, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 108回, 50 - 50, Japanese


• 「胆膵内視鏡診断の現況と展望」 胆道癌の術前診断における経口胆道鏡の役割

  増田 重人, 酒井 新, 小林 隆, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jun. 2022, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 108回, 64 - 64, Japanese


• 胆管空腸吻合部狭窄に対して直視型EUSを用いて再建腸管からの胆管空腸瘻孔形成術に成功した1例

  嶋田 侑記, 田中 雄志, 小林 隆, 三木 美香, 原田 宜幸, 猪股 典子, 植村 久尋, 孝橋 信哉, 長尾 佳映, 阿部 晶平, 権田 真知, 増田 重人, 芦名 茂人, 辻前 正弘, 山川 康平, 山田 恭孝, 酒井 新, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jun. 2022, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 108回, 85 - 85, Japanese


• Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma

  Kohei Yamakawa, Michiyo Koyanagi-Aoi, Keiichiro Uehara, Atsuhiro Masuda, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto, Yuzo Kodama, Takashi Aoi

  Objectives Small proline-rich protein 1A (SPRR1A) is recognized as a squamous differentiation marker but is also upregulated in some non-squamous cancers. However, its expression in pancreatic ductal adenocarcinoma (PDAC) has not been investigated. This study elucidated the expression of SPRR1A in PDAC and its effect on the prognosis and malignant behavior of PDAC. Methods We examined the SPRR1A expression by immunohistochemistry in 86 surgical PDAC cases and revealed the relationship between its expression and the prognosis of the PDAC patients. Furthermore, we overexpressed SPRR1A in pancreatic cancer cell lines (PK-1 and Panc-1) and assessed the phenotype and gene expression changes in vitro. Results Among the 84 cases, excluding 2 with squamous differentiation, 31 (36.9%) had a high SPRR1A expression. The overall survival (median 22.1 months vs. 33.6 months, p = 0.0357) and recurrence-free survival (median 10.7 months vs. 15.5 months, p = 0.0298) were significantly lower in the high-SPRR1A-expression group than in the low-SPRR1A-expression group. A multivariate analysis indicated that a high SPRR1A expression (HR 1.706, 95% CI 1.018 to 2.862, p = 0.0427) and residual tumor status (HR 2.687, 95% CI 1.487 to 4.855, p = 0.00106) were independent prognostic factors. The analysis of TCGA transcriptome data demonstrated that the high-SPRR1A-expression group had a significantly worse prognosis than the low-SPRR1A-expression group, which supported our data. SPRR1A overexpression in PK-1 and Panc-1 did not result in remarkable changes to in vitro phenotypes, such as the cell proliferation, chemo-resistance, EMT, migration or global gene expression. Conclusion Increased expression of SPRR1A is associated with a poor prognosis in PDAC and may serve as a novel prognostic marker. However, our in vitro study suggests that the SPRR1A expression may be a consequence, not a cause, of the aggressive behavior of PDAC.

  Public Library of Science (PLoS), May 2022, PLOS ONE, 17(5) (5), e0266620 - e0266620, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm.

  Masahiro Tsujimae, Atsuhiro Masuda, Takuya Ikegawa, Takeshi Tanaka, Jun Inoue, Hirochika Toyama, Keitaro Sofue, Hisahiro Uemura, Shinya Kohashi, Noriko Inomata, Kae Nagao, Shigeto Masuda, Shohei Abe, Masanori Gonda, Kohei Yamakawa, Shigeto Ashina, Yasutaka Yamada, Shunta Tanaka, Ryota Nakano, Arata Sakai, Takashi Kobayashi, Hideyuki Shiomi, Maki Kanzawa, Tomoo Itoh, Takumi Fukumoto, Yoshihide Ueda, Yuzo Kodama

  BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) concomitant with intraductal papillary mucinous neoplasm (IPMN) is defined as PDAC occurring apart from IPMN. This study comprehensively investigated the molecular biologic characteristics of PDAC concomitant with IPMN in major genetic alterations, tumor microenvironment, and prognosis by contrast with those of conventional PDAC. METHODS: The study retrospectively reviewed the data of 158 surgically resected PDAC patients. The driver gene alteration status (KRAS, TP53, CDKN2A, SMAD4, and GNAS) together with the immune and fibrotic status in tumor was evaluated. The prognosis of PDAC concomitant with IPMN and that of conventional PDAC also were compared. RESULTS: No statistically significant difference was found between PDAC concomitant with IPMN and conventional PDAC in the alteration frequency analysis of the major driver genes and the immune and fibrotic status in the tumor microenvironment. Overall survival and disease-free survival between patients who had PDAC concomitant with IPMN and those who had conventional PDAC did not show statistically significant differences in propensity-matched subjects. Furthermore, the co-existence of IPMN was not a poor prognostic factor in the multivariable-adjusted Cox proportional hazards model (hazard ratio, 0.95; 95 % confidence interval, 0.51-1.78). CONCLUSIONS: In this study, PDAC concomitant with IPMN had tumor characteristics similar to those of conventional PDAC in terms of the major driver gene alterations, tumor microenvironment, and prognosis.

  May 2022, Annals of surgical oncology, 29(8) (8), 4924 - 4934, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• ASO Visual Abstract: Comprehensive Analysis of Molecular Biological Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm.

  Masahiro Tsujimae, Atsuhiro Masuda, Takuya Ikegawa, Takeshi Tanaka, Jun Inoue, Hirochika Toyama, Keitaro Sofue, Hisahiro Uemura, Shinya Kohashi, Noriko Inomata, Kae Nagao, Shigeto Masuda, Shohei Abe, Masanori Gonda, Kohei Yamakawa, Shigeto Ashina, Yasutaka Yamada, Shunta Tanaka, Ryota Nakano, Arata Sakai, Takashi Kobayashi, Hideyuki Shiomi, Maki Kanzawa, Tomoo Itoh, Takumi Fukumoto, Yoshihide Ueda, Yuzo Kodama

  May 2022, Annals of surgical oncology, English, International magazine

  Scientific journal


• Feasibility and safety of endoscopic submucosal dissection for lesions in proximity to a colonic diverticulum.

  Nobuaki Ikezawa, Takashi Toyonaga, Shinwa Tanaka, Tetsuya Yoshizaki, Toshitatsu Takao, Hirofumi Abe, Hiroya Sakaguchi, Kazunori Tsuda, Satoshi Urakami, Tatsuya Nakai, Taku Harada, Kou Miura, Takahisa Yamasaki, Stuart Kostalas, Yoshinori Morita, Yuzo Kodama

  BACKGROUND/AIMS: Endoscopic submucosal dissection (ESD) for diverticulum-associated colorectal lesions is generally contraindicated because of the high risk of perforation. Several studies on patients with such lesions treated with ESD have been reported recently. However, the feasibility and safety of ESD for lesions in proximity to a colonic diverticulum (D-ESD) have not been fully clarified. The aim of this study was to evaluate the feasibility and safety of D-ESD. METHODS: D-ESD was defined as ESD for lesions within approximately 3 mm of a diverticulum. Twenty-six consecutive patients who underwent D-ESD were included. Two strategic approaches were used depending on whether submucosal dissection of the diverticulum-related part was required (strategy B) or not (strategy A). Treatment outcomes and adverse events associated with each strategy were analyzed. RESULTS: The en bloc resection rate was 96.2%. The rates of R0 and curative resection in strategies A and B were 80.8%, 73.1%, 84.6%, and 70.6%, respectively. Two cases of intraoperative perforation and one case of delayed perforation occurred. The delayed perforation case required emergency surgery, but the other cases were managed conservatively. CONCLUSION: D-ESD may be a feasible treatment option. However, it should be performed in a high-volume center by expert hands because it requires highly skilled endoscopic techniques.

  May 2022, Clinical endoscopy, 55(3) (3), 417 - 425, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Acid-treated high-amylose corn starch suppresses high-fat diet-induced steatosis.

  Ryutaro Yoshida, Yoshihiko Yano, Namiko Hoshi, Norihiro Okamoto, Yunlong Sui, Atsushi Yamamoto, Naoki Asaji, Yuuki Shiomi, Eiichiro Yasutomi, Yuri Hatazawa, Hiroki Hayashi, Yoshihide Ueda, Yuzo Kodama

  Resistant starch (RS) has been reported to improve steatosis as well as obesity. Type 4 resistant starch (RS4), a chemically modified starch, is particularly hard to digest and suggesting higher efficacy. However, because the effects of RS4 on steatosis are not yet fully understood, the effects of RS4 on steatosis were examined using a murine high-fat diet model. Seven-week-old male mice were divided into three groups and fed a normal diet, a high-fat diet (HFD), or a high-fat diet with added RS (HFD + RS). Amylofiber SH® produced from acid-treated corn starch was used as the dietary RS. At 22 weeks old, hepatic steatosis and short chain fatty acid (SCFA) content and gut microbiota in cecum stool samples were analyzed. The ratio of body weight to 7 weeks was significantly suppressed in the HFD + RS group compared to the HFD group (132.2 ± 1.4% vs. 167.2 ± 3.9%, p = 0.0076). Macroscopic and microscopic steatosis was also suppressed in the HFD + RS group. Analysis of cecum stool samples revealed elevated SCFA levels in the HFD + RS group compared with the HFD group. Metagenome analysis revealed that Bifidobacterium (17.9 ± 1.9% vs. 3.6 ± 0.7%, p = 0.0019) and Lactobacillus (14.8 ± 3.4% vs. 0.72 ± 0.23%, p = 0.0045), which degrade RS to SCFA, were more prevalent in the HFD + RS group than the HFD group. In conclusion, RS4 suppressed steatosis, and increased Bifidobacterium and Lactobacillus, and SCFAs. RS4 may prevent steatosis by modulating the intestinal environment.

  May 2022, Journal of food science, 87(5) (5), 2173 - 2184, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• The importance of pH adjustment for preventing fibrin glue dissolution in the stomach: an in vitro study.

  Yoshitaka Takegawa, Toshitatsu Takao, Hiroya Sakaguchi, Tatsuya Nakai, Kazuhiro Takeo, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama

  Combined use of fibrin glue and polyglycolic acid (PGA) sheets has attracted attention as a preventive measure for complications associated with endoscopic submucosal dissection. However, fibrin glue is a protein that may be dissolved by gastric acid. We evaluated the effect of artificial gastric acid on fibrin clot. The dissolution time of three layers of fibrin glue with PGA sheets was measured in five groups (pH 1.2, 2.0, 4.0, 5.5, and 6.0 with pepsin). Measurements of three samples per group were made. The mean number of the remaining layers at each measurement point was observed for 168 h. The time to complete dissolution of the three layers of fibrin gel in the three samples was 2.5 h at pH 1.2, 5 h at pH 2.0, 24 h at pH 4.0, and 48 h and 6 h at pH 5.5. In order to maintain fibrin glue in the stomach for a long period, there was a need to avoid pepsin activation secondary to acidification of gastric juice. The use of strong antacids is recommended.

  Apr. 2022, Scientific reports, 12(1) (1), 6986 - 6986, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Clinical impact of a novel device delivery system in the diagnosis of bile duct lesions: A single-center experience.

  Tomoaki Matsumori, Norimitsu Uza, Masahiro Shiokawa, Takahisa Maruno, Yoshihiro Nishikawa, Toshihiro Morita, Takeshi Kuwada, Saiko Marui, Hirokazu Okada, Kojiro Taura, Yuzo Kodama, Hiroshi Seno

  BACKGROUND AND AIM: Pathological evaluation is essential for the diagnosis of biliary tract diseases. However, existing evaluation methods have various challenges in terms of operability and diagnostic performance. The present study aimed to evaluate the feasibility, utility, and safety of a novel device delivery system for bile duct biopsy. METHODS: This study was conducted as a retrospective, descriptive analysis at a single center. Overall, 25 examinations in 14 consecutive patients who underwent transpapillary biopsies for biliary lesions using the novel device delivery system from July to November 2020 were reviewed. Number and time of biopsy, technical success rate, adequate tissue sampling rate, adverse events, and diagnostic performance of bile duct biopsies using the novel device were evaluated. Moreover, negative surgical margins were assessed in patients who underwent surgical resection after mapping biopsy. RESULTS: The median number of biopsy samples was five (range: 2-13), with a median biopsy time of 11.6 min. The technical success rate was 100% (140/140), with an adequate sampling rate of 82.9% (116/140). These rates did not differ depending on the biopsy site or purpose. There were no serious adverse events related to the procedures. The diagnostic sensitivity, specificity, and accuracy of biliary stricture were 90%, 100%, and 92.3%, respectively. Negative surgical margins were confirmed in all patients undergoing surgical resection, including one patient with a surgical procedure changed based on the results of mapping biopsy. CONCLUSIONS: The novel device delivery system has potentials in diagnosing biliary tract diseases and determining appropriate treatment strategies.

  Apr. 2022, Journal of gastroenterology and hepatology, 37(7) (7), 1360 - 1366, English, International magazine

  Scientific journal


• 悪性輸入脚狭窄に対する内視鏡的ステント留置術の検討

  山田 恭孝, 酒井 新, 三木 美香, 原田 宜幸, 増田 充弘, 猪股 典子, 孝橋 信哉, 長尾 佳映, 植村 久尋, 増田 重人, 阿部 晶平, 權田 真知, 芦名 茂人, 山川 康平, 辻前 正弘, 田中 雄志, 小林 隆, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2022, Gastroenterological Endoscopy, 64(Suppl.1) (Suppl.1), 810 - 810, Japanese


• IgG4関連疾患の診断・治療における胆膵内視鏡の現状と問題点 自己免疫性膵炎診断におけるEUS-FNAの位置づけに関する多機関共同研究

  辻前 正弘, 増田 充弘, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2022, Gastroenterological Endoscopy, 64(Suppl.1) (Suppl.1), 596 - 596, Japanese


• 悪性輸入脚狭窄に対する内視鏡的ステント留置術の検討

  山田 恭孝, 酒井 新, 三木 美香, 原田 宜幸, 増田 充弘, 猪股 典子, 孝橋 信哉, 長尾 佳映, 植村 久尋, 増田 重人, 阿部 晶平, 權田 真知, 芦名 茂人, 山川 康平, 辻前 正弘, 田中 雄志, 小林 隆, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2022, Gastroenterological Endoscopy, 64(Suppl.1) (Suppl.1), 810 - 810, Japanese


• Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.

  Haruka Miyazaki, Daisuke Watanabe, Norihiro Okamoto, Eri Tokunaga, Yuna Ku, Haruka Takenaka, Namiko Hoshi, Makoto Ooi, Yuzo Kodama

  BACKGROUND: Behçet's disease (BD) is a recurrent multisystem inflammatory disease. Anti-tumor necrosis factor (TNF) α agents have been used to treat patients with intestinal BD with severe disease activity or those who are resistant to conventional treatments; however, the long-term efficacy of anti-TNFα agents in intestinal BD remains unclear. In the present study, we investigated the clinical outcomes and predictors of discontinuation of anti-TNFα agents in patients with intestinal BD. METHODS: We reviewed the medical records of patients with intestinal BD who received first-line anti-TNFα agents between January 2009 and June 2020. The primary outcome was the percentage of patients who continued anti-TNFα therapy for 48 weeks. Secondary outcomes included the percentage of patients who achieved marked improvement, complete remission, and mucosal healing, as well as predictors of discontinuation of anti-TNFα agents. RESULTS: A total of 29 patients were included in the study. Twenty-two (75.9%) patients continued anti-TNFα therapy for 48 weeks. The percentage of patients who achieved marked improvement, complete remission, and mucosal healing at week 48 was 48.3%, 37.9%, and 48.3%, respectively. At week 96, 11 (37.9%) patients achieved marked improvement, complete remission, and mucosal healing. A higher C-reactive protein level (CRP; ≥ 1 mg/dL) at baseline was a predictor of discontinuation of anti-TNFα agents. CONCLUSIONS: The 48-week continuation rate of anti-TNFα agents was 75.9% in bio-naïve patients with intestinal BD. However, a higher baseline CRP level (≥ 1 mg/dL) was associated with discontinuation of anti-TNFα agents.

  Mar. 2022, BMC gastroenterology, 22(1) (1), 149 - 149, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 重症急性膵炎の病態解明と治療戦略 改定Atlanta分類と本邦ガイドラインを組み合わせた急性壊死性貯留の新診断基準の有用性検討

  江口 考明, 辻 喜久, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2022, 日本消化器病学会雑誌, 119(臨増総会) (臨増総会), A146 - A146, Japanese


• ESD traineeからExpertを目指して

  池澤 伸明, 森田 圭紀, 中井 達也, 津田 一範, 賀来 英俊, 松本 慶, 阪口 博哉, 阿部 洋文, 吉崎 哲也, 田中 心和, 鷹尾 まど佳, 鷹尾 俊達, 豊永 高史, 児玉 裕三

  (一社)日本胃癌学会, Mar. 2022, 日本胃癌学会総会記事, 94回, 515 - 515, Japanese


• 【診療ガイドライン改訂後の膵炎診療】EUS所見は何を見ているのか 組織像との対比など

  猪股 典子, 山川 康平, 増田 充弘, 児玉 裕三

  (株)アークメディア, Mar. 2022, 肝胆膵, 84(3) (3), 335 - 342, Japanese


• IPMNの病態解明にもとづくマネージメント IPMNの膵体積測定による悪性化予測およびHRSに対する上乗せ効果の検討

  田中 雄志, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2022, 日本消化器病学会雑誌, 119(臨増総会) (臨増総会), A157 - A157, Japanese


• 自己免疫性肝胆膵疾患の新展開 自己免疫性膵炎の長期経過における再燃・ステロイド依存のリスク因子および悪性腫瘍の発症に関する検討

  權田 真知, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2022, 日本消化器病学会雑誌, 119(臨増総会) (臨増総会), A181 - A181, Japanese


• ESD traineeからExpertを目指して

  池澤 伸明, 森田 圭紀, 中井 達也, 津田 一範, 賀来 英俊, 松本 慶, 阪口 博哉, 阿部 洋文, 吉崎 哲也, 田中 心和, 鷹尾 まど佳, 鷹尾 俊達, 豊永 高史, 児玉 裕三

  (一社)日本胃癌学会, Mar. 2022, 日本胃癌学会総会記事, 94回, 515 - 515, Japanese


• Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Kaori Kuramitsu, Atsushi Yamamoto, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: Atezolizumab plus bevacizumab therapy is the new standard treatment option for advanced hepatocellular carcinoma (HCC). The clinical details and sequential course after atezolizumab plus bevacizumab therapy remain to be determined. PATIENTS AND METHODS: Thirty-four consecutive patients who received atezolizumab plus bevacizumab therapy were evaluated. Their clinical outcomes were assessed according to liver function classified by modified albumin-bilirubin (ALBI) grade 1 and 2a (1/2a) versus 2b and treatment line (first-line versus second- or later-line). Furthermore, the treatment sequence after atezolizumab plus bevacizumab therapy was also assessed. RESULTS: The objective response and disease control rates were 15.6% and 93.8%, respectively. The median proportions of ALBI scores at 1, 2, and 3 months relative to the baseline scores were 0.94, 0.97, and 0.93, respectively. The median proportions of α-fetoprotein (AFP) scores at 1, 2, and 3 months relative to the baseline scores were 0.98, 1.12, and 1.83, respectively. There were no significant differences in the changes in the proportions of AFP and ALBI scores according to both liver function and treatment line. Twelve patients were administered lenvatinib treatment after the failure of atezolizumab plus bevacizumab therapy. The proportions of AFP and ALBI scores at 1 month relative to the baseline scores were 0.55 and 0.81, respectively. CONCLUSION: Atezolizumab plus bevacizumab therapy can be effective for advanced HCC irrespective of the patients' liver function and treatment line. Lenvatinib administration after atezolizumab plus bevacizumab therapy can be effective, although special attention should be paid to the deterioration of liver function.

  Mar. 2022, Anticancer research, 42(3) (3), 1403 - 1412, English, International magazine

  Scientific journal


• Estimation of pancreatic fibrosis and prediction of postoperative pancreatic fistula using extracellular volume fraction in multiphasic contrast-enhanced CT.

  Keitaro Sofue, Eisuke Ueshima, Atsuhiro Masuda, Sachiyo Shirakawa, Yoh Zen, Yoshiko Ueno, Yushi Tsujita, Takeru Yamaguchi, Shinji Yabe, Takeshi Tanaka, Noriko Inomata, Hirochika Toyama, Takumi Fukumoto, Yuzo Kodama, Takamichi Murakami

  OBJECTIVE: To investigate the diagnostic performance of the extracellular volume (ECV) fraction in multiphasic contrast-enhanced computed tomography (CE-CT) for estimating histologic pancreatic fibrosis and predicting postoperative pancreatic fistula (POPF). METHODS: Eighty-five patients (49 men; mean age, 69 years) who underwent multiphasic CE-CT followed by pancreaticoduodenectomy with pancreaticojejunal anastomosis between January 2012 and December 2018 were retrospectively included. The ECV fraction was calculated from absolute enhancements of the pancreas and aorta between the precontrast and equilibrium-phase images, followed by comparisons among histologic pancreatic fibrosis grades (F0‒F3). The diagnostic performance of the ECV fraction in advanced fibrosis (F2‒F3) was evaluated using receiver operating characteristic curve analysis. Multivariate logistic regression analysis was used to evaluate the associations of the risk of POPF development with patient characteristics, histologic findings, and CT imaging parameters. RESULTS: The mean ECV fraction of the pancreas was 34.4% ± 9.5, with an excellent intrareader agreement of 0.811 and a moderate positive correlation with pancreatic fibrosis (r = 0.476; p < 0.001). The mean ECV fraction in advanced fibrosis was significantly higher than that in no/mild fibrosis (44.4% ± 10.8 vs. 31.7% ± 6.7; p < 0.001), and the area under the receiver operating characteristic curve for the diagnosis of advanced fibrosis was 0.837. Twenty-two patients (25.9%) developed clinically relevant POPF. Multivariate logistic regression analysis demonstrated that the ECV fraction was a significant predictor of POPF. CONCLUSIONS: The ECV fraction can offer quantitative information for assessing pancreatic fibrosis and POPF after pancreaticojejunal anastomosis. KEY POINTS: • There was a moderate positive correlation of the extracellular volume (ECV) fraction of the pancreas in contrast-enhanced CT with the histologic grade of pancreatic fibrosis (r = 0.476; p < 0.001). • The ECV fraction was higher in advanced fibrosis (F2‒F3) than in no/mild fibrosis (F0‒F1) (p < 0.001), with an AUC of 0.837 for detecting advanced fibrosis. • The ECV fraction was an independent risk factor for predicting subclinical (odds ratio, 0.81) and clinical (odds ratio, 0.80) postoperative pancreatic fistula.

  Mar. 2022, European radiology, 32(3) (3), 1770 - 1780, English, International magazine

  Scientific journal


• Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020.

  Kazuichi Okazaki, Shigeyuki Kawa, Terumi Kamisawa, Tsukasa Ikeura, Takao Itoi, Tetsuhide Ito, Kazuo Inui, Atsushi Irisawa, Kazushige Uchida, Hirotaka Ohara, Kensuke Kubota, Yuzo Kodama, Kyoko Shimizu, Ryosuke Tonozuka, Takahiro Nakazawa, Takayoshi Nishino, Kenji Notohara, Yasunari Fujinaga, Atsushi Masamune, Hiroshi Yamamoto, Takayuki Watanabe, Toshimasa Nishiyama, Mitsuhiro Kawano, Keiko Shiratori, Tooru Shimosegawa, Yoshifumi Takeyama

  In response to the latest knowledge and the amendment of the Japanese diagnostic criteria for autoimmune pancreatitis (AIP) in 2018, the Japanese consensus guidelines for managing AIP in 2013 were required to be revised. Three committees [the professional committee for developing clinical questions (CQs) and statements by Japanese specialists; the expert panelist committee for rating statements by the modified Delphi method; and the evaluating committee of moderators] were organized. Twenty specialists in AIP extracted the specific clinical statements from a total of 5218 articles (1963-2019) from a search in PubMed and the Cochrane Library. The professional committee made 14, 9, 5, and 11 CQs and statements for the current concept and diagnosis, extra-pancreatic lesions, differential diagnosis, and treatment, respectively. The expert panelists regarded the statements as valid after a two-round modified Delphi approach with individually rating these clinical statements, in which a clinical statement receiving a median score greater than 7 on a 9-point scale from the panel was regarded as valid. After evaluation by the moderators, the amendment of the Japanese consensus guidelines for AIP has been proposed in 2020.

  Feb. 2022, Journal of gastroenterology, 57(4) (4), 225 - 245, English, Domestic magazine

  Scientific journal


• In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy.

  Hirokazu Okada, Ken Takahashi, Hiroaki Yaku, Kouji Kobiyama, Keiko Iwaisako, Xiangdong Zhao, Masahiro Shiokawa, Norimitsu Uza, Yuzo Kodama, Ken J Ishii, Hiroshi Seno

  Although checkpoint inhibitors (CPIs) have changed the paradigm of cancer therapy, low response rates and serious systemic adverse events remain challenging. In situ vaccine (ISV), intratumoral injection of immunomodulators that stimulate innate immunity at the tumor site, allows for the development of vaccines in patients themselves. K3-SPG, a second-generation nanoparticulate Toll-like receptor 9 (TLR9) ligand consisting of K-type CpG oligodeoxynucleotide (ODN) wrapped with SPG (schizophyllan), integrates the best of conventional CpG ODNs, making it an ideal cancer immunotherapy adjuvant. Focusing on clinical feasibility for pancreaticobiliary and gastrointestinal cancers, we investigated the antitumor activity of K3-SPG-ISV in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). K3-SPG-ISV suppressed tumor growth more potently than K3-ISV or K3-SPG intravenous injections, prolonged survival, and enhanced the antitumor effect of CPIs. Notably, in PDAC model, K3-SPG-ISV alone induced systemic antitumor effect and immunological memory. ISV combination of K3-SPG and agonistic CD40 antibody further enhanced the antitumor effect. Our results imply that K3-SPG-based ISV can be applied as monotherapy or combined with CPIs to improve their response rate or, conversely, with CPI-free local immunotherapy to avoid CPI-related adverse events. In either strategy, the potency of K3-SPG-based ISV would provide the rationale for its clinical application to puncturable pancreaticobiliary and gastrointestinal malignancies.

  Feb. 2022, Scientific reports, 12(1) (1), 2132 - 2132, English, International magazine

  Scientific journal


• 膵癌診療の進歩と今後の展望 膵癌の腫瘍内線維化の予後における意義

  芦名 茂人, 増田 充弘, 小林 隆, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2022, 日本消化器病学会近畿支部例会プログラム・抄録集, 116回, 60 - 60, Japanese


• 免疫チェックポイント阻害剤をめぐる諸問題 当院での免疫チェックポイント阻害剤投与患者におけるirAE膵障害についての検討

  長尾 佳映, 酒井 新, 増田 充弘, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2022, 日本消化器病学会近畿支部例会プログラム・抄録集, 116回, 79 - 79, Japanese


• 貧血症状を契機に発見されESDにて切除し得た巨大十二指腸Brunner腺過形成の一例

  賀来 英俊, 吉崎 哲也, 中井 達也, 高山 弘志, 津田 一範, 松本 慶, 池澤 伸明, 阪口 博哉, 阿部 洋文, 鷹尾 まど佳, 鷹尾 俊達, 森田 圭紀, 豊永 高史, 児玉 貴之, 横崎 宏, 伊藤 智雄, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2022, 日本消化器病学会近畿支部例会プログラム・抄録集, 116回, 124 - 124, Japanese


• Esophageal motility disorders missed during endoscopy

  Hirofumi Abe, Shinwa Tanaka, Fumiaki Kawara, Takashi Toyonaga, Hiroya Sakaguchi, Tatsuya Nakai, Nobuaki Ikezawa, Chise Ueda, Satoshi Urakami, Yuzo Kodama

  BACKGROUND: Esophageal motility disorders are sometimes misdiagnosed on endoscopic examination. We aimed to identify the proportion of patients with esophageal motility disorders missed during endoscopy and their clinical characteristics. METHODS: Patients diagnosed with either disorder with esophagogastric junction outflow obstruction or major disorders of peristalsis using high-resolution manometry in our hospital from April 2015 to March 2021 were included in this study. Missed esophageal motility disorders were defined as patients with any endoscopic misdiagnosis such as normal esophagus or esophagitis within 1 year before the manometric diagnosis. We determined the proportion of missed esophageal motility disorders and identified independent predictors of missed esophageal motility disorders using multivariate analysis. RESULTS: A total of 41/273 esophageal motility disorders (15.0%; 95% confidence interval 11.3-19.7%) were missed during endoscopy within 1 year before manometric diagnosis. In the stepwise logistic regression analysis, the following variables were selected as independent variables for patients with missed esophageal motility disorders during endoscopy: non-dilated esophagus (odds ratio = 4.87, 95% confidence interval: 1.81-13.12, p = 0.002), the presence of epiphrenic diverticulum (odds ratio = 8.95, 95% confidence interval: 1.88-42.65, p = 0.006), the use of transnasal endoscopy (odds ratio = 4.71, 95% confidence interval: 1.59-13.92, p = 0.005), and the combined use of esophagram (odds ratio = 0.023, 95% confidence interval: 0.0025-0.20, p = 0.0008). CONCLUSIONS: Based on retrospective analysis, 15% of esophageal motility disorders were missed during endoscopy. Understanding the clinical characteristics of missed esophageal motility disorders could help improve endoscopic diagnoses.

  Jan. 2022, Esophagus, 19(3) (3), 486 - 492, English, Domestic magazine

  [Refereed]

  Scientific journal


• Multiple pancreatic neuroendocrine tumors in OFCD syndrome caused by somatic BCOR mosaicism.

  Yuki Yamauchi, Yuzo Kodama, Nobuyuki Kakiuchi, Hiroshi Seno

  Jan. 2022, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], English, International magazine


• 胃腫瘍内視鏡治療における工夫 幽門側胃切除後の残胃吻合部の早期胃癌に対する内視鏡的粘膜下層剥離術の再建術式に基づく治療困難性および有効性、安全性の検討

  松本 慶, 鷹尾 俊達, 田中 心和, 森田 圭紀, 豊永 高史, 児玉 裕三

  (一社)日本消化管学会, Jan. 2022, 日本消化管学会雑誌, 6(Suppl.) (Suppl.), 168 - 168, Japanese


• 胃腫瘍内視鏡治療における工夫 幽門側胃切除後の残胃吻合部の早期胃癌に対する内視鏡的粘膜下層剥離術の再建術式に基づく治療困難性および有効性、安全性の検討

  松本 慶, 鷹尾 俊達, 田中 心和, 森田 圭紀, 豊永 高史, 児玉 裕三

  (一社)日本消化管学会, Jan. 2022, 日本消化管学会雑誌, 6(Suppl.) (Suppl.), 168 - 168, Japanese


• Whole-exome sequencing for a more accurate diagnosis of intraductal papillary neoplasms of the bile duct.

  Tomoaki Matsumori, Norimitsu Uza, Nobuyuki Kakiuchi, Toshihiro Morita, Yoshihiro Nishikawa, Masahiro Shiokawa, Kojiro Taura, Yuzo Kodama, Hiroshi Seno

  2022, Gastroenterology report, 10, goab014, English, International magazine

  Scientific journal


• 難治性胆膵疾患に対する内視鏡診療の取り組み 当院における膵癌に対する術前診断法の現状と課題

  三木 美香, 増田 充弘, 小林 隆, 酒井 新, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 107回, 54 - 54, Japanese


• 胆膵内視鏡 治療困難症例を克服するための工夫 治療困難な膵石症に対する内視鏡治療における工夫

  原田 宜幸, 酒井 新, 増田 充弘, 塩見 英之, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 107回, 77 - 77, Japanese


• 合流部結石による胆嚢結腸瘻の一例

  三好 未紗, 小林 隆, 田中 雄志, 三木 美香, 原田 宜幸, 猪股 典子, 孝橋 信哉, 長尾 佳映, 植村 久尋, 芦名 茂人, 増田 重人, 權田 真知, 阿部 晶平, 山川 康平, 辻前 正弘, 山田 恭孝, 酒井 新, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 107回, 89 - 89, Japanese


• 膵臓に多発結節を認めEUS-FNAで診断し得たAIDS関連バーキットリンパ腫の一例

  長谷川 貴久, 孝橋 信哉, 酒井 新, 原田 宜幸, 三木 美香, 猪股 典子, 長尾 佳映, 植村 久尋, 増田 重人, 阿部 晶平, 權田 真知, 芦名 茂人, 山川 康平, 辻前 正弘, 田中 雄志, 山田 恭孝, 小林 隆, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 107回, 93 - 93, Japanese


• 低分化型腺癌と鑑別を要した乳癌胃転移の一例

  井上 築, 吉崎 哲也, 中井 達也, 高山 弘志, 津田 一範, 松本 慶, 賀来 英俊, 阪口 博哉, 阿部 洋文, 池澤 伸明, 鷹尾 まど佳, 鷹尾 俊達, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 107回, 113 - 113, Japanese


• Barrett食道腺癌ESD後の異時性多発病変に対し残存Barrett粘膜を含めESDで完全切除した一例

  津田 一範, 豊永 高史, 高山 弘志, 阿部 洋文, 中井 達也, 嶋本 有策, 賀来 英俊, 松本 慶, 池澤 伸明, 阪口 博哉, 吉崎 哲也, 鷹尾 まど佳, 鷹尾 俊達, 森田 圭紀, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 107回, 120 - 120, Japanese


• 胃前庭部の粘膜下層剥離術後通過障害に対するバルーン拡張術無効例の検討

  高山 弘志, 豊永 高史, 吉崎 哲也, 中井 達也, 賀来 英俊, 松本 慶, 津田 一範, 阪口 博哉, 阿部 洋文, 池澤 伸明, 鷹尾 まど佳, 鷹尾 俊達, 森田 圭紀, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 107回, 121 - 121, Japanese


• 【胆と膵のスペシャリストが取るべき専門医/指導医とは?】膵癌登録について 登録の実際

  水間 正道, 海野 倫明, 糸井 隆夫, 江川 新一, 児玉 裕三, 里井 壯平, 仲田 興平, 濱田 晋, 安田 一朗, 竹山 宜典

  医学図書出版(株), Nov. 2021, 胆と膵, 42(11) (11), 1371 - 1374, Japanese


• 膵癌の進展機構の解明と新たな治療 膵癌のTLS(Tertiary lymphoid structure)を介した腫瘍免疫機構の解明

  田中 雄志, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Oct. 2021, 日本消化器病学会雑誌, 118(臨増大会) (臨増大会), A637 - A637, Japanese


• 膵癌切除例における腫瘍内線維化と術後化学療法感受性および予後との関連性

  芦名 茂人, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Oct. 2021, 日本消化器病学会雑誌, 118(臨増大会) (臨増大会), A721 - A721, Japanese


• 表在性非乳頭部十二指腸上皮性腫瘍に対する腹腔鏡内視鏡合同手術の当院の成績

  鷹尾 俊達, 森田 圭紀, 児玉 裕三

  (一社)日本消化器内視鏡学会, Oct. 2021, Gastroenterological Endoscopy, 63(Suppl.2) (Suppl.2), 1860 - 1860, Japanese


• The clinical efficacy of azathioprine as maintenance treatment for autoimmune pancreatitis: a systematic review and meta-analysis.

  Yoshiharu Masaki, Hiroshi Nakase, Yoshihisa Tsuji, Masanori Nojima, Kyoko Shimizu, Nobumasa Mizuno, Tsukasa Ikeura, Kazushige Uchida, Akio Ido, Yuzo Kodama, Hiroshi Seno, Kazuichi Okazaki, Seiji Nakamura, Atsushi Masamune

  The effectiveness of azathioprine (AZA) in preventing relapse and maintaining autoimmune pancreatitis (AIP) remission has been reported; however, most of these studies are case series with no randomized control trials available in the literature. Therefore, this study performed a systematic review and meta-analysis of the existing literature on this subject to determine the clinical efficacy of AZA as maintenance therapy for AIP patients. A systematic search was performed to identify studies on the clinical efficacy of AZA as maintenance therapy in AIP patients. The crude multiple relapse rate was estimated to assess the ability of AZA to control relapses in AIP. Pooled estimates were obtained using a random-effects model with the DerSimonian-Laird method. We identified AIP patients who did not respond to initial steroid treatment, experienced steroid weaning failure, or those who relapsed during remission as refractory cases. After reviewing the studies, ten articles fulfilled the inclusion criteria and were selected for meta-analysis. Of all 4504 patients, 3534 patients were treated with steroids, and 346 patients were treated with AZA for relapsed AIP. In this meta-analysis, 14/73 (19.2%) patients receiving AZA for refractory AIP relapsed. Meanwhile, 14/47 (29.8%) patients without AZA experienced relapse. The integrated odds ratio for relapse risk in patients receiving AZA was estimated to be 0.52 (p = 0.15). This systematic review and meta-analysis demonstrated the efficacy of AZA in preventing relapse of AIP, which supports the use of AZA as a maintenance treatment in patients with AIP who relapse upon withdrawal of steroid therapy.

  Oct. 2021, Journal of gastroenterology, 56(10) (10), 869 - 880, English, Domestic magazine

  Scientific journal


• New practical scoring system to predict post-endoscopic retrograde cholangiopancreatography pancreatitis: Development and validation

  Koichi Fujita, Shujiro Yazumi, Norimitsu Uza, Akira Kurita, Masanori Asada, Yuzo Kodama, Masashi Goto, Toshiro Katayama, Takahiro Anami, Akihiko Watanabe, Atsushi Sugahara, Hidekazu Mukai, Takashi Kawamura

  John Wiley and Sons Inc, Sep. 2021, JGH Open, 5(9) (9), 1078 - 1084, English

  Scientific journal


• 慢性炎症に伴う胆管上皮におけるクローン拡大

  前田 紘奈, 垣内 伸之, 伊藤 孝司, 小川 絵里, 塩川 雅広, 宇座 徳光, 田中 洋子, 南谷 泰仁, 牧島 秀樹, 保田 宏明, 児玉 裕三, 上本 伸二, 宮野 悟, 小川 誠司

  (一社)日本癌学会, Sep. 2021, 日本癌学会総会記事, 80回, [E3 - 3], English


• 【膵疾患に対する内視鏡診療のすべて】膵疾患に対する内視鏡治療 急性膵炎後局所合併症に対するEUS下治療

  塩見 英之, 中野 遼太, 太田 匠悟, 辻前 正弘, 小林 隆, 酒井 新, 増田 充弘, 児玉 裕三, 飯島 尋子

  (株)東京医学社, Sep. 2021, 消化器内視鏡, 33(9) (9), 1467 - 1475, Japanese


• 自己免疫性膵炎を背景とした膵頭部に肺癌転移を来した一例

  春山 忠佑, 小林 隆, 田中 雄志, 原田 宜幸, 三木 美香, 猪股 典子, 植村 久尋, 孝橋 信哉, 長尾 佳映, 阿部 晶平, 權田 真知, 増田 重人, 芦名 茂人, 辻前 正弘, 山川 康平, 酒井 新, 増田 充弘, 児玉 裕三

  日本消化器病学会-近畿支部, Sep. 2021, 日本消化器病学会近畿支部例会プログラム・抄録集, 115回, 91 - 91, Japanese


• 肝胆膵がんにおける基礎および臨床研究の進展 同時性・異時性多発膵癌の遺伝子解析

  平野 智紀, 垣内 伸之, 竹内 康英, 増井 俊彦, 白石 友一, 宮野 悟, 宇座 徳光, 田中 雄志, 増田 充弘, 児玉 裕三, 妹尾 浩, 千葉 勉, 小川 誠司

  (一社)日本癌学会, Sep. 2021, 日本癌学会総会記事, 80回, [SST2 - 6], English


• 早期胃癌で発見された胎児消化管上皮類似癌の3例

  山中 大樹, 池澤 伸明, 中井 達也, 高山 弘志, 上田 千勢, 津田 一範, 松本 慶, 賀来 英俊, 阪口 博哉, 阿部 洋文, 吉崎 哲也, 鷹尾 まど佳, 鷹尾 俊達, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器病学会-近畿支部, Sep. 2021, 日本消化器病学会近畿支部例会プログラム・抄録集, 115回, 68 - 68, Japanese


• Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Hiroaki Yanagimoto, Hirochika Toyama, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: While there is increasing evidence supporting the role of several first- and second-line treatment regimens for advanced hepatocellular carcinomas (HCC), the clinical relevance of rechallenge treatment with previously administered drugs, however, remains to be explored. PATIENTS AND METHODS: Five consecutive patients with advanced HCC who received lenvatinib rechallenge treatment after ramucirumab were assessed. RESULTS: All patients were clinically diagnosed with failure after ramucirumab treatment, and the frequencies of ramucirumab administration before lenvatinib re-administration ranged from 3 to 11. The alfa-fetoprotein level in four of five patients decreased 1 month after the lenvatinib rechallenge. Radiological findings via the modified Response Evaluation Criteria in Solid Tumors showed stable diseases in four patients and a partial response in one. CONCLUSION: Rechallenge treatment with lenvatinib after ramucirumab can be effective, and may be a treatment option for HCC in cases wherein the disease progressed after an initial response to lenvatinib treatment.

  Sep. 2021, Anticancer research, 41(9) (9), 4555 - 4562, English, International magazine

  Scientific journal


• Clinical Impact of Different Reconstruction Methods on Remnant Gastric Cancer at the Anastomotic Site after Distal Gastrectomy

  Kei Matsumoto, Shinwa Tanaka, Takashi Toyonaga, Nobuaki Ikezawa, Mari Nishio, Masanao Uraoka, Tomoatsu Yoshihara, Hiroya Sakaguchi, Hirofumi Abe, Tetsuya Yoshizaki, Madoka Takao, Toshitatsu Takao, Yoshinori Morita, Hiroshi Yokozaki, Yuzo Kodama

  Background/Aims: The anastomotic site after distal gastrectomy is the area most affected by duodenogastric reflux. Different reconstruction methods may affect the lesion characteristics and treatment outcomes of remnant gastric cancers at the anastomotic site. We retrospectively investigated the clinicopathologic and endoscopic submucosal dissection outcomes of remnant gastric cancers at the anastomotic site.Methods: We recruited 34 consecutive patients who underwent endoscopic submucosal dissection for remnant gastric cancer at the anastomotic site after distal gastrectomy. Clinicopathology and treatment outcomes were compared between the Billroth II and non-Billroth II groups.Results: The tumor size in the Billroth II group was significantly larger than that in the non-Billroth II group (22 vs. 19 mm; p=0.048). More severe gastritis was detected endoscopically in the Billroth II group (2 vs. 1.33; p=0.0075). Moreover, operation time was longer (238 vs. 121 min; p=0.004) and the frequency of bleeding episodes was higher (7.5 vs. 3.1; p=0.014) in the Billroth II group.Conclusions: Compared to remnant gastric cancers in non-Billroth II patients, those in the Billroth II group had larger lesions with a background of severe remnant gastritis. Endoscopic submucosal dissection for remnant gastric cancers in Billroth II patients involved longer operative times and more frequent bleeding episodes than that in patients without Billroth II.

  The Korean Society of Gastrointestinal Endoscopy, Aug. 2021, Clinical Endoscopy, 55(1) (1), 86 - 94

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 急性膵炎診療をめぐる諸問題 ANC合併急性膵炎患者へのrTM早期投与におけるWON抑制効果の検討

  江口 考明, 辻 喜久, 岡田 明彦, 児玉 裕三, 妹尾 浩

  (一社)日本膵臓学会, Aug. 2021, 膵臓, 36(3) (3), A140 - A140, Japanese


• 急性膵炎診療をめぐる諸問題 Walled-off necrosisに対する内視鏡的治療戦略

  塩見 英之, 辻前 正弘, 中野 遼太, 酒井 新, 児玉 裕三

  (一社)日本膵臓学会, Aug. 2021, 膵臓, 36(3) (3), A142 - A142, Japanese


• IgG4関連疾患up-to-date:病態、診断、治療の最新知見 当院における自己免疫性膵炎の長期予後と悪性腫瘍の発症および再燃リスク因子の検討

  權田 真知, 孝橋 信哉, 長尾 佳映, 猪股 典子, 植村 久尋, 増田 重人, 芦名 茂人, 阿部 晶平, 山川 康平, 辻前 正弘, 田中 雄志, 柿原 茉耶, 田中 俊多, 山田 恭孝, 中野 遼太, 酒井 新, 小林 隆, 塩見 英之, 増田 充弘, 児玉 裕三

  (一社)日本膵臓学会, Aug. 2021, 膵臓, 36(3) (3), A209 - A209, Japanese


• 膵炎・膵癌のbench to bed:病態解明から新規治療法開発に向けて 急性膵炎におけるPLCεを介した炎症制御機構の解明

  辻前 正弘, 増田 充弘, 植村 久尋, 猪股 典子, 長尾 佳映, 阿部 晶平, 權田 真知, 増田 重人, 山川 康平, 芦名 重人, 山田 恭孝, 田中 雄志, 中野 遼太, 酒井 新, 小林 隆, 塩見 英之, 吉川 陽子, 片岡 徹, 児玉 裕三

  (一社)日本膵臓学会, Aug. 2021, 膵臓, 36(3) (3), A236 - A236, Japanese


• 肝門部胆管狭窄に対する内視鏡的胆道ドレナージ術におけるUneven double-lumen cannulaの有用性

  増田 重人, 酒井 新, 児玉 裕三, 阿部 晶平, 權田 真知, 芦名 茂人, 山川 康平, 辻前 正弘, 田中 雄志, 山田 恭孝, 田中 俊多, 中野 遼太, 小林 隆, 増田 充弘, 塩見 英之

  (一社)日本胆道学会, Aug. 2021, 胆道, 35(3) (3), 505 - 505, Japanese


• Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine Expression.

  Gyanu Parajuli, Murat Tekguc, James B Wing, Ari Hashimoto, Daisuke Okuzaki, Takeshi Hirata, Atsushi Sasaki, Takahide Itokazu, Haruka Handa, Hirokazu Sugino, Yoshihiro Nishikawa, Hozaifa Metwally, Yuzo Kodama, Shinya Tanaka, Hisataka Sabe, Toshihide Yamashita, Shimon Sakaguchi, Tadamitsu Kishimoto, Shigeru Hashimoto

  The acquisition of mesenchymal traits leads to immune evasion in various cancers, but the underlying molecular mechanisms remain unclear. In this study, we found that the expression levels of AT-rich interaction domain-containing protein 5a (Arid5a), an RNA-binding protein, were substantially increased in mesenchymal tumor subtypes. The deletion of Arid5a in tumor cell lines enhanced antitumor immunity in immunocompetent mice, but not in immunodeficient mice, suggesting a role for Arid5a in immune evasion. Furthermore, an Arid5a-deficient tumor microenvironment was shown to have robust antitumor immunity, as manifested by suppressed infiltration of granulocytic myeloid-derived suppressor cells and regulatory T cells. In addition, infiltrated T cells were more cytotoxic and less exhausted. Mechanistically, Arid5a stabilized Ido1 and Ccl2 mRNAs and augmented their expression, resulting in enhanced tryptophan catabolism and an immunosuppressive tumor microenvironment. Thus, our findings demonstrate the role of Arid5a beyond inflammatory diseases and suggest Arid5a as a promising target for the treatment of immunotolerant malignant tumors.See related Spotlight by Van den Eynde, p. 854.

  Aug. 2021, Cancer immunology research, 9(8) (8), 862 - 876, English, International magazine

  Scientific journal


• Long-term outcome of stent placement inside the bile duct for biliary strictures after living-donor liver transplantation.

  Yoshihiro Nishikawa, Norimitsu Uza, Koichiro Hata, Saiko Marui, Takeshi Kuwada, Tomoaki Matsumori, Takahisa Maruno, Masahiro Shiokawa, Katsutoshi Kuriyama, Akira Kurita, Shujiro Yazumi, Yuzo Kodama, Atsushi Yoshizawa, Takayuki Anazawa, Takashi Ito, Shinji Uemoto, Hiroshi Seno

  BACKGROUND AND AIMS: In living-donor liver transplantation (LDLT), anastomotic biliary stricture is a serious and refractory complication. In this study, we reviewed the transition of post-LDLT anastomotic biliary strictures and evaluated long-term outcome of stent placement inside the bile duct, which is referred to as an "inside-stent". METHODS: Of 805 consecutive adult LDLT recipients in our institution (2000-2018), we reviewed 639 patients with duct-to-duct biliary reconstruction and analyzed chronological changes of post-LDLT biliary strictures. Moreover, we focused on 2006 when various surgical modifications were introduced and compared the details of post-LDLT biliary strictures before and after 2006, especially focusing on the long-term outcome of inside-stent placement. RESULTS: The proportion of left-lobe grafts had increased from 1.8% before 2005 to 39.3% after 2006 (P < 0.001) to maximize the living-donor safety. Overall, post-LDLT anastomotic biliary strictures occurred in 21.3% of the patients with a median follow-up period of 106.1 months, which was decreased from 32.6% before 2005 to 12.8% after 2006 (P < 0.001). Anastomotic biliary strictures were less in patients with a left-lobe graft than with a right-lobe (9.4% vs. 25.4%, P < 0.001). The overall technical success rate of inside-stent placement was 82.4%, with an improvement from 75.3% before 2005 up to 95.7% after 2006 (P < 0.01). Furthermore, the stricture resolution rate remained high at approximately 90% throughout the observation period. CONCLUSION: Increased use of left-lobe grafts with several surgical modifications significantly reduced post-LDLT anastomotic biliary strictures, leading to favorable long-term outcome of inside-stent placement for this condition.

  Jul. 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 28(1) (1), 88 - 97, English, International magazine

  Scientific journal


• Distinctive detection of insulinoma using [18F]FB(ePEG12)12-exendin-4 PET/CT.

  Takaaki Murakami, Hiroyuki Fujimoto, Keita Hamamatsu, Yuki Yamauchi, Yuzo Kodama, Naotaka Fujita, Junji Fujikura, Yoichi Shimizu, Yuji Nakamoto, Hiroyuki Kimura, Hideo Saji, Nobuya Inagaki

  Specifying the exact localization of insulinoma remains challenging due to the lack of insulinoma-specific imaging methods. Recently, glucagon-like peptide-1 receptor (GLP-1R)-targeted imaging, especially positron emission tomography (PET), has emerged. Although various radiolabeled GLP-1R agonist exendin-4-based probes with chemical modifications for PET imaging have been investigated, an optimal candidate probe and its scanning protocol remain a necessity. Thus, we investigated the utility of a novel exendin-4-based probe conjugated with polyethylene glycol (PEG) for [18F]FB(ePEG12)12-exendin-4 PET imaging for insulinoma detection. We utilized [18F]FB(ePEG12)12-exendin-4 PET/CT to visualize mouse tumor models, which were generated using rat insulinoma cell xenografts. The probe demonstrated high uptake value on the tumor as 37.1 ± 0.4%ID/g, with rapid kidney clearance. Additionally, we used Pdx1-Cre;Trp53R172H;Rbf/f mice, which developed endogenous insulinoma and glucagonoma, since they enabled differential imaging evaluation of our probe in functional pancreatic neuroendocrine neoplasms. In this model, our [18F]FB(ePEG12)12-exendin-4 PET/CT yielded favorable sensitivity and specificity for insulinoma detection. Sensitivity: 30-min post-injection 66.7%, 60-min post-injection 83.3%, combined 100% and specificity: 30-min post-injection 100%, 60-min post-injection 100%, combined 100%, which was corroborated by the results of in vitro time-based analysis of internalized probe accumulation. Accordingly, [18F]FB(ePEG12)12-exendin-4 is a promising PET imaging probe for visualizing insulinoma.

  Jul. 2021, Scientific reports, 11(1) (1), 15014 - 15014, English, International magazine

  Scientific journal


• Clinical management for malignant afferent loop obstruction.

  Arata Sakai, Hideyuki Shiomi, Atsuhiro Masuda, Takashi Kobayashi, Yasutaka Yamada, Yuzo Kodama

  Afferent loop obstruction (ALO) is defined as duodenal or jejunal mechanical obstruction at the proximal anastomosis site of a gastrojejunostomy. With advances in chemotherapy, the incidence of malignant ALO is increasing. Malignant ALO can be complicated by ischemia, gangrenous bowel, pancreatitis, and ascending cholangitis. Moreover, the general condition of patients with recurrent cancer is often poor. Therefore, accurate and rapid diagnosis and minimally invasive treatments are required. However, no review articles on the diagnosis and treatment of malignant ALO have been published. Through literature searching, we reviewed related articles published between 1959 and 2020 in the PubMed database. Herein, we present recent advances in the diagnosis and treatment of malignant ALO and describe future perspectives. Endoscopic transluminal self-expandable metal stent (SEMS) placement is considered the standard treatment for malignant ALO, as this procedure is well established and less invasive. However, with the development of interventional endoscopic ultrasound (EUS) in recent years, the usefulness of EUS-guided gastrojejunostomy has been reported. Moreover, through indirect comparison, this approach has been reported to be superior to transluminal SEMS placement. It is expected that a safer and less invasive treatment method will be established through the continued advancement and innovation of interventional endoscopy techniques.

  Jul. 2021, World journal of gastrointestinal oncology, 13(7) (7), 684 - 692, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• AIDS-Related Burkitt Lymphoma Presenting Multiple Nodules in the Pancreas.

  Shinya Kohashi, Arata Sakai, Yuzo Kodama

  Jul. 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 肝外門脈閉塞で形成されたCavernous transformationを合併した遠位胆管癌の一例

  三輪 一貴, 長尾 佳映, 酒井 新, 孝橋 真哉, 猪股 典子, 植村 久尋, 増田 重人, 芦名 茂人, 阿部 昌平, 権田 真知, 山川 康平, 辻前 正弘, 田中 雄志, 田中 俊多, 山田 恭孝, 中野 遼太, 小林 隆, 塩見 英之, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jul. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 106回, 88 - 88, Japanese


• 【早期大腸癌内視鏡治療の新展開】大腸T1b癌を完全一括切除するために必要な内視鏡的切除技術

  豊永 高史, 阪口 博哉, 池澤 伸明, 中野 佳子, 田中 心和, 石田 司, 阿部 洋文, 吉崎 哲也, 鷹尾 俊達, 森田 圭紀, 馬場 慎一, 滝原 浩守, 西野 栄世, 横崎 宏, 児玉 裕三

  (株)医学書院, Jul. 2021, 胃と腸, 56(8) (8), 1047 - 1056, Japanese


• 下部消化管腫瘍性病変に対する内視鏡的切除方法の戦略 当院における憩室内および近接病変に対する大腸ESDの治療成績と工夫

  池澤 伸明, 豊永 高史, 森田 圭紀, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jul. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 106回, 72 - 72, Japanese


• 正中弓状靱帯症候群に合併した後下膵十二指腸動脈瘤破裂に対するコイル塞栓後に十二指腸狭窄をきたした一例

  中辻 政志, 池澤 伸明, 鷹尾 俊達, 中井 達也, 賀来 英俊, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jul. 2021, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 106回, 96 - 96, Japanese


• Peroral endoscopic myotomy for achalasia with esophageal varices.

  Satoshi Urakami, Shinwa Tanaka, Yuzo Kodama

  Jul. 2021, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 33(5) (5), e91-e92, English, International magazine

  Scientific journal


• Essential role of Notch/Hes1 signaling in postnatal pancreatic exocrine development.

  Katsutoshi Kuriyama, Yuzo Kodama, Masahiro Shiokawa, Yoshihiro Nishikawa, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Nobuyuki Kakiuchi, Teruko Tomono, Tomoaki Matsumori, Atsushi Mima, Toshihiro Morita, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Ryoichiro Kageyama, Tsutomu Chiba, Hiroshi Seno

  BACKGROUND: Notch/Hes1 signaling has been shown to play a role in determining the fate of pancreatic progenitor cells. However, its function in postnatal pancreatic maturation is not fully elucidated. METHODS: We generated conditional Hes1 knockout and/or Notch intracellular domain (NICD) overexpression mice in Ptf1a- or Pdx1-positive pancreatic progenitor cells and analyzed pancreatic tissues. RESULTS: Both Ptf1acre/+; Hes1f/f and Ptf1acre/+; Rosa26NICD mice showed normal pancreatic development at P0. However, exocrine tissue of the pancreatic tail in Ptf1acre/+; Hes1f/f mice atrophied and was replaced by fat tissue by 4 weeks of age, with increased apoptotic cells and fewer centroacinar cells. This impaired exocrine development was completely rescued by NICD overexpression in Ptf1acre/+; Hes1f/f; Rosa26NICD mice, suggesting compensation by a Notch signaling pathway other than Hes1. Conversely, Pdx1-Cre; Hes1f/f mice showed impaired postnatal exocrine development in both the pancreatic head and tail, revealing that the timing and distribution of embryonic Hes1 expression affects postnatal exocrine tissue development. CONCLUSIONS: Notch signaling has an essential role in pancreatic progenitor cells for the postnatal maturation of exocrine tissue, partly through the formation of centroacinar cells.

  Jul. 2021, Journal of gastroenterology, 56(7) (7), 673 - 687, English, Domestic magazine

  Scientific journal


• Reducing the risk of developing walled-off necrosis in patients with acute necrotic collection using recombinant human soluble thrombomodulin.

  Takaaki Eguchi, Yoshihisa Tsuji, Akihiko Okada, Dai Inoue, Hironobu Tokumasu, Kosuke Iwane, Yoshitaka Nakai, Toshihiro Kusaka, Yoshito Uenoyama, Koichi Fujita, Masataka Yokode, Yukimasa Yamashita, Yugo Sawai, Masanori Asada, Takao Mikami, Chiharu Kawanami, Yasushi Kudo, Shujiro Yazumi, Tsuyoshi Sanuki, Arata Sakai, Toshihiro Morita, Yojiro Sakuma, Norimitsu Uza, Yutaka Takada, Toshinao Itani, Katsutoshi Kuriyama, Kazuyoshi Matsumura, Kazuki Ikeda, Hitoshi Someda, Eiji Funatsu, Shinji Katsushima, Yuzo Kodama, Hiroshi Seno

  BACKGROUND/PURPOSE: The purpose of the present study was to investigate the possibility of reducing clinical impacts of acute necrotic collection (ANC) on patients with acute pancreatitis (AP) using recombinant human soluble thrombomodulin (rTM). METHODS: In this retrospective multicenter study, 233 consecutive AP patients with ANC and acute peripancreatic fluid collection (APFC) from 2012 to 2016 were enrolled. To assess clinical impacts of ANC, severity on admission (JPN score, JPN CT grade, and Modified CT severity index), development of walled-off necrosis (WON), imaging costs for follow-up, and mortality were recorded. Finally, we investigated whether rTM could reduce the clinical impacts, adjusting the severity using propensity analysis with Inverse probability of treatment weighting. RESULTS: Patients with ANC developed WON with higher ratio than APFC (58/98 [59.2%] vs 20/135 [14.8%], OR = 8.3, P < .01]. Severity on admission and imaging costs for follow-up in ANC patients were significantly higher than those in APFC (P < .01). However, regarding mortality, there was no significant difference between patients with ANC and APFC (P = .41). Adjusting severity, it was revealed that rTM administration significantly reduced the risk of ANC developed WON (OR = 0.23, P = .01). CONCLUSIONS: While ANC had a higher clinical impact than that of APFC, we found that early administration of rTM may reduce the impact.

  Jun. 2021, Journal of hepato-biliary-pancreatic sciences, 28(9) (9), 788 - 797, English, Domestic magazine

  Scientific journal


• Correction: CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma.

  Toshihiro Morita, Yuzo Kodama, Masahiro Shiokawa, Katsutoshi Kuriyama, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Tomoaki Matsumori, Nobuyuki Kakiuchi, Teruko Tomono, Atsushi Mima, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Yoshihiro Nishikawa, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Takashi Nagasawa, Tsutomu Chiba, Hiroshi Seno

  Jun. 2021, Cancer research, 81(12) (12), 3427 - 3427, English, International magazine

  Scientific journal


• Timing of pyloric stenosis and effectiveness of endoscopic balloon dilation after pyloric endoscopic submucosal dissection.

  Hiroshi Takayama, Takashi Toyonaga, Tetsuya Yoshizaki, Hirofumi Abe, Tatsuya Nakai, Chise Ueda, Satoshi Urakami, Hidetoshi Kaku, Yusaku Shimamoto, Kei Matsumoto, Kazunori Tsuda, Hiroya Sakaguchi, Koki Matsuoka, Shinichi Baba, Hiroshi Takihara, Nobuaki Ikezawa, Shinwa Tanaka, Madoka Takao, Toshitatsu Takao, Yoshinori Morita, Yuzo Kodama

  BACKGROUND AND AIM: There have been studies on risk factors for stenosis after pyloric endoscopic submucosal dissection (ESD). However, the most appropriate strategies for the management of cases with these risk factors have not been established. This study aimed to investigate post-ESD management by evaluating the timing of stenosis and the effectiveness of endoscopic balloon dilation (EBD) after pyloric ESD. METHODS: We retrospectively reviewed cases of pyloric ESD. We first reassessed risk factors for stenosis in multivariate analysis and receiver operating characteristic curve and defined patients with the identified risk factors as the risk group. The primary outcome was the timing of stenosis in the risk group assessed by the Kaplan-Meier method. RESULTS: We reviewed 159 cases with pyloric ESD and observed pyloric stenosis in 25 cases. Cases with circumferential mucosal defect ≥ 76% were identified as the risk group. The stenosis-free probability in the risk group was 97% (95% confidence interval [CI]: 79-100%), 94% (95% CI: 76-98%), and 85% (95% CI: 66-93%) on days 7, 14, and 21, respectively. It decreased every week thereafter and did not significantly change after day 56. Twenty-three stenosis cases, except for conservative improvement, including six whole circumferential pyloric ESD cases, were improved by EBD without complications. CONCLUSIONS: Post-ESD stenosis often developed from the third to the eighth week. In all pyloric ESD cases, including whole circumferential pyloric ESD cases, pyloric stenosis was improved following EBD without complications.

  Jun. 2021, Journal of gastroenterology and hepatology, 36(11) (11), 3158 - 3163, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Stent placement above the sphincter of Oddi is a useful option for patients with inoperable malignant hilar biliary obstruction.

  Akira Kurita, Norimitsu Uza, Masanori Asada, Kenichi Yoshimura, Tadamasa Takemura, Shujiro Yazumi, Yuzo Kodama, Hiroshi Seno

  BACKGROUND AND AIMS: Endoscopic biliary drainage (EBD) is essential for the management of malignant hilar biliary obstruction (MHBO). We prospectively evaluated the efficacy and safety of "inside-stent" therapy, where a plastic stent is placed above the sphincter of Oddi without endoscopic sphincterotomy, in patients with inoperable MHBO. METHODS: This study was a multicenter, single-blinded, randomized controlled trial at three centers. Patients with inoperable MHBO were enrolled in this study, and randomly assigned to receive an inside-stent or conventional-stent therapy. The primary endpoint was cumulative stent patency of the initial stent. The secondary endpoints were second stent patency, technical and clinical success rate, adverse events, re-intervention rate, and overall patient survival. RESULTS: Forty-three patients were randomly assigned to the inside-stent group (n = 21) or the conventional-stent group (n = 22). The median cumulative stent patency of the initial stent was 123 days in the inside-stent group and 51 days in the conventional-stent group (P = .031). For patients with the initial stent dysfunction in the conventional-stent group, the inside-stent was placed as a second stent, and its patency was significantly longer than that of the initial stent (P = .0001). The technical and clinical success rate, re-intervention rate, second stent patency, adverse events, and survival probability did not differ between the groups. CONCLUSIONS: Inside-stent therapy appears to be useful not only as an initial stent but also as a second stent for patients with inoperable MHBO. TRIAL REGISTRATION NUMBER: UMIN000004587.

  Jun. 2021, Surgical endoscopy, English, International magazine

  Scientific journal


• Development and validation of an endoscopic submucosal dissection video assessment tool.

  Madoka Takao, Elif Bilgic, Pepa Kaneva, Kevin Waschke, Satoshi Endo, Yoshiko Nakano, Fumiaki Kawara, Shinwa Tanaka, Tsukasa Ishida, Yoshinori Morita, Takashi Toyonaga, Eiji Umegaki, Yuzo Kodama, Gerald M Fried

  BACKGROUND: Despite a need for assessment of endoscopic submucosal dissection (ESD) skills in order to track progress and determine competence, there is no structured measure of assessing competency in ESD performance. The present study aims to develop and examine validity evidence for an assessment tool to evaluate the recorded performance of ESD for gastric neoplasms. METHODS: The ESD video assessment tool (EVAT) was systematically developed by ESD experienced endoscopists. The EVAT consists of a 25-item global rating scale and 3-item checklist to assess competencies required to perform ESD. Five unedited videos were each evaluated by 2-blinded experienced ESD endoscopists to assess inter-rater reliability using intraclass correlation coefficients (ICC). Seventeen unedited videos in total were rated by 3 blinded experienced ESD endoscopists. Validity evidence for relationship to other variables was examined by comparing scores of inexperienced (fellows) and experienced endoscopists (attending staff), and by evaluating the relationship between the EVAT scores and ESD case experience. Internal consistency was evaluated using Cronbach's alpha. RESULTS: The inter-rater reliability for the total score was high at 0.87 (95% confidence interval 0.11 to 0.99). The total score [median, interquartile range (IQR)] was significantly different between the inexperienced (71, 63-77) and experienced group (95, 91-97) (P = 0.005). The total scores demonstrated high correlation with the number of ESD cases (Spearman's ρ = 0.79, P < 0.01). The internal consistency was 0.97. CONCLUSIONS: This study provides preliminary validity evidence for the assessment of video-recorded ESD performances for gastric neoplasms using EVAT.

  Jun. 2021, Surgical endoscopy, 35(6) (6), 2671 - 2678, English, International magazine

  Scientific journal


• A novel technique for mapping biopsy of bile duct cancer.

  Hirokazu Okada, Norimitsu Uza, Tomoaki Matsumori, Shimpei Matsumoto, Yuya Muramoto, Sakiko Ota, Takeharu Nakamura, Hiroyuki Yoshida, Tomonori Hirano, Takeshi Kuwada, Saiko Marui, Yuko Sogabe, Toshihiro Morita, Nobuyuki Kakiuchi, Atsushi Mima, Tatsuki Ueda, Yoshihiro Nishikawa, Motoyuki Tsuda, Takahisa Maruno, Masahiro Shiokawa, Ken Takahashi, Kojiro Taura, Sachiko Minamiguchi, Yuzo Kodama, Hiroshi Seno

  BACKGROUND : Accurate preoperative assessment of the longitudinal extension of perihilar cholangiocarcinoma (PHCC) is essential for treatment planning. Mapping biopsies for PHCC remain challenging owing to technical difficulties and insufficient sample amounts. The aim of this study was to investigate the usefulness of a novel technique for mapping biopsies of PHCC. METHODS : Our novel method focused on a biliary stent delivery system for mapping biopsies. Fifty patients with PHCC undergoing endoscopic transpapillary mapping biopsy using the novel method were reviewed from August 2015 to June 2019. RESULTS : The median number of biopsy samples was six (range 1 - 17), and the rate of adequate sampling was 91.4 % (266 /291). Biopsy from the intrahepatic bile duct was possible in 82.0 % of patients (41 /50), and negative margins were confirmed in the resected specimens from 34 /39 patients who underwent surgery (87.2 %). None of the patients had post-endoscopic retrograde cholangiopancreatography pancreatitis. CONCLUSIONS : With our novel method, accurate assessment of the longitudinal extension of PHCC might be expected with minimal trauma to the duodenal papilla.

  Jun. 2021, Endoscopy, 53(6) (6), 647 - 651, English, International magazine

  Scientific journal


• Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers.

  Atsushi Yamamoto, Yoshihiko Yano, Yoshihide Ueda, Eiichiro Yasutomi, Yuri Hatazawa, Hiroki Hayashi, Ryutaro Yoshida, Naoki Asaji, Yuuki Shiomi, Kazutoshi Tobimatsu, Arata Sakai, Yuzo Kodama

  PURPOSE: The risk factors and clinical characteristics of ICI-induced immune-mediated hepatotoxicity (IMH) are not fully understood. Thus, the present study sought to clarify the clinical features of IMH. METHODS: All patients treated with ICIs between September 2014 and April 2019 at our institution were included. Clinical data were retrospectively collected from medical records. The frequency of grade ≥ 2 liver damage, clinical characteristics, and risk factors for developing IMH were examined. RESULTS: Overall, 250 patients (median age 71 years; range 30-87 years; 202 males and 48 females) were included in the analyses. Forty-five patients had elevated transaminase levels (> threefold the upper limit of normal). Of these, 21 were considered to have IMH. The remaining 24 patients had other causes of elevated transaminase levels. Steroids were administered to 13/21 patients with IMH. Although all patients exhibited improvement, IMH was not associated with the anticancer efficacy of the ICIs or OS. A multivariable analysis revealed that IMH was significantly associated with malignant melanoma (odds ratio [OR] 11.6; 95% confidence interval [CI] 3.5-38.0; P = 0.0002) and ipilimumab-nivolumab combination therapy (OR 61.2; 95% CI 7.9-1275.3; P < 0.0001). CONCLUSION: Immune-mediated hepatotoxicity occurred in 9.5% of patients treated with ICIs. Appropriate therapeutic interventions are important to avoid affecting the patient's prognosis, and accurate diagnosis of IMH is essential for this purpose. The frequency of IMH varied according to the type of cancer and the drug used, and was significantly higher in patients with malignant melanoma and in patients given ipilimumab-nivolumab combination therapy.

  Jun. 2021, Journal of cancer research and clinical oncology, 147(6) (6), 1747 - 1756, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Identification of an Anti-Integrin αvβ6 Autoantibody in Patients With Ulcerative Colitis.

  Takeshi Kuwada, Masahiro Shiokawa, Yuzo Kodama, Sakiko Ota, Nobuyuki Kakiuchi, Yasuhito Nannya, Hajime Yamazaki, Hiroyuki Yoshida, Takeharu Nakamura, Shimpei Matsumoto, Yuya Muramoto, Shuji Yamamoto, Yusuke Honzawa, Katsutoshi Kuriyama, Kanako Okamoto, Tomonori Hirano, Hirokazu Okada, Saiko Marui, Yuko Sogabe, Toshihiro Morita, Tomoaki Matsumori, Atsushi Mima, Yoshihiro Nishikawa, Tatsuki Ueda, Kazuyoshi Matsumura, Norimitsu Uza, Tsutomu Chiba, Hiroshi Seno

  BACKGROUND AND AIMS: Ulcerative colitis is the most frequent type of inflammatory bowel disease and is characterized by colonic epithelial cell damage. Although involvement of autoimmunity has been suggested in ulcerative colitis, specific autoantigens/antibodies have yet to be elucidated. METHODS: Using 23 recombinant integrin proteins, we performed enzyme-linked immunosorbent assays on sera from patients with ulcerative colitis and controls. Integrin expression and IgG binding in the colon tissues of patients with ulcerative colitis and controls were examined using immunofluorescence and coimmunoprecipitation, respectively. The blocking activity of autoantibodies was examined using solid-phase binding and cell adhesion assays. RESULTS: Screening revealed that patients with ulcerative colitis had IgG antibodies against integrin αvβ6. In the training and validation groups, 103 of 112 (92.0%) patients with ulcerative colitis and only 8 of 155 (5.2%) controls had anti-integrin αvβ6 antibodies (P < .001), resulting in a sensitivity of 92.0% and a specificity of 94.8% for diagnosing ulcerative colitis. Anti-integrin αvβ6 antibody titers coincided with ulcerative colitis disease activity, and IgG1 was the major subclass. Patient IgG bound to the integrin αvβ6 expressed on colonic epithelial cells. Moreover, IgG of patients with ulcerative colitis blocked integrin αvβ6-fibronectin binding through an RGD (Arg-Gly-Asp) tripeptide motif and inhibited cell adhesion. CONCLUSIONS: A significant majority of patients with ulcerative colitis had autoantibodies against integrin αvβ6, which may serve as a potential diagnostic biomarker with high sensitivity and specificity.

  Jun. 2021, Gastroenterology, 160(7) (7), 2383 - 2394, English, International magazine

  Scientific journal


• Beta-catenin-activated hepatocellular adenoma in a male.

  Ryosuke Ishida, Yoshihiko Yano, Atsushi Yamamoto, Eiichiro Yasutomi, Yuri Hatazawa, Hiroki Hayashi, Yuuki Shiomi, Hidetoshi Gon, Satoshi Omiya, Maki Kanzawa, Tomoo Itoh, Yoshihide Ueda, Yuzo Kodama

  Beta-catenin-activated hepatocellular adenoma is potentially malignant and warrants careful follow-up and surgical resection. Here, we report a 48-year-old man in whom a 55 mm single liver tumor was incidentally detected in the S1 segment. Contrast-enhanced computed tomography scans showed no enhancement in the early phase and a slight defection in the late phase. The tumor was enhanced hyperintensity in the hepatobiliary phase on Gd-ethoxybenzyl-diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging. The histologic features of ultrasound-guided fine-needle aspiration biopsy indicated hepatocellular adenoma, and the tumor was immunohistochemically positive for glutamine synthetase and β-catenin. Considering the risk of malignant transformation, he underwent laparoscopic-assisted partial liver resection. The resected tumor did not contain any malignant lesions. This case indicates that aspiration needle biopsy and immunohistochemistry were useful for histological diagnosis and treatment decisions based on the molecular definition of hepatocellular adenoma.

  Jun. 2021, Clinical journal of gastroenterology, 14(3) (3), 831 - 835, English, Domestic magazine

  Scientific journal


• Pancreatic metastasis of renal cell carcinoma filling into the duct of Santorini.

  Yasutaka Yamada, Arata Sakai, Shohei Abe, Masanori Gonda, Takashi Kobayashi, Atsuhiro Masuda, Hideyuki Shiomi, Sachiyo Shirakawa, Hirochika Toyama, Toshiki Hyodo, Maki Kanzawa, Tomoo Itoh, Yuzo Kodama

  A 78-year-old man who underwent right nephrectomy for renal cell carcinoma (RCC) 18 years ago visited our hospital complaining of abdominal pain. Imaging revealed that the pancreatic head tumor obstructed the Santorini duct. We suspected a pancreatic intraductal tumor, such as an intraductal tubulopapillary neoplasm or intraductal papillary mucinous neoplasm. Thus, the patient underwent subtotal stomach-preserving pancreaticoduodenectomy. Pathological findings confirmed the diagnosis of metastatic RCC. Herein, we report a case of pancreatic metastasis of an RCC that presented with a tumor in the pancreatic duct.

  Jun. 2021, Clinical journal of gastroenterology, 14(3) (3), 905 - 909, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• EUS-guided cholecystoduodenostomy using novel dumbbell-shaped fully covered metal stent (with video).

  Hassan Atalla, Hideyuki Shiomi, Ryota Nakano, Arata Sakai, Takashi Kobayashi, Atsuhiro Masuda, Yuzo Kodama

  Highlight Atalla and colleagues present a novel dumbbell-shaped fully covered self-expandable metal stent which, with its anti-migration property and relatively lower cost, is a feasible and cost-effective option as an alternative to lumen-apposing metal stents for endoscopic ultrasound-guided transduodenal gallbladder drainage for acute cholecystitis in patients who are ineligible for surgery.

  May 2021, Journal of hepato-biliary-pancreatic sciences, 28(5) (5), e19-e20, English, Domestic magazine

  Scientific journal


• Review of Diagnostic Biomarkers in Autoimmune Pancreatitis: Where Are We Now?

  Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama

  Autoimmune pancreatitis (AIP) is a pancreatic manifestation of an IgG4-related disease (IgG4-RD). AIP lacks disease-specific biomarkers, and therefore, it is difficult to distinguish AIP from malignancies, especially pancreatic cancer. In this review, we have summarized the latest findings on potential diagnostic biomarkers for AIP. Many investigations have been conducted, but no specific biomarkers for AIP are identified. Therefore, further studies are required to identify accurate diagnostic biomarkers for AIP.

  Apr. 2021, Diagnostics (Basel, Switzerland), 11(5) (5), English, International magazine

  Scientific journal


• The risk scoring system for assessing the technical difficulty of endoscopic submucosal dissection in cases of remnant gastric cancer after distal gastrectomy.

  Shinwa Tanaka, Tetsuya Yoshizaki, Yoshinobu Yamamoto, Takayuki Ose, Tsukasa Ishida, Yasuaki Kitamura, Daisuke Obata, Mineo Iwatate, Mikio Fujita, Atsushi Ikeda, Ryusuke Ariyoshi, Fumiaki Kawara, Hirofumi Abe, Toshitatsu Takao, Yoshinori Morita, Yasushi Sano, Eiji Umegaki, Hogara Nishisaki, Takashi Toyonaga, Yuzo Kodama

  BACKGROUND: Endoscopic submucosal dissection (ESD) for remnant gastric cancer (RGC) after distal gastrectomy (DG) is considered technically challenging due to the narrow working space, and severe fibrosis and staples from the previous surgery. Technical difficulties of ESD for RGC after DG have not been thoroughly investigated. This study aimed to develop and validate a risk-scoring system for assessing the technical difficulty of ESD for RGC after DG in a large multicenter cohort. METHODS: We investigated patients who underwent ESD for RGC after DG in 10 institutions between April 2008 and March 2018. A difficult case was defined as ESD lasting ≥ 120 min, involving piecemeal resection, or the occurrence of perforation during the procedure. A risk-scoring system for the technical difficulty of the procedure was developed based on multiple logistic regression analyses, and its performance was internally validated using bootstrapping. RESULTS: A total of 197 consecutive patients with 201 lesions were analyzed. There were 90 and 111 difficult and non-difficult cases, respectively. The scoring model consisted of four independent risk factors and points of risk scores were assigned for each as follows: tumor size > 20 mm: 2 points; anastomosis site: 2 points; suture line: 1 point; and non-expert endoscopist: 2 points. The C-statistics of the scoring system for technical difficulty was 0.72. CONCLUSIONS: We developed a validated risk-scoring model for predicting the technical difficulty of ESD for RGC after DG that can contribute to its safer and more reliable performance.

  Apr. 2021, Surgical endoscopy, 36(2) (2), 1482 - 1489, English, International magazine

  Scientific journal


• Peroral endoscopic myotomy for advanced achalasia with megaesophagus.

  Chise Ueda, Hirofumi Abe, Shinwa Tanaka, Fumiaki Kawara, Takashi Toyonaga, Ryusuke Ariyoshi, Tomoya Sako, Hiroya Sakaguchi, Nobuaki Ikezawa, Satoshi Urakami, Tatsuya Nakai, Yuzo Kodama

  BACKGROUND: The outcomes of peroral endoscopic myotomy for advanced achalasia are not well known. This study aimed to evaluate the outcomes of peroral endoscopic myotomy for achalasia with megaesophagus, which is one of the characteristics of advanced achalasia. METHODS: In total, 234 patients with achalasia who underwent peroral endoscopic myotomy in our hospital from April 2015 to March 2019 were included in this retrospective observational study. Megaesophagus was defined as a maximum esophageal diameter of 6 cm or more. Outcomes, including clinical success (Eckardt score ≤ 3 without retreatment) at the 1-year follow-up, technical success, and perioperative complications, were investigated and compared between patients with and without megaesophagus. RESULTS: Eleven patients (4.7%) were diagnosed with megaesophagus. The clinical success rate achieved was 63.6% in patients with megaesophagus, with a significant decrease in the Eckardt score (6 vs. 2, p = 0.003) and integrated relaxation pressure (28 mmHg vs. 9 mmHg, p = 0.028). The technical success rate was 100%. However, patients with megaesophagus had a significantly lower clinical success rate than those without megaesophagus (63.6% vs. 96.0%, p = 0.002). Furthermore, patients with megaesophagus had significantly higher rates of major adverse events than those without megaesophagus (18.2% vs. 2.7%, p = 0.048). CONCLUSIONS: Peroral endoscopic myotomy improved achalasia-related symptoms, and this was technically feasible in patients with megaesophagus. However, the clinical success rate was somewhat low, and the rate of major adverse events was high. Therefore, peroral endoscopic myotomy should be carefully performed for advanced achalasia with megaesophagus.

  Apr. 2021, Esophagus : official journal of the Japan Esophageal Society, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 胆道出血に対する内視鏡治療の現状と課題 特に肝細胞癌からの胆道出血に関して

  芦名 茂人, 酒井 新, 増田 充弘, 猪股 典子, 孝橋 信哉, 長尾 佳映, 増田 重人, 植村 久尋, 阿部 晶平, 権田 真知, 山川 康平, 辻前 正弘, 田中 雄志, 田中 俊多, 山田 恭孝, 中野 遼太, 小林 隆, 塩見 英之, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 892 - 892, Japanese


• EUS-hepaticogastrostomyにおけるトラブルを未然に回避するためのダブルガイドワイヤー法

  權田 真知, 塩見 英之, 児玉 裕三, 猪股 典子, 孝橋 信哉, 長尾 佳映, 植村 久尋, 増田 重人, 芦名 茂人, 阿部 晶平, 辻前 正弘, 田中 俊多, 田中 雄志, 山田 恭孝, 中野 遼太, 酒井 新, 小林 隆, 増田 充弘

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 907 - 907, Japanese


• 内視鏡的乳頭切除術を行った早期十二指腸乳頭部腫瘍の予後に関する検討

  阿部 晶平, 酒井 新, 児玉 裕三, 猪股 典子, 増田 重人, 權田 真知, 芦名 茂人, 山川 康平, 辻前 正弘, 田中 雄志, 田中 俊多, 山田 泰孝, 中野 遼太, 小林 隆, 塩見 英之, 増田 充弘, 柳本 泰明, 福本 巧

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 980 - 980, Japanese


• 十二指腸表在型腫瘍に対する内視鏡診療(LECS vs EMR vs ESD vs経過観察) 表在型非乳頭部十二指腸上皮性腫瘍に対する腹腔鏡内視鏡合同手術の治療成績

  鷹尾 俊達, 森田 圭紀, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 848 - 848, Japanese


• 進行食道癌に対する食道ステント留置後の食事摂取状況に関する検討

  賀来 英俊, 鷹尾 俊達, 中井 達也, 高山 弘志, 嶋本 有策, 上田 千勢, 津田 一範, 松本 慶, 池澤 伸明, 阪口 博哉, 松岡 晃生, 阿部 洋文, 吉崎 哲也, 鷹尾 まど佳, 森田 圭紀, 豊永 高史, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 910 - 910, Japanese


• 幽門側胃切除後の残胃吻合部の早期胃癌に対する内視鏡的粘膜下層剥離術の再建術式に基づく治療困難性および有効性、安全性の検討

  松本 慶, 鷹尾 俊達, 田中 心和, 森田 圭紀, 豊永 高史, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 956 - 956, Japanese


• Jejunal variceal rupture in a patient with myelofibrosis: a case report.

  Tomonori Wada, Yoshihiko Yano, Atsushi Yamamoto, Masato Kinoshita, Eiichiro Yasutomi, Yuri Hatazawa, Hiroki Hayashi, Yuuki Shiomi, Kimihiro Yamashita, Yoshihide Ueda, Yuzo Kodama

  An 80-year old man with myelofibrosis and chronic renal disease was admitted to our hospital because of severe anemia and gastrointestinal bleeding. Although no bleeding was observed by upper or lower endoscopy, contrast-enhanced computed tomography revealed an enhanced area in the small intestinal wall that was suspected of being the bleeding site, and was confirmed by double-balloon endoscopy. Based on endoscopic findings, it was difficult to differentiate between variceal rupture and collapse of a submucosal tumor. We performed segmental resection of the small intestine to make a definitive diagnosis and achieve reliable hemostasis. The gross findings confirmed a variceal rupture from the small intestine. His gastrointestinal bleeding stopped and his anemia improved following surgery. Although some cases of portal hypertension in association with myelofibrosis have been reported, we are aware of no prior reports of variceal rupture in the small intestine. To our knowledge, this is the first reported case of ectopic jejunal varices in a patient with myelofibrosis.

  Apr. 2021, Clinical journal of gastroenterology, 14(2) (2), 542 - 545, English, Domestic magazine

  Scientific journal


• Clinical outcome of conservatively managed pancreatic intraductal papillary mucinous neoplasms with mural nodules and main duct dilation.

  Arata Sakai, Atsuhiro Masuda, Takaaki Eguchi, Takahiro Anami, Katsuhisa Nishi, Keisuke Furumatsu, Yoshihiro Okabe, Saori Kakuyama, Yu Sato, Chiharu Nishioka, Tsuyoshi Sanuki, Yosuke Yagi, Takashi Kobayashi, Hideyuki Shiomi, Yuzo Kodama

  BACKGROUND: Surgical resection of intraductal papillary mucinous neoplasm (IPMN) is strongly recommended for patients exhibiting high-risk stigmata (HRS). However, determining surgical indications for elderly patients with comorbidities is challenging, as clinical outcomes are not well characterized. This multicenter observational study elucidated the clinical outcomes of patients with IPMN exhibiting HRS who did not undergo surgery. METHODS: This study enrolled 101 IPMN patients exhibiting HRS with follow-up observations at 11 hospitals in Japan (2011-2016). The median observation period was 37 months (maximum: 86 months). Primary outcomes were estimated 5-year overall survival (OS) and disease-specific survival (DSS). Survival was also stratified based on HRS features. RESULTS: Of 101 patients, 32 (31.7%) had the main pancreatic duct (MPD) measuring ≥ 10 mm and 80 (79.2%) had mural nodules measuring ≥ 5 mm. The estimated 5-year OS and DSS were 74% and 91%, respectively. In the stratified analysis, the co-presence of MPD ≥ 10 mm and mural nodules ≥ 5 mm or mural nodule ≥ 10 mm were related to worse 5-year DSS (MPD ≥ 10 mm and mural nodules ≥ 5 mm vs other characteristics: 60% vs 95%, log-rank test: p = 0.049; mural nodules ≥ 10 mm vs < 10 mm: 77% vs 95%, log-rank test: p = 0.003). CONCLUSIONS: The estimated 5-year DSS of conservatively managed IPMN patients with mural nodules and main duct dilation was 91%. Only IPMN patients with plural HRS or large nodule formation might have an increased mortality risk. This is an important insight that can help facilitate appropriate clinical decision-making, especially in the elderly or high-surgical risk IPMN patients.

  Mar. 2021, Journal of gastroenterology, 56(3) (3), 285 - 292, English, Domestic magazine

  Scientific journal


• Development and validation of an analysis method for pesticide residues by gas chromatography-tandem mass spectrometry in Daikenchuto.

  Hirokazu Saegusa, Hiroshi Nomura, Masaki Takao, Takashi Hamaguchi, Masaru Yoshida, Yuzo Kodama

  Daikenchuto (DKT) is one of the most widely used "Kampo" in Japan as a representative of herbal medicine. Because DKT is made from a natural product like food, it requires the management of pesticides; therefore, an analysis of residual pesticides in Kampo is required. The World Health Organization (WHO) indicates that pesticide residue analysis by the U.S. Pharmacopeia (USP) is required. USP defines 107 compounds containing organochlorine pesticides and organophosphorus pesticides and their metabolites, which have a high residual risk. Accordingly, to guarantee the safety of herbal medicines according to global standards is a very important issue. In this study, we developed an analytical method for 91 compounds, which are listed in USP, using DKT as the subject. The method could extract pesticides from DKT with acetone, elute pesticides with acetonitrile using a SepPak C18 column (5 g) and with ethyl acetate using a DSC-NH2 column (2 g), and perform simultaneous analyses by gas chromatography-tandem mass spectrometry (GC-MS/MS). This method, which could quantify 88 compounds, was validated according to USP. A pesticide residue analysis method that meets USP requirements enables the analysis of pesticide residues with a high residue risk and contributes to improving the safety of "Kampo" and other herbal medicines.

  Mar. 2021, Journal of natural medicines, 75(2) (2), 344 - 360, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Fibrin glue: Novel submucosal injection agent for endoscopic submucosal dissection.

  Madoka Takao, Yoshitaka Takegawa, Toshitatsu Takao, Hiroya Sakaguchi, Yoshiko Nakano, Shinwa Tanaka, Yoshinori Morita, Takashi Toyonaga, Eiji Umegaki, Hiromu Kutsumi, Yuzo Kodama

  Background and study aims  Adequate mucosal elevation by submucosal injection is crucial for patient safety and efficiency during endoscopic submucosal dissection (ESD). This study aimed to evaluate the efficacy of fibrin glue (FG) as a long-lasting submucosal injection agent and to evaluate the technical feasibility of FG injection for ESD. Materials and methods  To compare the capabilities of different agents in maintaining submucosal evaluation, we injected FG, hyaluronic acid solution, and normal saline into the porcine gastric specimen that was incised into approximately 5 × 5 cm squares. Then, we measured the height of submucosal elevations over time. Moreover, three hypothetical lesions from the resected porcine stomach underwent ESD with FG injection. Thereafter, we conducted macroscopic and histopathologic analyses. Results FG maintained the greatest submucosal elevation among all the injection agents. Three ESD procedures were performed with en bloc resection. Both macroscopic and histopathologic findings showed a thick FG clot on the ulcers. Conclusions  The FG solution can be potentially used as an ESD submucosal injection agent in an in vitro model.

  Mar. 2021, Endoscopy international open, 9(3) (3), E319-E323, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Modified double-guidewire technique using a unique double-lumen sphincterotome for difficult biliary cannulation.

  Hideyuki Shiomi, Hiromu Kutsumi, Shomei Ryozawa, Atsushi Irisawa, Yuzo Kodama

  Mar. 2021, VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy, 6(3) (3), 124 - 128, English, International magazine

  Scientific journal


• Endoscopic submucosal dissection involving the anal canal presents a risk factor for postoperative stricture.

  Tomoya Sako, Takashi Toyonaga, Yoshiko Nakano, Shinwa Tanaka, Toshitatsu Takao, Shinichi Baba, Hiroshi Takihara, Yoshinori Morita, Eiji Umegaki, Yuzo Kodama

  BACKGROUND: Although postoperative strictures after endoscopic submucosal dissection (ESD) in the rectum are relatively rare, some rectal lesions require resection involving the anal canal, which is a narrow tract comprising squamous epithelium. To the best of our knowledge, no studies have investigated narrow anal canals when evaluating post-ESD strictures. This study aimed to evaluate the impact of resections involving the anal canal on postoperative stricture development. METHODS: Between April 2005 and October 2017, 707 rectal lesions were treated with ESD. We retrospectively investigated 102 lesions that required ≥ 75% circumferential resection. Risk factors for post-ESD stricture and, among patients with strictures, obstructive symptoms, and number of dilation therapies required were investigated. RESULTS: Post-ESD stricture occurred in 18 of 102 patients (17.6%). In the multivariate analysis, circumferential resection ≥ 90% and ESD involving the anal canal (ESD-IAC) were risk factors for postoperative strictures (P ≤ 0.0001 and 0.0115, respectively). Among the patients with strictures, obstructive symptoms were significantly related to anal strictures compared to rectal strictures (100% vs. 27.2%, P = 0.0041). Furthermore, the number of dilation therapies required was significantly greater among patients with anal strictures compared to those with rectal strictures (6.5 times vs. 2.7 times, P = 0.0263). CONCLUSION: Not only circumferential resection ≥ 90% but also ESD-IAC was a significant risk factor for the stricture after rectal ESD. Furthermore, anal strictures were associated with a significantly higher frequency of obstructive symptoms and larger number of required dilation therapies than were rectal strictures.

  Mar. 2021, Surgical endoscopy, 35(3) (3), 1307 - 1316, English, International magazine

  [Refereed]

  Scientific journal


• Feasibility of laparoscopic endoscopic cooperative surgery for non-ampullary superficial duodenal neoplasms: Single-arm confirmatory trial.

  Shingo Kanaji, Yoshinori Morita, Yuta Yamazaki, Yasunori Otowa, Toshitatsu Takao, Shinwa Tanaka, Naoki Urakawa, Masashi Yamamoto, Takeru Matsuda, Taro Oshikiri, Tetsu Nakamura, Satoshi Suzuki, Takashi Toyonaga, Yuzo Kodama, Yoshihiro Kakeji

  OBJECTIVE: Laparoscopic endoscopic cooperative surgery for duodenal tumors (D-LECS) has been developed to prevent duodenal leakage by reinforcing the endoscopic submucosal dissection site. However, there has been no prospective trial showing the feasibility of D-LECS. Herein, we conducted a single-arm confirmatory trial to evaluate the safety of D-LECS for non-ampullary superficial duodenal neoplasms. METHODS: This prospective single-center single-arm confirmatory trial analyzed patients with non-ampullary superficial duodenal neoplasms who underwent D-LECS. The primary endpoint was the incidence of any postoperative leakage occurring on the duodenal wall within 1 month postoperatively. The planned sample size was 20 patients, considering a threshold of 28% and one-sided alpha value of 5%. RESULTS: Between January 2015 and September 2018, 20 eligible patients were enrolled. Sixteen tumors were located in the second portion, three in the first portion, and one in the third portion of the duodenal region. The median operative time was 225 (134-361) min and the median blood loss was 0 (0-150) mL. Curative resection (R0) with negative margins was achieved in 19 cases. One case of postoperative leakage and one case of bleeding of grade 2 according to the Clavien-Dindo classification were observed in this series. The median duration of postoperative hospital stay was 9 (5-12) days. No local recurrence was observed in any patient during the median follow-up of 15.0 (12.0-38.0) months. CONCLUSIONS: This trial confirmed the safety and feasibility of D-LECS for non-ampullary superficial duodenal neoplasms with respect to the low incidence of postoperative duodenal leakage.

  Mar. 2021, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 33(3) (3), 373 - 380, English, International magazine

  [Refereed]

  Scientific journal


• 膵管内腫瘍様の形態を呈した腎癌膵臓転移症例の一例

  青山 雄一郎, 山田 恭孝, 酒井 新, 猪股 典子, 孝橋 信哉, 長尾 佳映, 植村 久尋, 増田 重人, 阿部 晶平, 山川 康平, 辻前 正弘, 田中 雄志, 田中 俊多, 中野 遼太, 白川 幸代, 小林 隆, 塩見 英之, 増田 充弘, 外山 博近, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2021, 日本消化器病学会近畿支部例会プログラム・抄録集, 114回, 59 - 59, Japanese


• A unique device enabling electrohydraulic lithotripsy with an ultraslim scope for difficult stones after endoscopic ultrasound-guided biliary drainage.

  Hassan Atalla, Hideyuki Shiomi, Takuya Ikegawa, Takashi Kobayashi, Arata Sakai, Atsuhiro Masuda, Yuzo Kodama

  Feb. 2021, Endoscopy, 53(2) (2), E52-E53, English, International magazine

  Scientific journal


• Liver abscess caused by Cutibacterium namnetense after transarterial chemoembolization for hepatocellular carcinoma.

  Eiichiro Yasutomi, Yoshihide Ueda, Naoki Asaji, Atsushi Yamamoto, Ryutaro Yoshida, Yuri Hatazawa, Hiroki Hayashi, Yuuki Shiomi, Yoshihiko Yano, Yuzo Kodama

  A 72-year-old man underwent transarterial chemoembolization (TACE) for solitary hepatocellular carcinoma (HCC) located on the S6 segment. He had a history of anti-viral therapy for hepatitis C virus and was being treated for diabetes mellitus with inadequate control. On day 28 after TACE, he visited our hospital again, with complaints of fever and abdominal pain in the right upper quadrant. Blood examination showed elevated levels of white blood cells and C-reactive protein. Computed tomography showed a poorly marginated, low-density lesion measuring 9.5 × 8.0 × 4.0 cm, forming multiple small gas bubbles, located superiorly, and in contact with HCC treated by TACE. Ultrasound-guided puncture revealed whiffy and muddy pus. Gram staining of the pus showed the presence of numerous gram-positive rods, which were identified as Cutibacterium namnetense. He underwent percutaneous trans-hepatic abscess drainage and received antibiotics treatment. The abscess was successfully treated, and he was discharged on day 19. The incidence of liver abscess after TACE is rare, and intestinal microbiota have been reported to be the common pathogens. To the best of our knowledge, this is the first case of liver abscess caused by Cutibacterium namnetense.

  Feb. 2021, Clinical journal of gastroenterology, 14(1) (1), 246 - 250, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Combined bridging and antegrade stent placement during transmural treatment for malignant hilar biliary obstruction in a patient with surgically altered anatomy.

  Hassan Atalla, Hideyuki Shiomi, Arata Sakai, Atsuhiro Masuda, Yuzo Kodama

  Feb. 2021, VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy, 6(2) (2), 87 - 89, English, International magazine

  Scientific journal


• Development of a preoperative risk-scoring system for predicting poor responders to peroral endoscopic myotomy.

  Satoshi Urakami, Hirofumi Abe, Shinwa Tanaka, Fumiaki Kawara, Takashi Toyonaga, Ryusuke Ariyoshi, Tomoya Sako, Nobuaki Ikezawa, Chise Ueda, Yuzo Kodama

  BACKGROUND AND AIMS: Peroral endoscopic myotomy (POEM) is an effective treatment for esophageal motility disorder. However, some people are poor responders who will probably need retreatments, such as endoscopic pneumatic dilation or re-POEM, and a scoring system for the prediction of poor responders preoperatively has not yet been established. We aimed to develop and validate a preoperative scoring system for predicting poor responders. METHODS: Overall, 244 patients who underwent POEM for esophageal motility disorders in our hospital from April 2015 to March 2019 were retrospectively included in this study. Poor responders were defined as patients with any of following: (1) Eckardt score ≥3 at 1-year follow-up, (2) endoscopic findings of food retention at 1-year follow-up, and (3) retreatments within 1 year after POEM. A risk-scoring system for poor responders was developed based on multiple logistic regression analysis, and its performance was internally validated using bootstrapping. RESULTS: Forty patients were diagnosed as poor responders at the 1-year follow-up. In the multivariate study, points for risk scores were assigned for 4 independent risk factors as follows: pretreatment Eckardt score (1-point increments), previous treatments (4 points), sigmoid-type esophagus (4 points), and esophageal dilation grade ≥II (4 points). The scoring system could predict an estimated risk for poor responders and provided satisfactory discrimination (area under the receiver operating characteristic curve, 0.78; 95% confidence interval, 0.68-0.88) and calibration (slope = 0.93; 95% confidence interval, 0.62-1.31). CONCLUSIONS: A validated risk-scoring system for predicting poor responders preoperatively was established; this system could be useful for selecting treatment strategies and postoperative surveillance.

  Feb. 2021, Gastrointestinal endoscopy, 93(2) (2), 398 - 405, English, International magazine

  [Refereed]

  Scientific journal


• A case of autoimmune enteropathy with CTLA4 haploinsufficiency.

  Haruka Miyazaki, Namiko Hoshi, Michitaka Kohashi, Eri Tokunaga, Yuna Ku, Haruka Takenaka, Makoto Ooi, Nobuyuki Yamamoto, Suguru Uemura, Noriyuki Nishimura, Kazumoto Iijima, Keisuke Jimbo, Tsubasa Okano, Akihiro Hoshino, Kohsuke Imai, Hirokazu Kanegane, Ichiro Kobayashi, Yuzo Kodama

  Autoimmune enteropathy (AIE) is a rare disease, characterized by intractable diarrhea, villous atrophy of the small intestine, and the presence of circulating anti-enterocyte autoantibodies. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, and mutations in FOXP3, which is a master gene of regulatory T cells (Tregs), are major causes of AIE. Recent studies have demonstrated that mutations in other Treg-associated genes, such as CD25 and CTLA4, show an IPEX-like phenotype. We present the case of a 13-year-old girl with CTLA4 haploinsufficiency, suffering from recurrent immune thrombocytopenic purpura and intractable diarrhea. We detected an autoantibody to the AIE-related 75 kDa antigen (AIE-75), a hallmark of the IPEX syndrome, in her serum. She responded well to a medium dose of prednisolone and a controlled dose of 6-mercaptopurine (6-MP), even after the cessation of prednisolone administration. Serum levels of the soluble interleukin-2 receptor and immunoglobulin G (IgG) were useful in monitoring disease activity during 6-MP therapy. In conclusion, autoimmune-mediated mechanisms, similar to the IPEX syndrome, may be involved in the development of enteropathy in CTLA4 haploinsufficiency. Treatment with 6-MP and monitoring of disease activity using serum levels of soluble interleukin-2 receptor and IgG is suggested for such cases.

  Jan. 2021, Intestinal research, 20(1) (1), 144 - 149, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• Effect of Daikenchuto On Spontaneous Intestinal Tumors in ApcMin/+ Mice.

  Lingling Kong, Namiko Hoshi, Daisuke Watanabe, Yasutaka Yamada, Eiichiro Yasutomi, Soichiro Adachi, Makoto Ooi, Yunlong Sui, Ryutaro Yoshida, Ryohei Sekimoto, Eri Tokunaga, Haruka Miyazaki, Yuna Ku, Haruka Takenaka, Tadao Kunihiro, Jun Inoue, Zibin Tian, Yuzo Kodama

  Daikenchuto (TU-100) is herbal medicine which predominantly contains ginger, Japanese pepper, and ginseng. We investigated whether TU-100 can affect the composition of gut flora and intestinal tumor development using ApcMin/+ mice, a murine model of intestinal tumor. Bacterial 16S rRNA sequencing and short-chain fatty acid analysis were performed on faecal samples. Tumor number and size were analysed. Any change in gene expression of the tumor tissues was assessed by real-time PCR. Principal coordinate analysis (PCoA) showed that the faecal microbiota cluster of TU-100-fed mice was different from the microbiota of control mice. However, no significant difference was observed in the concentration of short-chain fatty acids, tumor number, and gene expression levels between the two groups. Our data showed that TU-100 can affect the intestinal environment; however, it does not contribute in tumor progression or inhibition in our setting.

  Jan. 2021, The Kobe journal of medical sciences, 66(4) (4), E139-E148, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• GPR43 suppresses intestinal tumor growth by modification of the mammalian target of rapamycin complex 1 activity in ApcMin/+ mice

  Lingling Kong, Namiko Hoshi, Yunlong Sui, Yasutaka Yamada, Ryutaro Yoshida, Makoto Ooi, Zibin Tian, Ikuo Kimura, Yuzo Kodama

  S. Karger AG, 2021, Medical Principles and Practice, English

  Scientific journal


• Efficacy of the Envelope Method in Applying Polyglycolic Acid Sheets to Post-Endoscopic Submucosal Dissection Ulcers in Living Pigs.

  Hiroya Sakaguchi, Toshitatsu Takao, Yoshitaka Takegawa, Yuki Koga, Kazunori Yamanaka, Masataka Sagata, Shinwa Tanaka, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama

  BACKGROUND/AIMS: Application of polyglycolic acid (PGA) sheets using fibrin glue in post-endoscopic submucosal dissection (ESD) ulcers to prevent bleeding has been reported to be difficult with the conventional delivery method because of gravity. This study assessed the usefulness of the envelope-based delivery system with and against gravity in living pigs. METHODS: PGA sheets were applied on post-ESD ulcers with and against gravity six times each using the conventional and envelope methods, respectively. The PGA sheet delivery time and the endoscopic and histological findings of the treated ulcer floors were compared. RESULTS: With gravity, the median PGA sheet application time was 1.00 (0.68-1.30) min/cm2 and 0.32 (0.18-0.52) min/cm2 with the conventional and envelope techniques (p=0.002), respectively, and against gravity, it was 1.20 (1.13-1.63) min/cm2 and 0.50 (0.39-0.58) min/cm2 (p=0.002), respectively. Against gravity, the endoscopic and histological findings revealed that the conventional group had insufficient fixation of the PGA sheets, but the envelope groups had sufficient fixation. The results with gravity were similar between the groups. CONCLUSION: The envelope method makes it possible to deliver PGA sheets to the stomach quickly and cover ulcers appropriately both with and against gravity in living pigs.

  Jan. 2021, Clinical endoscopy, 54(1) (1), 64 - 72, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).

  Satoshi Sai, Masanori Toyoda, Kazutoshi Tobimatsu, Hironaga Satake, Hisateru Yasui, Shiro Kimbara, Taiji Koyama, Yoshimi Fujishima, Yoshinori Imamura, Yohei Funakoshi, Naomi Kiyota, Hirochika Toyama, Yuzo Kodama, Hironobu Minami

  PURPOSE: We conducted a phase 1 study to determine the maximum tolerated dose and the recommended dose of gemcitabine/nab-paclitaxel/S-1 combination chemotherapy in patients with unresectable pancreatic cancer. METHODS: We enrolled patients aged 20 years or older with unresectable pancreatic cancer and who had not been treated with chemotherapy or radiation therapy. Gemcitabine and nab-paclitaxel were administered on days 1 and 8, and S-1 was administered orally twice daily for 2 weeks, repeated every 3 weeks. The starting dose was level 0 [gemcitabine 700 mg/m2, nab-paclitaxel 90 mg/m2, S-1 60/80/100 mg/day (< 1.25 m2/1.25-1.50 m2/ > 1.5 m2)]. Dose-limiting toxicities were determined during the first course, and a classical 3 + 3 dose finding design was planned. RESULTS: From March 2018 to October 2019, 20 patients were enrolled. At dose level 0, three of six patients experienced dose-limiting toxicities; one grade 3 skin rash on day 8, and two grade 3 or 4 neutropenia on day 8. At dose level-1 (gemcitabine 600 mg/m2, nab-paclitaxel 90 mg/m2, and S-1 50/70/80 mg/day), two of twelve patients experienced dose-limiting toxicities, all of which were grade 3 neutropenia on day 8. The most frequently observed toxicity during eight courses was neutropenia. Other treatment-related adverse events were mild. Eleven out of 19 (58%) patients achieved partial response. CONCLUSION: We defined the maximum tolerated dose and the recommended dose for combination therapy with gemcitabine/nab-paclitaxel/S-1 as dose level-1. Considering the observed response rate, further studies are warranted in order to determine the efficacy of this regimen (UMIN-CTR 000030007).

  Jan. 2021, Cancer chemotherapy and pharmacology, 87(1) (1), 65 - 71, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• An autopsy case of severe acute pancreatitis induced by administration of pazopanib following nivolumab.

  Takeshi Tanaka, Arata Sakai, Hideyuki Shiomi, Atsuhiro Masuda, Takashi Kobayashi, Shunta Tanaka, Ryota Nakano, Manabu Shigeoka, Yu-Ichiro Koma, Yuzo Kodama

  Drug-induced pancreatitis is often mild to moderate in severity, but severe and even fatal cases can occur. Here, we report a 74-year-old woman undergoing chemotherapy for recurrent renal cell carcinoma, who presented with abdominal pain after administration of pazopanib following nivolumab and was diagnosed with severe acute pancreatitis. Administration of methylprednisolone and conservative treatment were initiated, but clinical findings and laboratory tests rapidly worsened. When she died, an autopsy was performed. The autopsy findings suggested the possibility of pancreatitis as immune-related adverse events. To the best of our knowledge, no fatal cases of acute pancreatitis due to nivolumab or pazopanib have been reported. We considered that the effects of nivolumab were sustained in the pancreas, and pazopanib administration might have worsened the toxicity.

  Jan. 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 21(1) (1), 21 - 24, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Acute pancreatitis in intraductal papillary mucinous neoplasms correlates with pancreatic volume and epithelial subtypes.

  Takeshi Tanaka, Atsuhiro Masuda, Keitaro Sofue, Hirochika Toyama, Hideyuki Shiomi, Arata Sakai, Takashi Kobayashi, Shunta Tanaka, Ryota Nakano, Yasutaka Yamada, Shigeto Ashina, Masahiro Tsujimae, Kohei Yamakawa, Shohei Abe, Masanori Gonda, Shigeto Masuda, Noriko Inomata, Hisahiro Uemura, Shinya Kohashi, Kae Nagao, Maki Kanzawa, Tomoo Itoh, Takumi Fukumoto, Yuzo Kodama

  BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is associated with acute pancreatitis (AP) in some cases, however its causes have not been fully elucidated. We investigated the association of the incidence of AP with epithelial subtypes and pancreatic volume in IPMN. METHODS: This retrospective study included 182 consecutive surgically resected IPMN patients between January 2000 and December 2018. The relationship between the incidence of AP and epithelial subtypes of IPMN and pancreatic volume was investigated. Epithelial subtypes of IPMN were classified into gastric (G type: N = 116), intestinal (I type: N = 49), pancreatobiliary (PB type: N = 14), and oncocytic types (O type: N = 3). Pancreatic volume of the contrast-enhanced computed tomography scan was measured using Ziostation2 software. Histological pancreatic parenchymal atrophy was also evaluated. RESULTS: AP occurred more frequently in I-types (I-type vs. G-type, 22.4% [11/49] vs 3.4% [4/116], P = 0.003) and PB-types (PB type vs. G-type, 35.7% [5/14] vs. 3.4% [4/116], P = 0.007) in comparison with G-types, which constituted the majority of the resected IPMNs. AP occurred more frequently in I-type patients with high pancreatic volumes (I-type with high pancreatic volume vs. I-type with low pancreatic volume, 37.0% [10/27] vs. 4.7% [1/21], P = 0.02). However, histological atrophy did not show an additional influence on the association between the incidence of AP and epithelial subtypes. The elevation of serum pancreatic enzymes was not significantly related to epithelial subtypes. CONCLUSION: Epithelial subtypes and the degree of pancreatic volume may be closely associated with the incidence of AP in IPMN.

  Jan. 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 21(1) (1), 138 - 143, English, International magazine

  Scientific journal


• Overtube-guided electrohydraulic lithotripsy through digital cholangioscopy for difficult biliary stones in a postoperative patient: challenging points with salvage techniques.

  Hassan Atalla, Arata Sakai, Hideyuki Shiomi, Shohei Abe, Yuzo Kodama

  Jan. 2021, VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy, 6(1) (1), 19 - 21, English, International magazine

  Scientific journal


• Phenotyping of IgG4-related diseases based on affected organ pattern: A multicenter cohort study using cluster analysis.

  Takafumi Niwamoto, Tomohiro Handa, Shoko Matsui, Hiroshi Yamamoto, Hajime Yoshifuji, Hiroyasu Abe, Hisako Matsumoto, Yuzo Kodama, Tsutomu Chiba, Hiroshi Seno, Tsuneyo Mimori, Toyohiro Hirai

  Jan. 2021, Modern rheumatology, 31(1) (1), 235 - 240, English, International magazine

  [Refereed]

  Scientific journal


• Feasibility and Safety of Endoscopic Submucosal Dissection for Recurrent Rectal Lesions that after Transanal Endoscopic Microsurgery: A Case Series.

  Nobuaki Ikezawa, Takashi Toyonaga, Shinwa Tanaka, Yoshiko Nakano, Tsukasa Ishida, Tomoatsu Yoshihara, Masanao Uraoka, Yoshinori Morita, Noriko Suzuki, Amyn Haji, Yuzo Kodama

  2021, Digestion, 102(3) (3), 446 - 452, English, International magazine

  [Refereed]

  Scientific journal


• Endoscopic Submucosal Dissection Using EndoTrac, a Novel Traction Device.

  Hidetoshi Kaku, Takashi Toyonaga, Shinwa Tanaka, Hiroshi Takihara, Shinichi Baba, Eiji Tsubouchi, Yoshio Ikeda, Hitoshi Orita, Manabu Nakamoto, Yohei Horikawa, Hiroki Chiba, Hiromitsu Ban, Youhei Furumoto, Ryushin Morita, Yuzo Kodama

  BACKGROUND: Endoscopic submucosal dissection (ESD) is recognized as a minimally invasive and curative treatment for superficial gastrointestinal (GI) cancers. However, ESD is still challenging and time-consuming with a high risk of adverse events such as bleeding and perforation. Various traction methods have been explored for maintaining good visualization of the submucosal layer during ESD. We developed a novel traction device (the EndoTrac) which can easily tie the thread and has the ability to change the towing direction. The aim of this study is to evaluate safety and feasibility of ESD using the EndoTrac for GI neoplasms. PATIENTS AND METHODS: We retrospectively analyzed 44 patients (45 lesions) with esophageal, gastric, duodenal, and colorectal neoplasms who had undergone ESD using the EndoTrac device between June 2018 and May 2019. Primary outcome measures were preparation time, procedural success using the EndoTrac device, and ease of ability to change towing direction. RESULTS: Mean preparation time was 2 (2-5) min in esophagus, 3 (1-5) min in stomach, 6 (5-9) min in duodenum, and 4 (2-8) min in colorectum. The procedural success rate was 100% (8/8) in esophagus, 100% (21/21) in stomach, 100% (4/4) in duodenum, and 100% (12/12) in colorectum. The rate of successful towing to both proximal and distal sides was 100% (8/8) in esophagus, 100% (21/21) in stomach, 0% (0/4) in duodenum, and 100% (12/12) in colorectum. CONCLUSIONS: Use of the EndoTrac device appears to be a feasible approach to ESD for GI neoplasms.

  Dec. 2020, Digestion, 1 - 8, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 自己免疫性膵炎診療ガイドライン2020

  岡崎 和一, 川 茂幸, 神澤 輝実, 池浦 司, 糸井 隆夫, 伊藤 鉄英, 乾 和郎, 入澤 篤志, 内田 一茂, 大原 弘隆, 窪田 賢輔, 児玉 裕三, 清水 京子, 殿塚 亮祐, 中沢 貴宏, 西野 隆義, 能登原 憲司, 藤永 康成, 正宗 淳, 山本 洋, 渡辺 貴之, 下瀬川 徹, 白鳥 敬子, 川野 充弘, 西山 利正, 竹山 宜典, 井上 大, 入江 裕之, 岩崎 栄典, 植木 敏晴, 上原 剛, 菅野 敦, 洪 繁, 阪上 順一, 新倉 則和, 多田 稔, 濱野 英明, 平野 賢二, 廣岡 芳樹, 増田 充弘, 水野 伸匡, 吉田 仁, 日本膵臓学会・厚生労働省IgG4関連疾患の診断基準並びに治療指針を目指す研究班, 自己免疫性膵炎診療ガイドライン2020改訂委員会

  (一社)日本膵臓学会, Dec. 2020, 膵臓, 35(6) (6), 465 - 550, Japanese


• 自己免疫性膵炎診療ガイドライン2020

  岡崎 和一, 川 茂幸, 神澤 輝実, 池浦 司, 糸井 隆夫, 伊藤 鉄英, 乾 和郎, 入澤 篤志, 内田 一茂, 大原 弘隆, 窪田 賢輔, 児玉 裕三, 清水 京子, 殿塚 亮祐, 中沢 貴宏, 西野 隆義, 能登原 憲司, 藤永 康成, 正宗 淳, 山本 洋, 渡辺 貴之, 下瀬川 徹, 白鳥 敬子, 川野 充弘, 西山 利正, 竹山 宜典, 井上 大, 入江 裕之, 岩崎 栄典, 植木 敏晴, 上原 剛, 菅野 敦, 洪 繁, 阪上 順一, 新倉 則和, 多田 稔, 濱野 英明, 平野 賢二, 廣岡 芳樹, 増田 充弘, 水野 伸匡, 吉田 仁, 日本膵臓学会・厚生労働省IgG4関連疾患の診断基準並びに治療指針を目指す研究班, 自己免疫性膵炎診療ガイドライン2020改訂委員会

  (一社)日本膵臓学会, Dec. 2020, 膵臓, 35(6) (6), 465 - 550, Japanese


• Helicobacter pylori未感染胃に生じたラズベリー様腺窩上皮型胃癌の1例

  堀谷 晋, 松岡 晃生, 鷹尾 俊達, 田中 心和, 阿部 洋文, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 105回, 60 - 60, Japanese


• PGAシートにて胃ESD後遅発性穿孔を閉鎖し得た一例

  山本 顕, 賀来 英俊, 鷹尾 俊達, 中井 達也, 高山 弘志, 嶋本 有策, 上田 千勢, 津田 一範, 松本 慶, 池澤 伸明, 阪口 博哉, 松岡 晃生, 阿部 洋文, 吉崎 哲也, 鷹尾 まど佳, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 105回, 60 - 60, Japanese


• A case of high-grade pancreatic intraepithelial neoplasia diagnosed based on focal pancreatic parenchymal atrophy after acute pancreatitis.

  Noriko Inomata, Takashi Kobayashi, Atsuhiro Masuda, Shigeto Masuda, Shigeto Ashina, Masanori Gonda, Shohei Abe, Kohei Yamakawa, Masahiro Tsujimae, Takeshi Tanaka, Yasutaka Yamada, Shunta Tanaka, Maya Kakihara, Ryota Nakano, Takuya Ikegawa, Arata Sakai, Hideyuki Shiomi, Maki Kannzawa, Hirochika Toyama, Tomoo Itoh, Takumi Fukumoto, Yuzo Kodama

  A 60-year-old male visited a previous hospital with upper abdominal pain. He was diagnosed with localized mild acute pancreatitis. Three months later, abdominal contrast-enhanced computed tomography showed focal parenchymal atrophy of the pancreas with distal pancreatic duct dilation. No obvious solid mass could be found at the site of the pancreatic duct stenosis on imaging examinations. Endoscopic retrograde pancreatography showed focal mild stenosis with distal pancreatic duct dilation in the tail of the pancreas. Carcinoma in situ of the pancreas was strongly suspected, especially based on the presence of focal atrophy of the pancreas around the site of stenosis of the main pancreatic duct and the distal pancreatic duct dilation. Laparoscopic distal pancreatectomy was performed. Histologically, high-grade pancreatic intraepithelial neoplasia was found in the epithelium of the stenotic main pancreatic duct and its branches. This case suggests that localized acute pancreatitis and focal atrophy of the pancreas with distal dilation of the pancreatic duct could be important clinical manifestations of pancreatic carcinoma in situ.

  Dec. 2020, Clinical journal of gastroenterology, 13(6) (6), 1338 - 1342, English, Domestic magazine

  Scientific journal


• Hes1 Is Essential in Proliferating Ductal Cell-Mediated Development of Intrahepatic Cholangiocarcinoma.

  Tomoaki Matsumori, Yuzo Kodama, Atsushi Takai, Masahiro Shiokawa, Yoshihiro Nishikawa, Tomonori Matsumoto, Haruhiko Takeda, Saiko Marui, Hirokazu Okada, Tomonori Hirano, Takeshi Kuwada, Yuko Sogabe, Nobuyuki Kakiuchi, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Katsutoshi Kuriyama, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Hiroyuki Marusawa, Ryoichiro Kageyama, Tsutomu Chiba, Hiroshi Seno

  Intrahepatic cholangiocarcinoma (ICC) is frequently driven by aberrant KRAS activation and develops in the liver with chronic inflammation. Although the Notch signaling pathway is critically involved in ICC development, detailed mechanisms of Notch-driven ICC development are still unknown. Here, we use mice whose Notch signaling is genetically engineered to show that the Notch signaling pathway, specifically the Notch/Hes1 axis, plays an essential role in expanding ductular cells in the liver with chronic inflammation or oncogenic Kras activation. Activation of Notch1 enhanced the development of proliferating ductal cells (PDC) in injured livers, while depletion of Hes1 led to suppression. In correlation with PDC expansion, ICC development was also regulated by the Notch/Hes1 axis and suppressed by Hes1 depletion. Lineage-tracing experiments using EpcamcreERT2 mice further confirmed that Hes1 plays a critical role in the induction of PDC and that ICC could originate from PDC. Analysis of human ICC specimens showed PDC in nonneoplastic background tissues, confirming HES1 expression in both PDC and ICC tumor cells. Our findings provide novel direct experimental evidence that Hes1 plays an essential role in the development of ICC via PDC. SIGNIFICANCE: This study contributes to the identification of the cells of origin that initiate ICC and suggests that HES1 may represent a therapeutic target in ICC.

  Dec. 2020, Cancer research, 80(23) (23), 5305 - 5316, English, International magazine

  Scientific journal


• Peroral endoscopic myotomy alone is effective for esophageal motility disorders and esophageal epiphrenic diverticulum: a retrospective single-center study.

  Masato Kinoshita, Shinwa Tanaka, Fumiaki Kawara, Hiroya Sakaguchi, Hirofumi Abe, Ryusuke Ariyoshi, Takashi Toyonaga, Yuzo Kodama

  Dec. 2020, Surgical endoscopy, 34(12) (12), 5447 - 5454, English, International magazine

  [Refereed]

  Scientific journal


• Adrenic acid induces oxidative stress in hepatocytes.

  Jing Zhao, Shin Nishiumi, Ryoma Tagawa, Yoshihiko Yano, Jun Inoue, Namiko Hoshi, Masaru Yoshida, Yuzo Kodama

  Adrenic acid (ADA), which is an endogenously synthesized polyunsaturated free fatty acid, was significantly increased in nonalcoholic fatty liver disease (NAFLD) patients and NAFLD-model mice compared with the corresponding controls in our previous study. To elucidate the involvement of ADA in NAFLD and nonalcoholic steatohepatitis (NASH), we examined ADA-induced lipotoxicity in human hepatocarcinoma HepG2 cells. The ROS production in HepG2 cells was increased by exposure to ADA. It was also shown that the treatment with ADA decreased cell viability in a dose-dependent manner. The N-Acetyl-L-Cysteine pretreatment counteracted this ADA-induced ROS production and cell death. Furthermore, ADA modulated the expressions of SOD2, HO-1 and Gpx1 as antioxidant enzymes. These findings suggest that ADA could induce oxidative stress accompanied by cell death, providing new insights into lipotoxicity that is involved in the pathogenesis of NAFLD and NASH.

  Nov. 2020, Biochemical and biophysical research communications, 532(4) (4), 620 - 625, English, International magazine

  Scientific journal


• A case of mediastinal pancreatic pseudocysts mimicking esophageal varices with successful endoscopic drainage.

  Noriko Inomata, Arata Sakai, Shohei Abe, Yuzo Kodama

  Nov. 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Non-Alcoholic Fatty Liver Disease Is Strongly Associated with Smoking Status and Is Improved by Smoking Cessation in Japanese Males: A Retrospective Study.

  Haruka Takenaka, Tsuyoshi Fujita, Atsuhiro Masuda, Yoshihiko Yano, Akihiko Watanabe, Yuzo Kodama

  BACKGROUND: Cigarette smoking is known to be a significant risk factor associated with non-alcoholic fatty liver disease (NAFLD). We aimed to examine the association between smoking status and the severity of fatty liver with regard to sex and smoking cessation. METHODS: In total, 13,466 subjects (6,642 males and 6,824 females) who had undergone abdominal ultrasonography for health check-up, multivariable logistic regression analysis was retrospectively conducted to assess the association between smoking status and the prevalence of NAFLD stratified by sex after adjusting for other potential confounders. RESULTS: Male sex (odds ratio [OR] 3.27, 95% confidence interval [CI] 3.00-3.57) and smoking history (former smoker: OR 1.23, 95% CI 1.10-1.38, current smoker: OR 1.31, 95% CI 1.17-1.47) were significantly associated with NAFLD. In males with a smoking history, an increased pack-year was strongly associated with the prevalence and severity of NAFLD (prevalence of moderate to severe fatty liver: Pack-year from 0.01 to 9.99, 21.3%; Pack-year from 10.00 to 19.99, 27.2%; Pack-year ≥20.00, 33.7%; P<0.0001), although the prevalence of moderate to severe fatty liver was inversely associated with the duration of smoking cessation (more than 10 years vs. within 5 years, OR 0.71, 95% CI 0.53-0.96). In female subjects, light current smoking was negatively associated with NAFLD (current smoker with a pack-year from 0.01 to 9.99 vs. never smoker, OR 0.41, 95% CI 0.19-0.76). CONCLUSIONS: Smoking status and pack-year were strongly associated with the prevalence and severity of NAFLD, especially in Japanese males. However, smoking cessation improved NAFLD in this population.

  Nov. 2020, The Kobe journal of medical sciences, 66(3) (3), E102-E112, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• A Case in which an Intraductal Papillary Neoplasm of the Bile Duct Was Surgically Resected 12 Years after the Initial Diagnosis.

  Masahiro Tsujimae, Arata Sakai, Atsuhiro Masuda, Noriko Inomata, Shigeto Masuda, Masanori Gonda, Shohei Abe, Kohei Yamakawa, Shigeto Ashina, Maya Kakihara, Yasutaka Yamada, Takeshi Tanaka, Shunta Tanaka, Ryota Nakano, Takuya Ikegawa, Takashi Kobayashi, Hideyuki Shiomi, Tetsuo Ajiki, Takumi Fukumoto, Tomoo Ito, Yuzo Kodama

  A 66-year-old Japanese man was referred to our hospital with multiple giant liver cysts. The cysts had already been detected as multiple 3-cm cysts with small nodules at another hospital 12 years prior to this presentation. The cysts were diagnosed as an intraductal papillary neoplasms of the bile duct (IPNB) occupying the right lobe of the liver. Extended right lobectomy was performed. Based on the pathological findings, the tumor was diagnosed to be an oncocytic-type IPNB with minimal invasion. This experience suggests that the progression of IPNBs occur relatively slowly. The present case might provide important information for understanding the natural history of IPNBs.

  Nov. 2020, Internal medicine (Tokyo, Japan), 59(22) (22), 2879 - 2883, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• A novel technique for performing gallbladder tumor biopsy using a stent delivery system and biopsy forceps.

  Tomoaki Matsumori, Norimitsu Uza, Hirokazu Okada, Takahisa Maruno, Masahiro Shiokawa, Yuzo Kodama, Hiroshi Seno

  Nov. 2020, Endoscopy, 52(11) (11), E415-E417, English, International magazine

  Scientific journal


• Intraductal papillary neoplasm of the bile duct diagnosed by upper gastrointestinal endoscopy through a duodenobiliary fistula.

  Arata Sakai, Seiji Fujigaki, Yuzo Kodama

  Nov. 2020, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 32(7) (7), 1114 - 1114, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• 消化器領域から見たIgG4関連疾患研究の進歩 造影CTによる自己免疫性膵炎ステロイド治療後の耐糖能異常予測

  山田 恭孝, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Oct. 2020, 日本消化器病学会雑誌, 117(臨増大会) (臨増大会), A679 - A679, Japanese


• CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma.

  Toshihiro Morita, Yuzo Kodama, Masahiro Shiokawa, Katsutoshi Kuriyama, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Tomoaki Matsumori, Nobuyuki Kakiuchi, Teruko Tomono, Atsushi Mima, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Yoshihiro Nishikawa, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Takashi Nagasawa, Tsutomu Chiba, Hiroshi Seno

  Pancreatic ductal adenocarcinoma (PDAC) features abundant stromal cells with an excessive extracellular matrix (ECM), termed the desmoplastic reaction. CXCR4 is a cytokine receptor for stromal cell-derived factor-1 (CXCL12) expressed in PDAC, but its roles in PDAC and the characteristic desmoplastic reaction remain unclear. Here, we generated a mouse model of PDAC with conditional knockout of Cxcr4 (KPC-Cxcr4-KO) by crossing Cxcr4 flox mice with Pdx1-Cre;KrasLSL-G12D/+;Trp53LSL-R172H/+ (KPC-Cxcr4-WT) mice to assess the development of pancreatic intraepithelial neoplasia (PanIN) and pancreatic cancers. Tumor cell characteristics of those two types were analyzed in vitro. In addition, CXCR4 expression in human pancreatic cancer specimens was evaluated by IHC staining. In KPC-Cxcr4-KO mice, the number and pathologic grade of PanIN lesions were reduced, but the frequency of pancreatic cancers did not differ from that in KPC-Cxcr4-WT mice. The pancreatic tumor phenotype in KPC-Cxcr4-KO mice was significantly larger and undifferentiated, characterized by abundant vimentin-expressing cancer cells, significantly fewer fibroblasts, and markedly less deposition of ECM. In vitro, KPC-Cxcr4-KO tumor cells exhibited higher proliferative and migratory activity than KPC-Cxcr4-WT tumor cells. Myofibroblasts induced invasion activity in KPC-Cxcr4-WT tumor cells, showing an epithelial-mesenchymal interaction, whereas KPC-Cxcr4-KO tumor cells were unaffected by myofibroblasts, suggesting their unique nature. In human pancreatic cancer, undifferentiated carcinoma did not express CXCR4 and exhibited histologic and IHC features similar to those in KPC-Cxcr4-KO mice. In summary, the CXCL12/CXCR4 axis may play an important role in the desmoplastic reaction in PDAC, and loss of CXCR4 induces phenotype changes in undifferentiated carcinoma without a desmoplastic reaction. SIGNIFICANCE: The current study uncovers CXCR4 as a key regulator of desmoplastic reaction in PDAC and opens the way for new therapeutic approaches to overcome the chemoresistance in patients with PDAC.

  Oct. 2020, Cancer research, 80(19) (19), 4058 - 4070, English, International magazine

  Scientific journal


• Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups.

  Hiroki Tanaka, Susumu Hijioka, Waki Hosoda, Makoto Ueno, Noritoshi Kobayashi, Masafumi Ikeda, Tetsuhide Ito, Yuzo Kodama, Chigusa Morizane, Kenji Notohara, Hiroki Taguchi, Masayuki Kitano, Izumi Komoto, Akihito Tsuji, Syunpei Hashigo, Atsushi Kanno, Katsuyuki Miyabe, Tadayuki Takagi, Hiroshi Ishii, Yasushi Kojima, Hideyuki Yoshitomi, Hiroaki Yanagimoto, Junji Furuse, Nobumasa Mizuno

  BACKGROUND/OBJECTIVES: Pancreatic neuroendocrine carcinoma (PanNEC)-G3 often presents along with genetic abnormalities such as KRAS, RB1, and TP53 mutations. However, the association between these genetic findings and response to chemotherapy and prognosis has not been clarified. This study aimed to clarify the clinicopathological features of PanNEC-G3. METHODS: We performed a subgroup analysis of the Japanese PanNEN-G3 study (multicenter, retrospective study), which revealed that Rb loss and KRAS mutation were predictors of the response to platinum-based regimen in PanNEN-G3. We re-classified WHO grades of PanNENs using the 2017 WHO classification and then analyzed the clinicopathological features and prognostic factors in 49 patients with PanNEC-G3. RESULTS: The rates of Rb loss and KRAS mutation in PanNEC-G3 were 54.5% and 48.7%, respectively. Patients with Rb loss and/or KRAS mutation showed a higher response rate to first-line platinum-based regimen than those without Rb loss or KRAS mutation (object response rate 70.0% vs 33.3%, odds ratio 9.22; 95% CI 1.26-67.3, P = 0.029), but tended to have shorter overall survival rates than those without Rb loss or KRAS mutation (median 239 vs 473 days, hazard ratio 2.11; 95% CI 0.92-4.86, P = 0.077). CONCLUSIONS: Patients with PanNEC-G3 have varied clinical outcomes for platinum-based regimen. When grouped based on Rb loss and KRAS mutation, there seemed to be two groups with distinct prognoses and responses to the platinum-based regimen. PanNEC-G3 could, therefore, be classified into two distinct groups based on immunohistochemical and genetic findings.

  Oct. 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 20(7) (7), 1421 - 1427, English, International magazine

  Scientific journal


• Influence of sex on the association between body mass index and frequency of upper gastrointestinal symptoms.

  Kyohei Ogisu, Atsuhiro Masuda, Tsuyoshi Fujita, Yukinao Yamazaki, Masao Kobayashi, Shuichi Terao, Tsuyoshi Sanuki, Akihiko Okada, Masayasu Adachi, Yoshifumi Arisaka, Haruka Miyazaki, Hayato Yoshinaka, Hiromu Kutsumi, Eiji Umegaki, Yuzo Kodama

  Background and Aim: Upper gastrointestinal symptoms (UGSs), including reflux and dyspeptic symptoms (postprandial distress syndrome [PDS] and epigastric pain syndrome [EPS]), affect health-related quality of life. However, the influence of sex on the relationship between body mass index (BMI) and UGSs remains controversial. This study investigates the influence of sex on this association in healthy subjects. Methods and Results: We utilized the database of a prospective, multicenter, cohort study of 7112 subjects who underwent upper endoscopy for health screening. A multivariable logistic regression analysis was conducted to assess the association between BMI and UGSs stratified by sex, adjusting for clinical features. The influence of sex on the association between the overlapping of UGSs and BMI in symptomatic subjects was also investigated. Reflux symptoms were significantly associated with high BMI (multivariable odds ratio [OR] 1.36; 95% confidence interval [CI] 1.10-1.67, P = 0.004). PDS symptoms were significantly associated with low BMI (OR 2.37; 95% CI 1.70-3.25; P < 0.0001), but EPS symptoms were not associated with BMI. The association between reflux symptoms and higher BMI was limited to men (men: OR 1.40; 95% CI 1.10-1.77; P = 0.005, women: P = 0.40). sex did not influence the association between the presence of PDS symptoms and lower BMI. The percentage of overlapping of all three symptoms (reflux, PDS, and EPS) was higher in women than in men (19.9% [58/292] vs 10.5% [49/468], P = 0.0002). Conclusions: The influence of BMI on the presence of UGSs was significantly different according to sex in this large-scale cohort.

  Oct. 2020, JGH open : an open access journal of gastroenterology and hepatology, 4(5) (5), 937 - 944, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Low-dose Selective Arterial Calcium Stimulation Test for Localizing Insulinoma: A Single-center Experience of Five Consecutive Cases.

  Tomonobu Hatoko, Takaaki Murakami, Masakatsu Sone, Daisuke Yabe, Toshihiko Masui, Yuji Nakamoto, Akihiro Furuta, Norimitsu Uza, Yuzo Kodama, Norio Harada, Masahito Ogura, Akihiro Yasoda, Nobuya Inagaki

  The selective arterial calcium stimulation test (SACST) is one of the most useful localization tests for insulinoma but can cause false-positive and/or unexpected multi arterial positive results that hamper clinical decisions. There are also several adverse effects, such as nausea and hypoglycemia, at the conventional dose (0.025 mEq/kg) of calcium injection. We herein report five consecutive insulinoma cases in which low-dose (0.005-0.007 mEq/kg) calcium injection for SACST led to successful insulinoma localization. No adverse effects of SACST were observed. In conclusion, a low-dose SACST can be a favorable option as an insulinoma localization test in terms of accuracy and safety.

  Oct. 2020, Internal medicine (Tokyo, Japan), 59(19) (19), 2397 - 2403, English, Domestic magazine

  [Refereed]

  Scientific journal


• Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis.

  Shohei Komatsu, Yoshihiko Yano, Keitaro Sofue, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, Masahide Awazu, Hidetoshi Gon, Atsushi Yamamoto, Hiroaki Yanagimoto, Hirochika Toyama, Yuzo Kodama, Takamichi Murakami, Takumi Fukumoto

  BACKGROUND: The present study aimed to assess the clinical features of patients who received lenvatinib treatment for unresectable hepatocellular carcinoma (HCC). METHODS: The clinical characteristics, adverse events, and radiological responses were evaluated for 51 consecutive patients. RESULTS: Of the study subjects, 37 patients had Child-Pugh class A (CPA) liver function, and 14 patients had Child-Pugh class B (CPB) liver function. The overall response rates in the CPA and CPB groups were 42.9% and 25.0%, respectively, and disease control rates were 82.9% and 83.3%, respectively, without significant difference (p = 0.2621 and 0.9697). There was no significant difference between CPA and CPB groups regarding the incidence of adverse events, except for hepatic coma. No significant difference was observed in the relative dose intensity between the CPA and CPB groups, for the first month, 1-2 months, or 2-3 months (p = 0.2368, 0.9368, and 0.9293). CONCLUSION: The comparable outcomes between the CPA and CPB groups suggest the acceptability of lenvatinib treatment in patients with impaired liver function, at least in the acute phase. With careful follow-up, the dose can be relatively intensified, even in patients with impaired liver function and this may contribute to offering comparable treatment.

  Oct. 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association, 22(10) (10), 1450 - 1456, English, International magazine

  [Refereed]

  Scientific journal


• Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer.

  Yu Sato, Takashi Kobayashi, Shin Nishiumi, Akihiko Okada, Tsuyoshi Fujita, Tsuyoshi Sanuki, Masao Kobayashi, Masakyo Asahara, Masayasu Adachi, Arata Sakai, Hideyuki Shiomi, Atsuhiro Masuda, Masaru Yoshida, Keiko Takeuchi, Yuzo Kodama, Hiromu Kutsumi, Kengo Nagashima, Kazufumi Honda

  Apolipoprotein A2-ATQ/AT (apoA2-ATQ/AT) has been identified as a minimally invasive biomarker for detecting pancreatic cancer (PC) and high-risk (HR) individuals for PC. To establish an efficient enrichment strategy for HR, we carried out a plasma apoA2-ATQ/AT level-based prospective screening study among the general population. The subjects for the screening study were recruited at six medical check-up facilities in Japan between October 2015 and January 2017. We evaluated the positive predictive value (PPV) of the plasma apoA2-ATQ/AT level of ≤35 μg/mL for detecting PC and HR. Furthermore, we prospectively confirmed its diagnostic accuracy with another post-diagnosis population in a cross-sectional study. We enrolled 5120 subjects in experimental screening, with 84 subjects (1.3%) showing positive results for apoA2-ATQ/AT. Pancreatic abnormalities were recognized in 26 of the 84 subjects from imaging examinations. Pancreatic abnormalities detected included 1 PC and 15 HR abnormalities, such as cystic lesions including intraductal papillary mucinous neoplasm. The PPV of apoA2-ATQ/AT for detecting PC and HR was 33.3%. Moreover, a combination study with another cross-sectional study revealed that the area under the curve for apoA2-ATQ/AT to distinguish PC from healthy controls was 0.903. ApoA2-ATQ/AT has the potential to enrich PC and HR by increasing the diagnostic probability before imaging examinations.

  Sep. 2020, Cancers, 12(9) (9), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Changes in imaging features of immunoglobulin G4-related sclerosing cholecystitis.

  Kohei Yamakawa, Arata Sakai, Masato Komatsu, Yuzo Kodama

  Sep. 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53(11) (11), 1511 - 1512, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors

  Yuki Yamauchi, Yuzo Kodama, Masahiro Shiokawa, Nobuyuki Kakiuchi, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tomoaki Matsumori, Tatsuki Ueda, Motoyuki Tsuda, Yoshihiro Nishikawa, Katsutoshi Kuriyama, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Atsuhiro Masuda, Hisato Tatsuoka, Daisuke Yabe, Sachiko Minamiguchi, Toshihiko Masui, Nobuya Inagaki, Shinji Uemoto, Tsutomu Chiba, Hiroshi Seno

  American Association for Cancer Research (AACR), Sep. 2020, Cancer Research, 80(17) (17), 3620 - 3630

  [Refereed]

  Scientific journal


• Endoscopic shielding technique using polyglycolic acid sheets with fibrin glue for perforation following endoscopic ampullectomy.

  Hideyuki Shiomi, Atsuhiro Masuda, Yuzo Kodama

  Sep. 2020, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 32(6) (6), 992 - 992, English, International magazine


• Different Frequencies of Antibody Responses in IgG4-Related Disease: Comment on the Article by Liu et al.

  Masahiro Shiokawa, Hiroshi Seno, Yuzo Kodama, Tsutomu Chiba

  Sep. 2020, Arthritis & rheumatology (Hoboken, N.J.), 72(9) (9), 1584 - 1585, English, International magazine


• Reasons for Diagnostic Failure in Forty-Five Consecutive Mucosal Cutting Biopsy Examinations of Gastric Subepithelial Tumors.

  Yoshiko Nakano, Toshitatsu Takao, Yoshinori Morita, Shinwa Tanaka, Takashi Toyonaga, Eiji Umegaki, Yuzo Kodama

  BACKGROUND/AIMS: Mucosal cutting biopsy (MCB) is useful for the histopathological diagnosis of gastric subepithelial tumors (SETs). However, there is little information on cases in which MCB did not establish a diagnosis. In the current study, we aimed to investigate the characteristics of cases in which MCB was unsuccessful. METHODS: Cases in which MCB was used to histopathologically diagnose gastric SETs at Kobe University Hospital between August 2012 and October 2018 were retrospectively reviewed. RESULTS: Forty-five cases in which MCB was used to diagnose 43 gastric SETs in 43 patients were analyzed. The median tumor size was 20 mm (range, 8-50 mm). Pathological examinations resulted in definitive and suspected diagnoses and no diagnosis in 29 (gastrointestinal stromal tumor: n=17, leiomyoma: n=7, aberrant pancreas: n=3, others: n=2), 6, and 10 cases, respectively. Failure to expose the tumor according to retrospective examinations of endoscopic images was significantly associated with no diagnosis. Other possible explanations included a less elevated tumor, biopsy of the surrounding field instead of the tumor due to the mobility, and poor endoscope maneuverability due to the tumor being close to the cardia. CONCLUSION: Clear exposure of gastric SETs during MCB may improve the diagnostic rate of such examinations.

  Sep. 2020, Clinical endoscopy, 53(5) (5), 575 - 582, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors.

  Yuki Yamauchi, Yuzo Kodama, Masahiro Shiokawa, Nobuyuki Kakiuchi, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tomoaki Matsumori, Tatsuki Ueda, Motoyuki Tsuda, Yoshihiro Nishikawa, Katsutoshi Kuriyama, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Atsuhiro Masuda, Hisato Tatsuoka, Daisuke Yabe, Sachiko Minamiguchi, Toshihiko Masui, Nobuya Inagaki, Shinji Uemoto, Tsutomu Chiba, Hiroshi Seno

  Pancreatic neuroendocrine tumors (PanNET) were classified into grades (G) 1 to 3 by the World Health Organization in 2017, but the precise mechanisms of PanNET initiation and progression have remained unclear. In this study, we used a genetically engineered mouse model to investigate the mechanisms of PanNET formation. Although pancreas-specific deletion of the Rb gene (Pdx1-Cre;Rbf/f ) in mice did not affect pancreatic exocrine cells, the α-cell/β-cell ratio of islet cells was decreased at 8 months of age. During long-term observation (18-20 months), mice formed well-differentiated PanNET with a Ki67-labeling index of 2.7%. In contrast, pancreas-specific induction of a p53 mutation (Pdx1-Cre;Trp53R172H ) had no effect on pancreatic exocrine and endocrine tissues, but simultaneous induction of a p53 mutation with Rb gene deletion (Pdx1-Cre;Trp53R172H;Rb f/f ) resulted in the formation of aggressive PanNET with a Ki67-labeling index of 24.7% over the short-term (4 months). In Pdx1-Cre;Trp53R172H;Rbf/f mice, mRNA expression of Pten and Tsc2, negative regulators of the mTOR pathway, significantly decreased in the islet cells, and activation of the mTOR pathway was confirmed in subsequently formed PanNET. Thus, by manipulating Rb and p53 genes, we established a multistep progression model from dysplastic islet to indolent PanNET and aggressive metastatic PanNET in mice. These observations suggest that Rb and p53 have distinct roles in the development of PanNET. SIGNIFICANCE: Pancreas-specific manipulation of Rb and p53 genes induced malignant transformation of islet cells, reproducing stepwise progression from microadenomas to indolent (grade 1) and subsequent aggressive PanNETs (grade 2-3).

  Sep. 2020, Cancer research, 80(17) (17), 3620 - 3630, English, International magazine

  [Refereed]

  Scientific journal


• 家族性膵癌高危険群のサーベイランス法(エキスパート・コンセンサス) 日本膵臓学会家族性膵癌レジストリ委員会・家族性膵癌に関する小班会議

  北野 雅之, 森実 千種, 肱岡 範, 松林 宏行, 蘆田 玲子, 池浦 司, 伊藤 鉄英, 神澤 輝実, 川口 喬久, 河邉 顕, 小杉 眞司, 児玉 裕三, 清水 京子, 高橋 秀明, 谷内田 真一, 寺島 健志, 鳥嶋 雅子, 花田 敬士, 古川 徹, 古川 正幸, 古瀬 純司, 真口 宏介, 眞島 喜幸, 水野 伸匡, 水間 正道, 水本 雅己, 吉田 岳市, 和田 慶太, 高折 恭一

  (一社)日本膵臓学会, Aug. 2020, 膵臓, 35(4) (4), 322 - 330, Japanese


• 十二指腸乳頭部腫瘍に対する診断と治療戦略 十二指腸乳頭部腫瘍に対する内視鏡的乳頭切除術後の病理学的評価と予後

  酒井 新, 増田 充弘, 児玉 裕三

  日本胆道学会, Aug. 2020, 胆道, 34(3) (3), 434 - 434, Japanese


• A novel closure technique using the EndoTrac for mucosal incision closure in peroral endoscopic myotomy.

  Tomoya Sako, Shinwa Tanaka, Takashi Toyonaga, Hirofumi Abe, Hiroya Sakaguchi, Nobuaki Ikezawa, Yuzo Kodama

  Aug. 2020, Endoscopy, 52(8) (8), E291-E292, English, International magazine

  Scientific journal


• Utility of laser-cut covered self-expandable metal stents for unresectable malignant distal biliary obstruction: a single-center experience.

  Saiko Marui, Norimitsu Uza, Hajime Yamazaki, Sakiko Ota, Takeharu Nakamura, Hiroyuki Yoshida, Hirokazu Okada, Tomonori Hirano, Takeshi Kuwada, Yuko Sogabe, Teruko Tomono, Tomoaki Matsumori, Toshihiro Morita, Yoshihiro Nishikawa, Motoyuki Tsuda, Takahisa Maruno, Masahiro Shiokawa, Yuzo Kodama, Hiroshi Seno

  BACKGROUND: Few reports have evaluated the effectiveness of laser-cut, covered, self-expandable metal stents (LC-CSEMS) for unresectable malignant distal biliary obstruction (MDBO) and whether reintervention is feasible after placement. We describe our experience with LC-CSEMS placement for unresectable MDBO. METHODS: Patients undergoing LC-CSEMS placement for unresectable MDBO from November 2014 to December 2018 were reviewed. Recurrent biliary obstruction (RBO), median time to RBO (TRBO), and reintervention were analyzed. RESULTS: 52 patients who underwent LC-CSEMS placement for unresectable MDBO were included in the analysis. The RBO rate was 15 % and the median TRBO was 445 days. Reintervention was attempted in nine patients and stent removal was successful in eight patients. CONCLUSIONS: Our experience suggests the effectiveness of LC-CSEMS in patients with unresectable MDBO in terms of stent patency and feasibility of reintervention.

  Georg Thieme Verlag KG, Aug. 2020, Endoscopy, 52(8) (8), 664 - 668, English, International magazine

  [Refereed]

  Scientific journal


• Early gastric cancer involving a pure enteroblastic differentiation component that was curatively resected via endoscopic submucosal dissection.

  Nobuaki Ikezawa, Shinwa Tanaka, Hidetoshi Kaku, Toshitatsu Takao, Yoshinori Morita, Takashi Toyonaga, Masato Komatsu, Hiroshi Yokozaki, Tomoo Ito, Yuzo Kodama

  Gastric adenocarcinoma with enteroblastic differentiation (GAED) is a very rare variant of alpha-fetoprotein-producing gastric cancer (AFPGC). GAED is histologically characterized by cuboidal or columnar cells, which resemble those found in the primitive gut and have clear cytoplasm. In previously reported cases, GAED exhibit more aggressive behavior, as well as AFPGC, than conventional gastric cancer, such as marked lymphovascular invasion, lymph node metastasis, and liver metastasis. And also GAED was usually located in a deep mucosal layer and was covered by a conventional adenocarcinoma (CA) component. Based on these findings, GAED is considered to develop from CA during the process of tumor invasion and proliferation. We present a very rare case of early-stage GAED achieved curatively resected via endoscopic submucosal dissection, in which the lesion was composed of a pure enteroblastic differentiation component without a CA component.

  Aug. 2020, Clinical journal of gastroenterology, 13(4) (4), 512 - 516, English, Domestic magazine

  [Refereed]

  Scientific journal


• Prediction of pancreatic atrophy after steroid therapy using equilibrium-phase contrast computed tomography imaging in autoimmune pancreatitis.

  Yasutaka Yamada, Atsuhiro Masuda, Keitaro Sofue, Eisuke Ueshima, Hideyuki Shiomi, Arata Sakai, Takashi Kobayashi, Takuya Ikegawa, Shunta Tanaka, Ryota Nakano, Takeshi Tanaka, Maya Kakihara, Shigeto Ashina, Masahiro Tsujimae, Kohei Yamakawa, Shohei Abe, Masanori Gonda, Shigeto Masuda, Noriko Inomata, Hiromu Kutsumi, Tomoo Itoh, Takamichi Murakami, Yuzo Kodama

  Aug. 2020, JGH open : an open access journal of gastroenterology and hepatology, 4(4) (4), 677 - 683, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 膵全摘術の現状と展望 National clinical databaseによる膵全摘術の術後重症合併症リスクモデル

  橋本 大輔, 水間 正道, 隈丸 拓, 宮田 裕章, 近本 亮, 五十嵐 久人, 糸井 隆夫, 江川 新一, 児玉 裕三, 里井 壯平, 濱田 晋, 水元 一博, 山上 裕機, 山本 雅一, 掛地 吉弘, 瀬戸 泰之, 馬場 秀夫, 海野 倫明, 下瀬川 徹, 岡崎 和一

  (一社)日本膵臓学会, Jul. 2020, 膵臓, 35(3) (3), A119 - A119, Japanese


• 健診受診者における無症候性びらん性食道炎の4年間の自然経過

  松永 心祐, 藤田 剛, 山崎 幸直, 小林 正夫, 寺尾 秀一, 岡田 明彦, 佐貫 毅, 安達 政恭, 吉中 勇人, 久津見 弘, 増田 充弘, 梅垣 英次, 児玉 裕三

  (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A229 - A229, Japanese


• 若年で発症した膵癌症例の臨床像 日本膵臓学会膵癌登録データによる解析

  江口 英利, 山上 裕機, 海野 倫明, 水間 正道, 濱田 晋, 五十嵐 久人, 黒木 保, 里井 壯平, 清水 泰博, 谷 眞至, 丹野 誠志, 廣岡 芳樹, 藤井 努, 正宗 淳, 水元 一博, 糸井 隆夫, 江川 新一, 児玉 裕三, 田中 雅夫, 下瀬川 徹, 岡崎 和一

  (一社)日本膵臓学会, Jul. 2020, 膵臓, 35(3) (3), A100 - A100, Japanese


• 膵全摘術の現状と展望 National clinical databaseによる膵全摘術の術後重症合併症リスクモデル

  橋本 大輔, 水間 正道, 隈丸 拓, 宮田 裕章, 近本 亮, 五十嵐 久人, 糸井 隆夫, 江川 新一, 児玉 裕三, 里井 壯平, 濱田 晋, 水元 一博, 山上 裕機, 山本 雅一, 掛地 吉弘, 瀬戸 泰之, 馬場 秀夫, 海野 倫明, 下瀬川 徹, 岡崎 和一

  (一社)日本膵臓学会, Jul. 2020, 膵臓, 35(3) (3), A119 - A119, Japanese


• Endoscopic Self-Expandable Metal Stent Placement for Malignant Afferent Loop Obstruction After Pancreaticoduodenectomy: A Case Series and Review.

  Arata Sakai, Hideyuki Shiomi, Takao Iemoto, Ryota Nakano, Takuya Ikegawa, Takashi Kobayashi, Atsuhiro Masuda, Yuzo Kodama

  In this study, we assessed a series of our cases in which endoscopic self-expandable metal stents (SEMSs) were used to treat malignant afferent loop obstruction (ALO) that arose after pancreaticoduodenectomy (PD). We retrospectively examined the records of 7 patients who underwent endoscopic SEMS placement for malignant ALO following PD. Clinical success was achieved in all cases. The median procedure time was 30 min (range, 15-50 min). There were no cases of stent occlusion, and no procedure-related adverse events were encountered. All patients died of their primary disease, and the median overall survival period was 155 days (range, 96-374 days). A re-intervention involving endoscopic ultrasound-guided hepaticogastrostomy combined with antegrade stenting was performed for obstructive jaundice and acute cholangitis in 1 case. In conclusion, endoscopic SEMS placement may be an effective and safe treatment for malignant ALO that arises after PD.

  Jul. 2020, Clinical endoscopy, 53(4) (4), 491 - 496, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• Troubleshooting for severe acute cholangitis caused by proximally migrated metal stent into the intrahepatic bile duct: Stent shortening via a balloon catheter.

  Kohei Yamakawa, Atsuhiro Masuda, Yuzo Kodama

  Jul. 2020, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 32(5) (5), e112-e113, English, International magazine

  Scientific journal


• Possibility of detecting intraductal papillary mucinous neoplasms using metabolite biomarkers for pancreatic cancer.

  Ryota Nakano, Shin Nishiumi, Takashi Kobayashi, Takuya Ikegawa, Yuzo Kodama, Masaru Yoshida

  Aim: The aim of this study was to identify whether metabolite biomarker candidates for pancreatic cancer (PC) could aid detection of intraductal papillary mucinous neoplasms (IPMN), recognized as high-risk factors for PC. Materials & methods: The 12 metabolite biomarker candidates, which were found to be useful to detect PC in our previous study, were evaluated for plasma samples from patients with PC (n = 44) or IPMN (n = 24) or healthy volunteers (n = 46). Results: Regarding the performance of individual biomarkers of PC and PC high-risk IPMN, lysine exhibited the best performance (sensitivity: 67.8%; specificity: 86.9%). The multiple logistic regression analysis-based detection model displayed high sensitivity and specificity values of 92.5 and 90.6%, respectively. Conclusion: Metabolite biomarker candidates for PC are useful for detecting high-risk IPMN, which can progress to PC.

  Jul. 2020, Biomarkers in medicine, 14(11) (11), 1009 - 1020, English, International magazine

  Scientific journal


• Efficacy and limitations of the histological diagnosis of type 1 autoimmune pancreatitis with endoscopic ultrasound-guided fine needle biopsy with large tissue amounts.

  Kenji Notohara, Terumi Kamisawa, Atsushi Kanno, Itaru Naitoh, Eisuke Iwasaki, Kyoko Shimizu, Yasuhiro Kuraishi, Masayo Motoya, Yuzo Kodama, Satomi Kasashima, Takayoshi Nishino, Kensuke Kubota, Junichi Sakagami, Tsukasa Ikeura, Shigeyuki Kawa, Kazuichi Okazaki

  OBJECTIVES: We examined the efficacy and limitations of acquiring large specimens by endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) for diagnosing type 1 autoimmune pancreatitis (AIP). METHODS: Patients from 12 institutions with non-neoplastic diseases or pancreatic ductal adenocarcinoma (PDAC) with large EUS-FNB specimens were investigated. Slides stained with hematoxylin-eosin, elastic, IgG4, and IgG stains were evaluated. The IgG4- and IgG-positive cell numbers were counted in three foci. The diagnoses were based on the Japan Pancreas Society 2011 (JPS 2011) criteria and the International Consensus Diagnostic Criteria (ICDC). RESULTS: We analyzed 85 non-neoplastic (definite type 1 AIP in 73/85 based on the ICDC) cases and 64 PDAC cases. IgG4-positive cells were numerous (>10 in 85.9%), and the IgG4/IgG ratios were high (>40% in 81.2%). Plasma cell crushing by an artifact caused unsuccessful immunostaining, notably in smaller samples. Tissue lengths were an important factor for the presence of storiform fibrosis and obliterative phlebitis, but storiform fibrosis was equivocal even in large tissues. A definite or possible histological diagnosis was achieved in 45.9% (39/85) and 41.2% (35/85), respectively, and contributed to the definite final diagnosis of type 1 AIP in 33.3% (ICDC) and 55.6% (JPS 2011) in cases with segmental/focal lesions. In the PDAC group, >10 IgG4-positive cells was rare (2/58), but elastic stains revealed fibrous venous occlusions in 10.3% (6/58). CONCLUSIONS: EUS-FNB with large tissue amounts was useful for diagnosing type 1 AIP, notably by facilitating successful IgG4 immunostaining, but definite diagnosis may not be achieved even in cases with large specimens.

  Jul. 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 20(5) (5), 834 - 843, English, International magazine

  [Refereed]

  Scientific journal


• Effects of Helicobacter pylori on the glutathione-related pathway in gastric epithelial cells.

  Koki Matsuoka, Shin Nishiumi, Masaru Yoshida, Yuzo Kodama

  Virulence factors of Helicobacter pylori (H. pylori) are diverse, so various biological responses happen in a host infected with H. pylori. The aim of this study is to conduct the metabolomics-based evaluation on H. pylori infection. AGS human gastric carcinoma cells were infected with H. pylori strain 26695, and then the altered metabolite pathways in the infected AGS cells were analyzed by metabolomics. Metabolites related to the glutathione (GSH) cycle were downregulated by H. pylori infection. Next, we evaluated the effects of H. pylori on the GSH-related pathway in AGS cells infected with H. pylori isolated from patients with atrophic gastritis (AG), duodenal ulcer (DU) and gastric cancer (GC). We found that the declined degree of GSH levels and oxidative stress were greater in AGS cells infected with GC strains than DU and AG-derived strains. There were no significant differences in almost mRNA expressions of GSH-related factors among different clinical strains, but the protein expression of glutathione synthetase was lower in AGS cells infected with GC-derived strains than DU and AG-derived strains. Our data demonstrates that GC-derived H. pylori-induced oxidative stress in a host is stronger and GC-derived strains may have suppressive influences on the host's GSH-related defense systems.

  Jun. 2020, Biochemical and biophysical research communications, 526(4) (4), 1118 - 1124, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Detection of Novel Amino Acid Polymorphisms in the East Asian CagA of Helicobacter Pylori with Full Sequencing Data.

  Hiroki Hayashi, Jun Inoue, Katsuaki Oyama, Koki Matsuoka, Shin Nishiumi, Masaru Yoshida, Yoshihiko Yano, Yuzo Kodama

  Cytotoxin-associated gene A (CagA) is generally accepted to be the most important virulence factor of Helicobacter pylori and increases the risk of developing gastric cancer. East Asian CagA, which includes the EPIYA-D segment at the C-terminal region, has a significantly higher gastric carcinogenic rate than Western CagA including the EPIYA-C segment. Although the amino acid polymorphism surrounding the EPIYA motif in the C-terminal region has been examined in detail, limited information is currently available on the amino acid polymorphism of the N-terminal region of East Asian CagA. In the present study, we analyzed the sequencing data of East Asian CagA that we obtained previously to detect amino acid changes (AACs) in the N-terminal region of East Asian CagA. Four highly frequent AACs in the N-terminal region of East Asian CagA were detected in our datasets, two of which (V356A, Y677F) exhibited reproducible specificity using a validation dataset from the NCBI database, which are candidate AACs related to the pathogenic function of CagA. We examined whether these AACs affect the functions of CagA in silico model. The computational docking simulation model showed that binding affinity between CagA and phosphatidylserine remained unchanged in the model of mutant CagA reflecting both AAC, whereas that between CagA and α5β1 integrin significantly increased. Based on whole genome sequencing data we herein identified novel specific AACs in the N-terminal regions of EPIYA-D that have the potential to change the function of CagA.

  Jun. 2020, The Kobe journal of medical sciences, 66(1) (1), E22-E31, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• An autopsy case of granulocyte colony-stimulating factor-producing pancreatic adenosquamous carcinoma.

  Noriko Inomata, Atsuhiro Masuda, Toshinao Itani, Motohito Hayashi, Yukari Shimada, Kanna Adachi, Kimio Hashimoto, Yasuhiro Tanaka, Atsushi Tanaka, Takashi Kobayashi, Arata Sakai, Hideyuki Shiomi, Yuzo Kodama

  A 60-year-old female was admitted to hospital with a continuous fever, a decreased appetite, and abdominal pain. Laboratory tests showed an elevated peripheral leukocyte count (13,800/μl) and increased C-reactive protein (19.1 mg/dl) and carbohydrate antigen 19-9 (4057 U/ml) levels. Abdominal contrast-enhanced computed tomography showed multiple bulky hypovascular nodules in the liver, swelling of the paraaortic lymph nodes, and a hypovascular mass (diameter 3.0 cm) in the pancreatic body. The serum concentrations of granulocyte colony-stimulating factor (G-CSF) and interleukin-6 were 172 pg/μl and 541 pg/µl, respectively. Liver biopsy specimens revealed an adenosquamous carcinoma, which was positively immunostained for G-CSF. We diagnosed the patient with G-CSF-producing pancreatic cancer with multiple metastases. Four courses of gemcitabine with dexamethasone and one course of nab-paclitaxel and gemcitabine were administered. Although the pancreatic tumor and paraaortic lymph node metastases decreased in size, the liver metastases continued to grow. The patient died 4 months after the diagnosis of pancreatic cancer. An autopsy resulted in the tumor being diagnosed as poorly differentiated adenosquamous pancreatic carcinoma, which was histopathologically G-CSF-positive. Although G-CSF-producing pancreatic adenosquamous carcinomas are extremely rare, they have been encountered more frequently in recent years. In such cases, chemotherapy combined with dexamethasone might be effective at temporarily improving the patient's condition.

  Jun. 2020, Clinical journal of gastroenterology, 13(3) (3), 448 - 454, English, Domestic magazine

  Scientific journal


• A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: BTS-NAC Study.

  Kei Saito, Yousuke Nakai, Hiroyuki Isayama, Ryuichi Yamamoto, Kazumichi Kawakubo, Yuzo Kodama, Akio Katanuma, Atsushi Kanno, Masahiro Itonaga, Kazuhiko Koike

  Background/Aims: ; The aim of this study was to evaluate the safety and efficacy of partially covered self-expandable metallic stents (PCSEMS) in patients undergoing neoadjuvant chemo(radio) therapy (NAC) for pancreatic cancer (PC). Methods: This was a prospective multicenter study to evaluate the safety and efficacy of PCSEMS in patients receiving NAC for resectable and borderline resectable PC. The primary endpoint was the rate of recurrent biliary obstruction (RBO). Results: Twenty-six patients with PC (three with resectable PC and 23 with borderline resectable PC) who underwent NAC at seven Japanese centers were included in the analysis. Both the technical and functional success rates of PCSEMS placement were 100%. Early stent-related complications were observed in three patients (11.5%): mild pancreatitis (n=2) and mild liver abscess (n=1). The median time to surgery or palliation was 4.0 months. Surgical resection was eventually performed in 73.1% of patients, and stent removal during surgery was successful in all patients. RBO was observed in nine patients (34.6%): seven with stent occlusion, one with kinking and one with migration. The RBO rates in resected cases and nonresected cases were 36.8% and 28.6%, respectively. Conclusions: Biliary drainage by PCSEMS was safe and feasible in patients undergoing NAC for resectable and borderline resectable PC.

  Apr. 2020, Gut and liver, 15(1) (1), 135 - 141, English, International magazine

  [Refereed]

  Scientific journal


• Gastrointestinal: Gastric outlet obstruction caused by a hamartomatous inverted polyp and an ectopic pancreas

  S Ashina, A Sakai, A Masuda, M Tsujimae, T Kobayashi, Y Shiomi, H Shiomi, S Kanaji, T Itoh, Y Kakeji, Y Kodama

  Wiley, Apr. 2020, Journal of Gastroenterology and Hepatology, 35(10) (10), 1667 - 1667

  [Refereed]

  Scientific journal


• The number and size of Lugol-voiding areas were reduced by pneumatic dilation in a patient with achalasia and esophageal cancer.

  Shinwa Tanaka, Hirofumi Abe, Ryusuke Ariyoshi, Hiroya Sakaguchi, Taro Oshikiri, Tetsu Nakamura, Yoshiko Nakano, Yoshinori Morita, Takashi Toyonaga, Eiji Umegaki, Hiroshi Yokozaki, Yoshihiro Kakeji, Yuzo Kodama

  Apr. 2020, JGH open : an open access journal of gastroenterology and hepatology, 4(2) (2), 309 - 311, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Shortening antibiotic duration in the treatment of acute cholangitis: rationale and study protocol for an open-label randomized controlled trial.

  Kentaro Iwata, Asako Doi, Yuichiro Oba, Hiroo Matsuo, Kei Ebisawa, Manabu Nagata, Sho Nishimura, Kenichi Yoshimura, Atsuhiro Masuda, Hideyuki Shiomi, Yuzo Kodama

  Jan. 2020, Trials, 21(1) (1), 97 - 97, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Surveillance for the early diagnosis of familial pancreatic cancer (Expert consensus)

  KITANO Masayuki, KAWABE Ken, KOSUGI Shinji, KODAMA Yuzo, SHIMIZU Kyoko, TAKAHASHI Hideaki, YACHIDA Shinichi, TERASHIMA Takeshi, TORISHIMA Masako, HANADA Keiji, FURUKAWA Toru, MORIZANE Chigusa, FURUKAWA Masayuki, FURUSE Junji, MAGUCHI Hiroyuki, MAJIMA Yoshiyuki, MIZUNO Nobumasa, MIZUMA Masamichi, MIZUMOTO Masaki, YOSHIDA Takeichi, WADA Keita, TAKAORI Kyoichi, HIJIOKA Susumu, MATSUBAYASHI Hiroyuki, ASHIDA Reiko, IKEURA Tsukasa, ITO Tetsuhide, KAMISAWA Terumi, KAWAGUCHI Takahisa

  The incidence of pancreatic cancer in families with at least two affected first-degree relatives who have pancreatic cancer is significantly higher than in the general population. In 2014, the Japan Pancreas Society started the nationwide Japan Familial Pancreatic Cancer Registry to investigate familial pancreatic cancer in Japan. The aim of this paper is to describe an expert consensus for surveillance in people with an increased risk using the Japan Familial Pancreatic Cancer Registry. A working group constituted by experts in imaging and genetic diagnosis of pancreatic cancer first proposed 22 statements regarding (1) the definition of those at high risk, (2) initial work-up and (3) follow-up of the high-risk group. Agreement of the councilors of Japan Pancreas Society was obtained for the 21 of the 22 statements by a vote. We expect that this expert consensus will contribute to the early diagnosis and an improved prognosis in people with familial pancreatic cancer.

  Japan Pancreas Society, 2020, Suizo, 35(4) (4), 322 - 330, Japanese


• Risk model for severe postoperative complications after total pancreatectomy based on a nationwide clinical database

  D. Hashimoto, M. Mizuma, H. Kumamaru, H. Miyata, A. Chikamoto, H. Igarashi, T. Itoi, S. Egawa, Y. Kodama, S. Satoi, S. Hamada, K. Mizumoto, H. Yamaue, M. Yamamoto, Y. Kakeji, Y. Seto, H. Baba, M. Unno, T. Shimosegawa, K. Okazaki

  2020, British Journal of Surgery

  [Refereed]

  Scientific journal


• Urinary bladder metastasis of hepatocellular carcinoma incidentally revealed by hematuria.

  Eiichiro Yasutomi, Yoshihiko Yano, Yuzo Kodama

  Jan. 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 52(1) (1), 115 - 115, English, International magazine

  [Refereed]

  Scientific journal


• Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.

  Hiroyoshi Tsuchida, Tsutomu Fujii, Masamichi Mizuma, Sohei Satoi, Hisato Igarashi, Hidetoshi Eguchi, Tamotsu Kuroki, Yasuhiro Shimizu, Masaji Tani, Satoshi Tanno, Yoshihisa Tsuji, Yoshiki Hirooka, Atsushi Masamune, Kazuhiro Mizumoto, Takao Itoi, Shinichi Egawa, Yuzo Kodama, Shin Hamada, Michiaki Unno, Hiroki Yamaue, Kazuichi Okazaki

  Dec. 2019, Surgery, 166(6) (6), 997 - 1003, English, International magazine

  [Refereed]

  Scientific journal


• Novel per-oral endoscopic myotomy method preserving oblique muscle using two penetrating vessels as anatomic landmarks reduces postoperative gastroesophageal reflux.

  Shinwa Tanaka, Takashi Toyonaga, Fumiaki Kawara, Daisuke Watanabe, Namiko Hoshi, Hirohumi Abe, Ryusuke Ariyoshi, Yoshiko Ohara, Toshitatsu Takao, Yoshinori Morita, Eiji Umegaki, Yuzo Kodama

  Dec. 2019, Journal of gastroenterology and hepatology, 34(12) (12), 2158 - 2163, English, International magazine

  [Refereed]

  Scientific journal


• IgG4-related disease in the Japanese population: a genome-wide association study

  Chikashi Terao, Masao Ota, Takeshi Iwasaki, Masahiro Shiokawa, Shuji Kawaguchi, Katsutoshi Kuriyama, Takahisa Kawaguchi, Yuzo Kodama, Izumi Yamaguchi, Kazushige Uchida, Koichiro Higasa, Motohisa Yamamoto, Kensuke Kubota, Shujiro Yazumi, Kenji Hirano, Yasufumi Masaki, Hiroyuki Maguchi, Tomoki Origuchi, Shoko Matsui, Takahiro Nakazawa, Hideyuki Shiomi, Terumi Kamisawa, Osamu Hasebe, Eisuke Iwasaki, Kazuo Inui, Yoshiya Tanaka, Koh ichi Ohshima, Takashi Akamizu, Shigeo Nakamura, Seiji Nakamura, Takako Saeki, Hisanori Umehara, Tooru Shimosegawa, Nobumasa Mizuno, Mitsuhiro Kawano, Atsushi Azumi, Hiroki Takahashi, Tsuneyo Mimori, Yoichiro Kamatani, Kazuichi Okazaki, Tsutomu Chiba, Shigeyuki Kawa, Fumihiko Matsuda, Atsushi Kanno, Yoshihiro Okabe, Shinji Katsushima, Tetsuro Inokuma, Yukitaka Yamashita, Yoshitaka Nakai, Takayoshi Nishino, Kozo Kajimura, Mitsushige Shibatoge, Naoki Kanda, Akio Ido, Masaya Ohana, Ichiro Moriyama, Hiroshi Tatsuta, Kazuyoshi Matsumura, Keita Fujikawa, Norimoto Gotoh, Takanobu Tsutsumi, Masakazu Shimizu, Kazuya Setoh, Meiko Takahashi, Yasuharu Tabara, Jun Mimura, Takefumi Nakamura, Toshiyuki Kimura, Chiharu Kawanami

  Sep. 2019, The Lancet Rheumatology, 1(1) (1), e14 - e22

  [Refereed]

  Scientific journal


• Significance of pancreatic calcification on preoperative computed tomography of intraductal papillary mucinous neoplasms.

  Masahiro Tsujimae, Atsuhiro Masuda, Hideyuki Shiomi, Hirochika Toyama, Keitaro Sofue, Eisuke Ueshima, Kohei Yamakawa, Shigeto Ashina, Yasutaka Yamada, Takeshi Tanaka, Shunta Tanaka, Ryota Nakano, Yu Sato, Takuya Ikegawa, Manabu Kurosawa, Seiji Fujigaki, Takashi Kobayashi, Arata Sakai, Hiromu Kutsumi, Yoh Zen, Tomoo Itoh, Takumi Fukumoto, Yuzo Kodama

  Sep. 2019, Journal of gastroenterology and hepatology, 34(9) (9), 1648 - 1655, English, International magazine

  [Refereed]

  Scientific journal


• ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer

  Shigeru Hashimoto, Shotaro Furukawa, Ari Hashimoto, Akio Tsutaho, Akira Fukao, Yurika Sakamura, Gyanu Parajuli, Yasuhito Onodera, Yutaro Otsuka, Haruka Handa, Tsukasa Oikawa, Soichiro Hata, Yoshihiro Nishikawa, Yusuke Mizukami, Yuzo Kodama, Masaaki Murakami, Toshinobu Fujiwara, Satoshi Hirano, Hisataka Sabe

  Aug. 2019, Proceedings of the National Academy of Sciences of the United States of America, 116(35) (35), 17450 - 17459

  [Refereed]

  Scientific journal


• Feasibility of endoscopic submucosal dissection of lesions at anastomosis site post-colorectal surgery: a case series.

  Chonlada Krutsri, Takashi Toyonaga, Tsukasa Ishida, Namiko Hoshi, Shinichi Baba, Nelson Tomio Miyajima, Yuzo Kodama

  Background and study aims  Patients who have undergone colorectal surgery for resection of cancer and benign lesions are at risk for recurrent, residual, or metachronous lesions at the anastomosis site. Surgical resection of such lesions is difficult because of adhesions, and a stoma may be required as there are risks for leakage after resection. The feasibility and safety of endoscopic submucosal dissection (ESD) for these lesions remain unknown. Therefore, this case series aimed to examine the feasibility and safety of ESD by evaluating the clinical outcomes. Patients and methods  We retrospectively investigated five patients who underwent ESD by a single expert for superficial neoplastic lesions at the anastomosis site after previous colorectal surgery. Results  R0 resections were achieved for all lesions. Mean procedure time was 160.6 minutes. Mean dimensions of the resected specimen and tumor were 52.4 mm and 31.8mm, respectively. None of the patients had complications or recurrence after surveillance colonoscopy 1-year post-resection. Conclusions  In an expert's hands, ESD at the anastomosis site might be feasible minimally invasive treatment for superficial neoplastic lesions.

  Aug. 2019, Endoscopy international open, 7(8) (8), E949-E954, English, International magazine

  [Refereed]

  Link to Kobe Univ. Repository (Kernel)


• Effective treatment improves the body composition of patients with esophageal motility disorders.

  Hirofumi Abe, Shinwa Tanaka, Fumiaki Kawara, Takashi Toyonaga, Ryusuke Ariyoshi, Yoshiko Nakano, Hiroya Sakaguchi, Yoshinori Morita, Eiji Umegaki, Yuzo Kodama

  Aug. 2019, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 32(8) (8), English, International magazine

  [Refereed]

  Scientific journal


• Genetic analysis of metachronous pancreatic cancers

  Tomonori Hirano, Kakiuchi Nobuyuki, Takeuchi Yasuhide, Inoue Yoshikage, Nishimura Tomomi, Fujii Yoichi, Yokoyama Akira, Makishima Hideki, Masui Toshihiko, Uemoto Shinji, Minamiguchi Sachiko, Haga Hironori, Chiba Kenichi, Tanaka Hiroko, Shiraishi Yuichi, Miyano Satoru, Uza Norimitsu, Kodama Yuzo, Seno Hiroshi, Chiba Tsutomu, Ogawa Seishi

  Jul. 2019, CANCER RESEARCH, 79(13) (13)

  [Refereed]


• Genetic analysis of pancreatic neuroendocrine neoplasms grade 3

  Kakiuchi Nobuyuki, Yoshida Kenichi, Shiozawa Yusuke, Yokoyama Akira, Kataoka Keisuke, Inoue Yoshikage, Takeuchi Yasuhide, Hirano Tomonori, Fujii Yoichi, Ueno Hiroo, Hijioka Susumu, Mizuno Nobumasa, Hosoda Waki, Yatabe Yasushi, Chiba Kenichi, Tanaka Hiroko, Shiraishi Yuichi, Miyano Satoru, Masui Toshihiko, Uemoto Shinji, Yoshizawa Akihiko, Haga Hironori, Uza Norimitsu, Seno Hiroshi, Kodama Yuzo, Ogawa Seishi

  Jul. 2019, CANCER RESEARCH, 79(13) (13), English

  [Refereed]


• MDM2 copy number increase: a poor prognostic, molecular event in esophageal squamous cell carcinoma.

  Ryuichiro Sawada, Ritsuko Maehara, Taro Oshikiri, Tetsu Nakamura, Tomoo Itoh, Yuzo Kodama, Yoshihiro Kakeji, Yoh Zen

  Jul. 2019, Human pathology, 89, 1 - 9, English, International magazine

  [Refereed]

  Scientific journal


• New Development for Safer Endoscopic Submucosal Dissection using the Carbon Dioxide (CO2) Laser (Secondary publication).

  Yoshinori Morita, Ryusuke Ariyoshi, Given-Names Norihiro Honda, Hisanao Hazama, Yuzo Kodama, Kunio Awazu

  Jun. 2019, Laser therapy, 28(2) (2), 89 - 96, English, Domestic magazine

  [Refereed]

  Scientific journal


• Eosinophilic Cholangitis Without Biliary Stricture After the Treatment of Eosinophilic Esophagitis.

  Shunta Tanaka, Arata Sakai, Atsuhiro Masuda, Shigeto Ashina, Kouhei Yamakawa, Masahiro Tsujimae, Manabu Kurosawa, Yuu Satou, Ryouta Nakano, Takeshi Tanaka, Yasutaka Yamada, Takuya Ikegawa, Seiji Fujigaki, Takashi Kobayashi, Shinwa Tanaka, Hideyuki Shiomi, Yuzo Kodama

  Eosinophilic cholangitis (EC) is an uncommon, benign, self-limiting disease, which typically causes bile duct stricture with eosinophil infiltration. We report the case of a 70-year-old woman who presented with abdominal pain diagnosed with EC after treatment for eosinophilic esophagitis. All previous reported cases of EC had bile duct stricture seen on magnetic resonance cholangiopancreatography or cholangiogram during endoscopic retrograde cholangiopancreatography, but only wall thickness of the common bile duct was noted in our case. Although rare, EC should be considered when wall thickening of the bile duct is observed, even without stricture.

  Jun. 2019, ACG case reports journal, 6(6) (6), e00099, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• Endoscopic plombage with polyglycolic acid sheets and fibrin glue for gastrointestinal fistulas.

  Yoshiko Nakano, Toshitatsu Takao, Yoshinori Morita, Hiroya Sakaguchi, Shinwa Tanaka, Tsukasa Ishida, Takashi Toyonaga, Eiji Umegaki, Yuzo Kodama

  Jun. 2019, Surgical endoscopy, 33(6) (6), 1795 - 1801, English, International magazine

  [Refereed]

  Scientific journal


• GC/MS and LC/MS-based Tissue Metabolomic Analysis Detected Increased Levels of Antioxidant Metabolites in Colorectal Cancer.

  Megumi Kibi, Shin Nishiumi, Takashi Kobayashi, Yuzo Kodama, Masaru Yoshida

  May 2019, The Kobe journal of medical sciences, 65(1) (1), E19-E27 - E27, English, Domestic magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately.

  Tsukasa Yoshida, Susumu Hijioka, Waki Hosoda, Makoto Ueno, Masayuki Furukawa, Noritoshi Kobayashi, Masafumi Ikeda, Tetsuhide Ito, Yuzo Kodama, Chigusa Morizane, Kenji Notohara, Hiroki Taguchi, Masayuki Kitano, Kei Yane, Yoshiaki Tsuchiya, Izumi Komoto, Hiroki Tanaka, Akihito Tsuji, Syunpei Hashigo, Tetsuya Mine, Atsushi Kanno, Go Murohisa, Katsuyuki Miyabe, Tadayuki Takagi, Nobutaka Matayoshi, Masafumi Sakaguchi, Hiroshi Ishii, Yasushi Kojima, Keitaro Matsuo, Hideyuki Yoshitomi, Shoji Nakamori, Hiroaki Yanagimoto, Yasushi Yatabe, Junji Furuse, Nobumasa Mizuno

  May 2019, Annals of surgical oncology, 26(5) (5), 1385 - 1393, English, International magazine

  [Refereed]

  Scientific journal


• Type 1 autoimmune pancreatitis with imaging appearance similar to that of malignant cystic tumor

  Takeshi Ezaki, Atsuhiro Masuda, Hideyuki Shiomi, Takashi Nakagawa, Keitaro Sofue, Hirochika Toyama, Yoh Zen, Yuzo Kodama

  May 2019, Case Reports in Gastroenterology, 13(2) (2), 265 - 270

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis.

  Yoshihiro Nishikawa, Yuzo Kodama, Masahiro Shiokawa, Tomoaki Matsumori, Saiko Marui, Katsutoshi Kuriyama, Takeshi Kuwada, Yuko Sogabe, Nobuyuki Kakiuchi, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Motonari Uesugi, Ryoichiro Kageyama, Tsutomu Chiba, Hiroshi Seno

  May 2019, Oncogene, 38(22) (22), 4283 - 4296, English, International magazine

  [Refereed]

  Scientific journal


• Recurrence of adenoma after curative endoscopic submucosal dissection for a rectal intramucosal adenocarcinoma in adenoma.

  Yoshiko Nakano, Takashi Toyonaga, Eisei Nishino, Taro Inoue, Isato Shinjo, Hajime Han-No, Shinwa Tanaka, Yoshinori Morita, Eiji Umegaki, Yuzo Kodama

  Background and study aims  A 71-year-old female underwent endoscopic submucosal dissection (ESD) for a subcircumferential lateral-spreading rectal tumor. Pathological examination showed an intramucosal adenocarcinoma in villous adenoma (size: 155 × 140 mm), which had been curatively resected with negative margins. However, follow-up colonoscopy revealed a tumor at the ulcer scar site, which soon grew into a circumferential lesion. Nineteen months after the first ESD procedure, additional ESD was performed for the recurrent lesion, which was resected en bloc without any adverse events, although severe fibrosis was noted in the submucosa. Pathological examination revealed a villous adenoma similar to the primary lesion with negative margins, but tumor cell nests were also present in the submucosa, which implied that tumor cell implantation had occurred during the first ESD. The post-ESD ulcer bed was subjected to argon plasma coagulation to prevent tumor recurrence after confirmation of the pathological results. There have not been any signs of recurrence during 9 years of follow-up.

  Apr. 2019, Endoscopy international open, 7(4) (4), E621-E624, English, International magazine

  [Refereed]

  Link to Kobe Univ. Repository (Kernel)


• Clinical impact of peroral endoscopic myotomy for esophageal motility disorders on esophageal muscle layer thickness.

  Daisuke Watanabe, Shinwa Tanaka, Fumiaki Kawara, Hirohumi Abe, Ryusuke Ariyoshi, Yoshiko Nakano, Toshitatsu Takao, Yoshinori Morita, Takashi Toyonaga, Eiji Umegaki, Yuzo Kodama

  Background and study aims  Previously, we reported that esophageal muscle layer thickness was associated with technical complexity of peroral endoscopic myotomy (POEM). However, there are no data regarding the mid-term effects of POEM procedures on esophageal muscle layer thickness. Therefore, we conducted this study to elucidate mid-term effects of POEM procedures, and to examine whether postoperative changes in esophageal muscle layer thickness were related to particular clinico-pathological features in patients with esophageal motility disorders. Patients and methods  Seventy-four consecutive patients with esophageal motility disorders who underwent POEM at Kobe University Hospital from April 2015 to December 2016 were prospectively recruited into this study. First, we investigated the esophageal muscle layer thickness values obtained at 1 year after POEM. Second, we evaluated the effects of a reduction in muscle layer thickness on various clinico-pathological features. Results  At 1 year after POEM, mean thickness of the inner circular muscle at 0 cm, 5 cm, and 10 cm from the esophagogastric junction was 1.06 ± 0.45 mm, 0.99 ± 0.36 mm, and 0.97 ± 0.44 mm, respectively. Among all sites, muscle layer thickness had significantly decreased after POEM. However, univariate logistic regression analysis demonstrated that no clinical factors were associated with esophageal muscle layer thickness after POEM procedure. Conclusions  We demonstrated for the first time that thickness of the esophageal muscle layer was significantly decreased after POEM. This result reveals that changes in esophageal muscle layer thickness caused by esophageal motility disorders are reversible.

  Apr. 2019, Endoscopy international open, 7(4) (4), E525-E532, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Evaluation of efficacy of pancreatic juice cytology for risk classification according to international consensus guidelines in patients with intraductal papillary mucinous neoplasm; a retrospective study.

  Kohei Yamakawa, Atsuhiro Masuda, Takashi Nakagawa, Hideyuki Shiomi, Hirochika Toyama, Mamoru Takenaka, Arata Sakai, Takashi Kobayashi, Masahiro Tsujimae, Shigeto Ashina, Yasutaka Yamada, Takeshi Tanaka, Shunta Tanaka, Ryota Nakano, Yu Sato, Takuya Ikegawa, Manabu Kurosawa, Seiji Fujigaki, Hiromu Kutsumi, Tomoo Itoh, Takumi Fukumoto, Yuzo Kodama

  Apr. 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 19(3) (3), 424 - 428, English, International magazine

  [Refereed]

  Scientific journal


• Defining competencies for endoscopic submucosal dissection (ESD) for gastric neoplasms.

  Madoka Takao, Elif Bilgic, Kevin Waschke, Pepa Kaneva, Satoshi Endo, Yoshiko Nakano, Shinwa Tanaka, Yoshinori Morita, Takashi Toyonaga, Eiji Umegaki, Yuzo Kodama, Gerald M Fried

  Apr. 2019, Surgical endoscopy, 33(4) (4), 1206 - 1215, English, International magazine

  [Refereed]

  Scientific journal


• Role of eosinophils in a murine model of inflammatory bowel disease.

  Zi Wang, Soichiro Adachi, Lingling Kong, Daisuke Watanabe, Yusuke Nakanishi, Toshiaki Ohteki, Namiko Hoshi, Yuzo Kodama

  Mar. 2019, Biochemical and biophysical research communications, 511(1) (1), 99 - 104, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Clinical outcomes of ampullary neoplasms in resected margin positive or uncertain cases after endoscopic papillectomy.

  Arata Sakai, Masahiro Tsujimae, Atsuhiro Masuda, Takao Iemoto, Shigeto Ashina, Kohei Yamakawa, Takeshi Tanaka, Shunta Tanaka, Yasutaka Yamada, Ryota Nakano, Yu Sato, Manabu Kurosawa, Takuya Ikegawa, Seiji Fujigaki, Takashi Kobayashi, Hideyuki Shiomi, Yoshifumi Arisaka, Tomoo Itoh, Yuzo Kodama

  Mar. 2019, World journal of gastroenterology, 25(11) (11), 1387 - 1397, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• β-hydroxybutyrate protects hepatocytes against endoplasmic reticulum stress in a sirtuin 1-independent manner.

  Ryoma Tagawa, Yuki Kawano, Akihiro Minami, Shin Nishiumi, Yoshihiko Yano, Masaru Yoshida, Yuzo Kodama

  Mar. 2019, Archives of biochemistry and biophysics, 663, 220 - 227, English, International magazine

  [Refereed]

  Scientific journal


• 無症状群におけるGERD症状発生の自然経過についての検討

  佐貫 毅, 梅垣 英次, 藤田 剛, 増田 充弘, 山崎 幸直, 小林 正夫, 寺尾 秀一, 岡田 明彦, 安達 政恭, 吉中 勇人, 久津見 弘, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2019, 日本消化器病学会雑誌, 116(臨増総会) (臨増総会), A274 - A274, Japanese


• IgG4-related hypophysitis in patients with autoimmune pancreatitis.

  Keitaro Kanie, Hironori Bando, Genzo Iguchi, Hideyuki Shiomi, Atsuhiro Masuda, Hidenori Fukuoka, Hitoshi Nishizawa, Yasunori Fujita, Arata Sakai, Takashi Kobayashi, Yuuki Shiomi, Kenichi Yoshida, Ryusaku Matsumoto, Kentaro Suda, Yuzo Kodama, Wataru Ogawa, Yutaka Takahashi

  Feb. 2019, Pituitary, 22(1) (1), 54 - 61, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Successful treatment of an esophageal perforation that occurred during endoscopic submucosal dissection for esophageal cancer using polyglycolic acid sheets and fibrin glue.

  Umaporn Seehawong, Yoshinori Morita, Yoshiko Nakano, Takehiro Iwasaki, Chonlada Krutsri, Hiroya Sakaguchi, Tomoya Sako, Toshitatsu Takao, Shinwa Tanaka, Takashi Toyonaga, Eiji Umegaki, Yuzo Kodama

  Feb. 2019, Clinical journal of gastroenterology, 12(1) (1), 29 - 33, English, Domestic magazine

  [Refereed]

  Scientific journal


• Comparison of venous and fingertip plasma using non-targeted proteomics and metabolomics.

  Shin Nishiumi, Tomohiro Kohata, Takashi Kobayashi, Yuzo Kodama, Sumio Ohtsuki, Masaru Yoshida

  Jan. 2019, Talanta, 192, 182 - 188, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Tumor invasion to the arteries feeding the gallbladder as a novel risk factor for cholecystitis after metallic stent placement in distal malignant biliary obstruction

  Yuko Sogabe, Yuzo Kodama, Hajime Honjo, Ikuo Aoyama, Yuya Muramoto, Eri Koga, Takafumi Yanaidani, Munenori Kawai, Teppei Yoshikawa, Shimpei Matsumoto, Astushi Matsumoto, Yoshiharu Mori, Chikage Ono, Miyu Nishida, Yoshihiro Nishida, Takao Mikami, Yasuhiro Matsunaga, Yukiko Miyamoto, Motoya Kitami, Koji Nishikawa, Masahiko Kondo, Naoki Miyake, Chiharu Kawanami, Hiroshi Seno

  Jan. 2019, Gastroenterological Endoscopy, 61(1) (1), 71 - 80

  [Refereed]

  Scientific journal


• Metabolomics-based Discovery of Serum Biomarkers to Predict the Side-effects of Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma.

  Shin Nishiumi, Seiji Fujigaki, Takashi Kobayashi, Takashi Kojima, Yoshinori Ito, Hiroyuki Daiko, Ken Kato, Hirokazu Shoji, Yuzo Kodama, Kazufumi Honda, Masaru Yoshida

  Jan. 2019, Anticancer research, 39(1) (1), 519 - 526, English, International magazine

  [Refereed]

  Scientific journal


• Pathogenesis of autoimmune pancreatitis

  Masahiro Shiokawa, Yuzo Kodama

  2019, Journal of Japanese Society of Gastroenterology, 116(4) (4), 279 - 285

  [Refereed]

  Scientific journal


• Short-Term and Long-Term Outcomes of Infliximab and Tacrolimus Treatment for Moderate to Severe Ulcerative Colitis: Retrospective Observational Study.

  Takafumi Otsuka, Makoto Ooi, Kazutoshi Tobimatsu, Chika Wakahara, Daisuke Watanabe, Soichiro Adachi, Eiichiro Yasutomi, Haruka Yamairi, Yuna Ku, Masaru Yoshida, Namiko Hoshi, Yuzo Kodama

  Dec. 2018, The Kobe journal of medical sciences, 64(4) (4), E140-E148 - E148, English, Domestic magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Chemokine CXCL16 mediates acinar cell necrosis in cerulein induced acute pancreatitis in mice

  Yojiro Sakuma, Yuzo Kodama, Takaaki Eguchi, Norimitsu Uza, Yoshihisa Tsuji, Masahiro Shiokawa, Takahisa Maruno, Katsutoshi Kuriyama, Yoshihiro Nishikawa, Yuki Yamauchi, Motoyuki Tsuda, Tatsuki Ueda, Tomoaki Matsumori, Toshihiro Morita, Teruko Tomono, Nobuyuki Kakiuchi, Atsushi Mima, Yuko Sogabe, Saiko Marui, Takeshi Kuwada, Akihiko Okada, Tomohiro Watanabe, Hiroshi Nakase, Tsutomu Chiba, Hiroshi Seno

  Dec. 2018, Scientific Reports, 8(1) (1), 8829

  [Refereed]

  Scientific journal


• Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study

  Mirei Shirakashi, Hajime Yoshifuji, Yuzo Kodama, Tsutomu Chiba, Motohisa Yamamoto, Hiroki Takahashi, Kazushige Uchida, Kazuichi Okazaki, Tetsuya Ito, Shigeyuki Kawa, Kazunori Yamada, Mitsuhiro Kawano, Shintaro Hirata, Yoshiya Tanaka, Masafumi Moriyama, Seiji Nakamura, Terumi Kamisawa, Shoko Matsui, Hiroto Tsuboi, Takayuki Sumida, Motoko Shibata, Hiroshi Goto, Yasuharu Sato, Tadashi Yoshino, Tsuneyo Mimori

  Dec. 2018, Scientific Reports, 8(1) (1), 10262

  [Refereed]

  Scientific journal


• Effect of mapping biopsy on surgical management of cholangiocarcinoma.

  Siyuan Yao, Kojiro Taura, Yukihiro Okuda, Yuzo Kodama, Norimitsu Uza, Naoki Gouda, Sachiko Minamiguchi, Hideaki Okajima, Toshimi Kaido, Shinji Uemoto

  Nov. 2018, Journal of surgical oncology, 118(6) (6), 997 - 1005, English, International magazine

  [Refereed]

  Scientific journal


• Prognosis

  Takeshi Kuwada, Masahiro Shiokawa, Teruko Tomono, Norimitsu Uza, Yuzo Kodama

  Oct. 2018, IgG4-Related Sclerosing Cholangitis, 119 - 124

  [Refereed]

  In book


• Unusual cause of a pancreatic mass

  Yuko Sogabe, Shuji Yamamoto, Yuzo Kodama

  Oct. 2018, Gastrointestinal Endoscopy, 88(4) (4), 770 - 771

  [Refereed]

  Scientific journal


• Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease

  Tomohiro Handa, Shoko Matsui, Hajime Yoshifuji, Yuzo Kodama, Hiroshi Yamamoto, Seijiro Minamoto, Yuko Waseda, Yasuharu Sato, Keishi Kubo, Tsuneyo Mimori, Tsutomu Chiba, Toyohiro Hirai, Michiaki Mishima

  Sep. 2018, Modern Rheumatology, 28(5) (5), 838 - 844

  [Refereed]

  Scientific journal


• Laminin 511 is a target antigen in autoimmune pancreatitis

  Masahiro Shiokawa, Yuzo Kodama, Kiyotoshi Sekiguchi, Takeshi Kuwada, Teruko Tomono, Katsutoshi Kuriyama, Hajime Yamazaki, Toshihiro Morita, Saiko Marui, Yuko Sogabe, Nobuyuki Kakiuchi, Tomoaki Matsumori, Atsushi Mima, Yoshihiro Nishikawa, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Yojiro Sakuma, Takahisa Maruno, Norimitsu Uza, Tatsuaki Tsuruyama, Tsuneyo Mimori, Hiroshi Seno, Tsutomu Chiba

  Aug. 2018, Science Translational Medicine, 10(453) (453)

  [Refereed]

  Scientific journal


• Pancreatic Mass in a Patient With an Increased Serum Level of IgG4

  Tomoaki Matsumori, Masahiro Shiokawa, Yuzo Kodama

  Aug. 2018, Gastroenterology, 155(2) (2), 269 - 270


• Successful endoscopic removal of fractured guidewire fragments from a peripheral bile duct using a biliary stent delivery system and biopsy forceps

  Yoshihiro Nishikawa, Norimitsu Uza, Yuki Yamauchi, Akihisa Fukuda, Yoshihide Ueda, Yuzo Kodama, Hiroshi Seno

  Jul. 2018, Endoscopy, 50(10) (10), E279 - E280


• Generation of CAR-iPS-T cells expressing CD8 beta

  Ueda Tatsuki, Iriguchi Shoichi, Kawai Yohei, Minagawa Atsutaka, Miyoshi Hiroyuki, Terakura Seitaro, Uemura Yasushi, Woltjen Knut, Kodama Yuzo, Seno Hiroshi, Hitoshi Yasumichi, Nakatsura Tetsuya, Tamada Koji, Kaneko Shin

  Jul. 2018, CANCER RESEARCH, 78(13) (13)

  [Refereed]


• Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer

  Yoko Goto, Akira Nakamura, Ryo Ashida, Katsuyuki Sakanaka, Satoshi Itasaka, Keiko Shibuya, Shigemi Matsumoto, Masashi Kanai, Hiroyoshi Isoda, Toshihiko Masui, Yuzo Kodama, Kyoichi Takaori, Masahiro Hiraoka, Takashi Mizowaki

  Jun. 2018, Radiation Oncology, 13(1) (1), 118

  [Refereed]

  Scientific journal


• Tumor invasion to the arteries feeding the gallbladder as a novel risk factor for cholecystitis after metallic stent placement in distal malignant biliary obstruction

  Yuko Sogabe, Yuzo Kodama, Hajime Honjo, Ikuo Aoyama, Yuya Muramoto, Eri Koga, Takafumi Yanaidani, Munenori Kawai, Teppei Yoshikawa, Shimpei Matsumoto, Astushi Matsumoto, Yoshiharu Mori, Chikage Ono, Miyu Nishida, Yoshihiro Nishida, Takao Mikami, Yasuhiro Matsunaga, Yukiko Miyamoto, Motoya Kitami, Koji Nishikawa, Masahiko Kondo, Naoki Miyake, Chiharu Kawanami, Hiroshi Seno

  May 2018, Digestive Endoscopy, 30(3) (3), 380 - 387

  [Refereed]

  Scientific journal


• Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac

  Yoko Goto, Ryo Ashida, Akira Nakamura, Satoshi Itasaka, Keiko Shibuya, Mami Akimoto, Nobutaka Mukumoto, Shigemi Matsumoto, Masashi Kanai, Hiroyoshi Isoda, Toshihiko Masui, Yuzo Kodama, Mitsuhiro Nakamura, Kyoichi Takaori, Takashi Mizowaki, Masahiro Hiraoka

  May 2018, Oncotarget, 9(34) (34), 23628 - 23635

  [Refereed]

  Scientific journal


• Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer

  Tomohiro Kondo, Masashi Kanai, Tadayuki Kou, Tomohiro Sakuma, Hiroaki Mochizuki, Mayumi Kamada, Masahiko Nakatsui, Norimitsu Uza, Yuzo Kodama, Toshihiko Masui, Kyoichi Takaori, Shigemi Matsumoto, Hidehiko Miyake, Yasushi Okuno, Manabu Muto

  Apr. 2018, Oncotarget, 9(28) (28), 19817 - 19825

  [Refereed]

  Scientific journal


• iPSC-based CAR-T therapy targeting for GPC3

  Ueda Tatsuki, Irigchi Shoich, Kawai Youhei, Minagawa Atsutaka, Miyoshi Hiroyuki, Terakura Seitaro, Uemura Yasushi, Woltjen Knut, Kodama Yuzo, Tamada Koji, Nakatsura Tetsuya, Seno Hiroshi, Kaneko Shin

  Jan. 2018, CANCER SCIENCE, 109, 294

  [Refereed]


• Small-molecule screening yields a compound that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone

  Amelie Perron, Yoshihiro Nishikawa, Jun Iwata, Hiromi Shimojo, Junichiro Takaya, Kumiko Kobayashi, Itaru Imayoshi, Naasson M. Mbenza, Mihoko Takenoya, Ryoichiro Kageyama, Yuzo Kodama, Motonari Uesugi

  2018, Journal of Biological Chemistry, 293(21) (21), 8285 - 8294


• Hypoglycemia unawareness in insulinoma revealed with flash glucose monitoring systems

  Taku Sugawa, Takaaki Murakami, Daisuke Yabe, Riko Kashima, Makiko Tatsumi, Shinobu Ooshima, Erina Joo, Keiko Wada, Atsushi Yoshizawa, Toshihiko Masui, Yuji Nakamoto, Yuki Yamauchi, Yuzo Kodama, Yoshiki Iemura, Masahito Ogura, Akihiro Yasoda, Nobuya Inagaki

  2018, Internal Medicine, 57(23) (23), 3407 - 3412

  [Refereed]

  Scientific journal


• Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report

  Yuji Eso, Norimitsu Uza, Hiroko Yamagishi, Kazuaki Imada, Yuto Kimura, Toshihiko Masui, Yuzo Kodama, Hiroshi Seno

  Dec. 2017, Medicine (United States), 96(50) (50), e9217

  [Refereed]

  Scientific journal


• Erratum to: Early diagnosis of pancreatic necrosis based on perfusion CT to predict the severity of acute pancreatitis.

  Yoshihisa Tsuji, Naoki Takahashi, Hiroyoshi Isoda, Koji Koizumi, Sho Koyasu, Miho Sekimoto, Yuichi Imanaka, Shujiro Yazumi, Masanori Asada, Yoshihiro Nishikawa, Hiroshi Yamamoto, Osamu Kikuchi, Tsukasa Yoshida, Tetsuro Inokuma, Shinji Katsushima, Naoki Esaka, Akihiro Okano, Chiharu Kawanami, Nobuyuki Kakiuchi, Masahiro Shiokawa, Yuzo Kodama, Ichiro Moriyama, Takafumi Kajitani, Yoshikazu Kinoshita, Tsutomu Chiba

  Oct. 2017, Journal of gastroenterology, 52(10) (10), 1147 - 1148, English, Domestic magazine

  [Refereed]

  Scientific journal


• Early diagnosis of pancreatic necrosis based on perfusion CT to predict the severity of acute pancreatitis.

  Yoshihisa Tsuji, Naoki Takahashi, Hiroyoshi Isoda, Koji Koizumi, Sho Koyasu, Miho Sekimoto, Yuichi Imanaka, Shujiro Yazumi, Masanori Asada, Yoshihiro Nishikawa, Hiroshi Yamamoto, Osamu Kikuchi, Tsukasa Yoshida, Tetsuro Inokuma, Shinji Katsushima, Naoki Esaka, Akihiro Okano, Chiharu Kawanami, Nobuyuki Kakiuchi, Masahiro Shiokawa, Yuzo Kodama, Ichiro Moriyama, Takafumi Kajitani, Yoshikazu Kinoshita, Tsutomu Chiba

  Oct. 2017, Journal of gastroenterology, 52(10) (10), 1130 - 1139, English, Domestic magazine

  [Refereed]

  Scientific journal


• Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort Study of 2 Countries

  Peng Xue, Junjie Hang, Weiyi Huang, Shaobo Li, Ning Li, Yuzo Kodama, Shigemi Matsumoto, Kyoichi Takaori, Lifei Zhu, Masashi Kanai

  Sep. 2017, Pancreas, 46(8) (8), 1011 - 1017, English

  [Refereed]

  Scientific journal


• Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.

  Susumu Hijioka, Waki Hosoda, Keitaro Matsuo, Makoto Ueno, Masayuki Furukawa, Hideyuki Yoshitomi, Noritoshi Kobayashi, Masafumi Ikeda, Tetsuhide Ito, Shoji Nakamori, Hiroshi Ishii, Yuzo Kodama, Chigusa Morizane, Takuji Okusaka, Hiroaki Yanagimoto, Kenji Notohara, Hiroki Taguchi, Masayuki Kitano, Kei Yane, Hiroyuki Maguchi, Yoshiaki Tsuchiya, Izumi Komoto, Hiroki Tanaka, Akihito Tsuji, Syunpei Hashigo, Yoshiaki Kawaguchi, Tetsuya Mine, Atsushi Kanno, Go Murohisa, Katsuyuki Miyabe, Tadayuki Takagi, Nobutaka Matayoshi, Tsukasa Yoshida, Kazuo Hara, Masayuki Imamura, Junji Furuse, Yasushi Yatabe, Nobumasa Mizuno

  Aug. 2017, Clinical cancer research : an official journal of the American Association for Cancer Research, 23(16) (16), 4625 - 4632, English, International magazine

  [Refereed]

  Scientific journal


• A case of cystic type intraductal papillary neoplasm of the bile duct diagnosed by SpyGlass DS, a novel peroral cholangioscopy

  Takeshi Kuwada, Masahiro Shiokawa, Norimitsu Uza, Yuzo Kodama

  Jun. 2017, Arab Journal of Gastroenterology, 18(2) (2), 118 - 119, English

  [Refereed]

  Scientific journal


• DISTINCTIVE ROLE OF RB AND P53 IN THE DEVELOPMENT OF PANCREATIC NEUROENDOCRINE TUMORS

  Yuki Yamauchi, Yuzo Kodama, Yuko Sogabe, Takeshi Kuwada, Saiko Marui, Atsushi Mima, Teruko Tomono, Toshihiro Morita, Nobuyuki Kakiuchi, Tomoaki Matsumori, Yoshihiro Nishikawa, Tatsuki Ueda, Motoyuki Tsuda, Katsutoshi Kuriyama, Yojiro Sakuma, Takahisa Maruno, Masahiro Shiokawa, Norimitsu Uza, Hiroshi Seno

  Apr. 2017, GASTROENTEROLOGY, 152(5) (5), S171 - S171, English

  [Refereed]


• A Tumor Localized in the Portal Vein

  Yoichi Nakayama, Akihisa Fukuda, Yuzo Kodama

  Apr. 2017, Gastroenterology, 152(5) (5), e7 - e9, English


• Impact of BRCAness on the efficacy of oxaliplatin-based chemotherapy in patients with unresectable pancreatic cancer.

  Kondo Tomohiro, Kanai Masashi, Kou Tadayuki, Sakuma Tomohiro, Mochizuki Hiroaki, Kamada Mayumi, Nakatsui Masahiko, Uza Norimitsu, Kodama Yuzo, Masui Toshihiko, Takaori Kyoichi, Matsumoto Shigemi, Miyake Hidehiko, Okuno Yasushi, Muto Manabu

  Feb. 2017, JOURNAL OF CLINICAL ONCOLOGY, 35(4) (4), English

  [Refereed]


• Diagnostic performance of a new endoscopic scraper for malignant biliary strictures: a multicenter prospective study.

  Yojiro Sakuma, Yuzo Kodama, Yuko Sogabe, Yoshitaka Nakai, Yukitaka Yamashita, Sakae Mikami, Kozo Kajimura, Kazuki Ikeda, Hiroyuki Tamaki, Satoru Iwamoto, Fumihiro Matsuda, Koichi Fujita, Norimitsu Uza, Takashi Kawamura, Shinji Uemoto, Hiroshi Seno, Tsutomu Chiba, Shujiro Yazumi

  Feb. 2017, Gastrointestinal endoscopy, 85(2) (2), 371 - 379, English, International magazine

  [Refereed]

  Scientific journal


• Familial pancreatic cancer: Concept, management and issues

  Hiroyuki Matsubayashi, Kyoichi Takaori, Chigusa Morizane, Hiroyuki Maguchi, Masamichi Mizuma, Hideaki Takahashi, Keita Wada, Hiroko Hosoi, Shinichi Yachida, Masami Suzuki, Risa Usui, Toru Furukawa, Junji Furuse, Takamitsu Sato, Makoto Ueno, Yoshimi Kiyozumi, Susumu Hijioka, Nobumasa Mizuno, Takeshi Terashima, Masaki Mizumoto, Yuzo Kodama, Masako Torishima, Takahisa Kawaguchi, Reiko Ashida, Masayuki Kitano, Keiji Hanada, Masayuki Furukawa, Ken Kawabe, Yoshiyuki Majima, Toru Shimosegawa

  2017, World Journal of Gastroenterology, 23(6) (6), 935 - 948, English


• A prospective study of intensity-modified radiation therapy in comparison with conventional 3D-RT for BR pancreatic cancer patients with arterial involvement

  Toshihiko Masui, Kyoichi Takaori, Takayuki Anazawa, Asahi Sato, Kenzo Nakano, Yuichiro Uchida, Akitada Yogo, Yoko Goto, Shigemi Matsumoto, Yuzo Kodama, Masashi Kanai, Hiroyoshi Isoda, Masaki Mizumoto, Yoshiya Kawaguchi, Keiko Shibuya, Satoshi Itasaka, Shinji Uemoto

  2017, Anticancer Research, 37(12) (12), 7023 - 7030, English

  [Refereed]

  Scientific journal


• Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: a prospective multicenter study

  Atsushi Kanno, Atsushi Masamune, Fumiyoshi Fujishima, Takuji Iwashita, Yuzo Kodama, Akio Katanuma, Hirotaka Ohara, Masayuki Kitano, Hiroyuki Inoue, Takao Itoi, Nobumasa Mizuno, Hiroyuki Miyakawa, Rintaro Mikata, Atsushi Irisawa, Satoko Sato, Kenji Notohara, Tooru Shimosegawa

  Nov. 2016, Gastrointestinal Endoscopy, 84(5) (5), 797 - 804.e1

  [Refereed]

  Scientific journal


• Clinicopathological Characteristics of Young Patients with Pancreatic Cancer

  Hidetoshi Eguchi, Hiroki Yamaue, Michiaki Unno, Masamichi Mizuma, Shin Hamada, Hisato Igarashi, Tamotsu Kuroki, Sohei Satoi, Yasuhiro Shimizu, Masaji Tani, Satoshi Tanno, Yoshiki Hirooka, Tsutomu Fujii, Atsushi Masamune, Kazuhiro Mizumoto, Takao Itoi, Shinichi Egawa, Yuzo Kodama, Masao Tanaka, Tooru Shimosegawa

  Nov. 2016, Pancreas, 45(10) (10), 1411 - 1417, English, International magazine

  [Refereed]

  Scientific journal


• Impact of EUS-FNA for preoperative para-aortic lymph node staging in patients with pancreatobiliary cancer

  Akira Kurita, Yuzo Kodama, Yuji Nakamoto, Hiroyoshi Isoda, Sachiko Minamiguchi, Kenichi Yoshimura, Katsutoshi Kuriyama, Yugo Sawai, Norimitsu Uza, Etsuro Hatano, Shinji Uemoto, Kaori Togashi, Hironori Haga, Tsutomu Chiba

  Sep. 2016, Gastrointestinal Endoscopy, 84(3) (3), 467 - 475.e1

  [Refereed]

  Scientific journal


• Expert consensus on surveillance methods for early detection of familial pancreatic cancer in Japan

  Masayuki Kitano, Chigusa Morizane, Susumu Hijioka, Hiroyuki Maguchi, Hideaki Takahashi, Keita Wada, Hiroyuki Matsubayashi, Nobumasa Mizuno, Takeshi Terashima, Masaki Mizumoto, Yuzo Kodama, Masako Torishima, Reiko Ashida, Keiji Hanada, Masayuki Furukawa, Ken Kawabe, Kyoichi Takaori

  Elsevier {BV}, Aug. 2016, Pancreatology, 16(4) (4)

  Scientific journal


• Pathogenicity of IgG in patients with IgG4-related disease

  Masahiro Shiokawa, Yuzo Kodama, Katsutoshi Kuriyama, Kenichi Yoshimura, Teruko Tomono, Toshihiro Morita, Nobuyuki Kakiuchi, Tomoaki Matsumori, Atsushi Mima, Yoshihiro Nishikawa, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Ryuki Minami, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Akira Kurita, Yugo Sawai, Yoshihisa Tsuji, Norimitsu Uza, Kazuyoshi Matsumura, Tomohiro Watanabe, Kenji Notohara, Tatsuaki Tsuruyama, Hiroshi Seno, Tsutomu Chiba

  Aug. 2016, Gut, 65(8) (8), 1322 - 1332

  [Refereed]

  Scientific journal


• Concomitant Case of Intraductal Papillary Mucinous Neoplasm of the Pancreas and Functioning Pancreatic Neuroendocrine Tumor (Vasoactive Intestinal Polypeptide-Producing Tumor): First Report

  Shoko Ishizu, Takeshi Setoyama, Taro Ueo, Yoshihide Ueda, Yuzo Kodama, Hiroshi Ida, Yoshiya Kawaguchi, Akihiko Yoshizawa, Tsutomu Chiba, Shin'Ichi Miyamoto

  Jul. 2016, Pancreas, 45(6) (6), e24 - e25


• Diagnostic Performance of a New "Earpick-type Endoscopic Scraper" for Malignant Biliary Stricture: A Multicenter Prospective Study

  Yojiro Sakuma, Yuzo Kodama, Yuko Sogabe, Nobuyuki Kakiuchi, Hajime Honjo, Chiharu Kawanami, Kotaro Watanabe, Kenshiro Hirohashi, Yoshitaka Nakai, Yukitaka Yamashita, Sakae Mikami, Yukimasa Yamashita, Kozo Kajimura, Kazuki Ikeda, Hiroyuki Tamaki, Satoru Iwamoto, Fumihiro Matsuda, Koichi Fujita, Maya Minami, Yugo Sawai, Norimitsu Uza, Takashi Kawamura, Shinji Uemoto, Tsutomu Chiba, Shujiro Yazumi

  May 2016, GASTROINTESTINAL ENDOSCOPY, 83(5) (5), AB138 - AB138, English

  [Refereed]


• Role of Activation-Induced Cytidine Deaminase (Aid) in Pancreatic Cancer Development

  Yuji Ota, Yuzo Kodama, Yugo Sawai, Nobuyuki Kakiuchi, Teruko Tomono, Tomoaki Matsumori, Atsushi Mima, Yuki Yamauchi, Yoshihiro Nishikawa, Motoyuki Tsuda, Katsutoshi Kuriyama, Yojiro Sakuma, Tatsuki Ueda, Takahisa Maruno, Masahiro Shiokawa, Norimitsu Uza, Hiroyuki Marusawa, Hiroshi Seno, Tsutomu Chiba

  Apr. 2016, GASTROENTEROLOGY, 150(4) (4), S915 - S915, English

  [Refereed]


• Biphasic Role of HES1 in Pancreatic Development

  Katsutoshi Kuriyama, Yuzo Kodama, Masahiro Shiokawa, Nobuyuki Kakiuchi, Tomoaki Matsumori, Atsushi Mima, Teruko Tomono, Yoshihiro Nishikawa, Motoyuki Tsuda, Tatsuki Ueda, Yuki Yamauchi, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Hiroshi Seno, Tsutomu Chiba

  Apr. 2016, GASTROENTEROLOGY, 150(4) (4), S143 - S143, English

  [Refereed]


• Experience of Endoscopy in the Kingdom of Bhutan

  二階堂 光洋, 宮本 心一, 児玉 裕三, 宇座 徳光, 辻 喜久, 角田 茂, 植村 忠廣, 岡島 英明, 前田 紗江, 高橋 陽子, 村本 佳奈美, 石井 鮎子, 西 洋子, 樋口 浩和, 武藤 学, 松原 和夫, 千葉 勉

  特集1: 京都大学ブータン友好プログラム特集 = Special Issue 1: Contribution from the Kyoto Bhutan Friendship Program京都大学医学部附属病院の国際支援事業によりブータン王国にて内視鏡診療に従事する機会を得た。ブータンでは消化器内視鏡検査は国内唯一の消化器内科医師と外科医師により行われており, 治療困難な症例は国外へ搬送されていた。内視鏡的逆行性膵胆管造影 (Endoscopic Retrograde Chorangiopancreatography: ERCP) 目的の国外搬送も絶えないため, ERCP 導入を中心とした内視鏡診療支援を行うこととなった。10週間の滞在中に約900件の内視鏡を施行した。大部分は上部消化管内視鏡検査であったが, ERCP に関しても, 現地の医師, 看護師を指導しながら, 23件を施行した。ブータンの内視鏡診療の現況に加え, ブータン人における消化器疾患の頻度及び ERCP 導入の実際について報告する。We provided medical care in the Kingdom of Bhutan from January to March in 2014 through the international medical support program of Kyoto University Hospital. Bhutan is a small, developing country with a population of about 700, 000 citizens located at the southern foot of the Himalayas. There are only 244 medical doctors in Bhutan (one-tenth of the number of doctors relative to population in Japan). Because of the shortage of doctors and the limited medical resources, patients with difficult-to-treat conditions are transferred to India or other countries. Gastrointestinal endoscopy is performed by the country's only gastroenterologist and six surgeons, mainly in Jigme Dorji Wangchuk National Referral Hospital (JDWNRH) at Thimphu. Several years before, a Bhutanese surgeon had learned to perform endoscopic retrograde cholangiopancreatography (ERCP) in Thailand. However, ERCP cannot be established in Bhutanese routine clinical practice because of its technical difficulty. Although a duodenoscope and some devices for ERCP are available, at least one patient who needs ERCP is transferred to India every month. In this context, I was asked to reintroduce ERCP into JDWNRH. ERCP was performed in 23 cases involving 17 patients with the cooperation of Bhutanese doctors, nurses, and technicians. My experience leads me to believe that we can build a platform to continue ERCP in JDWNRH. During the 10 weeks, I also helped to perform about 900 endoscopies, mainly esophagogastroduodenoscopy, and I taught endoscopic techniques and diagnostic approaches to Bhutanese doctors. In this report, I describe the current status of endoscopy in Bhutan including the incidence of Bhutanese gastrointestinal disorders and the experience specifically related to introducing ERCP.

  京都大学ヒマラヤ研究会; 京都大学ブータン友好プログラム; 京都大学霊長類学・ワイルドライフサイエンス・リーディング大学院, Mar. 2016, ヒマラヤ学誌 : Himalayan Study Monographs, 17, 77 - 84, Japanese


• Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy

  Tadayuki Kou, Masashi Kanai, Michio Yamamoto, Peng Xue, Yukiko Mori, Yasushi Kudo, Akira Kurita, Norimitsu Uza, Yuzo Kodama, Masanori Asada, Michiya Kawaguchi, Toshihiko Masui, Masaki Mizumoto, Shujiro Yazumi, Shigemi Matsumoto, Kyoichi Takaori, Satoshi Morita, Manabu Muto, Shinji Uemoto, Tsutomu Chiba

  Feb. 2016, International Journal of Clinical Oncology, 21(1) (1), 118 - 125

  [Refereed]

  Scientific journal


• Short-Term Biliary Stent Placement Contributing Common Bile Duct Stone Disappearance with Preservation of Duodenal Papilla Function

  Tatsuki Ueda, Masataka Kikuyama, Yuzo Kodama, Takafumi Kurokami

  2016, Gastroenterology Research and Practice, 2016, 6153893

  [Refereed]

  Scientific journal


• Bioactive insulin-like growth factors as a possible molecular target for non-islet cell tumor hypoglycemia

  Takashi Setoyama, Shin'ichi Miyamoto, Takahiro Horimatsu, Taro Funakoshi, Miutsuhiro Nikaido, Yuzo Kodama, Sachiko Minamiguchi, Tomoko Yamabata, Manabu Muto, Tsutomu Chiba

  Nov. 2015, ANNALS OF ONCOLOGY, 26, 95 - 96, English

  [Refereed]


• Plasmacytoid dendritic cell activation and IFN-α production are prominent features of murine autoimmune pancreatitis and human IgG4-related autoimmune pancreatitis

  Yasuyuki Arai, Kouhei Yamashita, Katsutoshi Kuriyama, Masahiro Shiokawa, Yuzo Kodama, Toshiharu Sakurai, Kiyomi Mizugishi, Kazushige Uchida, Norimitsu Kadowaki, Akifumi Takaori-Kondo, Masatoshi Kudo, Kazuichi Okazaki, Warren Strober, Tsutomu Chiba, Tomohiro Watanabe

  Oct. 2015, Journal of Immunology, 195(7) (7), 3033 - 3044

  [Refereed]

  Scientific journal


• Acute pancreatitis as a possible indicator of pancreatic cancer: The importance of mass detection

  Yuto Kimura, Masataka Kikuyama, Yuzo Kodama

  Sep. 2015, Internal Medicine, 54(17) (17), 2109 - 2114

  [Refereed]

  Scientific journal


• Activation-induced cytidine deaminase contributes to pancreatic tumorigenesis by inducing tumor-related gene mutations

  Yugo Sawai, Yuzo Kodama, Takahiro Shimizu, Yuji Ota, Takahisa Maruno, Yuji Eso, Akira Kurita, Masahiro Shiokawa, Yoshihisa Tsuji, Norimitsu Uza, Yuko Matsumoto, Toshihiko Masui, Shinji Uemoto, Hiroyuki Marusawa, Tsutomu Chiba

  Aug. 2015, Cancer Research, 75(16) (16), 3292 - 3301

  [Refereed]

  Scientific journal


• International consensus guidance statement on the management and treatment of IgG4-related disease

  A. Khosroshahi, Z. S. Wallace, J. L. Crowe, T. Akamizu, A. Azumi, M. N. Carruthers, S. T. Chari, E. Della-Torre, L. Frulloni, H. Goto, P. A. Hart, T. Kamisawa, S. Kawa, M. Kawano, M. H. Kim, Y. Kodama, K. Kubota, M. M. Lerch, M. Löhr, Y. Masaki, S. Matsui, T. Mimori, S. Nakamura, T. Nakazawa, H. Ohara, K. Okazaki, J. H. Ryu, T. Saeki, N. Schleinitz, A. Shimatsu, T. Shimosegawa, H. Takahashi, M. Takahira, A. Tanaka, M. Topazian, H. Umehara, G. J. Webster, T. E. Witzig, M. Yamamoto, W. Zhang, T. Chiba, J. H. Stone

  Jul. 2015, Arthritis and Rheumatology, 67(7) (7), 1688 - 1699

  [Refereed]

  Scientific journal


• A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)

  Masashi Kanai, Etsuro Hatano, Shogo Kobayashi, Yutaka Fujiwara, Shigeru Marubashi, Atsushi Miyamoto, Hisanori Shiomi, Shoji Kubo, Shinichi Ikuta, Hiroaki Yanagimoto, Hiroaki Terajima, Hisashi Ikoma, Daisuke Sakai, Yuzo Kodama, Satoru Seo, Satoshi Morita, Tetsuo Ajiki, Hiroaki Nagano, Tatsuya Ioka

  Feb. 2015, Cancer Chemotherapy and Pharmacology, 75(2) (2), 293 - 300

  [Refereed]

  Scientific journal


• Prognostic model for survival in patients with advanced pancreatic cancer receiving palliative chemotherapy.

  Uneno Yu, Kou Tadayuki, Kanai Masashi, Yamamoto Michio, Xue Peng, Mori Yukiko, Kudo Yasushi, Kurita Akira, Uza Norimitsu, Kodama Yuzo, Asada Masanori, Masui Toshihiko, Yazumi Shujiro, Matsumoto Shigemi, Takaori Kyoichi, Morita Satoshi, Muto Manabu, Chiba Tsutomu

  Jan. 2015, JOURNAL OF CLINICAL ONCOLOGY, 33(3) (3), English

  [Refereed]


• Future perspective

  T. Chiba, M. Shiokawa, Y. Kodama

  Jan. 2015, Autoimmune Pancreatitis, 207 - 209

  [Refereed]

  In book


• Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer

  Takahiro Kishi, Akira Nakamura, Satoshi Itasaka, Keiko Shibuya, Shigemi Matsumoto, Masashi Kanai, Yuzo Kodama, Kyoichi Takaori, Takashi Mizowaki, Masahiro Hiraoka

  2015, Pancreatology, 15(6) (6), 694 - 700

  [Refereed]

  Scientific journal


• Involvement of interleukin-17A-induced expression of heat shock protein 47 in intestinal fibrosis in Crohn's disease

  Yusuke Honzawa, Hiroshi Nakase, Masahiro Shiokawa, Takuya Yoshino, Hirotsugu Imaeda, Minoru Matsuura, Yuzo Kodama, Hiroki Ikeuchi, Akira Andoh, Yoshiharu Sakai, Kazuhiro Nagata, Tsutomu Chiba

  Dec. 2014, Gut, 63(12) (12), 1902 - 1912, English

  [Refereed]

  Scientific journal


• Bioactive insulin-like growth factors as a possible molecular target for non-islet cell tumor hypoglycemia

  Takeshi Setoyama, Shi N.Ichi Miyamoto, Takahiro Horimatsu, Taro Funakoshi, Mitsuhiro Nikaido, Yuzo Kodama, Sachiko Minamiguchi, Tomoko Yamabata, Manabu Muto, Tsutomu Chiba

  Dec. 2014, Cancer Biology and Therapy, 15(12) (12), 1588 - 1592

  [Refereed]

  Scientific journal


• Intraductal tubulopapillary neoplasm with expansile invasive carcinoma of the pancreas diagnosed by endoscopic ultrasonography-guided fine needle aspiration: A case report

  Ayako Furuhata, Sachiko Minamiguchi, Yoshiki Mikami, Yuzo Kodama, Shinji Sumiyoshi, Souichi Adachi, Hironori Haga

  Apr. 2014, Diagnostic Cytopathology, 42(4) (4), 314 - 320, English

  [Refereed]

  Scientific journal


• Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients

  Peng Xue, Masashi Kanai, Yukiko Mori, Takafumi Nishimura, Norimitsu Uza, Yuzo Kodama, Yoshiya Kawaguchi, Kyoichi Takaori, Shigemi Matsumoto, Shinji Uemoto, Tsutomu Chiba

  Apr. 2014, Cancer medicine, 3(2) (2), 406 - 415

  [Refereed]

  Scientific journal


• Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy

  Peng Xue, Masashi Kanai, Yukiko Mori, Takafumi Nishimura, Norimitsu Uza, Yuzo Kodama, Yoshiya Kawaguchi, Kyoichi Takaori, Shigemi Matsumoto, Shinji Uemoto, Tsutomu Chiba

  Apr. 2014, Pancreas, 43(3) (3), 411 - 416

  [Refereed]

  Scientific journal


• Non-functioning pancreatic neuroendocrine tumor accompanied with multiple liver metastases: Remorseful case and literature review

  Tomohide Hori, Kyoichi Takaori, Michiya Kawaguchi, Kohei Ogawa, Toshihiko Masui, Takamichi Ishii, Hiromitsu Nagata, Masato Narita, Yuzo Kodama, Norimitsu Uza, Shinji Uemoto

  2014, Journal of the Pancreas, 15(6) (6), 622 - 625

  [Refereed]

  Scientific journal


• Perfusion in the Tissue Surrounding Pancreatic Cancer and the Patient's Prognosis

  Yoshihiro Nishikawa, Yoshihisa Tsuji, Hiroyoshi Isoda, Yuzo Kodama, Tsutomu Chiba

  2014, BioMed Research International, 2014, 648021

  [Refereed]

  Scientific journal


• A phase i study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients

  Masashi Kanai, Yoshihiko Otsuka, Kazunori Otsuka, Maremi Sato, Takafumi Nishimura, Yukiko Mori, Michiya Kawaguchi, Etsuro Hatano, Yuzo Kodama, Shigemi Matsumoto, Yoshiki Murakami, Atsushi Imaizumi, Tsutomu Chiba, Jun Nishihira, Hiroyuki Shibata

  Jun. 2013, Cancer Chemotherapy and Pharmacology, 71(6) (6), 1521 - 1530, English

  [Refereed]

  Scientific journal


• Risk of cancer in patients with autoimmune pancreatitis

  Masahiro Shiokawa, Yuzo Kodama, Kenichi Yoshimura, Chiharu Kawanami, Jun Mimura, Yukitaka Yamashita, Masanori Asada, Masataka Kikuyama, Yoshihiro Okabe, Tetsuro Inokuma, Masaya Ohana, Hiroyuki Kokuryu, Kazuo Takeda, Yoshihisa Tsuji, Ryuki Minami, Yojiro Sakuma, Katsutoshi Kuriyama, Yuji Ota, Wataru Tanabe, Takahisa Maruno, Akira Kurita, Yugo Sawai, Norimitsu Uza, Tomohiro Watanabe, Hironori Haga, Tsutomu Chiba

  Apr. 2013, American Journal of Gastroenterology, 108(4) (4), 610 - 617, English

  [Refereed]

  Scientific journal


• Toll-like receptor activation in basophils contributes to the development of IgG4-related disease

  Tomohiro Watanabe, Kouhei Yamashita, Toshiharu Sakurai, Masatoshi Kudo, Masahiro Shiokawa, Norimitsu Uza, Yuzo Kodama, Kazushige Uchida, Kazuichi Okazaki, Tsutomu Chiba

  Feb. 2013, Journal of Gastroenterology, 48(2) (2), 247 - 253, English

  [Refereed]

  Scientific journal


• Bifid tail of the pancreas with localized acute pancreatitis

  Sho Koyasu, Hiroyoshi Isoda, Hiroshi Nakase, Yuzo Kodama, Tsutomu Chiba, Kaori Togashi

  2013, Magnetic Resonance in Medical Sciences, 12(4) (4), 315 - 318, English

  [Refereed]

  Scientific journal


• Endoscopic stent placement above the intact sphincter of Oddi for biliary strictures after living donor liver transplantation

  Akira Kurita, Yuzo Kodama, Ryuki Minami, Yojiro Sakuma, Katsutoshi Kuriyama, Wataru Tanabe, Yuji Ohta, Takahisa Maruno, Masahiro Shiokawa, Yugo Sawai, Norimitsu Uza, Shujiro Yazumi, Atsushi Yoshizawa, Shinji Uemoto, Tsutomu Chiba

  2013, Journal of Gastroenterology, 48(9) (9), 1097 - 1104, English

  [Refereed]

  Scientific journal


• A liver abscess deprived a healthy adult of eyesight: Endogenous endophthalmitis associated with a pyogenic liver abscess caused by serotype K1 Klebsiella pneumonia

  Takahisa Maruno, Yoko Ooiwa, Ken Takahashi, Yuzo Kodama, Shunji Takakura, Satoshi Ichiyama, Tsutomu Chiba

  2013, Internal Medicine, 52(8) (8), 919 - 922, English

  [Refereed]

  Scientific journal


• Relationship between pancreatic perfusion parameters and clinical complications of severe acute pancreatitis

  Tsubasa Watanabe, Yoshihisa Tsuji, Naoki Takahashi, Tsukasa Yoshida, Masashi Tamaoki, Osamu Kikuchi, Yuji Watanabe, Yuzo Kodama, Hiroyoshi Isoda, Hiroshi Yamamoto, Tsutomu Chiba

  Jan. 2013, Pancreas, 42(1) (1), 180 - 182, English


• Novel genetic mutations specific for intraductal papillary neoplasm of the pancreas

  Yuzo Kodama, Tsutomu Chiba

  Jun. 2012, Gastroenterology, 142(7) (7), 1617 - 1619, English


• Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist

  Keiko Iwaisako, Michael Haimerl, Yong Han Paik, Kojiro Taura, Yuzo Kodama, Claude Sirlin, Elizabeth Yu, Ruth T. Yu, Michael Downes, Ronald M. Evans, David A. Brenner, Bernd Schnabl

  May 2012, Proceedings of the National Academy of Sciences of the United States of America, 109(21) (21), E1369-E1376 - 76, English

  [Refereed]

  Scientific journal


• Phase i trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002)

  Masashi Kanai, Etsuro Hatano, Syogo Kobayashi, Yutaka Fujiwara, Daisuke Sakai, Yuzo Kodama, Tetsuo Ajiki, Hiroaki Nagano, Tatsuya Ioka

  May 2012, Cancer Chemotherapy and Pharmacology, 69(5) (5), 1181 - 1188, English

  [Refereed]

  Scientific journal


• Involvement of activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis

  Tomohiro Watanabe, Kouhei Yamashita, Saori Fujikawa, Toshiharu Sakurai, Masatoshi Kudo, Masahiro Shiokawa, Yuzo Kodama, Kazushige Uchida, Kazuichi Okazaki, Tsutomu Chiba

  Mar. 2012, Arthritis and Rheumatism, 64(3) (3), 914 - 924, English

  [Refereed]

  Scientific journal


• Relationship between serum angiopoietin-2 level and perfusion CT parameters in severe acute pancreatitis

  Tsubasa Watanabe, Yoshihisa Tsuji, Yuzo Kodama, Hiroyoshi Isoda, Hiroshi Yamamoto, Tsutomu Chiba

  Oct. 2011, American Journal of Gastroenterology, 106(10) (10), 1859 - 1861, English


• Autoimmune pancreatitis exhibiting multiple mass lesions

  Masahiro Shiokawa, Yuzo Kodama, Yukiko Hiramatsu, Akira Kurita, Yugo Sawai, Norimitsu Uza, Tomohiro Watanabe, Tsutomu Chiba

  Sep. 2011, Case Reports in Gastroenterology, 5(3) (3), 528 - 533, English

  [Refereed]

  Scientific journal


• Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase

  David A. Brenner, Ekihiro Seki, Kojiro Taura, Tatiana Kisseleva, Samuele Deminicis, Keiko Iwaisako, Sayaka Inokuchi, Bernd Schnabl, Christopher H. Oesterreicher, Yong H. Paik, Kouichi Miura, Yuzo Kodama

  Jul. 2011, Hepatology Research, 41(7) (7), 683 - 686, English


• Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMP-activated protein kinase suppression

  Yosuke Osawa, Ekihiro Seki, Yuzo Kodama, Atsushi Suetsugu, Kouichi Miura, Masayuki Adachi, Hiroyasu Ito, Yoshimune Shiratori, Yoshiko Banno, Jerrold M. Olefsky, Masahito Nagaki, Hisataka Moriwaki, David A. Brenner, Mitsuru Seishima

  Apr. 2011, FASEB Journal, 25(4) (4), 1133 - 1144, English

  [Refereed]

  Scientific journal


• Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis

  Seiji Shio, Yuzo Kodama, Hiroshi Ida, Masahiro Shiokawa, Koji Kitamura, Etsuro Hatano, Shinji Uemoto, Tsutomu Chiba

  Apr. 2011, Cancer Science, 102(4) (4), 776 - 783, English

  [Refereed]

  Scientific journal


• Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMP-activated protein kinase suppression.

  Osawa Yosuke, Seki Ekihiro, Kodama Yuzo, Suetsugu Atsushi, Miura Kouichi, Adachi Masayuki, Ito Hiroyasu, Shiratori Yoshimune, Banno Yoshiko, Olefsky Jerrold M, Nagaki Masahito, Moriwaki Hisataka, Brenner David A, Seishima Mitsuru

  Acid sphingomyelinase (ASM) regulates the homeostasis of sphingolipids, including ceramides and sphingosine-1-phosphate (S1P). Because sphingolipids regulate AKT activation, we investigated the role of ASM in hepatic glucose andlipid metabolism. Initially, we overexpressed ASM in the livers of wild-type and diabetic db/db mice by adenovirus vector (Ad5ASM). In these mice, glucose tolerance was improved, and glycogen and lipid accumulation in the liver were increased. Using primary cultured hepatocytes, we confirmed that ASM increased glucose uptake, glycogen deposition, and lipid accumulation through activation of AKT and glycogen synthase kinase-3β. In addition, ASM induced up-regulation of glucose transporter 2 accompanied by suppression of AMP-activated protein kinase (AMPK) phosphorylation. Loss of sphingosine kinase-1 (SphK1) diminished ASM-mediated AKT phosphorylation, but exogenous S1P induced AKT activation in hepatocytes. In contrast, SphK1 deficiency did not affect AMPK activation. These results suggest that the SphK/S1P pathway is required for ASM-mediated AKT activation but not for AMPK inactivation. Finally, we found that treatment with high-dose glucose increased gly

  Apr. 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 25(4) (4), 1133 - 1144, English

  [Refereed]

  Scientific journal


• Hemobilia: Another complication associated with anti-thrombotic therapy

  Yukiko Hiramatsu, Tomohiro Watanabe, Masahiro Shiokawa, Akira Kurita, Minoru Matsuura, Norimitsu Uza, Yuzo Kodama, Tsutomu Chiba

  Feb. 2011, Clinical Journal of Gastroenterology, 4(1) (1), 49 - 51, English

  [Refereed]

  Scientific journal


• Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis.

  Samuele De Minicis, Ekihiro Seki, Yong Han Paik, Christoph H. Osterreicher, Yuzo Kodama, Johannes Kluwe, Luciano Torozzi, Katsumi Miyai, Antonio Benedetti, Robert F. Schwabe, David A. Brenner

  Oct. 2010, Hepatology (Baltimore, Md.), 52(4) (4), 1420 - 1430, English

  [Refereed]

  Scientific journal


• Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis

  Eric E. Zhang, Yi Liu, Renaud Dentin, Pagkapol Y. Pongsawakul, Andrew C. Liu, Tsuyoshi Hirota, Dmitri A. Nusinow, Xiujie Sun, Severine Landais, Yuzo Kodama, David A. Brenner, Marc Montminy, Steve A. Kay

  Oct. 2010, Nature Medicine, 16(10) (10), 1152 - 1156, English

  [Refereed]

  Scientific journal


• [Tumors of the biliary tract and pancreas].

  Yuzo Kodama, Tsutomu Chiba

  Aug. 2010, Nippon rinsho. Japanese journal of clinical medicine, 68 Suppl 8, 462 - 467, English


• Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice

  Kouichi Miura, Yuzo Kodama, Sayaka Inokuchi, Bernd Schnabl, Tomonori Aoyama, Hirohide Ohnishi, Jerrold M. Olefsky, David A. Brenner, Ekihiro Seki

  Jul. 2010, Gastroenterology, 139(1) (1), 323 - 34.e7, English

  [Refereed]

  Scientific journal


• Enhanced cytokine responses to Toll-like and NOD-like receptor ligands in primary biliary cirrhosis-CREST overlap syndrome

  Manabu Fukuhara, Tomohiro Watanabe, Taro Ueo, Hiroshi Ida, Yuzo Kodama, Tsutomu Chiba

  Apr. 2010, Rheumatology, 49(8) (8), 1602 - 1604, English


• Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice

  Kojiro Taura, Kouichi Miura, Keiko Iwaisako, Christoph H. Ö Sterreicher, Yuzo Kodama, Melitta Penz-Ö Sterreicher, David A. Brenner

  Mar. 2010, Hepatology, 51(3) (3), 1027 - 1036, English

  [Refereed]

  Scientific journal


• Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis

  Sayaka Inokuchi, Tomonori Aoyama, Kouichi Miura, Christoph H. Österreicher, Yuzo Kodama, Katsumi Miyai, Shizuo Akira, David A. Brenner, Ekihiro Seki

  2010, Proceedings of the National Academy of Sciences of the United States of America, 107(2) (2), 844 - 849, English

  [Refereed]

  Scientific journal


• c-Jun N-terminal Kinase-1 From Hematopoietic Cells Mediates Progression From Hepatic Steatosis to Steatohepatitis and Fibrosis in Mice

  Yuzo Kodama, Tatiana Kisseleva, Keiko Iwaisako, Kouichi Miura, Kojiro Taura, Samuele De Minicis, Christoph H. Österreicher, Bernd Schnabl, Ekihiro Seki, David A. Brenner

  Oct. 2009, Gastroenterology, 137(4) (4), 1467 - 1477.e5, English

  [Refereed]

  Scientific journal


• Antiapoptotic Effect of c-Jun N-terminal Kinase-1 through Mcl-1 Stabilization in TNF-Induced Hepatocyte Apoptosis

  Yuzo Kodama, Kojiro Taura, Kouichi Miura, Bernd Schnabl, Yosuke Osawa, David A. Brenner

  Apr. 2009, Gastroenterology, 136(4) (4), 1423 - 1434, English

  [Refereed]

  Scientific journal


• Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice

  Christoph H. Österreicher, Kojiro Taura, Samuele De Minicis, Ekihiro Seki, Melitta Penz-Österreicher, Yuzo Kodama, Johannes Kluwe, Manfred Schuster, Gavin Y. Oudit, Josef M. Penninger, David A. Brenner

  2009, Hepatology, 50(3) (3), 929 - 938, English

  [Refereed]

  Scientific journal


• c-Jun N-terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: Multiple roles in multiple steps

  Yuzo Kodama, David A. Brenner

  2009, Hepatology, 49(1) (1), 6 - 8, English

  [Refereed]

  Scientific journal


• Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity

  Kouichi Miura, Kojiro Taura, Yuzo Kodama, Bernd Schnabl, David A. Brenner

  Nov. 2008, Hepatology, 48(5) (5), 1420 - 1429, English

  [Refereed]

  Scientific journal


• Hepatic Stellate Cells Secrete Angiopoietin 1 That Induces Angiogenesis in Liver Fibrosis

  Kojiro Taura, Samuele De Minicis, Ekihiro Seki, Etsuro Hatano, Keiko Iwaisako, Christoph H. Osterreicher, Yuzo Kodama, Kouichi Miura, Iwao Ikai, Shinji Uemoto, David A. Brenner

  Nov. 2008, Gastroenterology, 135(5) (5), 1729 - 1738, English

  [Refereed]

  Scientific journal


• CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury

  Nobuyuki Tamaki, Etsuro Hatano, Kojiro Taura, Masaharu Tada, Yuzo Kodama, Takashi Nitta, Keiko Iwaisako, Satoru Seo, Akio Nakajima, Iwao Ikai, Shinji Uemoto

  Feb. 2008, American Journal of Physiology - Gastrointestinal and Liver Physiology, 294(2) (2), G498 - 505, English

  [Refereed]

  Scientific journal


• Epimorphin, a morphogenic protein, induces proteases in rodent hepatocytes through NF-κB

  Kouichi Miura, Ryutaro Yoshino, Yohei Hirai, Takashi Goto, Shigetoshi Ohshima, Ken ichiro Mikami, Kazuo Yoneyama, Daisuke Watanabe, Mitsuru Sato, Haruki Senoo, Yuzo Kodama, Yosuke Osawa, David A. Brenner, Sumio Watanabe

  Dec. 2007, Journal of Hepatology, 47(6) (6), 834 - 843, English

  [Refereed]

  Scientific journal


• Alpha-1 antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis

  Ali Mencin, Ekihiro Seki, Yosuke Osawa, Yuzo Kodama, Samuele De Minicis, Michael Knowles, David A. Brenner

  Nov. 2007, Hepatology, 46(5) (5), 1443 - 1452, English

  [Refereed]

  Scientific journal


• Henoch-Schönlein purpura in an elderly patient with unusual manifestation.

  N. Uza, S. Yazumi, K. Tanabe, Y. Endo, Y. Kodama, Y. Matsumura, H. Sakashita, T. Chiba

  Feb. 2007, Endoscopy, 39 Suppl 1, E35-36, English

  [Refereed]

  Scientific journal


• Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis

  Tadayuki Kou, Hiroyuki Marusawa, Kazuo Kinoshita, Yoko Endo, Il Mi Okazaki, Yoshihide Ueda, Yuzo Kodama, Hironori Haga, Iwao Ikai, Tsutomu Chiba

  Feb. 2007, International Journal of Cancer, 120(3) (3), 469 - 476, English

  [Refereed]

  Scientific journal


• A case of ileal heterotopic pancreas with repeated melena

  Yoko Endo, Shujiro Yazumi, Yuto Kimura, Norimitsu Uza, Minoru Matsuura, Yuzo Kodama, Hiroshi Nakase, Tsutomu Chiba

  Jan. 2007, Gastrointestinal Endoscopy, 65(1) (1), 156 - 157, English

  [Refereed]

  Scientific journal


• Systemic mediators induce fibrogenic effects in normal liver after partial bile duct ligation

  Yosuke Osawa, Ekihiro Seki, Masayuki Adachi, Kojiro Taura, Yuzo Kodama, Soren V. Siegmund, Robert F. Schwabe, David A. Brenner

  Nov. 2006, Liver International, 26(9) (9), 1138 - 1147, English

  [Refereed]

  Scientific journal


• Anti-viral protein APOBEC3G is induced by interferon-α stimulation in human hepatocytes

  Yuichi Tanaka, Hiroyuki Marusawa, Hiroshi Seno, Yuko Matsumoto, Yoshihide Ueda, Yuzo Kodama, Yoko Endo, Junichi Yamauchi, Tomonori Matsumoto, Akifumi Takaori-Kondo, Iwao Ikai, Tsutomu Chiba

  Mar. 2006, Biochemical and Biophysical Research Communications, 341(2) (2), 314 - 319, English

  [Refereed]

  Scientific journal


• Hepatobiliary and pancreatic: Tonsillar metastases from hepatocellular carcinoma

  Y. Endo, S. Yazumi, Y. Kimura, N. Uza, Y. Kodama, T. Chiba

  Feb. 2006, Journal of Gastroenterology and Hepatology (Australia), 21(2) (2), 478

  [Refereed]

  Scientific journal


• The role of notch signaling in the development of intrahepatic bile ducts

  Yuzo Kodama, Makoto Hijikata, Ryoichiro Kageyama, Kunitada Shimotohno, Tsutomu Chiba

  Dec. 2004, Gastroenterology, 127(6) (6), 1775 - 1786, English

  [Refereed]

  Scientific journal


• Endoscopic management of biliary strictures after duct-to-duct biliary reconstruction in right-lobe living-donor liver transplantation

  Hiroshi Hisatsune, Shujiro Yazumi, Hiroto Egawa, Masanori Asada, Kazunori Hasegawa, Yuzo Kodama, Kazuichi Okazaki, Kyo Itoh, Hiroshi Takakuwa, Koichi Tanaka, Tsutomu Chiba

  Sep. 2003, Transplantation, 76(5) (5), 810 - 815, English

  [Refereed]

  Scientific journal


• Endoscopic management of postoperative biliary complications in donors for living donor liver transplantation

  Kazunori Hasegawa, Shujiro Yazumi, Hiroto Egawa, Hiroyuki Tamaki, Masanori Asada, Yuzo Kodama, Hiroshi Hisatsune, Kazuichi Okazaki, Koichi Tanaka, Tsutomu Chiba

  May 2003, Clinical Gastroenterology and Hepatology, 1(3) (3), 183 - 188, English

  [Refereed]

  Scientific journal


• Endoscopic Management of Postoperative Biliary Complications in Donors for Living Donor Liver Transplantation

  Kazunori Hasegawa, Shujiro Yazumi, Hiroto Egawa, Hiroyuki Tamaki, Masanori Asada, Yuzo Kodama, Hiroshi Hisatsune, Kazuichi Okazaki, Koichi Tanaka, Tsutomu Chiba

  May 2003, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 1(3) (3), 183 - 188, English

  [Refereed]

  Scientific journal


• Endoscopic retrieval of broken external biliary stents from the bile duct after right-lobe living-donor liver transplantation

  Masanori Asada, Shujiro Yazumi, Hiroshi Hisatsune, Yuzo Kodama, Kazunori Hasegawa, Kazuichi Okazaki, Hiroto Egawa, Koichi Tanaka, Tsutomu Chiba

  Apr. 2003, Gastrointestinal Endoscopy, 57(4) (4), 611 - 614, English

  [Refereed]

  Scientific journal


• Endoscopic retrieval of broken external biliary stents from the bile duct after right-lobe living-donor liver transplantation

  M Asada, S Yazumi, H Hisatsune, Y Kodama, K Hasegawa, K Okazaki, H Egawa, K Tanaka, T Chiba

  Apr. 2003, GASTROINTESTINAL ENDOSCOPY, 57(4) (4), 611 - 614, English

  [Refereed]

  Scientific journal


• Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?

  Tadashi Soga, Minoru Matsuura, Yuzo Kodama, Tsuyoshi Fujita, Ikufumi Sekimoto, Kazumasa Nishimura, Syunichi Yoshida, Hiromu Kutsumi, Sotaro Fujimoto

  Aug. 1999, Journal of Gastroenterology, 34(4) (4), 435 - 440, English

  [Refereed]

  Scientific journal


• MALT lymphoma simulating an extramedullary plasmacytoma of the stomach [4]

  Y. Kodama, K. Kawabata, S. Yoshida, K. Notohara, T. Fujimori, T. Chiba

  1999, American Journal of Medicine, 107(5) (5), 530 - 532, English

• Surveillance for the Early Diagnosis of Familial Pancreatic Cancer (Expert Consensus)

  Masayuki Kitano, Chigusa Morizane, Susumu Hijioka, Hiroyuki Matsubayashi, Reiko Ashida, Tsukasa Ikeura, Tetsuhide Ito, Terumi Kamisawa, Takahisa Kawaguchi, Ken Kawabe, Shinji Kosugi, Yuzo Kodama, Kyoko Shimizu, Hideaki Takahashi, Shinichi Yachida, Takeshi Terashima, Masako Torishima, Keiji Hanada, Toru Furukawa, Masayuki Furukawa, Junji Furuse, Hiroyuki Maguchi, Yoshiyuki Majima, Nobumasa Mizuno, Masamichi Mizuma, Masaki Mizumoto, Takeichi Yoshida, Keita Wada, Kyoichi Takaori

  Jul. 2021, PANCREAS, 50(6) (6), 899 - 899, English

  Summary international conference


• 大腸cT1b癌に対する内視鏡治療の最前線 MR signを伴う直腸腫瘍に対するPocket Creation Method・Peranal endoscopic myectomyによる断端陰性率向上の工夫

  阪口 博哉, 豊永 高史, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 795 - 795, Japanese


• 十二指腸表在型腫瘍に対する内視鏡診療(LECS vs EMR vs ESD vs経過観察) 表在型非乳頭部十二指腸上皮性腫瘍に対する腹腔鏡内視鏡合同手術の治療成績

  鷹尾 俊達, 森田 圭紀, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 848 - 848, Japanese


• 胆道出血に対する内視鏡治療の現状と課題 特に肝細胞癌からの胆道出血に関して

  芦名 茂人, 酒井 新, 増田 充弘, 猪股 典子, 孝橋 信哉, 長尾 佳映, 増田 重人, 植村 久尋, 阿部 晶平, 権田 真知, 山川 康平, 辻前 正弘, 田中 雄志, 田中 俊多, 山田 恭孝, 中野 遼太, 小林 隆, 塩見 英之, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 892 - 892, Japanese


• EUS-hepaticogastrostomyにおけるトラブルを未然に回避するためのダブルガイドワイヤー法

  權田 真知, 塩見 英之, 児玉 裕三, 猪股 典子, 孝橋 信哉, 長尾 佳映, 植村 久尋, 増田 重人, 芦名 茂人, 阿部 晶平, 辻前 正弘, 田中 俊多, 田中 雄志, 山田 恭孝, 中野 遼太, 酒井 新, 小林 隆, 増田 充弘

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 907 - 907, Japanese


• 進行食道癌に対する食道ステント留置後の食事摂取状況に関する検討

  賀来 英俊, 鷹尾 俊達, 中井 達也, 高山 弘志, 嶋本 有策, 上田 千勢, 津田 一範, 松本 慶, 池澤 伸明, 阪口 博哉, 松岡 晃生, 阿部 洋文, 吉崎 哲也, 鷹尾 まど佳, 森田 圭紀, 豊永 高史, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 910 - 910, Japanese


• 消化器内視鏡検査従事者における新型コロナウイルスSARS-CoV-2感染症の抗体保有率調査

  阪口 博哉, 阿部 洋文, 井上 潤, 上田 佳秀, 児玉 裕三, 白坂 大輔, 森田 周子, 猪熊 哲朗, 浅田 裕也

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 954 - 954, Japanese


• 幽門側胃切除後の残胃吻合部の早期胃癌に対する内視鏡的粘膜下層剥離術の再建術式に基づく治療困難性および有効性、安全性の検討

  松本 慶, 鷹尾 俊達, 田中 心和, 森田 圭紀, 豊永 高史, 児玉 裕三

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 956 - 956, Japanese


• 乳酸リンゲル液の投与によるERCP後膵炎発症予防効果の検討

  中野 遼太, 酒井 新, 児玉 裕三, 長尾 佳映, 猪俣 典子, 孝橋 信哉, 植村 久尋, 増田 重人, 芦名 茂人, 権田 真知, 阿部 晶平, 山川 康平, 田中 雄志, 田中 俊多, 山田 恭孝, 小林 隆, 増田 充弘, 塩見 英之

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 976 - 976, Japanese


• 内視鏡的乳頭切除術を行った早期十二指腸乳頭部腫瘍の予後に関する検討

  阿部 晶平, 酒井 新, 児玉 裕三, 猪股 典子, 増田 重人, 權田 真知, 芦名 茂人, 山川 康平, 辻前 正弘, 田中 雄志, 田中 俊多, 山田 泰孝, 中野 遼太, 小林 隆, 塩見 英之, 増田 充弘, 柳本 泰明, 福本 巧

  (一社)日本消化器内視鏡学会, Apr. 2021, Gastroenterological Endoscopy, 63(Suppl.1) (Suppl.1), 980 - 980, Japanese


• 予後向上を目指した膵癌診療 膵癌手術例における治療選択マーカーとしてのTLS(Tertiary lymphoid structure)の有用性

  田中 雄志, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2021, 日本消化器病学会雑誌, 118(臨増総会) (臨増総会), A88 - A88, Japanese


• 胆膵の内視鏡診断と治療 肝外胆管癌における術前の水平進展度診断の検討

  増田 重人, 塩見 英之, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2021, 日本消化器病学会雑誌, 118(臨増総会) (臨増総会), A90 - A90, Japanese


• 慢性膵炎を巡る諸問題:早期慢性膵炎から外科治療まで 膵切除検体を用いたEUSにおける早期慢性膵炎所見の妥当性の検証

  猪股 典子, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2021, 日本消化器病学会雑誌, 118(臨増総会) (臨増総会), A122 - A122, Japanese


• 消化器領域におけるバイオマーカーの新展開 膵癌におけるSPRR1Aの発現と予後

  山川 康平, 児玉 裕三, 青井 貴之

  (一財)日本消化器病学会, Mar. 2021, 日本消化器病学会雑誌, 118(臨増総会) (臨増総会), A151 - A151, Japanese


• 消化器領域の救急医療、集中治療:急性膵炎 Pancreatic fluid collectionに対する早期インターベンションの可能性

  辻前 正弘, 塩見 英之, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2021, 日本消化器病学会雑誌, 118(臨増総会) (臨増総会), A252 - A252, Japanese


• 治療困難胆管結石に対する電気衝撃波結石破砕術(EHL)の当院における現状と治療成績の検討

  植村 久尋, 中野 遼太, 猪俣 典子, 孝橋 信哉, 長尾 佳映, 芦名 茂人, 増田 重人, 阿部 昌平, 権田 真知, 山川 康平, 辻前 正弘, 田中 俊多, 田中 雄志, 山田 恭孝, 小林 隆, 酒井 新, 塩見 英之, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2021, 日本消化器病学会雑誌, 118(臨増総会) (臨増総会), A323 - A323, Japanese


• 当院における潰瘍性大腸炎での5-ASA不耐症の現状について

  岡本 典大, 宮崎 はる香, 徳永 英里, 松本 慶, 具 潤亜, 竹中 春香, 大井 充, 星 奈美子, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2021, 日本消化器病学会雑誌, 118(臨増総会) (臨増総会), A350 - A350, Japanese


• 免疫チェックポイント阻害薬によるirAE肝障害の臨床的特徴

  山本 淳史, 矢野 嘉彦, 朝治 直紀, 吉田 竜太郎, 安冨 栄一郎, 畑澤 友里, 林 宏樹, 塩見 優紀, 上田 佳秀, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2021, 日本消化器病学会雑誌, 118(臨増総会) (臨増総会), A393 - A393, Japanese


• Genetic analysis of metachronous pancreatic cancers

  Tomonori Hirano, Nobuyuki Kakiuchi, Yasuhide Takeuchi, Toshihiko Masui, Shinji Uemoto, Sachiko Minamiguchi, Hironori Haga, Yuichi Shiraishi, Satoru Miyano, Norimitsu Uza, Yuzo Kodama, Hiroshi Seno, Tsutomu Chiba, Seishi Ogawa

  Feb. 2021, CANCER SCIENCE, 112, 658 - 658, English

  Summary international conference


• 吸収不良症候群診療の進歩と課題 Lipomatous pseudohypertrophy of the pancreasの2例

  宮崎 はる香, 大井 充, 星 奈美子, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2021, 日本消化器病学会近畿支部例会プログラム・抄録集, 114回, 40 - 40, Japanese


• 膵管内腫瘍様の形態を呈した腎癌膵臓転移症例の一例

  青山 雄一郎, 山田 恭孝, 酒井 新, 猪股 典子, 孝橋 信哉, 長尾 佳映, 植村 久尋, 増田 重人, 阿部 晶平, 山川 康平, 辻前 正弘, 田中 雄志, 田中 俊多, 中野 遼太, 白川 幸代, 小林 隆, 塩見 英之, 増田 充弘, 外山 博近, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2021, 日本消化器病学会近畿支部例会プログラム・抄録集, 114回, 59 - 59, Japanese


• 消化管悪性腫瘍に対する化学療法中に発症した脳梗塞の3例

  原田 彩香, 高山 弘志, 阪口 博哉, 飛松 和俊, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2021, 日本消化器病学会近畿支部例会プログラム・抄録集, 114回, 72 - 72, Japanese


• 小腸多発血管異形成に対するダブルバルーン内視鏡、およびアルゴンプラズマ凝固術後に、遅発性小腸穿孔を来たした一例

  吉治 誠, 松本 慶, 鷹尾 俊達, 岡本 典大, 宮崎 はる香, 松岡 晃生, 竹中 春香, 大井 充, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2021, 日本消化器病学会近畿支部例会プログラム・抄録集, 114回, 72 - 72, Japanese


• Gastrointestinal: A case of a pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas filling the main pancreatic duct without visible mucin secretion

  R. Nakano, A. Sakai, T. Kobayashi, A. Masuda, H. Shiomi, H. Toyama, T. Ito, Y. Kodama

  John Wiley and Sons Inc, 2021, Journal of Gastroenterology and Hepatology (Australia), English

  Book review


• IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 EUS-FNAによる1自己免疫性膵炎の病理組織診断についての多施設共同研究-病理医による自己免疫性膵炎生検組織の正診能,ならびに膵癌との鑑別能の検証-

  能登原憲司, 神澤輝美, 岩崎栄典, 菅野敦, 菅野敦, 窪田賢輔, 倉石康弘, 児玉裕三, 阪上順一, 阪上順一, 清水京子, 内藤格, 仲瀬裕志, 西野隆義, 本谷雅代, 川茂幸, 上原剛, 笠島里美, 相島慎一, 大池信之, 川島篤弘, 小嶋基寛, 田尻琢磨, 内藤嘉紀, 平林健一, 福嶋敬宜, 福村由紀, 古川徹, 三橋智子, 山口浩, 池浦司, 岡崎和一

  2021, IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 令和2年度 総括・分担研究報告書(Web)


• Metabolomics for the Discovery of Biomarkers and Therapeutic Targets of Pancreatic Cancer

  小林隆, 西海信, 西海信, 中野遼太, 中野遼太, 植村久尋, 酒井新, 増田充弘, 塩見英之, 塩見英之, 児玉裕三, 吉田優, 吉田優

  2021, 胆と膵, 42(8) (8)


• 当院における急性肝不全に対する肝移植を含めた治療アプローチ

  山本淳史, 上田佳秀, 児玉裕三

  2021, 肝臓, 62(Supplement 1) (Supplement 1)


• 当院における肝細胞癌に対する全身化学療法の治療成績-肝予備能不良例に対する有効性と安全性を含めて-

  山本淳史, 矢野嘉彦, 朝治直紀, 吉田竜太郎, 安冨栄一郎, 畑澤友里, 林宏樹, 塩見優紀, 上田佳秀, 児玉裕三

  2021, 肝臓, 62(Supplement 1) (Supplement 1)


• 消化器内視鏡検査従事者における新型コロナウイルスSARS-CoV-2感染症の抗体保有率調査

  阪口博哉, 阿部洋文, 井上潤, 上田佳秀, 児玉裕三, 白坂大輔, 森田周子, 猪熊哲朗, 浅田裕也

  2021, Gastroenterological Endoscopy (Web), 63(Supplement1) (Supplement1)


• 当院における急性肝不全に対する治療成績

  山本淳史, 上田佳秀, 蔵満薫, 矢野嘉彦, 安冨栄一郎, 畑澤友里, 松浦敬憲, 塩見優紀, 吉田竜太郎, 朝治直紀, 木戸正浩, 福本巧, 児玉裕三

  2021, 日本門脈圧亢進症学会雑誌, 27(3) (3)


• 当院における原発性胆汁性胆管炎の臨床的特徴

  安冨栄一郎, 上田佳秀, 朝治直紀, 山本淳史, 吉田竜太郎, 畑澤友里, 林宏樹, 塩見優紀, 矢野嘉彦, 児玉裕三

  2021, 肝臓, 62(Supplement 2) (Supplement 2)


• Interventional EUS for benign pancreatobiliary disease

  塩見英之, 塩見英之, 中野遼太, 中野遼太, 小林隆, 酒井新, 塩見優紀, 増田充弘, 児玉裕三, 飯島尋子

  2021, 超音波医学 Supplement, 48


• 治療困難胆管結石に対する電気衝撃波結石破砕術(EHL)の当院における現状と治療成績の検討

  植村久尋, 中野遼太, 猪俣典子, 孝橋信哉, 長尾佳映, 芦名茂人, 増田重人, 阿部昌平, 権田真知, 山川康平, 辻前正弘, 田中俊多, 田中雄志, 山田恭孝, 小林隆, 酒井新, 塩見英之, 増田充弘, 児玉裕三

  2021, 日本消化器病学会雑誌(Web), 118


• 当院における潰瘍性大腸炎での5-ASA不耐症の現状について

  岡本典大, 宮崎はる香, 徳永英里, 松本慶, 具潤亜, 竹中春香, 大井充, 星奈美子, 児玉裕三

  2021, 日本消化器病学会雑誌(Web), 118


• 膵癌手術例における治療選択マーカーとしてのTLS(Tertiary lymphoid structure)の有用性

  田中雄志, 増田充弘, 児玉裕三

  2021, 日本消化器病学会雑誌(Web), 118


• 免疫チェックポイント阻害薬によるirAE肝障害の臨床的特徴

  山本淳史, 矢野嘉彦, 朝治直紀, 吉田竜太郎, 安冨栄一郎, 畑澤友里, 林宏樹, 塩見優紀, 上田佳秀, 児玉裕三

  2021, 日本消化器病学会雑誌(Web), 118


• 肝外胆管癌における術前の水平進展度診断の検討

  増田重人, 塩見英之, 児玉裕三

  2021, 日本消化器病学会雑誌(Web), 118


• 膵癌におけるSPRR1Aの発現と予後

  山川康平, 山川康平, 児玉裕三, 青井貴之

  2021, 日本消化器病学会雑誌(Web), 118


• 膵切除検体を用いたEUSにおける早期慢性膵炎所見の妥当性の検証

  猪股典子, 増田充弘, 児玉裕三

  2021, 日本消化器病学会雑誌(Web), 118


• Pancreatic fluid collectionに対する早期インターベンションの可能性

  辻前正弘, 塩見英之, 児玉裕三

  2021, 日本消化器病学会雑誌(Web), 118


• Endoscopic Resection Technique Used for Complete En Bloc Resection of T1b Colorectal Cancer

  豊永高史, 阪口博哉, 池澤伸明, 中野佳子, 田中心和, 石田司, 阿部洋文, 吉崎哲也, 鷹尾俊達, 森田圭紀, 馬場慎一, 滝原浩守, 西野栄世, 横崎宏, 児玉裕三

  2021, 胃と腸, 56(8) (8)


• Type 1 autoimmune pancreatitis (IgG4 related pancreatitis)

  酒井新, 増田充弘, 児玉裕三

  2021, 日本臨床


• The Cutting-edge of Medicine; Pathophysiology, treatment and diagnosis of IgG4-related disease.

  塩川雅広, 児玉裕三

  (一社)日本内科学会, 2021, 日本内科学会雑誌, 110(2) (2), 295 - 300, Japanese


• 多発性膵内分泌腫瘍モデルマウスを用いた新規¹⁸F標識GLP-1受容体標的イメージング法:質的診断を伴う非侵襲的局所診断法の開発にむけて

  村上隆亮, 藤本裕之, 浜松圭太, 山内雄揮, 児玉裕三, 中本裕士, 藤田直尚, 木村寛之, 佐治英郎, 稲垣暢也

  (一社)日本内分泌学会, 2021, 日本内分泌学会雑誌, 97(1) (1), 273 - 273, Japanese


• 胆膵内視鏡の診断・治療の基本手技 2 胆膵疾患のEUS-FNAの基本手技とコツ

  塩見英之, 中野遼太, 児玉裕三

  (株)医学出版, 2021, 消化器内科, 3(2) (2), 15 - 22, Japanese


• How to advance a duodenoscope through a cascade stomach

  塩見英之, 中野遼太, 児玉裕三

  (株)東京医学社, 2021, 消化器内視鏡, 33(2) (2), 222 - 224, Japanese


• Biliary drainage for biliary stricture caused by hepatocellular carcinoma

  塩見英之, 中野遼太, 芦名茂人, 田中俊多, 酒井新, 小林隆, 塩見優紀, 増田充弘, 児玉裕三

  (株)東京医学社, 2021, 消化器内視鏡, 33(3) (3), 635 - 641, Japanese


• Training in EUS-BD

  塩見英之, 中野遼太, 長尾佳映, 猪股典子, 孝橋信哉, 植村久尋, 田中俊多, 塩見優紀, 酒井新, 小林隆, 増田充弘, 児玉裕三

  医学図書出版(株), 2021, 胆と膵, 42(4) (4), 285 - 292, Japanese


• Sphincter oddi dysfunction

  酒井新, 増田充弘, 児玉裕三

  (株)日本臨床社, 2021, 日本臨床, 別冊(肝・胆道系症候群III) (肝・胆道系症候群III), 145 - 148, Japanese


• Diagnostic imaging and endoscopic treatment of colon cancer

  津田一範, 鷹尾俊達, 児玉裕三

  (株)へるす出版, 2021, 消化器外科, 44(6) (6), 730 - 737, Japanese


• Clinical outcome of conservatively managed pancreatic intraductal papillary mucinous neoplasms with high-risk stigmata

  酒井新, 増田充弘, 小林隆, 山田恭孝, 田中雄志, 岡部純弘, 平田祐一, 塩見英之, 中野遼太, 児玉裕三

  (株)アークメディア, 2021, 肝胆膵, 82(6) (6), 787 - 790, Japanese


• Clinical and molecular biological features of IPMN concomitant with PDAC, compared to conventional PDAC

  辻前正弘, 増田充弘, 池川卓哉, 田中雄志, 芦名茂人, 酒井新, 小林隆, 塩見英之, 外山博近, 児玉裕三

  (株)アークメディア, 2021, 肝胆膵, 82(6) (6), 797 - 802, Japanese


• Comparison of the safety and efficacy of peroral endoscopic myotomy between octogenarians and non-octogenarians.

  Hirofumi Abe, Shinwa Tanaka, Fumiaki Kawara, Takashi Toyonaga, Ryusuke Ariyoshi, Hiroya Sakaguchi, Tomoya Sako, Nobuaki Ikezawa, Yuzo Kodama

  OBJECTIVES: This study compared the safety and efficacy of peroral endoscopic myotomy for esophageal motility disorders between octogenarians and non-octogenarians. METHODS: This retrospective observational study recruited 321 patients (28 octogenarians and 293 non-octogenarians) who underwent peroral endoscopic myotomy from two institutions. Clinical success (postoperative Eckardt score ≤ 3), technical success (completion of gastric and esophageal myotomy), and perioperative adverse events were compared between octogenarians and non-octogenarians. Perioperative adverse events were classified into major and minor adverse events based on the International Peroral Endoscopic Myotomy Survey criteria and were subdivided into technical and non-technical adverse events according to the presence of a direct causal relationship with the procedure. RESULTS: There were no significant differences in the rates of clinical success 1 year after treatment (100% vs. 97.3%, P = 0.64) and technical success (100% vs. 99.7%, P = 0.91) between octogenarians and non-octogenarians. Octogenarians had a higher incidence of perioperative adverse events (28.6% vs. 10.2%, P = 0.00097), particularly major adverse events (25.0% vs. 3.0%, P < 0.0001). There were no significant differences in the incidence of minor adverse events (7.1% vs. 7.9%, P = 0.67). Although there was no difference in the incidence of technical adverse events (10.7% vs. 9.2%, P = 0.74), octogenarians had a significantly higher incidence of non-technical adverse events (17.9% vs. 1.0%, P = 0.0002). CONCLUSIONS: There were no significant differences in short-term clinical success and technical success between octogenarians and non-octogenarians. However, octogenarians showed a significantly higher incidence of perioperative adverse events, particularly in major adverse events and non-technical adverse events. Peroral endoscopic myotomy for octogenarians should be carefully applied.

  Jan. 2021, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 33(1) (1), 110 - 117, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• 胆膵内視鏡診断の工夫 EUS-FNAによる膵がん遺伝子診断の実現可能性の検討

  酒井 新, 増田 充弘, 塩見 英之, 池川 卓哉, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 105回, 47 - 47, Japanese


• Helicobacter pylori未感染胃に生じたラズベリー様腺窩上皮型胃癌の1例

  堀谷 晋, 松岡 晃生, 鷹尾 俊達, 田中 心和, 阿部 洋文, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 105回, 60 - 60, Japanese


• PGAシートにて胃ESD後遅発性穿孔を閉鎖し得た一例

  山本 顕, 賀来 英俊, 鷹尾 俊達, 中井 達也, 高山 弘志, 嶋本 有策, 上田 千勢, 津田 一範, 松本 慶, 池澤 伸明, 阪口 博哉, 松岡 晃生, 阿部 洋文, 吉崎 哲也, 鷹尾 まど佳, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 105回, 60 - 60, Japanese


• 縦隔内膵仮性嚢胞に対し内視鏡的ドレナージが奏功した1例

  大木元 彩夏, 猪股 典子, 酒井 新, 長尾 佳映, 孝橋 信哉, 植村 久尋, 増田 重人, 權田 真知, 阿部 晶平, 芦名 茂人, 山川 康平, 辻前 正弘, 田中 雄志, 山田 恭孝, 田中 俊多, 中野 遼太, 小林 隆, 塩見 英之, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 105回, 62 - 62, Japanese


• 食道運動異常に合併した表在型食道癌の8症例

  中井 達也, 阿部 洋文, 田中 心和, 上田 千勢, 浦上 聡, 阪口 博哉, 池澤 伸明, 豊永 高史, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Dec. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 105回, 79 - 79, Japanese


• IgG4関連疾患の自己抗原同定による病態解明と臨床応用

  児玉 裕三

  (公財)上原記念生命科学財団, Dec. 2020, 上原記念生命科学財団研究報告集, 34, 1 - 4, Japanese


• 消化器領域から見たIgG4関連疾患研究の進歩 造影CTによる自己免疫性膵炎ステロイド治療後の耐糖能異常予測

  山田 恭孝, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Oct. 2020, 日本消化器病学会雑誌, 117(臨増大会) (臨増大会), A679 - A679, Japanese


• 細菌性肝膿瘍の宿主因子と起因菌の検討

  安冨 栄一郎, 上田 佳秀, 朝治 直紀, 山本 淳史, 吉田 竜太郎, 畑澤 友里, 林 宏樹, 塩見 優紀, 矢野 嘉彦, 児玉 裕三

  (一財)日本消化器病学会, Oct. 2020, 日本消化器病学会雑誌, 117(臨増大会) (臨増大会), A787 - A787, Japanese


• 十二指腸乳頭部腫瘍に対する診断と治療戦略 十二指腸乳頭部腫瘍に対する内視鏡的乳頭切除術後の病理学的評価と予後

  酒井 新, 増田 充弘, 児玉 裕三

  日本胆道学会, Aug. 2020, 胆道, 34(3) (3), 434 - 434, Japanese


• 自己免疫性膵炎の診断と治療の最前線

  児玉 裕三

  (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1030 - 1030, Japanese


• 急性膵炎局所合併症に対する内視鏡治療 内視鏡治療を主軸としたWalled-off necrosisに対するStep-up approach

  辻前 正弘, 塩見 英之, 児玉 裕三

  (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1090 - 1090, Japanese


• 働き方改革に向けた女性内視鏡医のキャリアアップ 女性内視鏡医における内視鏡的粘膜下層剥離術トレーニングの取り組み

  鷹尾 まど佳, 田中 心和, 児玉 裕三

  (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1119 - 1119, Japanese


• 表在性非乳頭部十二指腸上皮性腫瘍に対する治療戦略 表在型非乳頭部十二指腸上皮性腫瘍に対する腹腔鏡内視鏡合同手術の治療成績(膵臓側病変を含む)

  鷹尾 俊達, 森田 圭紀, 児玉 裕三

  (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1169 - 1169, Japanese


• 内視鏡的乳頭部切除術の現状と課題 十二指腸乳頭部癌に対する内視鏡的乳頭切除術の適応拡大の可能性 膵頭十二指腸切除術との比較をふまえて

  阿部 晶平, 酒井 新, 児玉 裕三

  (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1180 - 1180, Japanese


• 進化し続ける内視鏡診療に対するチーム医療の挑戦-教育・安全管理の側面から- 全身麻酔下での内視鏡治療にあたっての当院での取り組み

  松本 慶, 森田 圭紀, 児玉 裕三

  (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1197 - 1197, Japanese


• 早期胃癌ESD非治癒切除例における高齢者症例の検討

  阿部 洋文, 田中 心和, 豊永 高史, 森田 圭紀, 阪口 博哉, 児玉 裕三

  (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1278 - 1278, Japanese


• ガイドライン追補版導入後の抗血栓薬服用者における胃ESDの後出血に関する検討

  津田 一範, 田中 心和, 池澤 伸明, 阿部 洋文, 鷹尾 俊達, 森田 圭紀, 豊永 高史, 児玉 裕三

  (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1322 - 1322, Japanese


• 当院における産学・医工連携による消化器内視鏡分野への取り組み

  森田 圭紀, 鷹尾 俊達, 児玉 裕三, 阪口 博哉

  (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1359 - 1359, Japanese


• 慢性膵炎の診断基準改訂の意義 膵切除例を用いた早期慢性膵炎のEUS所見と背景膵の病理所見との対比

  猪股 典子, 増田 充弘, 田中 雄志, 芦名 茂人, 増田 重人, 阿部 晶平, 權田 真知, 山川 康平, 柿原 茉耶, 辻前 正弘, 山田 恭孝, 田中 俊多, 中野 遼太, 池川 卓哉, 小林 隆, 酒井 新, 塩見 英之, 外山 博近, 福本 巧, 児玉 裕三

  (一社)日本膵臓学会, Jul. 2020, 膵臓, 35(3) (3), A150 - A150, Japanese


• IPMNに併存する浸潤性膵管癌の特徴 IPMN併存膵癌とIPMN非併存膵癌の分子病理学的特徴と予後の相違

  池川 卓哉, 増田 充弘, 井上 潤, 猪股 典子, 芦名 茂人, 増田 重人, 阿部 晶平, 權田 真知, 山川 康平, 辻前 正弘, 山田 恭孝, 田中 雄志, 田中 俊多, 中野 遼太, 小林 隆, 酒井 新, 塩見 英之, 外山 博近, 福本 巧, 児玉 裕三

  (一社)日本膵臓学会, Jul. 2020, 膵臓, 35(3) (3), A195 - A195, Japanese


• IPMN国際診療ガイドライン2017の検証 High risk stigmataを有するIPMN経過観察症例の予後からみたガイドラインの検証

  酒井 新, 増田 充弘, 江口 考明, 阿南 隆洋, 古松 恵介, 岡部 純弘, 佐貫 毅, 佐藤 悠, 八木 洋輔, 西 勝久, 小林 隆, 塩見 英之, 児玉 裕三

  (一社)日本膵臓学会, Jul. 2020, 膵臓, 35(3) (3), A202 - A202, Japanese


• 膵癌の予後におけるTLS(Tertiary lymphoid structure)の意義

  田中 雄志, 増田 充弘, 井上 潤, 猪股 典子, 芦名 茂人, 増田 重人, 阿部 昌平, 権田 真知, 山川 康平, 田中 俊多, 辻前 正弘, 中野 遼太, 山田 恭孝, 池川 卓哉, 小林 隆, 酒井 新, 塩見 英之, 外山 博近, 福本 巧, 児玉 裕三

  (一社)日本膵臓学会, Jul. 2020, 膵臓, 35(3) (3), A316 - A316, Japanese


• 特異な画像を呈した膵神経内分泌癌の1例

  阿部 晶平, 酒井 新, 猪股 典子, 芦名 茂人, 田中 俊多, 山田 恭孝, 中野 遼太, 池川 卓哉, 小林 隆, 塩見 英之, 増田 充弘, 児玉 裕三

  (一社)日本膵臓学会, Jul. 2020, 膵臓, 35(3) (3), A448 - A448, Japanese


• IgG4関連疾患患者における新規自己抗体測定についての多施設共同前向き臨床研究

  児玉 裕三

  (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A20 - A20, Japanese


• 慢性膵炎の診断と治療戦略 慢性膵炎に対する内視鏡治療の成績と治療後の予後

  酒井 新, 芦名 茂人, 児玉 裕三

  (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A123 - A123, Japanese


• 急性肝不全の病態と治療 急性肝不全におけるSOFAおよびqSOFAスコアの臨床的意義

  矢野 嘉彦, 上田 佳秀, 児玉 裕三

  (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A157 - A157, Japanese


• 自己免疫性肝疾患-発症機序と治療の最前線- 免疫関連有害事象としての肝障害の病態と治療反応性についての検討

  安冨 栄一郎, 矢野 嘉彦, 児玉 裕三

  (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A172 - A172, Japanese


• 自己免疫性膵胆道疾患診療の課題と展望 自己免疫性膵炎での造影CTによるfECVを用いた膵萎縮の予測

  山田 恭孝, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A200 - A200, Japanese


• 経口内視鏡的筋層切開術のpoor response症例を予測するrisk-scoring systemの構築と検証

  浦上 聡, 田中 心和, 児玉 裕三

  (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A265 - A265, Japanese


• 膵癌早期発見に向けての取り組み 当院における膵癌患者の診断前過去CT画像の検討

  權田 真知, 小林 隆, 増田 充弘, 猪股 典子, 増田 重人, 阿部 晶平, 芦名 茂人, 山川 康平, 辻前 正弘, 田中 雄志, 山田 恭孝, 田中 俊多, 中野 遼太, 柿原 茉耶, 池川 卓哉, 酒井 新, 塩見 英之, 児玉 裕三

  (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A342 - A342, Japanese


• 肝門部領域胆管癌の術前診断におけるSpyGlassDSの有用性

  増田 重人, 塩見 英之, 池川 卓哉, 小林 隆, 酒井 新, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A391 - A391, Japanese


• 知っておくべき特殊な膵炎 自己免疫性膵炎

  児玉 裕三

  京都消化器医会, Jun. 2020, 京都消化器医会会報, (36) (36), 78 - 78, Japanese


• EUS関連手技のトラブルシューティング Double-guidewire techniqueを用いた超音波内視鏡下胆道ドレナージ術

  權田 真知, 塩見 英之, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jun. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 104回, 55 - 55, Japanese


• 急性膵炎を契機に診断した膵上皮内癌の一例

  堀谷 晋, 小林 隆, 猪股 典子, 増田 重人, 芦名 茂人, 權田 真知, 阿部 晶平, 山川 康平, 辻前 正弘, 田中 雄志, 山田 恭孝, 田中 俊多, 柿原 茉耶, 中野 遼太, 池川 卓哉, 酒井 新, 塩見 英之, 増田 充弘, 児玉 裕三

  日本消化器内視鏡学会-近畿支部, Jun. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 104回, 74 - 74, Japanese


• IN SITU VACCINE IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS USING NOVEL NANOPARTICULATE TLR9 AGONIST K3-SPG

  Hirokazu Okada, Ken Takahashi, Kouji Kobiyama, Yoshihiro Nishikawa, Masahiro Shiokawa, Norimitsu Uza, Yuzo Kodama, Hiroshi Seno, Ken J. Ishii

  May 2020, GASTROENTEROLOGY, 158(6) (6), S195 - S195, English

  Summary international conference


• 肝外胆管に発育したIntraductal papillary neoplasm of the bile duct(IPNB)

  辻前 正弘, 塩見 英之, 増田 充弘, 神澤 真紀, 津川 大介, 児玉 裕三

  日本胆道学会, May 2020, 胆道, 34(2) (2), 244 - 250, Japanese


• IgG4関連疾患の診断基準並びに治療指針の確立を目指す研究 EUS-FNAによる1型自己免疫性膵炎の病理組織診断についての多施設共同研究

  能登原憲司, 神澤輝美, 岩崎栄典, 菅野敦, 窪田賢輔, 倉石康弘, 児玉裕三, 阪上順一, 清水京子, 内藤格, 仲瀬裕志, 西野隆義, 本谷雅代, 川茂幸, 上原剛, 笠島里美, 相島慎一, 大池信之, 川島篤弘, 小嶋基寛, 田尻琢磨, 内藤嘉紀, 平林健一, 福嶋敬宜, 福村由紀, 古川徹, 三橋智子, 山口浩, 池浦司, 岡崎和一

  2020, IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 令和元年度 総括・分担研究報告書(Web)


• Intraductal papillary neoplasm of the bile duct (IPNB) in extrahepatic ducts

  辻前正弘, 塩見英之, 増田充弘, 神澤真紀, 津川大介, 児玉裕三

  2020, 胆道(Web), 34(2) (2)


• Surveillance for the early diagnosis of familial pancreatic cancer (Expert consensus)

  北野雅之, 森実千種, 肱岡範, 松林宏行, 蘆田玲子, 池浦司, 伊藤鉄英, 神澤輝実, 川口喬久, 河邉顕, 小杉眞司, 児玉裕三, 清水京子, 高橋秀明, 谷内田真一, 寺島健志, 鳥嶋雅子, 花田敬士, 古川徹, 古川正幸, 古瀬純司, 真口宏介, 眞島喜幸, 水野伸匡, 水間正道, 水本雅己, 吉田岳市, 和田慶太, 高折恭一

  2020, 膵臓(Web), 35(4) (4)


• High risk stigmataを有するIPMN経過観察症例の予後からみたガイドラインの検証

  酒井新, 増田充弘, 江口考明, 阿南隆洋, 古松恵介, 岡部純弘, 佐貫毅, 佐藤悠, 八木洋輔, 西勝久, 小林隆, 塩見英之, 児玉裕三

  2020, 膵臓(Web), 35(3) (3)


• 特異な画像を呈した膵神経内分泌癌の1例

  阿部晶平, 酒井新, 猪股典子, 芦名茂人, 田中俊多, 山田恭孝, 中野遼太, 池川卓哉, 小林隆, 塩見英之, 増田充弘, 児玉裕三

  2020, 膵臓(Web), 35(3) (3)


• 膵癌の予後におけるTLS(Tertiary lymphoid structure)の意義

  田中雄志, 増田充弘, 井上潤, 猪股典子, 芦名茂人, 増田重人, 阿部昌平, 権田真知, 山川康平, 田中俊多, 辻前正弘, 中野遼太, 山田恭孝, 池川卓哉, 小林隆, 酒井新, 塩見英之, 外山博近, 福本巧, 児玉裕三

  2020, 膵臓(Web), 35(3) (3)


• 膵切除例を用いた早期慢性膵炎のEUS所見と背景膵の病理所見との対比

  猪股典子, 増田充弘, 田中雄志, 芦名茂人, 増田重人, 阿部晶平, 權田真知, 山川康平, 柿原茉耶, 辻前正弘, 山田恭孝, 田中俊多, 中野遼太, 池川卓哉, 小林隆, 酒井新, 塩見英之, 外山博近, 福本巧, 児玉裕三

  2020, 膵臓(Web), 35(3) (3)


• IPMN併存膵癌とIPMN非併存膵癌の分子病理学的特徴と予後の相違

  池川卓哉, 増田充弘, 井上潤, 猪股典子, 芦名茂人, 増田重人, 阿部晶平, 權田真知, 山川康平, 辻前正弘, 山田恭孝, 田中雄志, 田中俊多, 中野遼太, 小林隆, 酒井新, 塩見英之, 外山博近, 福本巧, 児玉裕三

  2020, 膵臓(Web), 35(3) (3)


• 造影CTによる自己免疫性膵炎ステロイド治療後の耐糖能異常予測

  山田恭孝, 増田充弘, 児玉裕三

  2020, 肝臓, 61(Supplement 2) (Supplement 2)


• 当院における産学・医工連携による消化器内視鏡分野への取り組み

  森田圭紀, 森田圭紀, 鷹尾俊達, 児玉裕三, 阪口博哉

  2020, Gastroenterological Endoscopy (Web), 62(Supplement1) (Supplement1)


• 内視鏡治療を主軸としたWalled-off necrosisに対するStep-up approach

  辻前正弘, 塩見英之, 児玉裕三

  2020, Gastroenterological Endoscopy (Web), 62(Supplement1) (Supplement1)


• 女性内視鏡医における内視鏡的粘膜下層剥離術トレーニングの取り組み

  鷹尾まど佳, 田中心和, 児玉裕三

  2020, Gastroenterological Endoscopy (Web), 62(Supplement1) (Supplement1)


• 十二指腸乳頭部癌に対する内視鏡的乳頭切除術の適応拡大の可能性~膵頭十二指腸切除術との比較をふまえて~

  阿部晶平, 酒井新, 児玉裕三

  2020, Gastroenterological Endoscopy (Web), 62(Supplement1) (Supplement1)


• 表在型非乳頭部十二指腸上皮性腫瘍に対する腹腔鏡内視鏡合同手術の治療成績(膵臓側病変を含む)

  鷹尾俊達, 森田圭紀, 森田圭紀, 児玉裕三

  2020, Gastroenterological Endoscopy (Web), 62(Supplement1) (Supplement1)


• 早期胃癌ESD非治癒切除例における高齢者症例の検討

  阿部洋文, 田中心和, 豊永高史, 森田圭紀, 阪口博哉, 児玉裕三

  2020, Gastroenterological Endoscopy (Web), 62(Supplement1) (Supplement1)


• 全身麻酔下での内視鏡治療にあたっての当院での取り組み

  松本慶, 松本慶, 森田圭紀, 森田圭紀, 児玉裕三

  2020, Gastroenterological Endoscopy (Web), 62(Supplement1) (Supplement1)


• 自己免疫性膵炎の診断と治療の最前線

  児玉裕三

  2020, Gastroenterological Endoscopy (Web), 62(Supplement1) (Supplement1)


• 健診受診者における無症候性びらん性食道炎の4年間の自然経過

  松永心祐, 藤田剛, 山崎幸直, 小林正夫, 寺尾秀一, 岡田明彦, 佐貫毅, 安達政恭, 吉中勇人, 久津見弘, 増田充弘, 梅垣英次, 児玉裕三

  2020, 日本消化器病学会雑誌(Web), 117


• 肝門部領域胆管癌の術前診断におけるSpyGlassDSの有用性

  増田重人, 塩見英之, 池川卓哉, 小林隆, 酒井新, 増田充弘, 児玉裕三

  2020, 日本消化器病学会雑誌(Web), 117


• ガイドライン追補版導入後の抗血栓薬服用者における胃ESDの後出血に関する検討

  津田一範, 田中心和, 池澤伸明, 阿部洋文, 鷹尾俊達, 森田圭紀, 豊永高史, 児玉裕三

  2020, Gastroenterological Endoscopy (Web), 62(Supplement1) (Supplement1)


• 膵癌早期発見に向けての取り組み-当院における膵癌患者の診断前過去CT画像の検討-

  權田真知, 小林隆, 増田充弘, 猪股典子, 増田重人, 阿部晶平, 芦名茂人, 山川康平, 辻前正弘, 田中雄志, 山田恭孝, 田中俊多, 中野遼太, 柿原茉耶, 池川卓哉, 酒井新, 塩見英之, 児玉裕三

  2020, 日本消化器病学会雑誌(Web), 117


• 自己免疫性膵炎での造影CTによるfECVを用いた膵萎縮の予測

  山田恭孝, 増田充弘, 児玉裕三

  2020, 日本消化器病学会雑誌(Web), 117


• 経口内視鏡的筋層切開術のpoor response症例を予測するrisk-scoring systemの構築と検証

  浦上聡, 田中心和, 児玉裕三

  2020, 日本消化器病学会雑誌(Web), 117


• 十二指腸乳頭部腫瘍に対する内視鏡的乳頭切除術後の病理学的評価と予後

  酒井新, 増田充弘, 児玉裕三

  2020, 胆道(Web), 34(3) (3)


• 急性肝不全におけるSOFAおよびqSOFAスコアの臨床的意義

  矢野嘉彦, 上田佳秀, 児玉裕三

  2020, 日本消化器病学会雑誌(Web), 117


• IgG4関連疾患患者における新規自己抗体測定についての多施設共同前向き臨床研究

  児玉裕三

  2020, 日本消化器病学会雑誌(Web), 117


• 免疫関連有害事象としての肝障害の病態と治療反応性についての検討

  安冨栄一郎, 矢野嘉彦, 児玉裕三

  2020, 日本消化器病学会雑誌(Web), 117


• 細菌性肝膿瘍の宿主因子と起因菌の検討

  安冨栄一郎, 上田佳秀, 朝治直紀, 山本淳史, 吉田竜太郎, 畑澤友里, 林宏樹, 塩見優紀, 矢野嘉彦, 児玉裕三

  2020, 日本消化器病学会雑誌(Web), 117


• 慢性膵炎に対する内視鏡治療の成績と治療後の予後

  酒井新, 芦名茂人, 児玉裕三

  2020, 日本消化器病学会雑誌(Web), 117


• IgG4関連疾患の新展開 IgG4関連疾患の自己抗体

  塩川雅広, 児玉裕三

  (株)先端医学社, 2020, 炎症と免疫, 28(4) (4), 300 - 303, Japanese


• IgG4関連疾患-診断と治療の最新動向 IgG4関連疾患の自己抗原

  塩川雅広, 児玉裕三

  (株)ライフメディコム, 2020, カレントテラピー, 38(7) (7), 716 - 719, Japanese


• Genetic analysis of metachronous pancreatic cancers

  平野智紀, 平野智紀, 垣内伸之, 竹内康英, 竹内康英, 増井俊彦, 上本伸二, 南口早智子, 羽賀博典, 白石友一, 宮野悟, 宇座徳光, 児玉裕三, 妹尾浩, 千葉勉, 小川誠司, 小川誠司, 小川誠司

  (一社)日本癌学会, 2020, 日本癌学会学術総会抄録集(Web), 79th, PJ7 - 7, English


• Technical tips and trouble-shooting for endoscopic transpapillary gallbladder drainage

  塩見英之, 池川卓哉, 酒井新, 小林隆, 塩見優紀, 増田充弘, 児玉裕三

  (株)東京医学社, 2020, 消化器内視鏡, 32(3) (3), 385 - 390, Japanese


• 大腸ESDの工夫 3 トラクション(4)エンドトラック法

  阪口博哉, 豊永高史, 豊永高史, 田中心和, 鷹尾俊達, 森田圭紀, 児玉裕三

  (株)日本メディカルセンター, 2020, 臨床消化器内科, 35(3) (3), 269 - 274, Japanese


• 当院における非代償性肝硬変に対する肝移植の現状

  安富栄一郎, 蔵満薫, 矢野嘉彦, 児玉裕三

  日本消化器病学会-近畿支部, 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 112th, 56 - 56, Japanese


• NSAIDs外用薬によって多発小腸潰瘍をきたした1例

  城端慧, 津田一範, 田中心話, 乾沙苗, 宮崎はる香, 徳永英里, 賀来英俊, 阿部洋文, 具潤亜, 迫智也, 池澤伸明, 若原ちか, 大井充, 鷹尾まど佳, 鷹尾俊達, 飛松和俊, 森田圭紀, 豊永高史, 児玉裕三

  日本消化器病学会-近畿支部, 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 112th, 110 - 110, Japanese


• Biomarker Discovery for the Early Detection of Pancreatic Cancer

  小林隆, 西海信, 西海信, 吉田優, 吉田優, 児玉裕三, 本田一文

  医学図書出版(株), 2020, 胆と膵, 41(4) (4), 387 - 391, Japanese


• IgG4関連疾患

  児玉裕三

  (一社)日本消化管学会, 2020, 日本消化管学会雑誌, 4(Supplement) (Supplement), 133 - 133, Japanese


• レーザー内視鏡診療の現状と近未来 CO2レーザーによる次世代の内視鏡治療技術の開発

  森田 圭紀, 賀来 英俊, 児玉 裕三

  (一社)日本消化管学会, Jan. 2020, 日本消化管学会雑誌, 4(Suppl.) (Suppl.), 226 - 226, Japanese


• ガイドライン追補版導入後の抗血栓薬服用者における胃ESDの後出血に関する検討

  池澤伸明, 田中心和, 森田圭紀, 豊永高史, 児玉裕三

  (一社)日本消化管学会, 2020, 日本消化管学会雑誌, 4(Supplement) (Supplement), 258 - 258, Japanese


• 肛門管切開を伴う内視鏡的粘膜下層剥離術(ESD)の術後狭窄の検討

  迫 智也, 豊永 高史, 中野 佳子, 田中 心和, 鷹尾 俊達, 森田 圭紀, 児玉 裕三

  (一社)日本消化管学会, Jan. 2020, 日本消化管学会雑誌, 4(Suppl.) (Suppl.), 265 - 265, Japanese


• CCSに合併した胃癌の1例

  徳永英里, 宮崎はる香, 松本慶, 阪口博哉, 具潤亜, 竹中春香, 大井充, 星奈美子, 児玉裕三, 掛地吉弘

  (一社)日本消化管学会, 2020, 日本消化管学会雑誌, 4(Supplement) (Supplement), 287 - 287, Japanese


• 当院における好酸球性食道炎の検討

  浦上聡, 田中心和, 児玉裕三

  (一社)日本消化管学会, 2020, 日本消化管学会雑誌, 4(Supplement) (Supplement), 305 - 305, Japanese


• 80歳以上の高齢食道運動機能異常患者に対する経口内視鏡的筋層切開術の有効性と安全性の検討

  阿部洋文, 田中心和, 豊永高史, 河原史明, 阪口博哉, 有吉隆佑, 児玉裕三

  (一社)日本消化管学会, 2020, 日本消化管学会雑誌, 4(Supplement) (Supplement), 305 - 305, Japanese


• Metabolomics on Pancreatic Tissue or Juice Obtained with EUS-FNA

  小林隆, 西海信, 西海信, 中野遼太, 池川卓哉, 酒井新, 塩見英之, 増田充弘, 吉田優, 吉田優, 児玉裕三

  医学図書出版(株), 2020, 胆と膵, 41(3) (3), 301 - 305, Japanese


• Endo Trac

  阪口博哉, 豊永高史, 豊永高史, 田中心和, 田中心和, 森田圭紀, 森田圭紀, 児玉裕三

  (株)東京医学社, 2020, 消化器内視鏡, 32(6) (6), 805 - 808, Japanese


• 当院におけるC型慢性肝炎に対するDAA治療後発癌についての検討

  畑澤友里, 矢野嘉彦, 山本淳史, 安冨栄一郎, 林宏樹, 塩見優紀, 上田佳秀, 児玉裕三

  (一社)日本肝臓学会, 2020, 肝臓, 61(Supplement 1) (Supplement 1), A471 - A471, Japanese


• 非代償性肝硬変の予後改善のための肝移植の現状と問題点

  安冨栄一郎, 上田佳秀, 山本淳史, 吉田竜太郎, 畑澤友里, 林宏樹, 塩見優紀, 矢野嘉彦, 蔵満薫, 木戸正浩, 福本巧, 児玉裕三

  (一社)日本肝臓学会, 2020, 肝臓, 61(Supplement 1) (Supplement 1), A481 - A481, Japanese


• 表在性非乳頭部十二指腸腫瘍に対する腹腔鏡内視鏡合同手術~腫瘍局在に応じた外科手技の工夫と治療成績~

  金治新悟, 森田圭紀, 鈴木知志, 山本将士, 瀧口豪介, 裏川直樹, 長谷川寛, 松田佳子, 山下公大, 松田武, 押切太郎, 豊永高史, 中村哲, 児玉裕三, 掛地吉弘

  (一社)日本外科学会, 2020, 日本外科学会定期学術集会(Web), 120th, SF - 6, Japanese


• 膵疾患の診断・治療の進歩 膵炎,膵癌の成因,危険因子と予防

  辻前正弘, 増田充弘, 児玉裕三

  (株)診断と治療社, 2020, 診断と治療, 108(8) (8), 970 - 975, Japanese


• 胆膵疾患 これだけは知っておきたい胆膵疾患の基礎知識-専門医受診を勧めるべきケースとは-自己免疫性膵炎

  酒井新, 児玉裕三

  (株)文光堂, 2020, Medical Practice, 37(8) (8), 1247 - 1251, Japanese


• アルコール性肝障害に対する肝移植の適応決定の現状と課題

  上田佳秀, 山敷宣代, 安冨栄一郎, 矢野嘉彦, 蔵満薫, 木戸正浩, 福本巧, 上本伸二, 児玉裕三

  (一社)日本移植学会, 2020, 日本移植学会総会プログラム抄録集, 56th(総会臨時) (総会臨時), 279 - 279, Japanese


• 当院における十二指腸乳頭部腫瘍に対する内視鏡的十二指腸乳頭切除術の術前診断の評価

  酒井新, 塩見英之, 増田充弘, 児玉裕三

  日本消化器病学会-近畿支部, 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 113th, 60 - 60, Japanese


• 当院における憩室内および近接病変に対する大腸ESDの治療成績と工夫

  池澤伸明, 豊永高史, 森田圭紀, 児玉裕三

  日本消化器病学会-近畿支部, 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 113th, 70 - 70, Japanese


• 悪性輸入脚症候群に対する内視鏡的アプローチの検討

  増田重人, 塩見英之, 酒井新, 児玉裕三

  日本消化器病学会-近畿支部, 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 113th, 72 - 72, Japanese


• 経口内視鏡的筋層切開術後に致死性不整脈を発症した食道運動機能異常の2例

  阿部洋文, 田中心和, 阪口博哉, 池澤伸明, 浦上聡, 上田千勢, 豊永高史, 児玉裕三

  日本消化器病学会-近畿支部, 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 113th, 112 - 112, Japanese


• C型非代償性肝硬変に対するソホスブビル/ベルパタスビル療法の治療経験

  安冨栄一郎, 上田佳秀, 朝治直紀, 山本淳史, 吉田竜太郎, 畑澤友里, 林宏樹, 塩見優紀, 矢野嘉彦, 児玉裕三

  (一社)日本肝臓学会, 2020, 肝臓, 61(Supplement 3) (Supplement 3), A880 - A880, Japanese


• 胆膵がん術前胆道ステント留置 2)メタリックステントの立場から

  塩見英之, 中野遼太, 小林隆, 酒井新, 増田充弘, 児玉裕三

  (株)メディカルレビュー社, 2020, 胆膵Oncology Forum, 1(1) (1), 15 - 19, Japanese


• 非B非C型肝癌の予後に関わる因子の検討

  林宏樹, 矢野嘉彦, 安冨栄一郎, 畑澤友里, 上田佳秀, 児玉裕三

  (一社)日本肝臓学会, 2020, 肝臓, 61(Supplement 2) (Supplement 2), A691 - A691, Japanese


• On-line HDF非施行施設における急性肝不全の治療成績

  山本淳史, 上田佳秀, 蔵満薫, 朝治直紀, 吉田竜太郎, 安冨栄一郎, 畑澤友里, 林宏樹, 塩見優紀, 矢野嘉彦, 木戸正浩, 福本巧, 児玉裕三

  (一社)日本肝臓学会, 2020, 肝臓, 61(Supplement 2) (Supplement 2), A700 - A700, Japanese


• CO2レーザーによる次世代の内視鏡治療技術の開発

  森田圭紀, 森田圭紀, 賀来英俊, 児玉裕三

  (一社)日本消化管学会, 2020, 日本消化管学会雑誌, 4(Supplement) (Supplement), 226 - 226, Japanese


• ガイドライン追補版導入後の抗血栓薬服用者における胃ESDの後出血に関する検討

  池澤 伸明, 田中 心和, 森田 圭紀, 豊永 高史, 児玉 裕三

  (一社)日本消化管学会, Jan. 2020, 日本消化管学会雑誌, 4(Suppl.) (Suppl.), 258 - 258, Japanese


• 肛門管切開を伴う内視鏡的粘膜下層剥離術(ESD)の術後狭窄の検討

  迫智也, 豊永高史, 豊永高史, 中野佳子, 田中心和, 鷹尾俊達, 森田圭紀, 児玉裕三

  (一社)日本消化管学会, 2020, 日本消化管学会雑誌, 4(Supplement) (Supplement), 265 - 265, Japanese


• 【結石除去を極める】膵石 膵石除去における乳頭処置とその実際

  酒井 新, 塩見 英之, 芦名 茂人, 田中 俊多, 山田 恭孝, 中野 遼太, 池川 卓哉, 小林 隆, 増田 充弘, 児玉 裕三

  (株)東京医学社, Nov. 2019, 消化器内視鏡, 31(11) (11), 1694 - 1699, Japanese


• 免疫チェックポイント阻害薬による肝障害の臨床病理学的特徴についての検討

  安冨 栄一郎, 矢野 嘉彦, 山本 淳史, 畑澤 友里, 平野 仁崇, 林 宏樹, 塩見 優紀, 児玉 裕三

  (一財)日本消化器病学会, Nov. 2019, 日本消化器病学会雑誌, 116(臨増大会) (臨増大会), A778 - A778, Japanese


• 【外科医とがん登録-NCDから見えてきたわが国のがん治療の実態-】膵がん登録

  水間 正道, 海野 倫明, 五十嵐 久人, 糸井 隆夫, 江川 新一, 児玉 裕三, 里井 壯平, 濱田 晋, 水元 一博, 下瀬川 徹, 岡崎 和一, 日本膵臓学会膵癌登録委員会

  (一社)日本外科学会, Nov. 2019, 日本外科学会雑誌, 120(6) (6), 676 - 680, Japanese


• 免疫チェックポイント阻害薬による肝障害の臨床病理学的特徴についての検討

  安冨 栄一郎, 矢野 嘉彦, 山本 淳史, 畑澤 友里, 平野 仁崇, 林 宏樹, 塩見 優紀, 児玉 裕三

  (一財)日本消化器病学会, Nov. 2019, 日本消化器病学会雑誌, 116(臨増大会) (臨増大会), A778 - A778, Japanese


• 自己免疫性膵炎の最近のトピックス

  児玉 裕三

  日本消化器病学会-中国支部, Nov. 2019, 日本消化器病学会中国支部例会プログラム・抄録集, 112回, 152 - 152, Japanese


• A rescue approach using a neo papilla for choledocholithiasis in patient with benign duodenal stricture.

  Hideyuki Shiomi, Arata Sakai, Takashi Kobayashi, Yuuki Shiomi, Atsuhiro Masuda, Jonard T Co, Yuzo Kodama

  Nov. 2019, Endoscopy, 51(11) (11), E327-E328 - E328, English, International magazine


• 外科的切除を行ったβ-catenin活性型肝細胞腺腫の一例

  石田 亮介, 矢野 嘉彦, 猪股 典子, 山本 淳史, 徳永 英里, 安冨 栄一郎, 畑澤 友里, 林 宏樹, 児玉 裕三, 権 英寿, 田中 基文, 木戸 正浩, 福本 巧

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 104 - 104, Japanese


• ステロイドへの反応性が良好であった小腸リンパ管拡張症の1例

  中井 沙紀, 具 潤亜, 上田 千勢, 松本 慶, 竹中 春香, 大井 充, 星 奈美子, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 82 - 82, Japanese


• ベーチェット病に伴う仙腸関節炎に対して抗TNFα阻害薬で治療中に、食道穿通病変と回盲部潰瘍が出現し、内科的治療で治療しえた腸管型ベーチェット病の1例

  能瀬 洋子, 井上 綾華, 上田 洋, 宮崎 はる香, 大井 充, 岡野 隆一, 千藤 荘, 明石 健吾, 大西 輝, 星 奈美子, 三枝 淳, 児玉 裕三, 森信 暁雄

  (一社)日本臨床免疫学会, Oct. 2019, 日本臨床免疫学会総会プログラム・抄録集, 47回, 112 - 112, Japanese


• 下部消化管腫瘍に対する低侵襲治療の最前線 大腸Endoscopic submcosal dissection(ESD)における新規トラクションデバイスの有用性と安全性

  阪口 博哉, 田中 心和, 豊永 高史, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 53 - 53, Japanese


• 好酸球性消化管障害の現状 当院における好酸球性食道炎の検討

  浦上 聡, 田中 心和, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 65 - 65, Japanese


• 正中弓状靱帯症候群に脾動脈瘤と膵体部腫瘤を合併した例

  城端 慧, 小林 隆, 猪股 典子, 増田 重人, 権田 真知, 阿部 晶平, 芦名 茂人, 山川 康平, 辻前 正弘, 柿原 茉耶, 山田 恭孝, 田中 雄志, 中野 遼太, 田中 俊多, 池川 卓哉, 酒井 新, 塩見 英之, 増田 充弘, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 89 - 89, Japanese


• 急性膵炎後の諸問題に対する内視鏡の役割 膵炎局所合併症に対する内視鏡的アプローチを軸とした治療戦略

  塩見 英之, 辻前 正弘, 児玉 裕三

  (一社)日本消化器内視鏡学会, Oct. 2019, Gastroenterological Endoscopy, 61(Suppl.2) (Suppl.2), 2065 - 2065, Japanese


• 80歳以上の高齢食道運動機能異常患者に対する経口内視鏡的筋層切開術の有効性と安全性の検討

  阿部 洋文, 田中 心和, 児玉 裕三

  (一社)日本消化器内視鏡学会, Oct. 2019, Gastroenterological Endoscopy, 61(Suppl.2) (Suppl.2), 2131 - 2131, Japanese


• 膵石症に対する内視鏡治療戦略

  芦名 茂人, 塩見 英之, 児玉 裕三

  (一社)日本消化器内視鏡学会, Oct. 2019, Gastroenterological Endoscopy, 61(Suppl.2) (Suppl.2), 2219 - 2219, Japanese


• 短期間で増大傾向を示した十二指腸低分化腺癌/印環細胞癌の一例

  土井 真由実, 迫 智也, 鷹尾 俊達, 池澤 伸明, 田中 心和, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 74 - 74, Japanese


• 抗PD-1抗体Pembrolizumabの免疫関連有害事象と考えられる胆管炎の1例

  田中 雄志, 酒井 新, 田中 俊多, 辻前 正弘, 池川 卓哉, 小林 隆, 塩見 英之, 増田 充弘, 児玉 裕三

  日本胆道学会, Oct. 2019, 胆道, 33(3) (3), 528 - 528, Japanese


• 12年の経過観察ののち外科手術を行ったIntraductal papillary neoplasm of the bile duct(IPNB)の1例

  辻前 正弘, 酒井 新, 田中 雄志, 田中 俊多, 池川 卓哉, 小林 隆, 塩見 英之, 増田 充弘, 上野 公彦, 伊藤 智雄, 味木 徹夫, 児玉 裕三

  日本胆道学会, Oct. 2019, 胆道, 33(3) (3), 585 - 585, Japanese


• 胃および十二指腸球部に瘻孔を形成し、上部消化管内視鏡で胆管内を観察し得たIPNBと考えられる胆道腫瘍の一例

  酒井 新, 藤垣 誠治, 田中 雄志, 辻前 正弘, 田中 俊多, 池川 卓哉, 小林 隆, 塩見 英之, 増田 充弘, 児玉 裕三

  日本胆道学会, Oct. 2019, 胆道, 33(3) (3), 644 - 644, Japanese


• ベーチェット病に伴う仙腸関節炎に対して抗TNFα阻害薬で治療中に、食道穿通病変と回盲部潰瘍が出現し、内科的治療で治療しえた腸管型ベーチェット病の1例

  能瀬 洋子, 井上 綾華, 上田 洋, 宮崎 はる香, 大井 充, 岡野 隆一, 千藤 荘, 明石 健吾, 大西 輝, 星 奈美子, 三枝 淳, 児玉 裕三, 森信 暁雄

  日本臨床免疫学会, Oct. 2019, 日本臨床免疫学会総会プログラム・抄録集, 47回, 112 - 112, Japanese


• 急性膵炎後の諸問題に対する内視鏡の役割 膵炎局所合併症に対する内視鏡的アプローチを軸とした治療戦略

  塩見 英之, 辻前 正弘, 児玉 裕三

  (一社)日本消化器内視鏡学会, Oct. 2019, Gastroenterological Endoscopy, 61(Suppl.2) (Suppl.2), 2065 - 2065, Japanese


• 80歳以上の高齢食道運動機能異常患者に対する経口内視鏡的筋層切開術の有効性と安全性の検討

  阿部 洋文, 田中 心和, 児玉 裕三

  (一社)日本消化器内視鏡学会, Oct. 2019, Gastroenterological Endoscopy, 61(Suppl.2) (Suppl.2), 2131 - 2131, Japanese


• 膵石症に対する内視鏡治療戦略

  芦名 茂人, 塩見 英之, 児玉 裕三

  (一社)日本消化器内視鏡学会, Oct. 2019, Gastroenterological Endoscopy, 61(Suppl.2) (Suppl.2), 2219 - 2219, Japanese


• 胃・十二指腸腫瘍に対する内科・外科合同手術の現状と展望 表在型非乳頭部十二指腸上皮性腫瘍に対する腹腔鏡内視鏡合同手術の検討 内視鏡医の立場から

  迫 智也, 森田 圭紀, 金治 新悟, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 51 - 51, Japanese


• ステロイドへの反応性が良好であった小腸リンパ管拡張症の1例

  中井 沙紀, 具 潤亜, 上田 千勢, 松本 慶, 竹中 春香, 大井 充, 星 奈美子, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 82 - 82, Japanese


• 外科的切除を行ったβ-catenin活性型肝細胞腺腫の一例

  石田 亮介, 矢野 嘉彦, 猪股 典子, 山本 淳史, 徳永 英里, 安冨 栄一郎, 畑澤 友里, 林 宏樹, 児玉 裕三, 権 英寿, 田中 基文, 木戸 正浩, 福本 巧

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 104 - 104, Japanese


• バルーン拡張術が有効であったPlummer-vinson症候群の一例

  津田 一範, 田中 心和, 阿部 洋文, 若原 ちか, 浦上 聡, 朝治 直紀, 松本 慶, 池澤 伸明, 賀来 英俊, 阪口 博哉, 迫 智也, 鷹尾 まど佳, 鷹尾 俊達, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 109 - 109, Japanese


• Endoscopic ultrasound-guided gastrojejunostomy using fully covered metal stent combined with large-loop double-pigtail stent for malignant afferent loop syndrome.

  Hideyuki Shiomi, Takashi Kobayashi, Arata Sakai, Yuuki Shiomi, Atsuhiro Masuda, Edgardo M Bondoc, Yuzo Kodama

  Oct. 2019, Endoscopy, 51(10) (10), E303-E304 - E304, English, International magazine


• 膵癌根治切除後の残膵再発例の遺伝子解析(Genetic analysis of metachronous pancreatic cancers)

  平野 智紀, 竹内 康英, 増井 俊彦, 白石 友一, 宮野 悟, 宇座 徳光, 児玉 裕三, 妹尾 浩, 千葉 勉

  (一社)日本癌学会, Sep. 2019, 日本癌学会総会記事, 78回, P - 3047, English


• 新規TLR9アゴニストK3-SPGを用いたがんワクチン免疫療法の消化器がんへの応用(Preclinical cancer vaccine immunotherapy for gastrointestinal cancers using novel nanoparticulate TLR9 agonist K3-SPG)

  岡田 浩和, 高橋 健, 宇座 徳光, 児玉 裕三, 石井 健, 妹尾 浩

  日本癌学会, Sep. 2019, 日本癌学会総会記事, 78回, P - 2273, English


• Successful endoscopic closure of an esophagobronchial fistula as a result of a pancreatic pseudocyst with the over-the-scope clip system and endoscopic nasopancreatic drainage.

  Takuya Ikegawa, Arata Sakai, Yuzo Kodama

  Jul. 2019, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 31(4) (4), 465 - 465, English, International magazine


• 家族性膵癌のマネージメント 家族性膵癌早期診断に向けたスクリーニング(エキスパート・コンセンサス)

  北野 雅之, 森実 千種, 肱岡 範, 吉田 岳一, 真口 宏介, 高橋 秀明, 和田 慶太, 松林 宏行, 水野 伸匡, 寺島 健志, 水本 雅己, 児玉 裕三, 鳥嶋 雅子, 蘆田 玲子, 花田 敬士, 古川 正幸, 河邉 顕, 高折 恭一

  (一社)日本膵臓学会, Jun. 2019, 膵臓, 34(3) (3), A96 - A97, Japanese


• 自己免疫性膵炎診療の進歩 自己免疫性膵炎における造影CT平衡層のCT値によるステロイド治療後の膵萎縮の予測

  山田 恭孝, 増田 充宏, 山川 康平, 辻前 正弘, 田中 雄志, 田中 俊多, 中野 遼太, 佐藤 悠, 黒澤 学, 池川 卓哉, 藤垣 誠治, 酒井 新, 小林 隆, 塩見 英之, 児玉 裕三

  (一社)日本膵臓学会, Jun. 2019, 膵臓, 34(3) (3), A49 - A50, Japanese


• 膵石症に対する内視鏡治療を軸とした治療戦略

  芦名 茂人, 塩見 英之, 児玉 裕三, 山川 康平, 辻前 正弘, 山田 恭孝, 田中 雄志, 中野 遼太, 佐藤 悠, 池川 卓哉, 藤垣 誠治, 酒井 新, 小林 隆, 増田 充弘

  (一社)日本膵臓学会, Jun. 2019, 膵臓, 34(3) (3), A166 - A167, Japanese


• IPMN術後の残膵再発に関与する因子の検討 糖尿病の新規発症及び増悪の関連性

  中野 遼太, 増田 充弘, 藤垣 誠治, 小林 隆, 酒井 新, 塩見 英之, 児玉 裕三

  (一社)日本膵臓学会, Jun. 2019, 膵臓, 34(3) (3), A209 - A210, Japanese


• 死亡の転帰となった薬剤性重症急性膵炎の一例

  田中 雄志, 酒井 新, 芦名 茂人, 山川 康平, 辻前 正弘, 柿原 茉耶, 田中 俊多, 佐藤 悠, 中野 遼太, 山田 恭孝, 池川 卓哉, 藤垣 誠治, 小林 隆, 塩見 英之, 増田 充弘, 児玉 裕三

  (一社)日本膵臓学会, Jun. 2019, 膵臓, 34(3) (3), A303 - A303, Japanese


• 膵神経内分泌腫瘍の病理とバイオマーカー 膵神経内分泌癌の網羅的ゲノム解析

  垣内 伸之, 宇座 徳光, 細田 和貴, 谷田部 恭, 桑原 崇通, 水野 伸匡, 児玉 裕三, 妹尾 浩, 小川 誠司

  (一社)日本膵臓学会, Jun. 2019, 膵臓, 34(3) (3), A63 - A63, Japanese


• 膵嚢胞性腫瘍に対する内視鏡診断 膵管内乳頭粘液産生腫瘍に対するERCP下膵液細胞診の役割 腫瘍の病理学的特徴との対比を含めて

  山川 康平, 増田 充弘, 児玉 裕三

  (一社)日本消化器内視鏡学会, May 2019, Gastroenterological Endoscopy, 61(Suppl.1) (Suppl.1), 733 - 733, Japanese


• 食道運動機能障害の診断と治療 横隔膜上憩室を合併する食道運動機能障害患者に対するper-oral endoscopic myotomyの有用性

  田中 心和, 木下 雅登, 児玉 裕三

  (一社)日本消化器内視鏡学会, May 2019, Gastroenterological Endoscopy, 61(Suppl.1) (Suppl.1), 759 - 759, Japanese


• 悪性輸入脚狭窄に対する内視鏡的金属ステント留置術の検討

  酒井 新, 塩見 英之, 児玉 裕三, 芦名 茂人, 山川 康平, 辻前 正弘, 田中 雄志, 田中 俊多, 柿原 茉耶, 山田 恭孝, 中野 遼太, 佐藤 悠, 黒沢 学, 池川 卓哉, 藤垣 誠治, 小林 隆, 増田 充弘

  (一社)日本消化器内視鏡学会, May 2019, Gastroenterological Endoscopy, 61(Suppl.1) (Suppl.1), 901 - 901, Japanese


• 十二指腸乳頭部腫瘍に対する内視鏡的乳頭切除術(EP)後の病理学的評価と予後の検討

  辻前 正弘, 酒井 新, 児玉 裕三, 芦名 茂人, 山川 康平, 田中 雄志, 山田 恭孝, 田中 俊多, 中野 遼太, 佐藤 悠, 黒澤 学, 池川 卓也, 藤垣 誠治, 小林 隆, 塩見 英之, 増田 充弘

  (一社)日本消化器内視鏡学会, May 2019, Gastroenterological Endoscopy, 61(Suppl.1) (Suppl.1), 923 - 923, Japanese


• Transanal Endoscopic Microsurgery(TEM)後の遺残再発病変に対するESDの有用性と安全性についての検討

  池澤 伸明, 田中 心和, 石田 司, 中野 佳子, 鷹尾 俊達, 森田 圭紀, 梅垣 英次, 豊永 高史, 児玉 裕三

  (一社)日本消化器内視鏡学会, May 2019, Gastroenterological Endoscopy, 61(Suppl.1) (Suppl.1), 940 - 940, Japanese


• 肛門管切開を伴う内視鏡的粘膜下層剥離術(ESD)の術後狭窄の検討

  迫 智也, 中野 佳子, 豊永 高史, 田中 心和, 鷹尾 俊達, 森田 圭紀, 梅垣 英次, 児玉 裕三

  (一社)日本消化器内視鏡学会, May 2019, Gastroenterological Endoscopy, 61(Suppl.1) (Suppl.1), 946 - 946, Japanese


• 当院で胃ESD後にPGAシートを貼付した16症例の検討

  阪口 博哉, 鷹尾 俊達, 森田 圭紀, 児玉 裕三

  (一社)日本消化器内視鏡学会, May 2019, Gastroenterological Endoscopy, 61(Suppl.1) (Suppl.1), 1019 - 1019, Japanese


• National clinical database(NCD)による膵全摘術の術後合併症リスクモデル

  橋本 大輔, 水間 正道, 隈丸 拓, 宮田 裕章, 近本 亮, 五十嵐 久人, 糸井 隆夫, 江川 新一, 児玉 裕三, 里井 壮平, 濱田 晋, 水元 一博, 山上 裕機, 山本 雅一, 掛地 吉弘, 瀬戸 泰之, 馬場 秀夫, 海野 倫明, 下瀬川 徹, 岡崎 和一

  (一社)日本外科学会, Apr. 2019, 日本外科学会定期学術集会抄録集, 119回, SF - 2, Japanese


• National Clinical Database(NCD)膵癌登録の第1回予後調査

  水間 正道, 海野 倫明, 隈丸 拓, 宮田 裕章, 五十嵐 久人, 糸井 隆夫, 江川 新一, 児玉 裕三, 里井 壮平, 濱田 晋, 水元 一博, 掛地 吉弘, 瀬戸 泰之, 下瀬川 徹, 岡崎 和一

  (一社)日本外科学会, Apr. 2019, 日本外科学会定期学術集会抄録集, 119回, SF - 1:[P], Japanese


• 【自己免疫性膵炎 最近の進歩】自己免疫性膵炎の病態解明

  塩川 雅広, 児玉 裕三

  (一財)日本消化器病学会, Apr. 2019, 日本消化器病学会雑誌, 116(4) (4), 279 - 285, Japanese


• A novel traction device (EndoTrac) for use during endoscopic submucosal dissection.

  Shinwa Tanaka, Takashi Toyonaga, Hidetoshi Kaku, Hiroya Sakaguchi, Shinichi Baba, Toshitatsu Takao, Yuzo Kodama

  Apr. 2019, Endoscopy, 51(4) (4), E90-E91 - E91, English, International magazine


• The crane technique: a novel traction method for use during rectal endoscopic submucosal dissection.

  Hiroya Sakaguchi, Takashi Toyonaga, Hidetoshi Kaku, Yoshiko Nakano, Shinwa Tanaka, Toshitatsu Takao, Yuzo Kodama

  Apr. 2019, Endoscopy, 51(4) (4), E88-E89 - E89, English, International magazine


• ERCP・EUS関連手技のトラブルシューティング 超音波内視鏡下胆道ドレナージ術を安全に成功へと導くDouble-guidewire technique

  塩見 英之, 増田 充弘, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2019, 日本消化器病学会雑誌, 116(臨増総会) (臨増総会), A224 - A224, Japanese


• 食道運動機能異常患者における経口内視鏡的筋層切開術後の骨格筋量の変化に関する検討

  阿部 洋文, 田中 心和, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2019, 日本消化器病学会雑誌, 116(臨増総会) (臨増総会), A276 - A276, Japanese


• EUS-FNAによるseedingが強く疑われた膵体部癌腹膜播種の1例

  外山 博近, 児玉 裕三, 福本 巧, 寺井 祥雄, 椋棒 英世, 白川 幸代, 山下 博成, 石田 潤, 李 東河, 朝倉 悠, 清水 貴, 上野 公彦, 味木 徹夫, 津川 大介, 木戸 正浩, 田中 基文, 小松 昇平, 蔵満 薫, 増田 充弘

  (一財)日本消化器病学会, Mar. 2019, 日本消化器病学会雑誌, 116(臨増総会) (臨増総会), A405 - A405, Japanese


• 食道憩室を有する食道運動障害患者に対してPOEMの安全性及び有効性についての検討

  木下 雅登, 田中 心和, 児玉 裕三, 阪口 博哉, 阿部 洋文, 有吉 隆佑, 河原 史明, 豊永 高史

  (一財)日本消化器病学会, Mar. 2019, 日本消化器病学会雑誌, 116(臨増総会) (臨増総会), A428 - A428, Japanese


• Novel approach for successful endoscopic ultrasound-guided hepaticogastrostomy using a double-guidewire technique.

  Hideyuki Shiomi, Atsuhiro Masuda, Yuzo Kodama

  Mar. 2019, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 31(2) (2), e50-e51 - e51, English, International magazine


• IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 IgG4関連疾患の性別・アレルギー・悪性腫瘍との関連

  三森経世, 吉藤元, 白柏魅怜, 千葉勉, 児玉裕三, 山本元久, 高橋弘樹, 内田一茂, 岡崎和一, 伊藤哲哉, 川茂幸, 山田和徳, 川野充弘, 田中良哉, 平田信太郎, 森山雅文, 中村誠司, 神澤輝美, 松井祥子, 坪井洋人, 住田孝之, 柴田元子, 後藤浩, 佐藤康晴, 吉野正

  2019, IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 平成30年度 総括・分担研究報告書(Web)


• Pancreatic KRAS/TP53 mutations promote ARF6-based immune evasion via activating mRNA translation and protein prenylation

  橋本あり, 橋本茂, 古川聖太郎, 古川聖太郎, 蔦保暁生, 蔦保暁生, 小野寺康人, 半田悠, 及川司, 水上裕輔, 西川義浩, 児玉裕三, 村上正晃, 平野聡, 佐邊壽孝

  2019, 日本癌学会学術総会抄録集(Web), 78th


• 本邦における高頻度マイクロサテライト不安定性大腸癌のスクリーニング方法の検討

  須藤洋崇, 豊田昌徳, 船越洋平, 今村善宣, 清田尚臣, 清田尚臣, 井上潤, 田中心和, 高瀬信尚, 長谷川寛, 山下公大, 松田武, 鈴木知志, 児玉裕三, 掛地吉弘, 南博信, 南博信

  2019, 日本家族性腫瘍学会学術集会プログラム・抄録集, 25th


• 膵神経内分泌癌の網羅的ゲノム解析

  垣内伸之, 宇座徳光, 細田和貴, 谷田部恭, 桑原崇通, 水野伸匡, 児玉裕三, 妹尾浩, 小川誠司

  2019, 膵臓(Web), 34(3) (3)


• 家族性膵癌早期診断に向けたスクリーニング(エキスパート・コンセンサス)

  北野雅之, 森実千種, 肱岡範, 吉田岳一, 真口宏介, 高橋秀明, 和田慶太, 松林宏行, 水野伸匡, 寺島健志, 水本雅己, 児玉裕三, 鳥嶋雅子, 蘆田玲子, 花田敬士, 古川正幸, 河邉顕, 高折恭一

  2019, 膵臓(Web), 34(3) (3)


• 自己免疫性膵炎における造影CT平衡層のCT値によるステロイド治療後の膵萎縮の予測

  山田恭孝, 増田充宏, 山川康平, 辻前正弘, 田中雄志, 田中俊多, 中野遼太, 佐藤悠, 黒澤学, 池川卓哉, 藤垣誠治, 酒井新, 小林隆, 塩見英之, 児玉裕三

  2019, 膵臓(Web), 34(3) (3)


• IPMN術後の残膵再発に関与する因子の検討-糖尿病の新規発症及び増悪の関連性-

  中野遼太, 増田充弘, 藤垣誠治, 小林隆, 酒井新, 塩見英之, 児玉裕三

  2019, 膵臓(Web), 34(3) (3)


• 死亡の転帰となった薬剤性重症急性膵炎の一例

  田中雄志, 酒井新, 芦名茂人, 山川康平, 辻前正弘, 柿原茉耶, 田中俊多, 佐藤悠, 中野遼太, 山田恭孝, 池川卓哉, 藤垣誠治, 小林隆, 塩見英之, 増田充弘, 児玉裕三

  2019, 膵臓(Web), 34(3) (3)


• 主膵管内に充満した粘液産生に乏しいpancreato-biliary type IPMNの1例

  中野遼太, 酒井新, 辻前正弘, 小林隆, 増田充弘, 塩見英之, 外山博近, 伊藤智雄, 児玉裕三

  2019, 日本消化器画像診断研究会プログラム・抄録集, 71st


• 当院における高頻度マイクロサテライト不安定性大腸癌のスクリーニング方法の検討

  高井亮, 山下公大, 須藤洋崇, 豊田昌徳, 船越洋平, 今村善宣, 清田尚臣, 清田尚臣, 井上潤, 田中心和, 松田武, 児玉裕三, 南博信, 南博信, 掛地吉弘

  2019, 日本消化器癌発生学会総会プログラム・抄録集, 30th


• Transanal Endoscopic Microsurgery(TEM)後の遺残再発病変に対するESDの有用性と安全性についての検討

  池澤伸明, 田中心和, 石田司, 石田司, 中野佳子, 鷹尾俊達, 森田圭紀, 梅垣英次, 豊永高史, 豊永高史, 児玉裕三

  2019, Gastroenterological Endoscopy (Web), 61(Supplement1) (Supplement1)


• 十二指腸乳頭部腫瘍に対する内視鏡的乳頭切除術(EP)後の病理学的評価と予後の検討

  辻前正弘, 酒井新, 児玉裕三, 芦名茂人, 山川康平, 田中雄志, 山田恭孝, 田中俊多, 中野遼太, 佐藤悠, 黒澤学, 池川卓也, 藤垣誠治, 小林隆, 塩見英之, 増田充弘

  2019, Gastroenterological Endoscopy (Web), 61(Supplement1) (Supplement1)


• 膵管内乳頭粘液産生腫瘍に対するERCP下膵液細胞診の役割-腫瘍の病理学的特徴との対比を含めて-

  山川康平, 増田充弘, 児玉裕三

  2019, Gastroenterological Endoscopy (Web), 61(Supplement1) (Supplement1)


• 肛門管切開を伴う内視鏡的粘膜下層剥離術(ESD)の術後狭窄の検討

  迫智也, 中野佳子, 豊永高史, 豊永高史, 田中心和, 鷹尾俊逹, 森田圭紀, 梅垣英次, 児玉裕三

  2019, Gastroenterological Endoscopy (Web), 61(Supplement1) (Supplement1)


• 当院で胃ESD後にPGAシートを貼付した16症例の検討

  阪口博哉, 鷹尾俊達, 森田圭紀, 児玉裕三

  2019, Gastroenterological Endoscopy (Web), 61(Supplement1) (Supplement1)


• 横隔膜上憩室を合併する食道運動機能障害患者に対するper-oral endoscopic myotomyの有用性

  田中心和, 木下雅登, 児玉裕三

  2019, Gastroenterological Endoscopy (Web), 61(Supplement1) (Supplement1)


• NUDT15遺伝子R139C多型を背景とし,アザチオプリンによる無顆粒球症を発症した潰瘍性大腸炎の1例

  塚本祥太, 渡邉大輔, 大塚崇史, 大井充, 阪口博哉, 具潤亜, 山入春香, 阿部洋文, 迫智也, 星奈美子, 吉田優, 児玉裕三

  2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 110th


• IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 IgG4関連疾患の罹患臓器パターンと臨床所見に関する検討

  半田知宏, 松井祥子, 山本洋, 吉藤元, 児玉裕三, 妹尾浩, 三森経世

  2019, IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 平成30年度 総括・分担研究報告書(Web)


• IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 自己免疫性膵炎の診療における新規自己抗体測定の有用性

  妹尾浩, 児玉裕三

  2019, IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 平成30年度 総括・分担研究報告書(Web)


• 膵石症に対する内視鏡治療戦略

  芦名茂人, 塩見英之, 児玉裕三

  2019, Gastroenterological Endoscopy (Web), 61(Supplement2) (Supplement2)


• 膵炎局所合併症に対する内視鏡的アプローチを軸とした治療戦略

  塩見英之, 辻前正弘, 児玉裕三

  2019, Gastroenterological Endoscopy (Web), 61(Supplement2) (Supplement2)


• 80歳以上の高齢食道運動機能異常患者に対する経口内視鏡的筋層切開術の有効性と安全性の検討

  阿部洋文, 田中心和, 児玉裕三

  2019, Gastroenterological Endoscopy (Web), 61(Supplement2) (Supplement2)


• 胃および十二指腸球部に瘻孔を形成し,上部消化管内視鏡で胆管内を観察し得たIPNBと考えられる胆道腫瘍の一例

  酒井新, 藤垣誠治, 田中雄志, 辻前正弘, 田中俊多, 池川卓哉, 小林隆, 塩見英之, 増田充弘, 児玉裕三

  2019, 胆道(Web), 33(3) (3)


• 12年の経過観察ののち外科手術を行ったIntraductal papillary neoplasm of the bile duct(IPNB)の1例

  辻前正弘, 酒井新, 田中雄志, 田中俊多, 池川卓哉, 小林隆, 塩見英之, 増田充弘, 上野公彦, 伊藤智雄, 味木徹夫, 児玉裕三

  2019, 胆道(Web), 33(3) (3)


• 抗PD-1抗体Pembrolizumabの免疫関連有害事象と考えられる胆管炎の1例

  田中雄志, 酒井新, 田中俊多, 辻前正弘, 池川卓哉, 小林隆, 塩見英之, 増田充弘, 児玉裕三

  2019, 胆道(Web), 33(3) (3)


• 無症状群におけるGERD症状発生の自然経過についての検討

  佐貫毅, 梅垣英次, 藤田剛, 増田充弘, 山崎幸直, 小林正夫, 寺尾秀一, 岡田明彦, 安達政恭, 吉中勇人, 久津見弘, 児玉裕三

  2019, 日本消化器病学会雑誌(Web), 116


• 食道運動機能異常患者における経口内視鏡的筋層切開術後の骨格筋量の変化に関する検討

  阿部洋文, 田中心和, 児玉裕三

  2019, 日本消化器病学会雑誌(Web), 116


• EUS-FNAによるseedingが強く疑われた膵体部癌腹膜播種の1例

  外山博近, 児玉裕三, 福本巧, 寺井祥雄, 椋棒英世, 白川幸代, 山下博成, 石田潤, 李東河, 朝倉悠, 清水貴, 上野公彦, 味木徹夫, 津川大介, 木戸正浩, 田中基文, 小松昇平, 蔵満薫, 増田充弘

  2019, 日本消化器病学会雑誌(Web), 116


• 免疫チェックポイント阻害薬による肝障害の臨床病理学的特徴についての検討

  安冨栄一郎, 矢野嘉彦, 山本淳史, 畑澤友里, 平野仁崇, 林宏樹, 塩見優紀, 児玉裕三

  2019, 日本消化器病学会雑誌(Web), 116


• 膵石症に対する内視鏡治療を軸とした治療戦略

  芦名茂人, 塩見英之, 児玉裕三, 山川康平, 辻前正弘, 山田恭孝, 田中雄志, 中野遼太, 佐藤悠, 池川卓哉, 藤垣誠治, 酒井新, 小林隆, 増田充弘

  2019, 膵臓(Web), 34(3) (3)


• Pathogenesis of autoimmune pancreatitis

  塩川雅広, 塩川雅広, 児玉裕三

  2019, 日本消化器病学会雑誌(Web), 116(4) (4)


• 超音波内視鏡下胆道ドレナージ術を安全に成功へと導くDouble-guidewire technique

  塩見英之, 増田充弘, 児玉裕三

  2019, 日本消化器病学会雑誌(Web), 116


• 悪性輸入脚狭窄に対する内視鏡的金属ステント留置術の検討

  酒井新, 塩見英之, 児玉裕三, 芦名茂人, 山川康平, 辻前正弘, 田中雄志, 田中俊多, 柿原茉耶, 山田恭孝, 中野遼太, 佐藤悠, 黒沢学, 池川卓哉, 藤垣誠治, 小林隆, 増田充弘

  2019, Gastroenterological Endoscopy (Web), 61(Supplement1) (Supplement1)


• 食道憩室を有する食道運動障害患者に対してPOEMの安全性及び有効性についての検討

  木下雅登, 田中心和, 児玉裕三, 阪口博哉, 阿部洋文, 有吉隆佑, 河原史明, 豊永高史

  2019, 日本消化器病学会雑誌(Web), 116


• Preclinical cancer vaccine immunotherapy for gastrointestinal cancers using novel nanoparticulate TLR9 agonist K3-SPG

  岡田浩和, 高橋健, 宇座徳光, 児玉裕三, 石井健, 妹尾浩

  (一社)日本癌学会, 2019, 日本癌学会学術総会抄録集(Web), 78th, P - 2273, English


• 膵管内乳頭粘液性腺癌との鑑別が困難であった自己免疫性膵炎の1例

  右馬悠暉, 酒井新, 増田重人, 芦名茂人, 權田真知, 阿部晶平, 山川康平, 辻前正弘, 田中雄志, 田中俊多, 山田恭孝, 中野遼太, 池川卓哉, 小林隆, 塩見英之, 増田充弘, 外山博近, 伊藤智雄, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111th, 78 - 78, Japanese


• 自己免疫性膵炎の最近のトピックス

  児玉裕三

  日本消化器病学会-中国支部, 2019, 日本消化器病学会中国支部例会プログラム・抄録集, 112th, 152 - 152, Japanese


• 表在型非乳頭部十二指腸上皮性腫瘍に対する腹腔鏡内視鏡合同手術の検討(内視鏡医の立場から)

  迫智也, 森田圭紀, 森田圭紀, 金治新悟, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111th, 51 - 51, Japanese


• バルーン拡張術が有効であったPlummer-vinson症候群の一例

  津田一範, 田中心和, 阿部洋文, 若原ちか, 浦上聡, 朝治直紀, 松本慶, 池澤伸明, 賀来英俊, 阪口博哉, 迫智也, 鷹尾まど佳, 鷹尾俊達, 森田圭紀, 豊永高史, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111th, 109 - 109, Japanese


• エキスパートへの道-上部消化管 胃 病変内に線維化を伴うESDのコツ

  豊永高史, 石田司, 鷹尾俊達, 児玉裕三

  (株)東京医学社, 2019, 消化器内視鏡, 31(1) (1), 80 - 84, Japanese


• エキスパートへの道-上部消化管 胃 残胃におけるESD

  豊永高史, 田中心和, 阪口博哉, 児玉裕三

  (株)東京医学社, 2019, 消化器内視鏡, 31(1) (1), 85 - 90, Japanese


• 胃癌診療アップデート 内視鏡治療

  森田圭紀, 豊永高史, 児玉裕三

  (株)へるす出版, 2019, 消化器外科, 42(2) (2), 145 - 151, Japanese


• 肝炎・肝癌 1 総論:変わりゆく肝炎・肝癌の診療

  児玉裕三

  (株)北隆館, 2019, Bio Clinica, 34(7) (7), 668 - 669, Japanese


• 当院におけるクローン病に対するウステキヌマブ使用例の検討

  大塚崇史, 大井充, 星奈美子, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 110th, 68 - 68, Japanese


• 胆管癌の側方進展度診断における新型経口胆道鏡(SpyGlass DS)の使用経験

  藤垣誠治, 塩見英之, 酒井新, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 110th, 74 - 74, Japanese


• 異所性膵を伴うHamartomatous inverted polypにより胃通過障害を来した一例

  神尾翼, 酒井新, 芦名茂人, 山川康平, 辻前正弘, 山田恭孝, 田中雄志, 中野遼太, 田中俊多, 佐藤悠, 黒澤学, 池川卓哉, 藤垣誠治, 小林隆, 塩見英之, 増田充弘, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 110th, 82 - 82, Japanese


• 術前に癌の確定診断困難であったT1a膵癌の1例

  山形大志, 辻前正弘, 酒井新, 芦名茂人, 山川康平, 田中雄志, 山田恭孝, 田中俊多, 中野遼太, 佐藤悠, 黒澤学, 池川卓哉, 藤垣誠治, 小林隆, 塩見英之, 増田充弘, 椋棒英世, 外山博近, 全陽, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 110th, 90 - 90, Japanese


• Walled off necrosisに対して経皮的ドレナージ術を施行6年後に結腸皮膚瘻を形成した一例

  河野未樹, 酒井新, 芦名茂人, 山川康平, 辻前正弘, 柿原茉耶, 山田恭孝, 田中雄志, 中野遼太, 田中俊多, 佐藤悠, 黒澤学, 池川卓哉, 藤垣誠治, 小林隆, 塩見英之, 増田充弘, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 110th, 113 - 113, Japanese


• 急性肝不全に重複感染症を併発するも,抗菌薬治療が奏功し肝移植に至った一例

  田村証司, 平野仁嵩, 山本敦史, 安冨栄一郎, 畑沢友里, 林宏樹, 塩見優紀, 矢野嘉彦, 蔵満薫, 三住拓誉, 児玉裕三, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 110th, 114 - 114, Japanese


• 十二指腸腫瘍に対する腹腔鏡内視鏡合同手術の安全性に関する検討

  金治新悟, 森田圭紀, 鈴木知志, 山本将士, 瀧口豪介, 高瀬信尚, 長谷川寛, 松田佳子, 山下公大, 松田武, 押切太郎, 豊永高史, 中村哲, 児玉裕三, 掛地吉弘

  (一社)日本外科学会, 2019, 日本外科学会定期学術集会(Web), 119th, SF - 8, Japanese


• 生物学的製剤投与中の炎症性腸疾患患者における妊娠・出産の経験

  大井充, 星奈美子, 児玉裕三, 青山伸郎

  (一社)日本消化管学会, 2019, 日本消化管学会雑誌, 3(Supplement) (Supplement), 101 - 101, Japanese


• レーザーが切り拓く次世代の内視鏡治療に向けての取り組み

  森田圭紀, 有吉隆佑, 間久直, 粟津邦男, 児玉裕三

  (一社)日本消化管学会, 2019, 日本消化管学会雑誌, 3(Supplement) (Supplement), 168 - 168, Japanese


• 膵癌の造影超音波内視鏡による客観的血流動態指標と化学療法感受性の関連性

  増田充弘, 池川卓哉, 佐藤悠, 塩見英之, 児玉裕三

  (一社)兵庫県医師会, 2019, 兵庫県医師会医学雑誌, 61(2) (2), 37 - 38, Japanese


• 当院における昏睡型急性肝不全の感染症の実態と抗菌剤の適正使用への取り組み

  矢野嘉彦, 児玉裕三, 福本巧

  (一社)日本肝臓学会, 2019, 肝臓, 60(Supplement 1) (Supplement 1), A530 - A530, Japanese


• 高齢者におけるERCP後膵炎のリスク解析

  増田重人, 酒井新, 増田充弘, 阿部晶平, 権田真知, 芦名茂人, 辻前正弘, 山川康平, 田中雄志, 柿原茉耶, 中野遼太, 山田恭孝, 田中俊多, 池川卓哉, 小林隆, 塩見英之, 児玉裕三

  (NPO)日本高齢消化器病学会, 2019, 日本高齢消化器病学会誌, 22(1) (1), 52 - 52, Japanese


• 早期胃癌ESD非治癒切除例における高齢者症例の検討

  阪口博哉, 田中心和, 児玉裕三

  (NPO)日本高齢消化器病学会, 2019, 日本高齢消化器病学会誌, 22(1) (1), 67 - 67, Japanese


• To avoid overlooking pancreatic disease in patients with upper abdominal symptoms

  辻前正弘, 酒井新, 増田充弘, 塩見英之, 児玉裕三

  (株)日本臨床社, 2019, 日本臨床, 77(10) (10), 1734 - 1739, Japanese


• 非B非C肝癌の予後に関わる因子の検討

  矢野嘉彦, 山本敦史, 吉田竜太郎, 林宏樹, 安冨栄一郎, 畑澤友里, 塩見優紀, 児玉裕三

  (一社)日本肝臓学会, 2019, 肝臓, 60(Supplement 3) (Supplement 3), A867 - A867, Japanese


• 閉塞性黄疸を来した多発肝嚢胞の1例

  畑澤友里, 矢野嘉彦, 山本淳史, 安冨栄一郎, 林宏樹, 児玉裕三

  (一社)日本肝臓学会, 2019, 肝臓, 60(Supplement 3) (Supplement 3), A932 - A932, Japanese


• 血尿で発症した肝細胞癌膀胱転移の一例

  安冨栄一郎, 山本淳史, 吉田竜太郎, 畑澤友里, 林宏樹, 塩見優紀, 矢野嘉彦, 児玉裕三

  (一社)日本肝臓学会, 2019, 肝臓, 60(Supplement 3) (Supplement 3), A962 - A962, Japanese


• 異なる免疫チェックポイント阻害剤によって多様な免疫関連有害事象(irAE)を呈した悪性黒色腫の一例

  山本淳史, 吉田竜太郎, 安冨栄一郎, 畑澤友里, 林宏樹, 塩見優紀, 矢野嘉彦, 児玉裕三

  (一社)日本肝臓学会, 2019, 肝臓, 60(Supplement 3) (Supplement 3), A1018 - A1018, Japanese


• CO2レーザーによる次世代の内視鏡治療技術の開発

  森田圭紀, 森田圭紀, 児玉裕三, 日吉勝海, 本郷晃史, 岡上吉秀, 間久直, 粟津邦男

  (NPO)日本レーザー医学会, 2019, 日本レーザー医学会誌, 40(3) (3), 233 - 233, Japanese


• 血中アポリポ蛋白A2アイソフォーム測定による膵がん検診の可能性

  小林 隆, 佐藤 悠, 西海 信, 岡谷 しのぶ, 吉田 優, 児玉 裕三, 長島 健悟, 本田 一文

  日本分子腫瘍マーカー研究会, Jan. 2019, 日本分子腫瘍マーカー研究会誌, 34, 59 - 60, Japanese


• クローン病との鑑別を要した家族性地中海熱の1例

  具潤亜, 星奈美子, 大井充, 竹中春香, 徳永英里, 宮崎はるか, 明本由衣, 櫻庭裕丈, 飯田智哉, 仲瀬裕志, 児玉裕三

  日本小腸学会, 2019, 日本小腸学会学術集会プログラム・抄録集, 57th, 66 - 66, Japanese


• 大腸Endoscopic submcosal dissection(ESD)における新規トラクションデバイスの有用性と安全性

  阪口博哉, 阪口博哉, 田中心和, 豊永高史, 豊永高史, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111th, 53 - 53, Japanese


• 当院における好酸球性食道炎の検討

  浦上聡, 田中心和, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111th, 65 - 65, Japanese


• 短期間で増大傾向を示した十二指腸低分化腺癌/印環細胞癌の一例

  土井真由実, 迫智也, 鷹尾俊達, 池澤伸明, 田中心和, 森田圭紀, 豊永高史, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111th, 74 - 74, Japanese


• 正中弓状靭帯症候群に脾動脈瘤と膵体部腫瘤を合併した例

  城端慧, 小林隆, 猪股典子, 増田重人, 権田真知, 阿部晶平, 芦名茂人, 山川康平, 辻前正弘, 柿原茉耶, 山田恭孝, 田中雄志, 中野遼太, 田中俊多, 池川卓哉, 酒井新, 塩見英之, 増田充弘, 児玉裕三

  日本消化器病学会-近畿支部, 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111th, 89 - 89, Japanese


• 結石除去を極める[各論 膵石]膵石除去における乳頭処置とその実際

  酒井新, 塩見英之, 芦名茂人, 田中俊多, 山田恭孝, 中野遼太, 池川卓哉, 小林隆, 増田充弘, 児玉裕三

  (株)東京医学社, 2019, 消化器内視鏡, 31(11) (11), 1694 - 1699, Japanese


• 胆嚢栄養動脈への腫瘍浸潤は遠位部悪性胆道狭窄に対するMetallic Stent留置後胆嚢炎の危険因子である

  曽我部 裕子, 児玉 裕三, 本庶 元, 青山 育雄, 村本 雄哉, 古閑 愛理, 柳井谷 駿史, 河相 宗矩, 吉川 哲平, 松本 慎平, 松本 淳, 森 義治, 大野 千景, 西田 未由, 西田 吉宏, 三上 貴生, 松永 康寛, 宮本 由貴子, 北見 元哉, 西川 浩史, 近藤 雅彦, 三宅 直樹, 河南 智晴, 妹尾 浩

  (一社)日本消化器内視鏡学会, Jan. 2019, Gastroenterological Endoscopy, 61(1) (1), 71 - 80, Japanese


• 自己免疫性膵炎2019 AIPの病因・病態 自己免疫性膵炎の新たな自己抗原-ラミニン511の同定とその意義-

  塩川雅広, 塩川雅広, 児玉裕三

  (株)アークメディア, 2019, 肝胆膵, 78(2) (2), 179 - 182, Japanese


• T細胞・B細胞研究の進展 自己免疫性膵炎の自己抗原はラミニン511である

  西川義浩, 塩川雅広, 塩川雅広, 桑田威, 宇座徳光, 児玉裕三, 妹尾浩

  (有)科学評論社, 2019, 月刊臨床免疫・アレルギー科, 71(6) (6), 572 - 575, Japanese


• Genetic analysis of metachronous pancreatic cancers

  平野智紀, 平野智紀, 竹内康英, 竹内康英, 増井俊彦, 白石友一, 宮野悟, 宇座徳光, 児玉裕三, 妹尾浩, 千葉勉

  日本癌学会, 2019, 日本癌学会学術総会抄録集(Web), 78th, P - 3047, English


• Endoscopic submucosal dissection in a patient with idiopathic mesenteric phlebosclerosis

  R. Schroder, Yoshiko Nakano, T. Toyonaga, H. Abe, R. Ariyoshi, S. Tanaka, T. Takao, Y. Morita, E. Umegaki, Y. Kodama

  2019, Acta Gastro-Enterologica Belgica, 82(2) (2), 341 - 342

  Report scientific journal


• Nivolumab-related pancreatitis with autoimmune pancreatitis-like imaging features

  T. Tanaka, A. Sakai, T. Kobayashi, A. Masuda, H. Shiomi, Y. Kodama

  2019, Journal of Gastroenterology and Hepatology (Australia), 34(8) (8), 1274

  Report scientific journal


• 罹患臓器パターンによるIgG4関連疾患の病型分類

  庭本 崇史, 半田 知宏, 松井 祥子, 山本 洋, 吉藤 元, 児玉 裕三, 千葉 勉, 妹尾 浩, 三森 経世, 平井 豊博

  (一社)日本内科学会, 2019, 日本内科学会雑誌, 108(Suppl.) (Suppl.), 252 - 252, Japanese


• Peri-pancreatic fluid collection drainageにおける偶発症予防と対処—The management of adverse event for peri-pancreatic fluid collection drainage—特集 Interventional EUSの偶発症予防と対処

  酒井 新, 塩見 英之, 芦名 茂人, 山川 康平, 辻前 正弘, 田中 雄志, 田中 俊多, 山田 恭孝, 中野 遼太, 黒澤 学, 佐藤 悠, 池川 卓哉, 藤垣 誠治, 小林 隆, 塩見 優紀, 増田 充弘, 児玉 裕三

  科学評論社, Dec. 2018, 消化器・肝臓内科 = Gastroenterology & hepatology / 消化器・肝臓内科編集委員会 編, 4(6) (6), 492 - 498, Japanese


• Genetic Analysis of Pancreatic Neuroendocrine Neoplasms Grade 3

  Nobuyuki Kakiuchi, Tomonori Hirano, Yasuhide Takeuchi, Yusuke Shiozawa, Akihiko Yoshizawa, Yuichi Shiraishi, Satoru Miyano, Susumu Hijioka, Yasushi Yatabe, Hiroshi Seno, Yuzo Kodama, Seishi Ogawa

  Dec. 2018, CANCER SCIENCE, 109, 1132 - 1132, English

  Summary international conference


• 報告 自己免疫性膵炎臨床診断基準2018 自己免疫性膵炎臨床診断基準2011改訂版

  竹山 宜典, 岡崎 和一, 新倉 則和, 池浦 司, 糸井 隆夫, 伊藤 鉄英, 乾 和郎, 井上 大, 入江 裕之, 入澤 篤志, 岩崎 栄典, 植木 敏晴, 上原 剛, 内田 一茂, 大原 弘隆, 神澤 輝実, 川 茂幸, 菅野 敦, 窪田 賢輔, 洪 繁, 児玉 裕三, 阪上 順一, 清水 京子, 全 陽, 多田 稔, 中沢 貴宏, 西野 隆義, 能登原 憲司, 浜野 英明, 平野 賢二, 廣岡 芳樹, 正宗 淳, 増田 充弘, 水野 伸匡, 吉田 仁, 井戸 章雄, 下瀬川 徹, 妹尾 浩, 滝川 一, 千葉 勉, 仲瀬 裕志, 伊佐山 浩通, 伊藤 哲也, 梅村 武司, 太田 正穂, 鎌田 研, 河邉 顕, 菅野 敦, 木村 理, 栗山 勝利, 小山 貴, 塩川 雅広, 田妻 進, 田中 篤, 玉木 長良, 露口 利夫, 内藤 格, 仲野 俊成, 濱田 晋, 藤永 康成, 村木 崇, 本谷 雅代, 渡邉 貴之, 渡邉 智裕, 日本膵臓学会・厚生労働科学研究費補助金(難治性疾患等政策研究事業)「IgG4関連疾患の診断基準並びに治療指針の確立を目指す研究」班, 自己免疫性膵炎臨床診断基準2011改訂合同委員会, 日本膵臓学会膵炎調査研究委員会

  (一社)日本膵臓学会, Dec. 2018, 膵臓, 33(6) (6), 902 - 913, Japanese


• Clinical utility of endoscopic therapy for bile leak associated with posthepatobiliary surgery

  Hideyuki Shiomi, Takeshi Tanaka, Kouhei Yamakawa, Masahiro Tsujimae, Seiji Fujigaki, Takashi Kobayashi, Arata Sakai, Yuuki Shiomi, Atsuhiro Masuda, Yuzo Kodama

  Nov. 2018, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 33, 119 - 119, English

  Summary international conference


• Significance of pancreatic calcification on preoperative CT image of intraductal papillary mucinous neoplasm

  Masahiro Tsujimae, Atsuhiro Masuda, Hideyuki Shiomi, Kohei Yamakawa, Takuya Ikegawa, Seiji Fujigaki, Takashi Kobayashi, Arata Sakai, Keitaro Sofue, Hirochika Toyama, Yoh Zen, Takumi Fukumoto, Yuzo Kodama

  Nov. 2018, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 33, 194 - 194, English

  Summary international conference


• The risk and benefit of preoperative pancreatic juice cytology under ERCP in patients with IPMNs

  Kohei Yamakawa, Atsuhiro Masuda, Hideyuki Shiomi, Takashi Nakagawa, Hirochika Toyama, Arata Sakai, Takashi Kobayashi, Masahiro Tsujimae, Yoh Zen, Takumi Fukumoto, Yuzo Kodama

  Nov. 2018, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 33, 537 - 537, English

  Summary international conference


• 悪性胆道狭窄に対する新規レーザーカット型自己拡張型金属ステント(EMS)の使用経験

  丸井 彩子, 岡田 浩和, 平野 智紀, 桑田 威, 曽我部 裕子, 友野 輝子, 松森 友昭, 森田 敏広, 津田 喬之, 西川 義浩, 山内 雄揮, 丸野 貴久, 塩川 雅広, 宇座 徳光, 児玉 裕三, 妹尾 浩

  (一社)日本消化器内視鏡学会, Oct. 2018, Gastroenterological Endoscopy, 60(Suppl.2) (Suppl.2), 2125 - 2125, Japanese


• 生存期間延長を目指す分子機構に立脚した肝癌診療の基礎と臨床 肝内胆管癌の形成におけるNotch/Hes1シグナルの機能解析と新規治療標的の探索

  松森 友昭, 児玉 裕三, 妹尾 浩

  (一財)日本消化器病学会, Oct. 2018, 日本消化器病学会雑誌, 115(臨増大会) (臨増大会), A591 - A591, Japanese


• 膵神経内分泌腫瘍の治療戦略 網羅的ゲノム解析による膵神経内分泌癌の分子病態の解明と治療薬選択への展望

  垣内 伸之, 児玉 裕三, 小川 誠司

  (一財)日本消化器病学会, Oct. 2018, 日本消化器病学会雑誌, 115(臨増大会) (臨増大会), A636 - A636, Japanese


• 【ここまで来た!膵癌の早期診断】膵癌の疫学 膵癌登録におけるT1膵癌の解析

  水間 正道, 海野 倫明, 五十嵐 久人, 糸井 隆夫, 江川 新一, 児玉 裕三, 里井 壯平, 濱田 晋, 水元 一博, 下瀬川 徹, 岡崎 和一, 日本膵臓学会膵癌登録委員会

  医学図書出版(株), Sep. 2018, 胆と膵, 39(9) (9), 763 - 767, Japanese


• 膵癌上皮におけるCXCR4は周囲のdesmoplastic reactionに対し重要な役割を示す(CXCR4 has critical role on desmoplastic reaction of PDAC)

  森田 敏広, 児玉 裕三, 塩川 雅広, 宇座 徳光, 妹尾 浩

  (一社)日本癌学会, Sep. 2018, 日本癌学会総会記事, 77回, 1075 - 1075, English


• 膵神経内分泌癌の網羅的ゲノム解析(Genetic Analysis of Pancreatic Neuroendocrine Neoplasms Grade 3)

  垣内 伸之, 平野 智紀, 竹内 康英, 塩澤 裕介, 吉澤 明彦, 白石 友一, 宮野 悟, 肱岡 範, 谷田部 恭, 妹尾 浩, 児玉 裕三, 小川 誠司

  (一社)日本癌学会, Sep. 2018, 日本癌学会総会記事, 77回, 1797 - 1797, English


• 【膵炎の基礎研究・病態解明】IgG4関連疾患におけるIgGの病原性と自己抗体

  塩川 雅広, 児玉 裕三, 千葉 勉, 妹尾 浩

  (一社)日本膵臓学会, Aug. 2018, 膵臓, 33(4) (4), 743 - 751, Japanese


• 正しい分化経路をたどったiPS細胞由来T細胞は固形腫瘍に対して優れた集積性および治療効果を示す

  上田 樹, 入口 翔一, 河合 洋平, 南川 淳隆, 三好 浩之, 寺倉 精太郎, 植村 靖史, 中面 哲也, 玉田 耕治, ウォルツェン・クヌート, 児玉 裕三, 妹尾 浩, 金子 新

  日本がん免疫学会, Jul. 2018, 日本がん免疫学会総会プログラム・抄録集, 22回, 70 - 70, Japanese


• 正しい分化経路をたどったiPS細胞由来T細胞は固形腫瘍に対して優れた集積性および治療効果を示す

  上田 樹, 入口 翔一, 河合 洋平, 南川 淳隆, 三好 浩之, 寺倉 精太郎, 植村 靖史, 中面 哲也, 玉田 耕治, ウォルツェン・クヌート, 児玉 裕三, 妹尾 浩, 金子 新

  日本がん免疫学会, Jul. 2018, 日本がん免疫学会総会プログラム・抄録集, 22回, 70 - 70, Japanese


• 消化器癌における個別化医療の進展 膵癌における遺伝子異常に基づく個別化医療を目指した取り組み

  平野 智紀, 垣内 伸之, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2018, 日本消化器病学会雑誌, 115(臨増総会) (臨増総会), A30 - A30, Japanese


• 膵癌に対する集学的治療の進歩 当院における局所進行膵癌に対すEUSガイド下金マーカー留置を用いた動体追尾IMRTの現状

  西川 義浩, 松森 友昭, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2018, 日本消化器病学会雑誌, 115(臨増総会) (臨増総会), A62 - A62, Japanese


• 発症早期の膵壊死診断とAPACHEIIスコアの重症化予測の精度の比較

  辻喜久, 児玉裕三, 千葉勉

  2018, 膵臓, 33(3) (3)


• Role of chemokines in the progression of severe acute pancreatitis

  佐久間洋二朗, 佐久間洋二朗, 児玉裕三, 妹尾浩

  2018, 膵臓, 33(4) (4)


• 完全型膵管癒合不全を背景に生じた膵粘液癌の1例

  桑田威, 松森友昭, 澤田賢治, 井口恵里子, 山内雄揮, 本澤有介, 宇座徳光, 児玉裕三, 八木真太郎, 片岡竜貴, 桜井孝規

  2018, 日本消化器画像診断研究会プログラム・抄録集, 69th


• 肝内胆管癌の形成におけるNotch/Hes1シグナルの機能解析と新規治療標的の探索

  松森友昭, 児玉裕三, 妹尾浩

  2018, 肝臓, 59(Supplement 2) (Supplement 2)


• 膵管内腫瘍の1例

  岡田浩和, 松森友昭, 児玉裕三, 宇座徳光, 妹尾浩, 瀬尾智, 南口早智子

  2018, 日本消化器画像診断研究会プログラム・抄録集, 68th


• 自己免疫性膵炎の診療における新規自己抗体測定の有用性

  児玉裕三, 妹尾浩, 塩川雅広, 栗山勝利, 友野輝子, 桑田威

  2018, IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 平成29年度 総括・分担研究報告書(Web)


• IgG4関連疾患における臓器別ステロイド使用実態とステロイド不使用例の特徴

  三森経世, 吉藤元, 白柏魅怜, 児玉裕三, 千葉勉, 山本元久, 高橋弘樹, 内田一茂, 岡崎和一, 伊藤哲哉, 川茂幸, 山田和徳, 川野充弘, 田中良哉, 森山雅文, 中村誠司, 神澤輝美, 松井祥子, 坪井洋人, 住田孝之, 後藤浩, 佐藤康晴, 吉野正

  2018, IgG4関連疾患の診断基準並びに診療指針の確立を目指す研究 平成29年度 総括・分担研究報告書(Web)


• 当院における局所進行膵癌に対するEUSガイド下金マーカー留置を用いた動体追尾IMRTの現状

  西川義浩, 松森友昭, 児玉裕三

  2018, 日本消化器病学会雑誌(Web), 115


• 膵癌における遺伝子異常に基づく個別化医療を目指した取り組み

  平野智紀, 垣内伸之, 児玉裕三

  2018, 日本消化器病学会雑誌(Web), 115


• 自己免疫性膵炎の自己抗原同定に関する研究

  塩川雅広, 児玉裕三, 妹尾浩

  2018, 日本消化器病学会雑誌(Web), 115


• 悪性胆道狭窄に対する新規レーザーカット型自己拡張型金属ステント(EMS)の使用経験

  丸井彩子, 岡田浩和, 平野智紀, 桑田威, 曽我部裕子, 友野輝子, 松森友昭, 森田敏広, 津田喬之, 西川義浩, 山内雄揮, 丸野貴久, 塩川雅広, 宇座徳光, 児玉裕三, 妹尾浩

  2018, Gastroenterological Endoscopy (Web), 60(Supplement2) (Supplement2)


• 網羅的ゲノム解析による膵神経内分泌癌の分子病態の解明と治療薬選択への展望

  垣内伸之, 垣内伸之, 児玉裕三, 小川誠司

  2018, Gastroenterological Endoscopy (Web), 60(Supplement2) (Supplement2)


• 傍腫瘍症候群としての自己免疫性膵炎の病態解明

  塩川雅広, 児玉裕三, 妹尾浩

  2018, Gastroenterological Endoscopy (Web), 60(Supplement2) (Supplement2)


• The pathogenicity of IgG in patients with IgG4-related disease

  塩川雅広, 児玉裕三, 児玉裕三, 千葉勉, 妹尾浩

  2018, 膵臓, 33(4) (4)


• 重症急性膵炎とその合併症に対するマネジメント Disconnected pancreatic duct syndromeの病態と治療

  塩見英之, 賀来英俊, 田中雄志, 田中俊多, 中野遼太, 佐藤悠, 山田恭孝, 吉田竜太郎, 池川卓哉, 藤垣誠治, 家本孝雄, 江崎健, 那賀川峻, 酒井新, 小林隆, 塩見優紀, 増田充弘, 児玉裕三

  (有)科学評論社, 2018, 月刊消化器・肝臓内科, 3(6) (6), 585 - 591, Japanese


• 胆膵疾患内視鏡アトラス I.膵臓 2.嚢胞性 膵漿液性嚢胞腫瘍-microcystic type,macrocystic type,solid type-

  塩見英之, 増田充弘, 児玉裕三

  (株)東京医学社, 2018, 消化器内視鏡, 30(増刊) (増刊), 74 - 77, Japanese


• 胃拡大内視鏡が変えたclinical practice 拡大内視鏡が早期胃癌の診断をどう変えたか スクリーニング(拾い上げ診断):同時性・異時性多発胃癌の診断における拡大内視鏡の有用性と問題点

  森田圭紀, 中野佳子, 田中心和, 豊永高史, 梅垣英次, 児玉裕三

  (株)医学書院, 2018, 胃と腸, 53(11) (11), 1455 - 1461, Japanese


• 血中アポリポ蛋白A2アイソフォーム測定による膵がん検診の可能性

  小林隆, 佐藤悠, 西海信, 岡谷しのぶ, 吉田優, 児玉裕三, 長島健悟, 本田一文

  日本分子腫瘍マーカー研究会, 2018, 日本分子腫瘍マーカー研究会プログラム・講演抄録, 38th, 76 - 77, Japanese


• 膵嚢胞診療最前線-IPMN国際診療コンセンサスガイドライン改訂を踏まえて-IPMN国際診療コンセンサスガイドライン最新版(2017年)分枝型IPMN経過観察方法

  塩見英之, 山川康平, 辻前正弘, 池川卓哉, 藤垣誠治, 酒井新, 小林隆, 塩見優紀, 増田充弘, 児玉裕三

  (株)アークメディア, 2018, 肝胆膵, 77(5) (5), 957 - 963, Japanese


• 腎不全・透析患者さんのよろず健康相談-ビタミン,ミネラル,サプリメントと漢方薬 腸内細菌叢と尿毒症物質

  井上潤, 星奈美子, 児玉裕三

  (株)東京医学社, 2018, 腎と透析, 85(5) (5), 629 - 634, Japanese


• Biliary access大辞典 VIII.アクセスルートの確保 EST困難例への対処

  塩見英之, 芦名茂人, 山川康平, 辻前正弘, 田中俊多, 田中雄志, 山田恭孝, 中野遼太, 佐藤悠, 池川卓哉, 藤垣誠治, 酒井新, 小林隆, 塩見優紀, 増田充弘, 児玉裕三

  医学図書出版(株), 2018, 胆と膵, 39(臨増特大) (臨増特大), 1179 - 1186, Japanese


• 切除企図肝門部領域胆道癌に対する術前胆道ドレナージの検討-inside stentの使用経験

  小林隆, 有坂好史, 児玉裕三

  日本胆道学会, 2018, 胆道, 32(3) (3), 422 - 422, Japanese


• 明らかな胆管狭窄を認めない好酸球性胆管炎の一例

  田中俊多, 酒井新, 塩見英之, 増田充弘, 全陽, 吉田竜太郎, 田中雄志, 山田恭孝, 中野遼太, 池川卓哉, 佐藤悠, 藤垣誠治, 小林隆, 児玉裕三

  日本胆道学会, 2018, 胆道, 32(3) (3), 490 - 490, Japanese


• 希少・難治性疾患の診断と治療の最前線 2.IgG4関連疾患

  塩川雅広, 児玉裕三

  (株)ライフ・サイエンス, 2018, Progress in Medicine, 38(12) (12), 1289 - 1293, Japanese


• Interventional EUSの偶発症予防と対処 Peri-pancreatic fluid collection drainageにおける偶発症予防と対処

  酒井新, 塩見英之, 芦名茂人, 山川康平, 辻前正弘, 田中雄志, 田中俊多, 山田恭孝, 中野遼太, 黒澤学, 佐藤悠, 池川卓哉, 藤垣誠治, 小林隆, 塩見優紀, 増田充弘, 児玉裕三

  (有)科学評論社, 2018, 月刊消化器・肝臓内科, 4(6) (6), 492 - 498, Japanese


• 膵管内乳頭粘液性腺癌との鑑別が困難であった自己免疫性膵炎の1例

  酒井新, 江崎健, 増田充弘, 藤垣誠治, 那賀川峻, 小林隆, 塩見英之, 全陽, 児玉裕三

  日本消化器病学会-近畿支部, 2018, 日本消化器画像診断研究会プログラム・抄録集, 69th, 78 - 78, Japanese


• 自己免疫性膵炎(AIP)3 自己免疫性膵炎の発症機序

  塩川雅広, 児玉裕三, 妹尾浩, 千葉勉

  (株)日本メディカルセンター, 2018, 臨床消化器内科, 33(2) (2), 165 - 171, Japanese


• 膵癌に対する術前化学放射線療法の治療効果判定と短期成績

  長井和之, 増井俊彦, 余語覚匡, 内田雄一郎, 仲野健三, 佐藤朝日, 穴澤貴行, 吉村通央, 吉村通央, 児玉裕三, 松本繁巳, 高折恭一, 上本伸二

  (一社)日本膵臓学会, 2018, 膵臓, 33(3) (3), 506 - 506, Japanese


• 遺伝性膵炎の原因と考えられる新規のPRSS1変異を同定した一例

  丸井彩子, 垣内伸之, 宇座徳光, 桑田威, 曽我部裕子, 友野輝子, 松森友昭, 森田敏広, 津田喬之, 西川義浩, 山内雄揮, 丸野貴久, 塩川雅広, 児玉裕三, 妹尾浩

  (一社)日本膵臓学会, 2018, 膵臓, 33(3) (3), 587 - 587, Japanese


• サルコイドーシスとIgG4関連疾患の合併と考えられた1例

  増尾優輝, 半田知宏, 半田知宏, 渡邉創, 谷澤公伸, 中塚賀也, 村瀬裕子, 庭本崇史, 池上直弥, 中西智子, 久保武, 中島直樹, 吉澤明彦, 長井苑子, 児玉裕三, 陳和夫, 平井豊博

  日本サルコイドーシス, 2018, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 38(サプリメント号) (サプリメント号), 73 - 73, Japanese


• 著明な石灰化を伴う胆嚢癌の1例

  松森友昭, 宇座徳光, 丸野貴久, 児玉裕三

  日本胆道学会, 2018, 胆道, 32(3) (3), 639 - 639, Japanese


• 膵癌に対するゲムシタビン・強度変調放射線療法(IMRT)を併用した術前化学放射線療法の治療成績

  長井和之, 増井俊彦, 穴澤貴行, 吉村通央, 児玉裕三, 松本繁巳, 高折恭一, 上本伸二

  (一社)日本消化器外科学会, 2018, 日本消化器外科学会雑誌(Web), 51(Supplement1) (Supplement1), 692 - 692, Japanese


• 膵癌形成におけるHes1の機能解析

  西川 義浩, 児玉 裕三, 山内 雄揮, 津田 喬之, 妹尾 浩

  (一社)日本癌学会, Sep. 2017, 日本癌学会総会記事, 76回, E - 1026, English


• GPC3を標的としたiPS細胞由来CAR-T療法

  上田 樹, 入口 翔一, 河合 洋平, 南川 淳隆, 三好 浩之, 寺倉 精太郎, 植村 靖史, ウォルツェン・クヌート, 児玉 裕三, 玉田 耕治, 中面 哲也, 妹尾 浩, 金子 新

  (一社)日本癌学会, Sep. 2017, 日本癌学会総会記事, 76回, P - 1251, English


• 膵発癌におけるケモカインCXCL16の役割

  佐久間 洋二朗, 児玉 裕三, 妹尾 浩

  (一社)日本癌学会, Sep. 2017, 日本癌学会総会記事, 76回, J - 2085, English


• 膵神経内分泌腫瘍形成におけるRb、p53の役割

  山内 雄揮, 児玉 裕三, 津田 喬之, 西川 義浩, 妹尾 浩

  (一社)日本癌学会, Sep. 2017, 日本癌学会総会記事, 76回, P - 2273, English


• Skull metastasis from cholangiolocellular carcinoma

  Yuji Eso, Satoshi Yoshiji, Yuzo Kodama, Hiroshi Seno

  Sep. 2017, Digestive and Liver Disease, 49(9) (9), 1057 - 1057, English

  [Refereed]


• IgG4関連疾患はHLA領域とFCGR2B領域に関連する

  寺尾 知可史, 太田 正穂, 塩川 雅広, 栗山 勝利, 児玉 裕三, 内田 一茂, 山口 泉, 川口 喬久, 川口 修治, 日笠 幸一郎, 三森 経世, 岡崎 和一, 千葉 勉, 川 茂幸, 松田 文彦

  (一社)日本臨床免疫学会, Aug. 2017, 日本臨床免疫学会会誌, 40(4) (4), 293 - 293, Japanese


• 膵癌の早期診断・治療の現状と展望 膵癌登録における2cm以下(TS1)膵癌の解析

  水間 正道, 海野 倫明, 五十嵐 久人, 糸井 隆夫, 江川 新一, 児玉 裕三, 里井 壯平, 濱田 晋, 水元 一博, 岡崎 和一, 日本膵臓学会膵癌登録委員会

  日本膵臓学会, May 2017, 膵臓, 32(3) (3), 321 - 321, Japanese


• 膵癌登録における膵癌リンパ節転移個数の予後解析 膵癌取扱い規約改訂におけるビッグデータ利活用

  水間 正道, 海野 倫明, 伊佐地 秀司, 五十嵐 久人, 糸井 隆夫, 江川 新一, 児玉 裕三, 里井 壯平, 濱田 晋, 水元 一博, 岸和田 昌之, 北川 裕久, 高折 恭一, 谷 眞至, 羽鳥 隆, 藤井 努, 村上 義昭, 山口 幸二, 吉富 秀幸, 岡崎 和一, 日本膵臓学会膵癌登録委員会

  (一社)日本外科学会, Apr. 2017, 日本外科学会定期学術集会抄録集, 117回, SF - 2, Japanese


• Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma from Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration

  Ayako Furuhata, Sachiko Minamiguchi, Hiroyuki Shirahase, Yuzo Kodama, Souichi Adachi, Takaki Sakurai, Hironori Haga

  Apr. 2017, Pancreas, 46(4) (4), 531 - 538, English

  [Refereed]


• 放射線治療により長期の腫瘍制御が得られたにもかかわらず肝不全が原因で死亡した胆道癌3例の検討

  土井恵太郎, 尾崎由直, 金井雅史, 児玉裕三, 飯塚裕介, 松尾幸憲, 松本繁巳, 武藤学

  2017, 日本臨床腫瘍学会学術集会(CD-ROM), 15th


• IgG4関連疾患の診断基準並びに治療指針の確立を目指した研究 IgG4関連疾患の自己抗原・自己抗体の探索

  児玉裕三

  2017, IgG4関連疾患の診断基準並びに治療指針の確立を目指した研究 平成28年度 総括・分担研究報告書(Web)


• スコアリングシステムによるERCP後膵炎の予測モデル

  藤田光一, 児玉裕三, 八隅秀二郎

  2017, Gastroenterological Endoscopy (Web), 59(Supplement1) (Supplement1)


• 自己免疫性膵炎の抗原同定

  塩川雅広, 児玉裕三, 妹尾浩, 千葉勉

  2017, 膵臓, 32(3) (3)


• iPS細胞由来キメラ抗原受容体発現再生T細胞療法の開発

  上田樹, 入口翔一, 河合洋平, 南川淳隆, 寺倉精太郎, 三好浩之, 中面哲也, 植村靖史, 玉田耕治, 児玉裕三, 妹尾浩, 金子新

  2017, 再生医療, 16


• IgG4関連疾患の診断基準並びに治療指針の確立を目指した研究 胆膵(消化器)分科会における研究活動報告

  岡崎和一, 岡崎和一, 下瀬川徹, 神澤輝実, 川茂幸, 井戸章雄, 滝川一, 能登原憲司, 岩崎栄典, 児玉裕三, 乾和郎, 全陽, 田中篤, 中沼安二, 窪田賢輔, 吉田仁, 太田正穂, 正宗淳, 伊藤鉄英, 中沢貴宏, 西野隆義, 浜野英明, 清水京子, 藤永康成, 内田一茂, 洪繁, 平野賢二, 水野伸匡, 塩見英之, 菅野敦, 濱田晋, 塩川雅広, 栗山勝利

  2017, IgG4関連疾患の診断基準並びに治療指針の確立を目指した研究 平成28年度 総括・分担研究報告書(Web)


• 膵扁平上皮癌の1例

  桑田威, 松森友昭, 三嶋眞紗子, 西川義浩, 高田裕, 山本修司, 宇座徳光, 児玉裕三, 瀬尾智, 桜井孝規

  2017, 日本消化器画像診断研究会プログラム・抄録集, 67th, 50, Japanese


• 自己免疫性膵炎・IgG4関連疾患における病因・病態の進歩:新規標的抗原を中心に

  塩川雅広, 児玉裕三, 千葉勉

  医歯薬出版(株), 2017, 医学のあゆみ, 261(1) (1), 65 - 68, Japanese


• 膵神経内分泌腫瘍形成におけるRb,p53の役割

  山内雄揮, 児玉裕三, 桑田威, 丸井彩子, 曽我部裕子, 森田敏広, 垣内伸之, 美馬淳志, 松森友昭, 友野輝子, 上田樹, 津田喬之, 西川義浩, 佐久間洋二朗, 栗山勝利, 丸野貴久, 塩川雅広, 宇座徳光, 妹尾浩

  (一社)日本膵臓学会, 2017, 膵臓, 32(3) (3), 471 - 471, Japanese


• Hes1は膵癌マウスモデルにおいて膵発癌を抑制する

  西川義浩, 児玉裕三, 桑田威, 丸井彩子, 曽我部裕子, 森田敏広, 垣内伸之, 美馬淳志, 松森友昭, 友野輝子, 上田樹, 津田喬之, 山内雄揮, 佐久間洋二朗, 栗山勝利, 丸野貴久, 塩川雅広, 宇座徳光, 妹尾浩

  (一社)日本膵臓学会, 2017, 膵臓, 32(3) (3), 500 - 500, Japanese


• 胆道悪性腫瘍におけるMapping Biopsyの意義

  姚思遠, 田浦康二朗, 奥田雄紀浩, 児玉裕三, 児玉裕三, 南口早智子, 瀬尾智, 安近健太郎, 岡島英明, 海道利実, 上本伸二

  (一社)日本消化器外科学会, 2017, 日本消化器外科学会雑誌(Web), 50(Supplement1) (Supplement1), PN2 - 4, Japanese


• 胆道悪性腫瘍に対するマッピング生検の意義の検討

  田浦康二朗, 姚思遠, 児玉裕三, 南口早智子, 奥田雄紀浩, 宇座徳光, 合田直樹, 瀬尾智, 石井隆道, 山本玄, 岡島英明, 海道利実, 上本伸二

  日本胆道学会, 2017, 胆道, 31(3) (3), 502 - 502, Japanese


• 胆嚢管原発神経内分泌腫瘍の一例

  栗山勝利, 栗山勝利, 桑田威, 友野輝子, 松森友昭, 森田敏広, 上田樹, 佐久間洋二朗, 丸野貴久, 宇座徳光, 児玉裕三, 増井俊彦, 上本伸二

  日本胆道学会, 2017, 胆道, 31(3) (3), 638 - 638, Japanese


• ケモカインCXCL16は壊死性膵炎の形成に重要である

  佐久間洋二朗, 児玉裕三, 宇座徳光, 辻喜久, 辻喜久, 塩川雅広, 渡邉智裕, 渡邉智裕, 仲瀬裕志, 仲瀬裕志, 千葉勉, 千葉勉, 妹尾浩

  (一社)日本膵臓学会, 2017, すい臓, 32(3) (3), 339 - 339, Japanese


• 急速な腫瘍の顕在化と進行にT細胞共刺激阻害薬アバタセプトの関与が推察された肝細胞癌の1例

  高橋健, 上田佳秀, 恵荘裕嗣, 李宗南, 盛田真弘, 児玉裕三, 丸澤宏之, 三森経世, 妹尾浩

  日本がん免疫学会, 2017, 日本がん免疫学会総会プログラム・抄録集, 21st, 144 - 144, Japanese


• 【IgG4関連疾患:全身から肝胆膵の病態に迫る】IgG4研究の過去と未来

  全 陽, 岡崎 和一, 児玉 裕三, 多田 稔

  (株)アークメディア, Oct. 2016, 肝胆膵, 73(4) (4), 623 - 638, Japanese


• 膵癌形成におけるHes1の機能解析

  西川 義浩, 児玉 裕三, 千葉 勉, 妹尾 浩

  (一社)日本癌学会, Oct. 2016, 日本癌学会総会記事, 75回, J - 1058, English


• 膵臓 局所進行膵がんに対する治療戦略 局所進行膵癌に対する化学放射線治療 IMRTの有用性の検討

  後藤 容子, 中村 晶, 岸 高宏, 坂中 克行, 板坂 聡, 澁谷 景子, 松本 繁巳, 児玉 裕三, 高折 恭一, 溝脇 尚志, 平岡 眞寛

  (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, MS13 - 4, Japanese


• 消化器領域におけるIgG4関連疾患の病態 IgG4関連疾患におけるIgGの病原性と標的抗原の解明

  塩川 雅広, 児玉 裕三, 千葉 勉

  (一財)日本消化器病学会, Sep. 2016, 日本消化器病学会雑誌, 113(臨増大会) (臨増大会), A636 - A636, Japanese


• Clinicopathological features and response to platinum-based chemotherapy (PBC) in pancreatic neuroendocrine carcinoma (pNEC): Updated results of Japan pNEC study.

  Nobumasa Mizuno, Waki Hosoda, Keitaro Matsuo, Makoto Ueno, Masayuki Furukawa, Hideyuki Yoshitomi, Masafumi Ikeda, Noritoshi Kobayashi, Shoji Nakamori, Hiroshi Ishii, Yuzo Kodama, Chigusa Morizane, Hiroaki Yanagimoto, Kei Yane, Yoshiaki Tsuchiya, Kenji Notohara, Junji Furuse, Yasushi Yatabe, Susumu Hijioka

  May 2016, JOURNAL OF CLINICAL ONCOLOGY, 34(15) (15), English

  Summary international conference


• Pathogenic Role of IgG in Patients With IgG4-Related Disease on Neonatal Mice

  Masahiro Shiokawa, Yuzo Kodama, Katsutoshi Kuriyama, Teruko Tomono, Tsutomu Chiba

  Apr. 2016, GASTROENTEROLOGY, 150(4) (4), S328 - S328, English

  Summary international conference


• Chemokine CXCL16 Plays a Critical Role in the Development of Severe Acute Pancreatitis

  Yojiro Sakuma, Yuzo Kodama, Tomoaki Matsumori, Teruko Tomono, Nobuyuki Kakiuchi, Atsushi Mima, Yuki Yamauchi, Yoshihiro Nishikawa, Motoyuki Tsuda, Tatsuki Ueda, Katsutoshi Kuriyama, Takahisa Maruno, Yuji Ota, Masahiro Shiokawa, Yoshihisa Tsuji, Norimitsu Uza, Tomohiro Watanabe, Hiroshi Nakase, Hiroshi Seno, Tsutomu Chiba

  Apr. 2016, GASTROENTEROLOGY, 150(4) (4), S327 - S327, English

  Summary international conference


• 臨床検体が切り拓く新たな消化器疾患病態研究 IgG4関連疾患におけるIgGの病原性と標的抗原の解明

  塩川 雅広, 児玉 裕三, 千葉 勉

  (一財)日本消化器病学会, Mar. 2016, 日本消化器病学会雑誌, 113(臨増総会) (臨増総会), A166 - A166, Japanese


• Clinicopathological features and response to platinum-based chemotherapy in pancreatic neuroendocrine carcinoma: A retrospective multicenter study of 70 patients

  Susumu Hijioka, Waki Hosoda, Keitaro Matsuo, Makoto Ueno, Masayuki Furukawa, Hideyuki Yoshitomi, Noritoshi Kobayashi, Masafumi Ikeda, Tetsuhide Ito, Shoji Nakamori, Hiroshi Ishii, Yuzo Kodama, Chigusa Morizane, Hiroaki Yanagimoto, Kei Yane, Kenji Notohara, Junji Furuse, Yasushi Yatabe, Nobumasa Mizuno

  Feb. 2016, JOURNAL OF CLINICAL ONCOLOGY, 34(4) (4), English

  Summary international conference


• A Case of Multiple Pancreatic Insulinoma Laparoscopically Resected through Precise Spatial Diagnosis by SACI Test

  K. Nakano, T. Masui, A. Sato, T. Ito, T. Anazawa, S. Matsumoto, Y. Kodama, K. Takaori, S. Uemoto

  2016, NEUROENDOCRINOLOGY, 103, 112 - 112, English

  Summary international conference


• Factors Affecting Recurrences of the Non-Functioning Pancreatic NET after Resection

  T. Masui, A. Sato, K. Nakano, Y. Nakamoto, S. Matsumoto, Y. Kodama, T. Shibata, S. Uemoto

  2016, NEUROENDOCRINOLOGY, 103, 100 - 100, English

  Summary international conference


• IgG4関連疾患の新知見 特定疾患としてのIgG4関連疾患-概念確立から難病指定まで

  千葉勉, 児玉裕三

  2016, 医学のあゆみ, 258(3) (3)


• 難治性膵疾患に関する調査研究 早期慢性膵炎および慢性膵炎疑診例の前向き予後調査

  正宗淳, 伊藤鉄英, 五十嵐久人, 安藤朗, 伊佐山浩通, 乾和郎, 入澤篤志, 糸井隆夫, 大原弘隆, 岡崎和一, 景岡正信, 神澤輝実, 菊田和宏, 濱田晋, 下瀬川徹, 北野雅之, 木田光広, 木原康之, 児玉裕三, 阪上順一, 清水京子, 田口雅史, 田妻進, 新倉則和, 能登原憲司, 花田敬士, 藤田基和, 峯徹哉, 宮川宏之, 吉田仁, 竹山宜典

  2016, 難治性膵疾患に関する調査研究 平成27年度 総括・分担研究報告書


• 難治性膵疾患に関する調査研究 自己免疫性膵炎の前向き予後調査

  正宗淳, 岡崎和一, 安藤朗, 伊藤鉄英, 伊佐山浩通, 糸井隆夫, 乾和郎, 入澤篤志, 大原弘隆, 神澤輝実, 川茂幸, 菅野敦, 北野雅之, 木原康之, 児玉裕三, 阪上順一, 清水京子, 田口雅史, 能登原憲司, 花田敬士, 廣岡芳樹, 下瀬川徹, 菊田和宏, 竹山宜典

  2016, 難治性膵疾患に関する調査研究 平成27年度 総括・分担研究報告書


• IgG4関連疾患におけるIgGの病原性と標的抗原の解明

  塩川雅広, 児玉裕三, 千葉勉

  2016, 日本消化器がん検診学会雑誌, 54(Supplement) (Supplement)


• IgG4関連疾患の診断基準並びに治療指針の確立を目指した研究 IgG4関連疾患の診断・治療における新規バイオマーカーの探索

  児玉裕三

  2016, IgG4関連疾患の診断基準並びに治療指針の確立を目指した研究 平成27年度 総括・分担研究報告書


• IgG4関連疾患の診断基準並びに治療指針の確立を目指した研究 胆膵(消化器)分科会における研究活動報告

  岡崎和一, 下瀬川徹, 神澤輝実, 川茂幸, 井戸章雄, 滝川一, 能登原憲司, 岩崎栄典, 児玉裕三, 乾和郎, 全陽, 田中篤, 中沼安二, 窪田賢輔, 吉田仁, 太田正穂, 正宗淳, 伊藤鉄英, 中沢貴宏, 西野隆義, 浜野英明, 浜野英明, 清水京子, 藤永康成, 内田一茂, 洪繁, 平野賢二, 水野伸匡, 塩見英之, 菅野敦, 濱田晋, 塩川雅広, 栗山勝利

  2016, IgG4関連疾患の診断基準並びに治療指針の確立を目指した研究 平成27年度 総括・分担研究報告書


• 多発膵腫瘤像を示した膵癌の1例

  友野輝子, 塩川雅広, 藤田真梨, 大田悠司, 丸野貴久, 澤井勇悟, 澤井勇悟, 宇座徳光, 児玉裕三

  2016, 日本消化器画像診断研究会プログラム・抄録集, 64th, 34, Japanese


• 同時性多発膵癌の1例

  松森友昭, 児玉裕三, 宇座徳光, 塩川雅広, 丸野貴久, 栗山勝利, 佐久間洋二朗, 山内雄揮, 西川義浩, 妹尾浩, 吉澤明彦

  2016, 日本消化器画像診断研究会プログラム・抄録集, 65th, 39, Japanese


• 膵臓 局所進行膵がんに対する治療戦略 局所進行膵癌に対する化学放射線治療 IMRTの有用性の検討

  後藤 容子, 中村 晶, 岸 高宏, 坂中 克行, 板坂 聡, 澁谷 景子, 松本 繁巳, 児玉 裕三, 高折 恭一, 溝脇 尚志, 平岡 眞寛

  (一社)日本癌治療学会, 2016, 日本癌治療学会学術集会抄録集, 54th, MS13 - 4, Japanese


• 生体肝移植後の吻合部胆管狭窄に対するインサイドステント留置の長期成績の検討

  宇座徳光, 桑田威, 児玉裕三

  日本胆道学会, 2016, 胆道, 30(3) (3), 412 - 412, Japanese


• 膵癌分子診断研究の最前線:リキッドバイオプシーから次世代DNAシークエンシングまで 網羅的癌関連遺伝子変異検査(OncoPrime)による膵癌ゲノム異常解析と治療への応用

  金井雅史, 高忠之, 松本繁巳, 武藤学, 児玉裕三, 増井俊彦, 高折恭一, 南口早智子, 鎌田真由美, 中津井雅彦, 奥野恭史, 佐久間朋寛, 望月洋明, 広島明宣

  医学図書出版(株), 2016, 胆と膵, 37(9) (9), 791 - 795, Japanese


• IgG4関連疾患:全身から肝胆膵の病態に迫る 病因・病態 IgG4抗体に病原性はあるのか?

  塩川雅広, 児玉裕三, 千葉勉

  (株)アークメディア, 2016, 肝胆膵, 73(4) (4), 481 - 489, Japanese


• 膵癌進展におけるactivation-induced cytidine deaminase(AID)の役割

  大田 悠司, 澤井 勇吾, 児玉 裕三, 丸澤 宏之, 千葉 勉

  (一社)日本癌学会, Oct. 2015, 日本癌学会総会記事, 74回, J - 1031, English


• 発症早期の集学的治療は、Walled-off necrosisに対する侵襲的治療の必要性を減ずる

  森田 敏広, 辻 喜久, 児玉 裕三

  (一財)日本消化器病学会, Sep. 2015, 日本消化器病学会雑誌, 112(臨増大会) (臨増大会), A555 - A555, Japanese


• Translational science消化器疾患診断・治療における医療機器・材料の進歩 ベンチからベッドへ 悪性胆管狭窄の診断における新デバイスの有用性に関する多施設共同研究

  佐久間 洋二朗, 児玉 裕三, 八隅 秀二郎

  (一社)日本消化器内視鏡学会, Sep. 2015, Gastroenterological Endoscopy, 57(Suppl.2) (Suppl.2), 2063 - 2063, Japanese


• 【microbiome(腸内細菌)と肝胆膵領域の新世紀】膵臓とmicrobiome 良性膵疾患と腸内細菌

  森田 敏広, 児玉 裕三, 大田 悠司, 辻 喜久, 渡邉 智裕

  (株)アークメディア, Jun. 2015, 肝胆膵, 70(6) (6), 895 - 900, Japanese


• 膵癌の発見経緯からみた切除可能症例の解析~院内がん登録と膵癌登録を用いて

  水元一博, 田中雅夫, 海野倫明, 五十嵐久人, 糸井隆夫, 江川新一, 児玉裕三, 里井壮平, 濱田晋, 水間正道

  18 May 2015, すい臓, 30(3) (3), 418, Japanese


• Impact of EUS-FNA for Preoperative Para-Aortic Lymph Node Staging in Patients With Pancreato-Biliary Neoplasm

  Akira Kurita, Yuzo Kodama, Tsutomu Chiba

  May 2015, GASTROINTESTINAL ENDOSCOPY, 81(5) (5), AB544 - AB544, English

  Summary international conference


• A MULTI-INSTITUTION PHASE II STUDY OF GEMCITABINE/CISPLATIN/S-1 (GCS) COMBINATION CHEMOTHERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCER (KHBO 1002)

  S. Kobayashi, M. Kanai, E. Hatano, Y. Fujiwara, S. Marubashi, A. Miyamoto, H. Shiomi, S. Kubo, S. Ikuta, H. Yanagimoto, H. Terajima, H. Ikoma, D. Sakai, Y. Kodama, S. Seo, S. Morita, T. Ajiki, H. Nagano, T. Ioka

  Apr. 2015, JOURNAL OF HEPATOLOGY, 62, S451 - S451, English

  Summary international conference


• Role of Early Prediction of Pancreatic Necrosis in Evaluating Severity of Acute Pancreatitis in the Early Stage

  Yoshihisa Tsuji, Yuzo Kodama, Tsutomu Chiba

  Apr. 2015, GASTROENTEROLOGY, 148(4) (4), S683 - S683, English

  Summary international conference


• 壊死性膵炎の予後改善を目指した治療の新展開 早期壊死診断および入院時臓器不全に基づいた重症急性膵炎診断予測

  辻 喜久, 児玉 裕三, 千葉 勉

  (一財)日本消化器病学会, Mar. 2015, 日本消化器病学会雑誌, 112(臨増総会) (臨増総会), A83 - A83, Japanese


• 慢性閉塞性肺疾患における抗酸化物質の関連性について

  児玉裕三, 岸本祐樹, 建部順子, 山本侑, 廣田直, 糸魚川幸成, 熱田了, 盛田俊介, 本間栄, 瀬山邦明, 高橋和久, 石神昭人

  2015, 日本呼吸器学会誌, 4


• 発症早期の集学的治療は,Walled-off necrosisに対する侵襲的治療の必要性を減ずる

  森田敏広, 辻喜久, 児玉裕三

  2015, 肝臓, 56(Supplement 2) (Supplement 2)


• 悪性胆管狭窄の診断における新デバイスの有用性に関する多施設共同研究

  佐久間洋二朗, 児玉裕三, 八隅秀二郎

  2015, 肝臓, 56(Supplement 2) (Supplement 2)


• 胆道癌における傍大動脈リンパ節転移の術前診断法の確立

  栗田亮, 児玉裕三, 千葉勉

  2015, 胆道, 29(3) (3)


• 胆管ステント留置の乳頭機能を温存した総胆管結石治療としての可能性

  菊山正隆, 上田樹, 児玉裕三

  2015, 胆道, 29(3) (3)


• IgG4関連疾患の診断基準並びに治療指針の確立を目指した研究 本邦におけるIgG4関連疾患の臨床的特徴についての研究

  児玉裕三

  2015, IgG4関連疾患の診断基準並びに治療指針の確立を目指した研究 平成26年度 総括・分担研究報告書


• IgG4関連疾患の病因病態解明と新規治療法確立に関する研究 IgG4関連疾患におけるIgGの役割に関する研究

  千葉勉, 児玉裕三

  2015, IgG4関連疾患の病因病態解明と新規治療法確立に関する研究 平成26年度 委託業務成果報告書


• 難治性膵疾患に関する調査研究 II.慢性膵炎 早期慢性膵炎および慢性膵炎疑診例の前向き予後調査

  正宗淳, 伊藤鉄英, 安藤朗, 五十嵐久人, 池上博司, 伊佐山浩通, 糸井隆夫, 乾和郎, 入澤篤志, 大原弘隆, 岡崎和一, 神澤輝実, 川茂幸, 菊田和宏, 濱田晋, 北野雅之, 木原康之, 久津見弘, 児玉裕三, 阪上順一, 清水京子, 田口雅史, 田妻進, 能登原憲司, 花田敬士, 藤田基和, 峯徹哉, 宮川宏之, 吉田仁, 下瀬川徹, 竹山宜典

  2015, 難治性膵疾患に関する調査研究 平成26年度 総括・分担研究報告書


• 幽門腺への分化を主体としたgastric typeのIPNBの1例

  松森友昭, 児玉裕三, 宇座徳光, 澤井勇悟, 塩川雅広, 大田悠司, 丸野貴久, 千葉勉, 南口早智子

  2015, 日本消化器画像診断研究会プログラム・抄録集, 63rd, 24, Japanese


• The relationship between autoimmune pancreatitis and malignant neoplasm including pancreatic cancer

  塩川雅広, 児玉裕三, 千葉勉

  (一社)日本膵臓学会, 2015, 膵臓, 30(1) (1), 101 - 106, Japanese


• 本邦におけるIgG4関連疾患の臨床的特徴

  栗山勝利, 塩川雅広, 児玉裕三, 千葉勉

  (一社)日本内科学会, 2015, 日本内科学会雑誌, 104(Suppl.) (Suppl.), 192 - 192, Japanese


• 肝転移症例に対する血管内治療を中心とした集学的治療の試み

  増井俊彦, 佐藤朝日, 松本繁巳, 児玉裕三, 柴田登志也, 高折恭一, 上本伸二

  (一社)日本膵臓学会, 2015, 膵臓, 30(3) (3), 319 - 319, Japanese


• 消化器疾患と遺伝子異常 遺伝性膵炎と孤発性膵炎の遺伝子異常

  美馬淳志, 垣内伸之, 福田晃久, 児玉裕三

  (株)先端医学社, 2015, 分子消化器病, 12(3) (3), 219 - 226, Japanese


• 消化器疾患と遺伝子異常 胆道疾患の遺伝子異常

  松森友昭, 児玉裕三

  (株)先端医学社, 2015, 分子消化器病, 12(3) (3), 246 - 252, Japanese


• 肝門部領域胆管における胆管細胞癌と肝外胆管癌の臨床病理学的特徴の検討

  松森友昭, 児玉裕三, 千葉勉

  日本胆道学会, 2015, 胆道, 29(3) (3), 555 - 555, Japanese


• IgG4関連疾患におけるIgG4の病原性

  児玉裕三

  (公財)日本膵臓病研究財団, 2015, 日本膵臓病研究財団研究報告書, 22nd, 55 - 61, Japanese


• 重症急性膵炎の病態と有効な初期治療をめざして 急性膵炎初期治療における早期壊死診断の臨床への影響

  辻 喜久, 児玉 裕三, 千葉 勉

  (一財)日本消化器病学会, Sep. 2014, 日本消化器病学会雑誌, 111(臨増大会) (臨増大会), A598 - A598, Japanese


• 早期動注療法およびトロンボモジュリンが奏功した重症急性膵炎の一例

  岩井 眞紗子, 辻 喜久, 平野 智紀, 船越 太郎, 福田 晃久, 児玉 裕三, 仲瀬 裕志, 千葉 勉

  (一財)日本消化器病学会, Mar. 2014, 日本消化器病学会雑誌, 111(臨増総会) (臨増総会), A374 - A374, Japanese


• 急性膵炎初期治療における早期壊死診断の臨床への影響

  辻喜久, 児玉裕三, 千葉勉

  2014, Gastroenterological Endoscopy, 56(Supplement 2) (Supplement 2)


• 難治性膵疾患に関する調査研究 急性膵炎初期治療における膵壊死診断の影響

  児玉裕三, 塩川雅広, 上田樹, 津田喬之, 西川義浩, 山内雄揮, 南竜城, 栗山勝利, 佐久間洋二郎, 大田悠司, 田辺渉, 丸野貴久, 栗田亮, 澤井勇悟, 辻喜久, 宇座徳光, 千葉勉

  2014, 難治性膵疾患に関する調査研究 平成25年度 総括・分担研究報告書, 146 - 147, Japanese


• 難治性膵疾患に関する調査研究 急性膵炎・重症急性膵炎の治療と予後に関する国際比較

  阪上順一, 片岡慶正, 保田宏明, 児玉裕三, 辻喜久, 平野賢二, 武田和憲, 竹山宜典, 伊佐地秀司, 丹藤雄介, 真弓俊彦, 江川新一, 北川元二, 佐藤晃彦, 古屋智規, 吉田仁, 下瀬川徹, 正宗淳

  2014, 難治性膵疾患に関する調査研究 平成25年度 総括・分担研究報告書, 72 - 76, Japanese


• PSC・IgG4-SC PSC・IgG4-SC臨床診断 IgG4関連硬化性胆管炎における胆道癌のリスク

  塩川雅広, 児玉裕三, 千葉勉

  (株)アークメディア, 2014, 肝胆膵, 68(1) (1), 47 - 50, Japanese


• Pancreatic perfusion CT in the early stage of severe acute pancreatitis

  辻喜久, 児玉裕三, 吉田司, 千葉勉

  (一社)日本膵臓学会, 2014, 膵臓, 29(2) (2), 178 - 182, Japanese


• 閉塞性化膿性膵管炎(AOSPD)を視野に入れた内視鏡による慢性膵炎治療

  大田悠司, 菊山正隆, 児玉裕三

  (一社)日本消化器内視鏡学会, 2014, Gastroenterological Endoscopy, 56(Supplement 1) (Supplement 1), 1139 - 1139, Japanese


• 肝胆膵・術後病態を學ぶ 肝移植後の病態・必要な治療 肝移植後胆管吻合部狭窄の頻度・治療法

  栗山勝利, 栗田亮, 上田樹, 津田喬之, 西川義浩, 山内雄揮, 佐久間洋二朗, 大田悠司, 丸野貴久, 塩川雅広, 澤井勇悟, 辻喜久, 宇座徳光, 児玉裕三, 八隅秀二郎, 千葉勉

  (株)アークメディア, 2014, 肝胆膵, 69(1) (1), 85 - 91, Japanese


• 胆管ステント留置による胆管結石治療の可能性

  上田樹, 菊山正隆, 児玉裕三

  日本胆道学会, 2014, 胆道, 28(3) (3), 385 - 385, Japanese


• Activation-induced cytidine deaminaseは発癌性変異を誘導し膵発癌に寄与している(Activation-induced cytidine deaminase(AID) contributes to pancreatic carcinogenesis by induction of oncogenic mutations)

  澤井 勇悟, 児玉 裕三, 丸澤 宏之, 千葉 勉

  (一社)日本癌学会, Oct. 2013, 日本癌学会総会記事, 72回, 86 - 86, English


• 超音波内視鏡下穿刺吸引法が確定診断に有用であったバーキットリンパ腫の2小児例

  濱端 隆行, 梅田 雄嗣, 納富 誠司郎, 大封 智雄, 森嶋 達也, 才田 聡, 日衛嶋 栄太郎, 加藤 格, 平松 英文, 渡邉 健一郎, 栗田 亮, 児玉 裕三, 平家 俊男, 足立 壯一

  (一社)日本血液学会-東京事務局, Jul. 2013, 臨床血液, 54(7) (7), 653 - 657, Japanese


• 膵疾患の克服を目指した基礎研究 膵発癌におけるActivation-induced cytidine deaminaseの意義

  澤井 勇悟, 児玉 裕三, 丸澤 宏之, 千葉 勉

  (一社)日本膵臓学会, Jun. 2013, 膵臓, 28(3) (3), 356 - 356, Japanese


• Activation-Induced Cytidine Deaminase (AID) Contributes to Pancreatic Cancer Initiation by Induction of Tumor Related Gene Mutations

  Yugo Sawai, Yuzo Kodama, Yuji Ota, Masahiro Shiokawa, Akira Kurita, Norimitsu Uza, Hiroyuki Marusawa, Tsutomu Chiba

  May 2013, GASTROENTEROLOGY, 144(5) (5), S98 - S98, English

  Summary international conference


• Risk of Immune Thrombocytopenic Purpura in Patients With Autoimmune Pancreatitis

  Masahiro Shiokawa, Yuzo Kodama, Chiharu Kawanami, Masanori Asada, Masataka Kikuyama, Masaya Ohana, Jun Mimura, Yukitaka Yamashita, Yoshihiro Okabe, Tetuo Inokuma, Hiroyuki Kokuryu, Tsutomu Chiba

  May 2013, GASTROENTEROLOGY, 144(5) (5), S477 - S477, English

  Summary international conference


• 自己免疫性膵炎の最前線 IgG4関連疾患の研究の動向

  千葉勉, 児玉裕三, 塩川雅広, 渡邊智裕

  2013, 胆と膵, 34(9) (9)


• 膵発癌におけるActivation-induced cytidine deaminaseの意義

  澤井勇悟, 児玉裕三, 丸澤宏之, 千葉勉

  2013, 膵臓, 28(3) (3)


• 難治性膵疾患に関する調査研究 急性膵炎重症化の早期予知としてのperfusion CTの有用性

  武田和憲, 下瀬川徹, 伊藤鉄英, 乾和郎, 片岡慶正, 片岡慶正, 竹山宜典, 木原康之, 阪上順一, 丹藤雄介, 峯徹哉, 五十嵐良典, 木村憲治, 植村正人, 桐山勢生, 田妻進, 吉田仁, 児玉裕三, 廣田衛久, 辻喜久

  2013, 難治性膵疾患に関する調査研究 平成24年度 総括・分担研究報告書


• IgG4関連疾患に関する調査研究 IgG4関連疾患 胆膵分科会報告

  岡崎和一, 下瀬川徹, 神澤輝実, 川茂幸, 能登原憲司, 日比紀文, 島津章, 乾和郎, 大原弘隆, 中沢貴宏, 太田正穂, 西野隆義, 伊藤鉄英, 浜野英明, 吉田仁, 平野賢二, 水野伸匡, 渡邉智裕, 児玉裕三, 窪田賢輔, 洪繁, 木梨達雄, 内田一茂

  2013, IgG4関連疾患に関する調査研究 平成24年度 総括・分担研究報告書


• 難治性膵疾患に関する調査研究 自己免疫性膵炎と悪性腫瘍の関係

  児玉裕三, 塩川雅広, 南竜城, 栗山勝利, 佐久間洋二郎, 大田悠司, 田辺渉, 丸野貴久, 栗田亮, 澤井勇吾, 宇座徳光, 千葉勉

  2013, 難治性膵疾患に関する調査研究 平成24年度 総括・分担研究報告書, 344 - 345, Japanese


• 難治性膵疾患に関する調査研究 急性膵炎・重症急性膵炎の治療と予後に関する国際比較

  阪上順一, 片岡慶正, 保田宏明, 児玉裕三, 辻喜久, 平野賢二, 武田和憲, 竹山宜典, 伊佐地秀司, 丹藤雄介, 真弓俊彦, 江川新一, 北川元二, 佐藤晃彦, 古屋智規, 吉田仁, 正宗淳

  2013, 難治性膵疾患に関する調査研究 平成24年度 総括・分担研究報告書, 58 - 62, Japanese


• 胆管・膵管拡張をみたら I.胆管拡張をみたら[典型的症例]肝門部胆管狭窄

  栗田亮, 児玉裕三, 千葉勉

  (株)東京医学社, 2013, 消化器内視鏡, 25(2) (2), 259 - 260, Japanese


• 自己免疫性膵炎確診例を用いたIgG4関連疾患包括診断基準の検討

  塩川雅広, 児玉裕三, 千葉勉

  (一財)日本消化器病学会, 2013, 日本消化器病学会雑誌, 110(臨増総会) (臨増総会), A86 - A86, Japanese


• 自己免疫性膵炎と悪性腫瘍の関係

  塩川雅広, 児玉裕三, 千葉勉

  (一社)日本内科学会, 2013, 日本内科学会雑誌, 102(Suppl.) (Suppl.), 200 - 200, Japanese


• 急性閉塞性化膿性膵管炎を発症した慢性膵炎に対する経乳頭的膵管ドレナージ術

  大田悠司, 菊山正隆, 児玉裕三

  (一社)日本消化器内視鏡学会, 2013, Gastroenterological Endoscopy, 55(Supplement 1) (Supplement 1), 945 - 945, Japanese


• 肝門・上部胆管狭窄に対するチューブステントの胆管内留置法の成績

  栗田亮, 児玉裕三, 千葉勉

  日本胆道学会, 2013, 胆道, 27(3) (3), 522 - 522, Japanese


• 原発性硬化性胆管炎として長期経過観察されたIgG4関連硬化性胆管炎の3例

  南竜城, 栗田亮, 栗山勝利, 佐久間洋二朗, 大田悠司, 田邊渉, 丸野貴久, 塩川雅広, 澤井勇悟, 辻喜久, 宇座徳光, 児玉裕三

  日本胆道学会, 2013, 胆道, 27(3) (3), 602 - 602, Japanese


• 自己免疫性膵炎の最前線 自己免疫性膵炎と悪性腫瘍

  塩川雅広, 児玉裕三, 千葉勉

  医学図書出版(株), 2013, 胆と膵, 34(9) (9), 745 - 749, Japanese


• IgG4と肝胆膵 悪性腫瘍とIgG4:悪性腫瘍とIgG4関連疾患の発生 IgG4関連疾患と悪性腫瘍;病因的相互関係

  塩川雅広, 児玉裕三, 千葉勉

  (株)アークメディア, 2013, 肝胆膵, 67(3) (3), 433 - 438, Japanese


• 知っていますか?急性膵炎はこう治す!造影CTおよびperfusion CTによる膵壊死診断の現状

  辻喜久, 児玉裕三, 千葉勉

  医学図書出版(株), 2013, 胆と膵, 34(10) (10), 1099 - 1104, Japanese


• 当院における肝門部領域癌の術前診断の検討

  南竜城, 栗田亮, 児玉裕三

  (一社)日本消化器内視鏡学会, 2013, Gastroenterological Endoscopy, 55(Supplement 2) (Supplement 2), 2700 - 2700, Japanese


• 切除不能胆道癌による肝門・上部胆管狭窄に対するチューブステントの胆管内留置法の成績

  栗田亮, 児玉裕三, 千葉勉

  (一社)日本消化器内視鏡学会, 2013, Gastroenterological Endoscopy, 55(Supplement 2) (Supplement 2), 2719 - 2719, Japanese


• 当院におけるリンパ節に対するEUS-FNAの検討-最適な治療方針決定に向けて-

  澤井勇悟, 栗山勝利, 佐久間洋二郎, 南竜城, 田邊渉, 大田悠司, 丸野貴久, 塩川雅広, 栗田亮, 辻喜久, 宇座徳光, 児玉裕三, 千葉勉

  (一社)日本消化器内視鏡学会, 2013, Gastroenterological Endoscopy, 55(Supplement 2) (Supplement 2), 2911 - 2911, Japanese


• 生体肝移植後の胆管吻合部狭窄に対する内視鏡治療の現況

  栗山勝利, 栗田亮, 児玉裕三

  (一社)日本肝臓学会, 2013, 肝臓, 54(Supplement 3) (Supplement 3), A662 - A662, Japanese


• Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002)

  Shogo Kobayashi, Masashi Kanai, Etsuro Hatano, Yutaka Fujiwara, Daisuke Sakai, Yuzo Kodama, Tetsuo Ajiki, Hiroaki Nagano, Tatsuya Ioka

  Oct. 2012, HEPATOLOGY, 56, 470A - 471A, English

  Summary international conference


• Risk of Cancer in Patients With Autoimmune Pancreatitis

  Masahiro Shiokawa, Yuzo Kodama, Jun Mimura, Chiharu Kawanami, Shujiro Yazumi, Yoshihiro Okabe, Masataka Kikuyama, Yukitaka Yamashita, Hiroyuki Kokuryu, Tetuo Inokuma, Masaya Oohana, Tsutomu Chiba

  May 2012, GASTROENTEROLOGY, 142(5) (5), S456 - S456, English

  Summary international conference


• 超音波内視鏡下穿刺吸引法(EUS-FNA)にて確定診断し得たバーキットリンパ腫の２症例

  納富誠司郎, 梅田雄嗣, 大封智雄, 日衛嶋栄太郎, 加藤格, 平松英文, 児玉裕三, 渡邉健一郎, 足立壮一, 平家俊男

  Mar. 2012, 第25回近畿小児科学会


• ゲムシタビンに抵抗性となった膵癌・胆道癌患者に対するナノ化クルクミン療法の第I相臨床試験

  金井雅史, 森由希子, 西村貴文, 松本繁巳, 柳原一弘, 千葉勉, 千葉勉, 波多野悦朗, 川口義弥, 児玉裕三, 西平順, 大塚和令, 柴田浩行

  2012, 日本臨床腫瘍学会学術集会プログラム・抄録集, 10th


• 難治性膵疾患に関する調査研究 I.急性膵炎 急性膵炎重症化の早期予知としてのperfusion CTの有用性

  武田和憲, 下瀬川徹, 伊藤鉄英, 乾和郎, 片岡慶正, 片岡慶正, 竹山宜典, 木原康之, 阪上順一, 丹藤雄介, 峯徹哉, 五十嵐良典, 木村憲治, 植村正人, 桐山勢生, 田妻進, 吉田仁, 児玉裕三, 廣田衛久

  2012, 難治性膵疾患に関する調査研究 平成23年度 総括・分担研究報告書


• 経乳頭的処置後に膵管感染症(急性閉塞性化膿性膵管炎:AOSPD)を発症した4例

  上田樹, 八隅秀二郎, 大田悠司, 児玉裕三

  2012, 膵臓, 27(3) (3)


• 難治性膵疾患に関する調査研究 I.急性膵炎 重症急性膵炎・局所/全身合併症の診断におけるPerfusion CTの有用性

  児玉裕三, 辻喜久, 塩川雅広, 栗田亮, 澤井勇吾, 宇座徳光, 千葉勉, 渡邉翼, 小泉幸司, 磯田裕義, 山本博

  2012, 難治性膵疾患に関する調査研究 平成23年度 総括・分担研究報告書, 126 - 127, Japanese


• 難治性膵疾患に関する調査研究 I.急性膵炎 急性膵炎・重症急性膵炎の治療と予後に関する国際比較

  阪上順一, 片岡慶正, 保田宏明, 児玉裕三, 辻喜久, 平野賢二, 武田和憲, 竹山宜典, 伊佐地秀司, 丹藤雄介, 真弓俊彦, 江川新一, 北川元二, 佐藤晃彦, 古屋智規, 吉田仁, 正宗淳, 下瀬川徹

  2012, 難治性膵疾患に関する調査研究 平成23年度 総括・分担研究報告書, 52 - 56, Japanese


• 胆嚢癌フロントライン 薬物治療 GEM/S-1併用療法による切除不能胆道癌の治療成績

  金井雅史, 波多野悦朗, 児玉裕三, 田浦康二朗, 石井隆道, 宇座徳光, 森由希子, 西村貴文, 松本繁巳, 千葉勉, 千葉勉, 上本伸二

  (株)アークメディア, 2012, 肝胆膵, 64(4) (4), 599 - 605, Japanese


• 生体肝移植後胆管狭窄に対するチューブステントの胆管内留置法の成績

  栗田亮, 児玉裕三, 千葉勉

  (一社)日本消化器内視鏡学会, 2012, Gastroenterological Endoscopy, 54(Supplement 1) (Supplement 1), 962 - 962, Japanese


• ERCP関連偶発症に対する予防対策の試み

  田邊渉, 栗田亮, 児玉裕三, 千葉勉

  (一社)日本消化器内視鏡学会, 2012, Gastroenterological Endoscopy, 54(Supplement 2) (Supplement 2), 1162 - 1162, Japanese


• 膵臓の画像診断update 膵Perfusion Imageの膵良性疾患における有用性

  辻喜久, 児玉裕三, 千葉勉

  医学図書出版(株), 2012, 胆と膵, 33(7) (7), 585 - 589, Japanese


• 膵管感染症(急性閉塞性化膿性膵管炎:AOSPD)を発症した慢性膵炎症例

  大田悠司, 児玉裕三, 菊山正隆, 上田樹, 黒上貴史, 重友美紀

  (一社)日本膵臓学会, 2012, 膵臓, 27(3) (3), 447 - 447, Japanese


• 膵内分泌腫瘍の画像診断

  栗田亮, 児玉裕三, 千葉勉

  (一社)日本膵臓学会, 2012, 膵臓, 27(3) (3), 464 - 464, Japanese


• ERCP関連偶発症に対する予防対策の試み

  田邊渉, 栗田亮, 児玉裕三

  (一社)日本消化器内視鏡学会, 2012, Gastroenterological Endoscopy, 54(Supplement 1) (Supplement 1), 2787 - 2787, Japanese


• Six cases of acute obstructive suppurative pancreatic ductitis

  大田悠司, 菊山正隆, 黒上貴文, 森田敏広, 重友美紀, 松村和宣, 児玉裕三, 千葉勉

  (一社)日本膵臓学会, 2012, 膵臓, 27(6) (6), 755 - 761, Japanese


• 内視鏡的胆膵管ドレナージのすべて 肝胆膵術後の内視鏡的胆管ドレナージ―胆摘後,肝移植後,胆管空腸吻合術後―

  栗田亮, 児玉裕三, 田邊渉, 大田裕司, 丸野貴久, 塩川雅弘, 澤井雄悟, 宇座徳光, 千葉勉

  (株)東京医学社, 2012, 消化器内視鏡, 24(3) (3), 323 - 329, Japanese


• 【NOMI(non-occlusive mesenteric ischemia)をいかに診断し、治療するか】重症急性膵炎とnon-occlusive mesenteric ischemia

  辻 喜久, 山本 博, 能登原 憲司, 児玉 裕三, 千葉 勉

  (一社)日本腹部救急医学会, Nov. 2011, 日本腹部救急医学会雑誌, 31(7) (7), 1029 - 1037, Japanese


• SERUM AMYLOID P ATTENUATES HEPATIC FIBROSIS IN MICE BY INHIBITING THE ACTIVATION OF FIBROCYTES AND HEPATIC STELLATE CELLS

  Min Cong, Chunyan Jiang, Kojiro Taura, Yuzo Kodama, Samuele De Minicis, Michael S. Kramer, Mark L. Lupher, David Brenner, Tatiana Kisseleva

  Oct. 2011, HEPATOLOGY, 54, 736A - 736A, English

  Summary international conference


• 【膵疾患画像診断における最近の進歩】重症急性膵炎発症早期における"可逆性-非可逆性膵虚血"の診断

  辻 喜久, 渡邉 翼, 塩川 雅広, 栗田 亮, 澤井 勇悟, 上野 憲司, 塩 せいじ, 宇座 徳光, 児玉 裕三, 小泉 幸司, 磯田 裕義, 渡邊 祐司, 山本 博, 千葉 勉

  (一社)日本膵臓学会, Feb. 2011, 膵臓, 26(1) (1), 59 - 65, Japanese


• IPMNを除く膵嚢胞性病変の診断アルゴリズムの検討

  藤田光一, 永倉千紗子, 栗田亮, 淺田全範, 八隅秀二郎, 菊山正隆, 児玉裕三

  2011, 日本消化器病学会雑誌, 108


• 効果的な内視鏡的嚢胞ドレナージ術を目指して

  山内淳嗣, 牟田優, 廣橋研志郎, 西川義浩, 渡辺昌樹, 佐久間洋二朗, 熊谷奈苗, 加藤洋子, 工藤寧, 小田弥生, 藤田光一, 浅田全範, 八隅秀二郎, 澤井勇悟, 栗田亮, 児玉裕三, 千葉勉

  2011, Gastroenterological Endoscopy, 53(Supplement 2) (Supplement 2)


• 肝移植後合併症に対するIVR 2.胆管吻合部狭窄に対する内視鏡的治療

  八隅秀二郎, 栗田亮, 児玉裕三, 千葉勉

  2011, IVR, 26(4) (4)


• Severe Acute Pancreatitis and Non Occlusive Mesenteric Ischemia

  辻喜久, 辻喜久, 山本博, 能登原憲司, 児玉裕三, 千葉勉

  2011, 日本腹部救急医学会雑誌, 31(7) (7)


• 難治性膵疾患に関する調査研究 重症急性膵炎・局所/全身合併症の診断におけるPerfusion CTの有用性

  児玉裕三, 辻喜久, 渡邉翼, 塩川雅広, 栗田亮, 澤井勇悟, 上野憲司, 塩せいじ, 宇座徳光, 千葉勉, 小泉幸司, 磯田裕義, 山本博

  2011, 難治性膵疾患に関する調査研究 平成20-22年度 総合研究報告書, 132 - 134, Japanese


• 難治性膵疾患に関する調査研究 重症急性膵炎・局所/全身合併症の診断におけるPerfusion CTの有用性

  児玉裕三, 辻喜久, 渡邉翼, 塩川雅広, 栗田亮, 澤井勇悟, 上野憲司, 塩せいじ, 宇座徳光, 千葉勉, 小泉幸司, 磯田裕義, 山本博

  2011, 難治性膵疾患に関する調査研究 平成22年度 総括・分担研究報告書, 104 - 106, Japanese


• Ischemic penumbra in early stage of severe acute pancreatitis

  辻喜久, 辻喜久, 渡邉翼, 塩川雅広, 栗田亮, 澤井勇悟, 上野憲司, 塩せいじ, 宇座徳光, 児玉裕三, 小泉幸司, 磯田裕義, 渡邊祐司, 山本博, 千葉勉

  2011, 膵臓, 26(1) (1), 59-65 (J-STAGE), Japanese


• 肝門・上部胆管狭窄に対するチューブステントの胆管内留置法の成績

  栗田亮, 児玉裕三, 千葉勉

  (一社)日本消化器内視鏡学会, 2011, Gastroenterological Endoscopy, 53(Supplement 1) (Supplement 1), 659 - 659, Japanese


• 当院における超音波内視鏡ガイド下穿刺吸引法(EUS-FNA)導入後の評価

  澤井勇悟, 塩川雅広, 栗田亮, 上田憲司, 辻喜久, 宇座徳光, 児玉裕三, 千葉勉

  (一社)日本消化器内視鏡学会, 2011, Gastroenterological Endoscopy, 53(Supplement 1) (Supplement 1), 897 - 897, Japanese


• 重症急性膵炎の病態解明と治療の新展開 重症急性膵炎における膵虚血,非閉塞性腸管膜虚血と肝血流との関係

  辻喜久, 辻喜久, 辻喜久, 子安翔, 磯田裕義, 渡邉翼, 塩川雅広, 栗田亮, 澤井勇悟, 上野憲司, 塩せいじ, 宇座徳光, 児玉裕三, 小泉幸司, 渡邊祐司, 山本博, 千葉勉

  (有)科学評論社, 2011, 月刊消化器内科, 52(2) (2), 214 - 218, Japanese


• 自己免疫性膵炎の臨床像の検討

  塩川雅広, 栗田亮, 澤井勇悟, 辻喜久, 宇座徳光, 児玉裕三, 河南智晴, 千葉勉

  (一財)日本消化器病学会, 2011, 日本消化器病学会雑誌, 108(臨増総会) (臨増総会), A268 - A268, Japanese


• 強化インスリン治療を継続した自己免疫性膵炎による糖尿病の一例

  菱澤方洋, 藤田義人, 船越生吾, 山野言, 松本久和, 児玉裕三, 長嶋一昭, 濱崎暁洋, 藤本新平, 稲垣暢也

  (一社)日本糖尿病学会, 2011, 糖尿病, 54(3) (3), 210 - 210, Japanese


• 経過を追えた小膵癌-この所見に気をつけろ!分枝型IPMNの経過観察中に通常型膵管癌を合併した1例

  澤井勇悟, 塩川雅広, 栗田亮, 宇座徳光, 児玉裕三, 近藤響子, 千葉勉

  (株)医学書院, 2011, 肝胆膵画像, 13(3) (3), 277 - 282, Japanese


• 膵癌術前診断におけるFDG-PET検査の臨床的役割と問題点

  栗田亮, 児玉裕三, 塩川雅広, 澤井勇悟, 宇座徳光, 中本裕士, 千葉勉

  (一財)日本消化器病学会, 2011, 日本消化器病学会雑誌, 108(臨増大会) (臨増大会), A912 - A912, Japanese


• 激烈な経過を辿った両眼性細菌性眼内炎の一例

  吉川宗光, 宇治彰人, 板谷正紀, 宮本和明, 村上智昭, 諸岡諭, 熊谷京子, 吉村長久, 児玉裕三, 高倉俊二

  金原出版(株), 2011, 眼科, 53(11) (11), 1674 - 1674, Japanese


• I.遺伝子診断(Genetic Diagnosis)がんのゲノム解析と診療への応用 胆・膵腫瘍

  児玉裕三, 千葉勉

  (株)日本臨床社, 2010, 日本臨床, 68(増刊8 遺伝子診療学) (増刊8 遺伝子診療学), 462 - 467, Japanese


• 膵仮性嚢胞に対するEUSガイド下嚢胞ドレナージ(EUS-CD)の検討

  澤井勇悟, 多田真輔, 児玉裕三

  (一社)日本消化器内視鏡学会, 2010, Gastroenterological Endoscopy, 52(Supplement 2) (Supplement 2), 2554 - 2554, Japanese


• 胆管癌におけるRUNX3の役割とその治療ターゲットとしての可能性

  塩せいじ, 児玉裕三, 依田広, 澤井勇悟, 千葉勉

  (一財)日本消化器病学会, 2010, 日本消化器病学会雑誌, 107(臨増大会) (臨増大会), A929 - A929, Japanese


• 胸水・腹水の病理 腹水の臨床所見と画像診断

  中泉明彦, 依田広, 児玉裕三, 白波瀬浩幸, 吉澤明彦, 千葉勉

  (株)文光堂, 2010, 病理と臨床, 28(11) (11), 1161 - 1166, Japanese


• Toll-Like Receptor (TLR) 9 Mediates Steatosis and Fibrosis Through Il1 beta in Diet-Induced Steatohepatitis in Mice

  Kouichi Miura, Ekihiro Seki, Yuzo Kodama, Sayaka Inokuchi, David A. Brenner

  May 2009, GASTROENTEROLOGY, 136(5) (5), A803 - A803, English

  Summary international conference


• SMP30ノックアウトマウスにおけるビタミンCの肺気腫発生予防効果の検討

  小池建吾, 瀬山邦明, 石神昭人, 近藤嘉高, 吉見格, 児玉裕三, 関谷充晃, 丸山直記, 高橋和久

  2009, 日本呼吸器学会雑誌, 47


• 呼吸不全に関する調査研究班 胸部CT画像の定量的解析を用いたBirt-Hogg-Dube症候群とリンパ脈管筋腫症の比較とその鑑別診断

  飛野和則, 瀬山邦明, 栗原正利, 平井豊博, 郡司陽子, 児玉裕三, 高橋和久

  2009, 呼吸不全に関する調査研究班 平成20年度 研究報告書


• SMP30ノックアウトマウスにおけるビタミンCの肺気腫発生予防効果の検討

  小池建吾, 瀬山邦明, 近藤嘉高, 児玉裕三, 関谷充晃, 丸山直記, 石神昭人, 高橋和久

  2009, 順天堂医学, 55(3) (3)


• 消化器疾患と遺伝子異常のかかわりを探る 遺伝子異常は先天性胆道疾患とどうかかわるのか

  児玉裕三, 千葉勉

  (株)先端医学社, 2009, 分子消化器病, 6(3) (3), 212 - 218, Japanese


• 骨髄由来細胞のJNK1はNASHの肝線維化を促進する

  児玉裕三, 丸澤宏之

  (一財)日本消化器病学会, 2009, 日本消化器病学会雑誌, 106(臨増大会) (臨増大会), A707 - A707, Japanese


• JNK1 IN HEMATOPOIETIC CELLS MEDIATES PROGRESSION FROM DIET-INDUCED HEPATIC STEATOSIS TO STEATOHEPATITS AND LIVER FIBROSIS

  Yuzo Kodama, Tatiana Kisseleva, Kouichi Miura, Kojiro Taura, Samuele De Minicis, Ekihiro Seki, David A. Brenner

  Oct. 2008, HEPATOLOGY, 48(4) (4), 366A - 366A, English

  Summary international conference


• HEPATOCYTES DO NOT UNDERGO EPITHELIAL MESENCHYMAL TRANSITION DURING CCL(4)-INDUCED LIVER FIBROSIS IN MICE

  Kojiro Taura, Kouichi Miura, Yuzo Kodama, Christoph H. Oesterreicher, Mellita P. Oesterreicher, David A. Brenner

  Oct. 2008, HEPATOLOGY, 48(4) (4), 381A - 381A, English

  Summary international conference


• HISTONE DEACETYLASE INHIBITION RESTORES HEPCIDIN EXPRESSION IN HCV REPLICON CELLS

  Kouichi Miura, Kojiro Taura, Yuzo Kodama, David A. Brenner

  Oct. 2008, HEPATOLOGY, 48(4) (4), 789A - 790A, English

  Summary international conference


• Anti-apoptotic effect of JNK1 through Mcl-1 stabilization in TNF alpha-induced flepatocyte apoptosis

  Yuzo Kodama, Kojiro Taura, Kouichi Miura, Yosuke Osawa, David A. Brenner

  Apr. 2008, GASTROENTEROLOGY, 134(4) (4), A766 - A767, English

  Summary international conference


• HCV-induced oxidative stress suppresses basal and I16-stimulated hepcidin expression in human hepatoma cell lines

  Kouichi Miura, Kojiro Taura, Yuzo Kodama, David A. Brenner

  Apr. 2008, GASTROENTEROLOGY, 134(4) (4), A768 - A768, English

  Summary international conference


• Human serum amyloid P (Hsap) inhibits bile duct ligation induced liver fibrosis in mice

  Tatiana Kisseleva, George Notas, Kojiro Taura, Yuzo Kodama, Samuele De Minicis, Mike Kramer, David P. Hesson, Tim Pelura, David A. Brenner

  Apr. 2008, GASTROENTEROLOGY, 134(4) (4), A768 - A768, English

  Summary international conference


• Phagocytic and non-phagocytic NADPH-oxidase isoforms differentially regulate fibrosis but not steatosis in the liver

  Samuele De Minicis, Ekihiro Seki, Christoph Oesterreicher, Yuzo Kodama, Johannes Kluwe, Robert F. Schwabe, David A. Brenner

  Apr. 2008, GASTROENTEROLOGY, 134(4) (4), A764 - A764, English

  Summary international conference


• 胸部CT画像の定量的解析を用いたBirt-Hogg-Dube症候群とリンパ脈管筋腫症の比較とその鑑別診断

  飛野和則, 瀬山邦明, 栗原正利, 平井豊博, 秋吉妙子, 郡司陽子, 児玉裕三, 高橋和久

  2008, 日本気胸・嚢胞性肺疾患学会雑誌, 8(1) (1)


• SMP30ノックアウトマウスにおけるビタミンC摂取によるCOPD発症リスク軽減効果の検討

  小池建吾, 瀬山邦明, 石神昭人, 近藤嘉高, 佐藤安訓, 袁益明, 秋吉妙子, 児玉裕三, 関谷充晃, 岸本祐樹, 岩間水輝, 天野晶子, 丸山直記, 高橋和久

  2008, 順天堂医学, 54(2) (2)


• Epimorphin induces Mmps and Upa in hepatocytes through NF-kB activation during recovery from liver injury

  Kouichi Miura, Ryutaro Yoshino, Yohei Hirai, Takashi Goto, Shigetoslu Ohshima, Ken-Ichiro Mikami, Kazuo Yoneyama, Daisuke Watanabe, Yuzo Kodama, Yosuke Osawa, David Brenner, Sumio Watanabe

  Apr. 2007, GASTROENTEROLOGY, 132(4) (4), A741 - A742, English

  Summary international conference


• 肝再生の分子機構を探る 肝細胞と胆管細胞の分化はどのように決定されるのか?

  児玉裕三, 千葉勉

  (株)先端医学社, 2007, 分子消化器病, 4(4) (4), 292 - 297, Japanese


• Aberrant expression of activation-induced cytidine deaminase (AID) and hepatocarcinogenesis

  Tadayuki Kou, Hiroyuki Marusawa, Kazuo Kinoshita, Il-Mi Okazaki, Yoshihide Ueda, Yuzo Kodama, Yoko Endo, Hironori Haga, Iwao Ikai, Tsutomu Chiba

  Apr. 2006, GASTROENTEROLOGY, 130(4) (4), A795 - A795, English

  Summary international conference


• 消化器疾患の分子生物学 第10回 先天性胆道疾患・嚢胞性肝疾患

  児玉裕三, 千葉勉

  (株)先端医学社, 2006, 分子消化器病, 3(2) (2), 166 - 171, Japanese


• 肝発生および病態形成におけるNotchシグナルの機能解析

  児玉裕三, 丸沢宏之, 千葉勉

  (一社)日本肝臓学会, 2005, 肝臓, 46(Supplement 2) (Supplement 2), A314 - A314, Japanese


• 肝発生および病態形成におけるNotchシグナルの機能解析

  児玉裕三, 丸沢宏之, 千葉勉

  (一財)日本消化器病学会, 2005, 日本消化器病学会雑誌, 102(臨増大会) (臨増大会), A388 - A388, Japanese


• HBc抗体陽性を示すHBV潜伏感染ドナーにおけるHBVの体内感染動態

  梅田誠, 丸沢宏之, 鍋島紀滋, 児玉裕三, 妹尾浩, 桂田哲, 上本伸二, 江川裕人, 田中紘一

  (一社)日本肝臓学会, 2004, 肝臓, 45(Supplement 2) (Supplement 2), A450 - A450, Japanese


• シグナル伝達を理解するために必要な知識 第4回 No.7 分化シグナルとしてのNotchシグナル伝達

  児玉裕三, 千葉勉

  (株)先端医学社, 2004, 分子消化器病, 1(4) (4), 356 - 359, Japanese


• グラフト肝における血管内皮chimerismの免疫組織学的検討-ABO血液型物質を用いて

  田中裕一, 山内淳一, 梅田誠, 高橋健, 高忠行, 松本裕子, 岩井晃男, 桜井俊治, 児玉裕三

  (一財)日本消化器病学会, 2004, 日本消化器病学会雑誌, 101(臨増大会) (臨増大会), A817 - A817, Japanese


• Hes1 is required for the development of intrahepatic bile ducts

  Y Kodama, J Hatakeyama, R Kageyama, M Hijikata, T Chiba, K Shimotohno

  Apr. 2003, GASTROENTEROLOGY, 124(4) (4), A123 - A123, English

  Summary international conference


• 加齢指標蛋白質30(SMP30)の肺における役割

  児玉裕三, 森貴紀, 瀬山邦明, 笠木聡, 石神昭人, 丸山直記, 福地義之助

  2003, 日本老年医学会雑誌, 40


• 肝臓発生過程におけるNotch Signalingの役割

  児玉裕三, 畠山淳, 影山龍一郎, 土方誠, 千葉勉, 下遠野邦忠

  (一社)日本肝臓学会, 2003, 肝臓, 44(Supplement 1) (Supplement 1), A100 - A100, Japanese


• 乳頭切開術を要さない把持かん子の胆管内挿入法 生体肝移植後胆管内遺残チューブの2症例

  浅田全範, 八隅秀二郎, 長谷川和範, 児玉裕三, 久恒洋, 岡崎和一, 千葉勉

  2002, 日本消化器病学会雑誌, 99


• 嚢胞性膵腫瘍における内視鏡診断の検討

  浅田 全範, 八隅 秀二郎, 松浦 稔, 児玉 裕三, 久恒 洋, 岡崎 和一, 千葉 勉, 藤本 康二, 和田 道彦, 土井 隆一郎

  (一社)日本膵臓学会, Jun. 2001, 膵臓, 16(3) (3), 319 - 319, Japanese


• 【超音波と内視鏡における最新動向】膵癌の内視鏡診断

  久恒 洋, 岡崎 和一, 児玉 裕三, 松村 和宜, 大花 正也, 魚瀬 優, 東條 正英, 八隅 秀二郎, 千葉 勉

  産業開発機構(株), May 2000, 映像情報Medical, 32(10) (10), 537 - 540, Japanese


• Usefulness of endoscopic treatment for persistent biliary leak due to hepatectomy.

  H Hisatsune, Y Kodama, K Matsumura, S Uose, S Yazumi, Y Hosotani, M Oohana, M Tojou, K Okazaki, T Chiba

  Apr. 2000, GASTROINTESTINAL ENDOSCOPY, 51(4) (4), AB282 - AB282, English

  Summary international conference


• 超音波と内視鏡における最新動向 すい癌の内視鏡診断

  久恒洋, 岡崎和一, 児玉裕三, 松村和宜, 大花正也, 魚瀬優, 東条正英, 八隅秀二郎, 千葉勉

  2000, 映像情報, 32(10) (10)


• 肝切後胆汁漏に対する内視鏡的治療の検討

  久恒洋, 児玉裕三, 松村和宜, 魚瀬優, 細谷泰久, 大花正也, 八隅秀二郎, 東条正英, 千葉勉

  (一社)日本消化器内視鏡学会, 2000, Gastroenterological Endoscopy, 42(Supplement 1) (Supplement 1), 618 - 618, Japanese